{"title": "PDF", "author": "PDF", "url": "https://www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2021/englisch/Gesamtdatei_englisch_mitVorspann.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "2021              vs1Diagnostik und Therapie \nfr\u00fcher und fortgeschrittener Mammakarzinome\nHerausgegeben von der Kommission Mamma\n(vertreten durch: Wolfgang Janni)\nder Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie e.V.\nin der Deutschen Gesellschaft f\u00fcr Gyn\u00e4kologie und Geburtshilfe e.V.\nsowie der Deutschen Krebsgesellschaft e.V.\n\u00d8Inhaltsverzeichnis\n\u00d8Levels ofEvidence and Grades ofRecommendation\n\u00d8Abbreviations\n\u00d8Members oftheAGO Breast Commission\n\u00d8Conflict ofInterest\n\u00d8How toUse these Slides\n\u00d8Editor & Copyright\nVorspann2021 vs1Inhaltsverzeichnis Diagnostik und Therapie fr\u00fcher und \nfortgeschrittener Mammakarzinome\nEmpfehlungen der AGO Kommission MammaLevels ofEvidence and Grades ofRecommendation\nAbbrevaiations\nMembers oftheAGO Breast Committee\nConflict ofInterest\nHow toUse theSlides\nEditor & Copyright\n1) Optionen der prim\u00e4ren Pr\u00e4vention: Ver\u00e4nderbare Lifestyle -Faktoren\n2) Brustkrebsrisiko und Pr\u00e4vention\n3) Fr\u00fcherkennung und Diagnostik\n4) Pathologie\n5) Prognostische und pr\u00e4diktive Faktoren\n6) L\u00e4sionen mit unsicherem Potential (B3) \u2013ADH, LIN, FEA, Papillom, Radi\u00e4re Narbe\n7) Duktales Carcinoma in situ (DCIS)\n8) Operative Therapie des Mammakarzinoms unter onkologischen Aspekten\n9) Onkoplastische und rekonstruktive Mammachirurgie\n10) Adjuvante endokrine Therapie bei Pr\u00e4 -und postmenopausalen Patientinnen\n11) Adjuvante zytostatische und zielgerichtete Therapien\n12) Neoadjuvante (Prim\u00e4re) systemische Therapie\n13) Adjuvante Strahlentherapie\n14) Supportive Therapie und Nebenwirkungsmanagement\n15) Brustkrebs: Spezielle Situationen\n16) Brustkrebs Nachsorge\n17) Lokoregion\u00e4res Rezidiv\n18) Endokrine und zielgerichtete Therapie des metastasierten Mammakarzinoms\n19) Chemotherapie mit oder ohne zielgerichtete Substanzen beim metastasierten Mammakarzinom\n20) Osteoonkologie und Knochengesundheit\n21) Besondere Situationen und Lokalisationen in der metastasierten Situation\n22) ZNS-Metastasen beim Mammakarzinom\n23) Komplement\u00e4re Therapie \u201e Survivorship \u201c\n24) Gy\nn\u00e4kologische Probleme bei Mammakarzinompatientinnen\n25) Gesundheitskompetenz und Kommunikation\n26) Therapiealgorithmen\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nOxford Levels ofEvidence (LoE)\nLoE Therapy/Prevention, Aetiology/Harm Prognosis\n1a Systematic review (with homogeneity) of randomised controlled trials Systematic review (with homogeneity) of inception cohort studies; clinical \ndecision rule validated in different populations \n1b Individual randomised controlled trials (with narrow Confidence Interval) Individual inception cohort study with >80% follow -up; clinical decision rule \nvalidated in a single population\n1c All or none All or none case -series\n2a Systematic review (with homogeneity) of cohort studies Systematic review (with homogeneity) of either retrospective cohort studies or untreated control groups in randomised controlled trials\n2b Individual cohort study (including low quality randomised controlled trials; e.g., <80% follow -up) Retrospective cohort study or follow -up of untreated control patients in a \nrandomised controlled trials; Derivation of clinical decision rule or validated on \nsplit -sample only\n2c \"Outcomes\" Research; Ecological studies \"Outcomes\" Research \n3a Systematic review (with homogeneity) of case- control studies\n3b Individual Case -Control Study\n4 Case -series (and poor quality cohort and case -control studies) Case -series (and poor quality prognostic cohort studies)\n5 Expert opinion without explicit critical appraisal, or based on \nphysiology, bench research or \"first principles\"Expert opinion without explicit critical appraisal, or based on physiology, bench research or \"first principles\"\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nOxford Grades ofRecommendation (GR)\nA consistent level 1 studies \nB consistent level 2 or 3 studies orextrapolations from level 1 \nstudies\nC level 4 studies orextrapolations from level 2 or 3 studies \nD level 5 evidence or troublingly inconsistent or inconclusive \nstudies of any level\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nAGO Grades ofRecommendation\n++ This investigation or therapeutic intervention is highly beneficial for patients, \ncan be recommended without restriction, and should be performed. \n+ This investigation or therapeutic intervention is of limited benefit for patientsand can be performed.\n+/- This investigation or therapeutic intervention has not shown benefit forpatients and may be performed only in individual cases. According to currentknowledge a general recommendation cannot be given\n.\n- Th\nis investigation or therapeutic intervention can be of disadvantage for\npatients and might not be performed.\n-- This investigation or therapeutic intervention is of clear disadvantage forpatients and should be avoided or omitted in any case.\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nAbbreviations \u2013I\nA Doxorubicin\nACC Adenoid -zystisches Karzinom (adenoid cystic carcinoma) \nADH Atypische duktale Hyperplasie\nADL Aktivit\u00e4ten des t\u00e4glichen Lebens ( activities ofdaily life)\nADM Azellul\u00e4re dermale Matrix\nADP atypische epitheliale Proliferation vom duktalen Typ\nAHT Arterielle Hypertonie \nAI Aromataseinhibitor\nAK Antik\u00f6rper\nALH Atypische lobul\u00e4re Hyperplasie\nAlip Liposomales Doxorubicin\nALND Axill\u00e4re Lymphknotendissektion\nAML akute myeloische Leuk\u00e4mie\nANC Absolute Neutrophilenzahl\nAPBI Akzelerierte Teilbrustbestrahlung\nAPR Aprepitant\nAR Androgenrezeptor\nARDS Acute Respiratory Distress Syndrome\nASS Acetylsalicyls\u00e4ure\nAT Anthrazyklin /Taxan\nAZ Allgemeinzustand\nBAL Bronchoalveol\u00e4re Lavage\nBC Mammakarzinom (breast cancer)\nBCFI Brustkrebs -freies Intervall\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nAbbreviations \u2013II\nBCI Breast Cancer Index\nBCS Brusterhaltende Operation (breast -conserving surgery)\nBCT Brusterhaltende Therapie (breast -conserving therapy)\nBEO Brusterhaltende Operation\nBET Brusterhaltende Therapie\nBev Bevacizumab\nBfARM Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte \nBIA-ALCL Brustimplantat -assoziiertes anaplastisches gro\u00dfzelliges Lymphom \nBMI Body Mass Index\nBP Bisphosphonat\nBR Brustrekonstruktion\nBSE Selbstuntersuchung ( breast self-examination ) \nBZ Brustkrebszentrum\nC Cyclophosphamid\nCa. Karzinom\nCAM Komplement\u00e4re und alternative Medizin\nCap Capecitabin\nCBE klinische Brustuntersuchung ( clinical breast examination )\nCDK4/6i Cyklin -abh\u00e4ngige Kinase 4/6- Inhibitor\nCESM Kontrastmittel -verst\u00e4rkte spektrale Mammographie ( contrast enhanced spectral Mammography )\nCEUS Kontrastmittel -Sonographie ( contrast enhanced ultrasound )  \ncfDNA zellfreie DNA   \nCGA Umfassende geriatrische Einsch\u00e4tzung ( Comprehensive Geriatric Assessment)\nCHF Kardiomyopathie (congestive heart failure)\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nAbbreviations \u2013III\nCHOP Cyclophosphamid , Doxorubicin, Vincristin , Prednison\nCI Konfidenzintervall (Confidence interval)\nCIA Chemotherapie -induzierte Amenorrhoe\nCIPN Chemotherapie -induzierte periphere Neuropathie\nCISH Chromogene in situ -Hybridisierung\nCMF Cyclophosphamid ,Methotrexat , 5-Fluorouracil\nCNB Stanzbiopsie (core needle biopsy)\nCOX2 Cyclooxygenase -2\nCPS Combined positive score\nCRA Chemotherapie -induzierte Amenorrhoe (chemotherapy -related amenorrhea ) \nCSL Komplexe sklerosierende L\u00e4sion\nCT Computertomographie\nCTC Zirkulierende Tumorzellen\nCTS Category of tumor marker study \nCTS5 Clinical Treatment Score 5\nCTx Chemotherapie\nCUP Cancer of unknown primary\nD Docetaxel\nDAC Docetaxel, Doxorubicin, Cyclophosphamid\nDBT Digitale Brust -Tomosynthese\nDCIS Duktales Carcinoma in situ\nDDFS Distant disease free survival \nDDT Dichlordiphenyltrichlorethan\nDES Diethylstilbestrol\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nAbbreviations \u2013IV\nDEX Dexamethason\nDFS Krankheitsfreies \u00dcberleben\nDHEA Dehydroepiandrosteron\nDIEP Deep Inferior Epigastric Perforator (Lappen)\nDK-FBEK Deutsches Konsortium f\u00fcr Famili\u00e4ren Brust -und Eierstockkrebs\nDM Digitale Mammographie \nDM Fernmetastasierung \nDmab Denosumab\nDMSO Dimethylsulfoxid\nDOP Dopaminrezeptor -Antagonist\nDPD Dihydropyrimidin -Dehydrogenase\nDS-GPA Diagnosis -specific Graded Prognostic Assessment\nDTC Disseminierte Tumorzellen\nDXA Dual -R\u00f6ntgen -Absorptiometrie\nE Epirubicin\nE2 Estradiol\nEAT Erweiterte adjuvante endokrine Therapie\neBC Fr\u00fches Mammakarzinom\nEBUS Endobronchialer Ultraschall\nECS Extrakapsul\u00e4res Tumorwachstum \nEFS Event -freies \u00dcberleben\nEGFR Epidermaler Wachstumsfaktorrezeptor\nEIC Extensive intraduktale Komponente\nEK Einschlusskriterien \nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nAbbreviations \u2013V\nELEE Gesch\u00e4tzte lebenslange Estrogen -Exposition ( Estimated lifetime estrogen exposure )\nEM Ca Endometriumkarzinom\nEMA European Medicines Agency\nER Estrogenrezeptor\nESF Erythropoese -stimulierender Faktor\nETx Endokrine Therapie\nF 5-Fluorouracil\nF/U Follow up\nFBC Blutbild (full blood count)\nFCI Fasciocutaneous Infragluteal Flap\nFDA Food and Drug Administration\nFDG -PET18F-2-Fluor -2-Desoxyglucose -Positronen -Emissions -Tomographie\nFEA Flache epitheliale Atypie\nFED Funktioneller Eisenmangel\nFFPE Formalin -fixiertes Paraffin -eingebettetes Gewebe\nFISH Fluoreszenz -in-situ-Hybridisierung\nFN Febrile Neutropenie\nFSH Follikelstimulierendes Hormon\nFSRT Fraktionierte stereotaktische Radiotherapie\nFul Fulvestrant\nG-CSF Granulozyten -Kolonie -stimulierender Faktor\nGC-HBOC German Consortium for Hereditary Breast and Ovarian Cancer \nGCP Gute klinische Praxis (Good Clinical Practice)\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nAbbreviations \u2013VI\nGEP Gexexpressionsprofil\nGI Gastrointestinal\nGJG Goshajinkigan\nGKP Gute klinische Praxis\nGKV Gesetzliche Krankenversicherung\nGnRH Gonadotropin -Releasing -Hormon\nGnRHa Gonadotropin -Releasing -Hormon -Agonist\nGR Oxford Grade of Recommendation\nHER2 Human epidermal growth factor receptor 2\nHFS Hand -Fu\u00df-Syndrom\nHR Hazard Ratio\nHR Hormonrezeptor\nHRQoL Gesundheitsbezogene Lebensqualit\u00e4t (Health -related quality of life)\nHRT Hormonersatztherapie\nHT Hormontherapie\nIADL The Lawton Instrumental Activities of Daily Living Scale\nIBC Inflammatorisches Mammakarzinom \nIBR Sofortrekonstruktion (immediate breast reconstruction ) \nIBTR Ipsilaterales Brustrezidiv (Ipsilateral Breast Tumor Recurrence)\nIC Immunzellen\nICG Indocyaningr\u00fcn\nICG Infraklavikul\u00e4rgrube\nICPi Immuncheckpointinhibitor\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nAbbreviations \u2013VII\niddETC Epirubicin, Paclitaxel , Cyclophosphamid , dosis -dicht, dosis -intensiviert\niDFS invasives krankheitsfreies \u00dcberleben\nIGAP Inferior gluteal artery perforator\nIHC Immunhistochemie\nILC Invasives lobul\u00e4res Karzinom\nILRR Ipsilaterales lokoregion\u00e4res Rezidiv\nIMC Mammaria interna Region (internal mammary lymph node chain)\nIMRT Intensit\u00e4tsmodulierte Radiotherapie\nIOERT Intraoperative Elektronen -Radiotherapie\nIORT Intraoperative Radiotherapie\nIR Implantat -Rekonstruktion \nirAE Immunbezogenes unerw\u00fcnschtes Ereignis (Immune -related adverse event )\nISH In-situ-Hybridisierung\nITC Isolierte Tumorzellen\nIUD Intrauterine device\nKFU Krebsfr\u00fcherkennungsuntersuchung \nLap Lapatinib\nLCIS Lobul\u00e4res Carcinoma in situ\nLH Luteinisierendes Hormon\nLHRH Luteinisierendes -Hormon -Releasing -Hormon\nLIN Lobul\u00e4re intraepitheliale Neoplasie\nLITT Laser -induzierte Tumortherapie\nLK Lymphknoten\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nAbbreviations \u2013VIII\nLN Lobul\u00e4re Neoplasie\nLoE Evidenzlevel (level of evidence)\nLR Lokalrezidiv\nLRFI Lokalrezidiv -freies Intervall\nLVEF Links -ventrikul\u00e4re Ejektionsfraktion\nLVI Lymphovaskul\u00e4re Invasion\nMaCa Mammakarzinom\nMAK Mamillen -Areola -Komplex\nmBC metastasierter Brustkrebs\nMBSR Mindfulness -Based Stress Reduction\nMCP Metoclopramid\nMDS Myelodysplastisches Syndrom\nME Mastektomie\nMedDRA Medical Dictionary for Regulatory Activities\nMF Multifokalit\u00e4t\nMG Mammographie\nMMF Mycophenolate mofetil\nMPA Medroxyprogesteronacetat\nMPE Maligner Pleuraerguss\nMRI Magnetresonanztomographie ( magnetic resonance imaging )\nMRM Modifiziert radikale Mastektomie\nMRT/MR Magnetresonanztomographie\nMS Mammasonographie\nMSI Mikrosatelliteninstabilit\u00e4t\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nAbbreviations \u2013IX\nMTX Methotrexat\nMUGA Multigated acquisition\nMZ Multizentrizit\u00e4t\nn.a. nicht verf\u00fcgbar (not available )\nn.r. nicht berichtet (not reported )\nn.s. Nicht signifikant\nNabPac Nab -Paclitaxel\nNACT Neoadjuvante Chemotherapie\nNEPA Netupitant / Palonosetron\nNET Neoadjuvante endokrine Therapie\nNGS Next -Generation -Sequencing\nNK1 Neurokinin -1\nNNT Number needed to treat\nNSAID Nicht -steroidale Antiphlogistika (non -steroidal anti -inflammatory drug)\nNSM Mamillensparende Mastektomie (nipple -sparing mastectomy)\nNST Kein spezieller Typ (no special type)\nNW Nebenwirkung\nNX Vinorelbin , Capecitabin\nOC Ovarialkarzinom\nOFS Ovarialfunktions -Suppression\nOLZ Olanzapin\nOM Orale Mukositis\nONJ Kieferosteonekrose (osteonecrosis of the jaw)\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nAbbreviations \u2013X\nOP Operation\nOPS Onkoplastische brusterhaltende Operation\nOR Odds Ratio\nOS Gesamt\u00fcberleben (overall survival) \nOSNA One Step Nucleic Acid Amplification\nPac Paclitaxel\nPAF Population attributable fractions \nPAI-1 Plasminogen -Aktivator -Inhibitor Typ 1\nPARP Poly -ADP -Ribose -Polymerase\nPARPi PARP -Inhibitor\nPBI Partielle Brustbestrahlung (partial breast irradiation)\nPCO Polycystic Ovarian Syndrome\npCR pathologische Komplettremission\nPD-1 Programmed cell death protein 1\nPD-L1 Programmed cell death 1 ligand 1\nPE Probeentnahme\nPEA Palmitoylethanolamid\nPET-CT Positronen -Emissions -Tomographie -Computertomographie\nPFS Progressionsfreies \u00dcberleben\nPJP Pneumocystis jiroveci -Pneumonie\nPLAC Placebo \nPMMA Polymethylmethacrylat\nPMRT Post -Mastektomie Radiotherapie\nPOI Pr\u00e4mature Ovarialinsuffizienz\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nAbbreviations \u2013XI\nPPE Palmares und plantares Erythem\nPPV Positiver pr\u00e4diktiver Wert\nPR Progesteronrezeptor\nPROM Patient -reported outcome measures\nPT Phylloides -Tumor\nPTV Zielvolumen (Planning Target Volume)\nPVP Povidon\nPw Paclitaxel weekly\nPz Pertuzumab\nQA Quality assurance \nQoL Lebensqualit\u00e4t (quality of life)\nRFA Radiofrequenzablation\nRFID Radiofrequenz -Identifikation\nRFS Rezidivfreies \u00dcberleben\nRR Relatives Risiko\nRRBM Risiko -reduzierende bilaterale Mastektomie  \nRRCM Risikoreduzierende kontralaterale Mastektomie\nRRSO Risiko -reduzierende bilaterale Salpingo -Oophorektomie\nRS Recurrence Score\nRT Radiotherapie\nRT-PCR Reverse -Transkriptase -Polymerase -Kettenreaktion\nSAE Schwerwiegendes unerw\u00fcnschtes Ereignis\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nAbbreviations \u2013XII\nSAPV Spezialisierte ambulante Palliativversorgung \nSCC Plattenepithelkarzinom ( squamous cellcarcinoma ) \nSCG Supraklavikul\u00e4rgrube\nSD Standardabweichung (Standard deviation )\nSGAP Superior gluteal artery perforator ( Lappen )\nSIEA Superficial inferior epigastric artery ( Lappen )\nSIR Standardized incidence ratio\nSIRT Selektive interne Radiotherapie\nSLN Sentinel -Lymphknoten\nSLNE Sentinel -Lymphknoten -Exzision\nSM Synthetische Mammographie\nSNP Single Nucleotide Polymorphism\nSNRI Serotonin -Noradrenalin -Wiederaufnahmehemmer\nSPIO Superparamagnetic Iron Oxide\nSRE Skeletal -related events\nSRS Stereotactic radiosurgery \nSRS- VMAT Stereotactic radiosurgery with volumetric modulated arc therapy\nSSE Symptomatic skeletal events\nSSI Wundinfektion (surgical site infection) \nSSM Hautsparende Mastektomie (Skin sparing mastectomy )\nSSRI Selektive Serotonin -Wiederaufnahmehemmer\nTAD Targeted Axillary Dissection\nTam Tamoxifen\nTB Tuberkulose\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nAbbreviations \u2013XIII\nTBP Treatment beyond progression\nTCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab\nTDLU Terminale duktulolobul\u00e4re Einheit\nTdP Torsade de Pointes\nTENS Transkutane elektrische Nervenstimulation\nTFI Therapiefreies Intervall\nTFT Schilddr\u00fcsenfunktionstest\nTIA Therapie -induzierte Amenorrhoe\nTIL Tumor -infiltrierende Lymphozyten\nTLNE Targeted Lymph Node Excision\nTMG Transverse Musculocutanaeus Gracilis (Lappen )\nTN triple -negativ\nTNBC triple -negatives Mammakarzinom\nTRAM Transverser Rectus abdominus Muskel (Lappen )\nTTR Zeit zum Rezidiv (time to recurrence)\nTxCHP Paclitaxel, Carboplatin, Trastuzumab, Pertuzumab\nTz Trastuzumab\nUCT Unkonventionelle Therapie\nUE Unerw\u00fcnschtes Ereignis\n\u00dcL \u00dcberleben \nuPA Urokinase -Typ Plasminogen Aktivator\nuPCR Urin -Protein:Kreatinin -Ratio\nVAB Vakuumbiopsie (vacuum -assisted breast biopsy)\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nAbbreviations \u2013XIV\nVAB Vakuumbiopsie (vacuum -assisted breast biopsy)\nVATS Videoassistierte Thorakoskopie\nVUS Variante unklarer Signifikanz (variant of unknown significance)\nWBI Ganzbrustbestrahlung ( whole breast irradiation )\nWBRT Ganzhirnradiatio (whole brain radiotherapy )\nZNS Zentrales Nervensystem\nVorspannDiagnosis and Treatment of Patients with early \nand advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1Members ofthe\nAGO Breast Committee\nwww.ago -online.de\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nMembers ofthe\nBreast Committee 1\n\u00d8Prof. Dr. Ute -Susann Albert, W\u00fcrzburg\n\u00d8PD Dr. M. Banys- Paluchowski, Hamburg\n\u00d8Dr. Ingo Bauerfeind, Landshut\n\u00d8Prof. Dr. Jens Uwe Blohmer, Berlin\n\u00d8Prof. Dr. Wilfried Budach, D\u00fcsseldorf\n\u00d8Prof. Dr. Peter Dall, L\u00fcneburg\n\u00d8Prof. Dr. Nina Ditsch, Augsburg\n\u00d8PD Dr. Eva Fallenberg, M\u00fcnchen\n\u00d8Prof. Dr. Peter Fasching, Erlangen\n\u00d8Prof. Dr. Tanja Fehm, D\u00fcsseldorf \n\u00d8Prof. Dr. Michael Friedrich, Krefeld\n\u00d8Prof. Dr. Bernd Gerber, Rostock\u00d8PD Dr. Oleg Gluz, M\u00f6nchengladbach\n\u00d8Prof. Dr. Nadia Harbeck, M\u00fcnchen \n\u00d8Prof. Dr. J\u00f6rg Heil, Heidelberg\n\u00d8Prof. Dr. Jens Huober, St. Gallen/Ulm\n\u00d8Prof. Dr. Christian Jackisch, Offenbach\n\u00d8Prof. Dr. Wolfgang Janni, Ulm\n\u00d8Prof. Dr. Cornelia Kolberg -Liedtke, Berlin\n\u00d8Prof. Dr. Hans H. Kreipe , Hannover (DGP)\n\u00d8Dr. David Krug, Kiel\n\u00d8Prof. Dr. Thorsten K\u00fchn, Esslingen\n\u00d8Prof. Dr. Sherko K\u00fcmmel, Essen\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nMembers ofthe\nBreast Committee 2\n\u00d8Prof. Dr. Sibylle Loibl, Neu -Isenburg / Frankfurt\n\u00d8Prof. Dr. Diana L\u00fcftner, Berlin\n\u00d8Prof. Dr. Michael Lux, Paderborn\n\u00d8Prof. Dr. Nicolai Maass, Kiel\n\u00d8Prof. Dr. Volkmar M\u00fcller, Hamburg\n\u00d8Prof. Dr. Christoph Mundhenke, Bayreuth\n\u00d8Prof. Dr. Ulrike Nitz, M\u00f6nchengladbach\n\u00d8Prof. Dr. T. -W. Park -Simon, Hannover\n\u00d8Prof. Dr. Toralf Reimer, Rostock\n\u00d8PD Dr. Kerstin Rhiem, K\u00f6ln\n\u00d8Prof. Dr. Achim Rody , L\u00fcbeck\u00d8Prof. Dr. Marcus Schmidt, Mainz\n\u00d8Prof. Dr. Andreas Schneeweiss, Heidelberg (AIO)\n\u00d8Prof. Dr. Florian Sch\u00fctz, Speyer\n\u00d8Prof. Dr. H. Peter Sinn, Heidelberg (Pathologie)\n\u00d8Prof. Dr. Christine Solbach, Frankfurt\n\u00d8Prof. Dr. Erich F. Solomayer, Homburg\n\u00d8Prof. Dr. Elmar Stickeler, Aachen\n\u00d8Prof. Dr. Marc Thill, Frankfurt\n\u00d8Prof. Dr. Christoph Thomssen, Halle\n\u00d8Prof. Dr. Michael Untch, Berlin\n\u00d8Prof. Dr. Isabell Witzel, Hamburg\n\u00d8Prof. Dr. Achim W\u00f6ckel, W\u00fcrzburg\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nPrevious Members of\nthe Breast Committee 1\n\u00d8 Prof. Dr. Werner Audretsch , D\u00fcsseldorf\n\u00d8 PD Dr. Joachim Bischoff, Dessau\n\u00d8 Dr. Michael B\u00f6hme, Magdeburg\n\u00d8 Dr. Klaus E. Brunnert , Osnabr\u00fcck\n\u00d8 Prof. Dr. Dr. Serban D. Costa, Magdeburg\n\u00d8 Prof. Dr. Ingo J. Diel, Mannheim\n\u00d8 PD Dr. Nikos Fersis , Duisburg\n\u00d8 PD Dr. Kay Friedrichs, Hamburg\n\u00d8 Prof. Dr. Uwe -Jochen G\u00f6hring , Bonn\n\u00d8 Prof. Dr. Volker Hanf, F\u00fcrth\n\u00d8 Dr. Georg Heinrich, F\u00fcrstenwalde\u00d8 Prof. Dr. Walter Jonat , Kiel (DKH)\n\u00d8 Dr. H. Junkermann, Bremen \n\u00d8 Prof. Dr. Manfred Kaufmann, Frankfurt\n\u00d8 Dr. Bj\u00f6rn Lisboa, Hamburg\n\u00d8 Prof. Dr. Hans- Joachim L\u00fcck, Hannover\n\u00d8 Prof. Dr. Gunter von Minckwitz , Neu -Isenburg / \nD\u00fcsseldorf \n\u00d8 Prof. Dr. Volker M\u00f6bus, Frankfurt\n\u00d8 Prof. Dr. Markus M\u00fcller -Schimpfle , Frankfurt\n\u00d8 PD Dr. Carsten Oberhoff , Essen\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nPrevious Members of\nthe Breast Committee 2\n\u00d8 Dr. Mahdi Rezai, D\u00fcsseldorf\n\u00d8 Prof. Dr. Gerhard Schaller, M\u00fcnchen\n\u00d8 Prof. Dr. Anton Scharl, Amberg\n\u00d8 Prof. Dr. Rita Schmutzler, K\u00f6ln\n\u00d8 Prof. Dr. Ingrid Schreer, Hamburg\n\u00d8 Prof. Dr. H. Seegenschmiedt , Essen\n\u00d8 Prof. Dr. W. Simon, Stuttgart\n\u00d8 Prof. Dr. Rainer Souchon , Berlin\n\u00d8 Prof. Dr. Frederik Wenz, Freiburg\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nPotential Conflict of Interest (COI)\n\u00d8 The members of theediting committee of these guidelines arespecialists in diagnosis , treatment, \nand research in breast cancer . Most of themembers therefore have cooperations with industry . Thus, \npotential conflict of interest cannot beexcluded .\n\u00d8 In order tominimize potential bias within thestatements wefollowed thepre-defined rules:\n\u00d8These guidelines arestrictly based on available evidence from thescientific literature .\n\u00d8The chapters of each edition were prepared byannually alternating teams of authors .\n\u00d8Each statement and thecorrespondent AGO -recommendations were thoroughly discussed\nwithin theentire group and accepted bymajority decisions . \n\u00d8Each member of theediting committee isrequired tosubmit a written declaration of his/her \nconflicts of interests toan elected internal COI committee on an annual basis .\n\u00d8Members who do not submit a COI declaration may not participate in theguideline\npreparation.\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nPotential Conflicts of Interest (COI) 2020 \u2013\n2021\nAllmembers oftheAGO Breast Committee have submitted their COIreport forthepast year.Members\noftheAGO Breast Committee indicated that they have received support (e.g.research funding, lecture\norconsulting honoraria etc.)from thefollowing commercial entities :\nAbbvie ,Amgen ,AstraZeneca ,Bayer, BioNTech ,BMS, Carl Zeiss Meditec ,Celgene ,Chugai ,ClearCut,\nClinsol research ,Clovis, Connectmedia ,Daiichi Sankyo ,Dialogservice GmbH, Eisai ,Endomagnetics ,\nEthikon ,Eusobi ,Exact Sciences ,Genentech, German Breast Group (GBG), GSK/ Tesaro Bio, Gyn-Onko -\nUpdate, I-MED Institute, Immunomedics ,Janssen -Cilag ,Lilly, LIV Pharma, L'Oreal ,Medac ,\nMedconcept ,Medexo ,medpublico ,Merck, Molecular Health, MSD, Mundipharma ,Mylan,\nNanostring, Nektar Pharmaceuticals, Neodynamics ,Novartis, onkowissen .de,PALLEOS, Pantarhei\nBioscience ,Pfizer, pfm medical ,Phaonscientific ,Pharma Mar, Pierre Fabre, Promedicis ,Puma,\nRiemser ,Roche, Samantree ,Sandoz/ Hexal ,Seagen ,Siemens, Sirtex ,Somatex ,SurgVision ,Sysmex ,\nTeva,Theraclion ,Theramex ,vfa,Vifor Pharma, Westdeutsche Studiengruppe (WSG).\nThe Committee didnot consider any ofthereported support torepresent aconflict ofinterest that\nwould preclude participation inAGO Breast Committee discussions orvoting .\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nHow toUse these Slides\n\u00d8 The AGO Breast Committee encourages everyone tousethese slides forhisorher own \ninformation , improvement ofpatient care, medical education, presentations , and publications .\n\u00d8 Forpresentations , theslides should only beused in their original version and layout , e.g. by\nusing a PDF -copy ofeach slide . The AGO -signet (\"logo\") should not be modified orerased . \nExtracting single phrases orparts of theslides may change theguideline content and istherefore\nnot allowed .\n\u00d8 The following citation needs tobeused: \"AGO Breast Committee. Diagnosis and Treatment of\nPatients with Primary and Metastatic Breast Cancer. Recommendations 2021 . www.ago -\nonline.de \"  \n\u00d8 Prior toanyprint media orelectronic publication (except fororal presentations ), the\ncorresponding tables orfigures have tobesubmitted tothechairman of theAGO Breast\nCommittee in order toobtain written permission (currently at direktion.frauenklinik@uniklinik -\nulm.de ). \n\u00d8 A summary of theslides isavailabe aspublication in thejournal \u201eBreast Care\u201c.\n\u00d8 Speaking of patients implicates that female / male / diverse gender isincluded .\nVorspannwww.ago -online.de\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nEditor & Copyright\nKommission \u201eMamma\u201c der \nArbeitsgemeinschaft f\u00fcr gyn\u00e4kologische\nOnkologie\n(AGO)\nwww.ago -online.de\nAddress for\ncorrespondence :          \nEditorial Assistance:Univ. -Prof. Dr. med. Wolfgang Janni\nFrauenklinik, Dpt. Obst&Gyn\nUniversit\u00e4tsklinikum Ulm\nPrittwitzstr. 43 | D -89075 Ulm\nP +49 731 500 58500 | F +49 731 500 58502\ndirektion.frauenklinik@uniklinik -ulm.de\nDr. Kristina ErnstProf. Dr. Volkmar M\u00fcllerUniversit\u00e4tsklinikum Hamburg -Eppendorf\nMartinistr. 52 | 20246 Hamburg\nP +49 40 7410 -52510 | F +49 40 7410 -54355\nv.mueller@uke.de\nVorspann\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1Options for Primary Prevention: \nModifiable Lifestyle Factors\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.dePrevention\n\u00a7Versions 2011 \u20132020:\nDall / Diel / Gerber / Hanf / Maass / Mundhenke / Solbach / Solomayer\n/ Thomssen / von Minckwitz\n\u00a7Version 2021:\nRhiem / Solomayer\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.de\nRisk Factors for Breast Cancer 1 \u00e0background\n\u00a7Older age *\n\u00a7Genetics \n\u00a7Family history of cancer *\n\u00a7Personal history of breast *\nlesions\n\u00a7Non -proliferative lesions\n\u00a7Proliferative lesions w/o atypia\n\u00a7High risk lesions (ADH, LIN)\n\u00a7Breast cancer (DCIS, Inv. BC)\n\u00a7Breast density\n\u00a7Chest irradiation\n\u00a7Type II Diabetes mellitus\n\u00a7Hyperthyreoidism\u00a7Lifetime number of \nmenstrual cycles\n\u00a7Early menarche, late menopause \n\u00a7Maternal pregnancy factors ( e.g.\npre-eclampsia) (risk reduction), and \nlow physical activity during \npregnancy (risk increase)\nSocial risk factors\n\u00a7Lower number of births or \nno pregnancy\n\u00a7Advanced age at first full \nterm delivery\nLegend: *explicitly also for DCIS\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.de\nRisk Factors for Breast Cancer 2 \u00e0background\n\u00a7Short duration or absence \nof breast feeding\n\u00a7BMI < 18.5 and > 25 and \nespecially > 40 (obesity)\n\u00a7Food content\n\u00a7Steroid hormone therapy\n\u00a7Recent oral contraceptive use\n\u00a7Hormone therapy \n(estrogen/ gestagen combination) in \npostmenopausal women\n\u00a7Alcohol intake*\n\u00a7nicotine\u00a7Light exposure at night (night shifts) \ncontradictory\n\u00a7Low physical activity\n\u00a7Endocrine disruptors in fetal and \nearly childhood development\n(e.g. DES, bisphenol -A, DDT)\n\u00a7Effect of carcinogenic substances / \nworking materials\n\u00a7Exposition to ionizing radiation\nLegend: explicitly also for DCIS\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.de\nDeodorant -use and risk\nBreast Cancer and Deodorants/Antiperspirants: a Systematic Review. \nAllam MF1: Cent Eur J Public Health. 2016 Sep;24(3):245 -247. doi: 10.21101/cejph.a4475.\nSo farthere isnoevidence ofa correlation between aluminum containing\ndeodorants and breast cancer risk\n\u00a7All observational studies that evaluated the association between breast \ncancer risk and deodorants/antiperspirants use were reviewed. We have only \nidentified two case- control studies, carried out between 2002 and 2006.\n\u00a7There was no risk of antiperspirants use in the pooled risk (odds ratio 0.40, \n95% confidence interval 0.35 -0.46).\n\u00a7Our comprehensive search has identified an insufficient number of studies to \nconduct a quantitative review and obtain reliable results. Further prospective \nstudies are strongly needed.\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.de\nHigh Proportion of Postmenopausal Breast \nCancer Attributable to Lifestyle Factors\nvan Germert et al., Int J Cancer 2015; 152: 155 -162Update 2019: Tamimi et al, 2016\nUSA: more than a third of \npostmenopausal breast cancers are \npreventable through changes in \nmodifiable risk factors population attributable fractions (PAFs) ofmodifiable riskfactors\nRisk factors: obesity, physical inactivity, alcohol, low -fiber intake, smoking\nResults: retrospective cohort study (Netherlands Cancer Registry)\n2000: subpopulations of obese women, inactive women, alcohol drinkers, smokers etc.\n2010: breast cancer incidence as compared to background incidence in these subgroups\n25.7% of postmenopausal breast cancer cases in the Netherlands \nin 2010 were attributable to lifestyle factors\n8.8% attributed to obesity\n6.6% attributed to alcohol\n5.5% attributed to physical inactivity\n3.2.% attributed to low fiber intake\n4.6% attributed to smoking\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.dePregnancy -Related Factors\nOxford\nPrevention LoE GR\n\u00a7 Any fullterm pregnancy 2b B\n\u00a7 High number ofpregnancies 2b B\n\u00a7 First full term pregnancy before age of 30 years 2b B\n\u00a7 Breast feeding (protective if total breast feeding time exceeds \n1.5\u2013 2 years)3a B\n\u00a7 Lower birth weight of the first born (3000 -3500 vs. > 4500g RR=1,53) 2b B\n\u00a7 Lower duration of pregnancy first born\n(26-31. WOP vs. 40- 41. WOP; HR=2,38, p=0,03)2b B\nNoinfluence\n\u00a7 Polycystic Ovarian Syndrome PCO 3b C\n\u00a7 Assisted reproduction 2b B\n\u00a7 Abortion 2b B\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.deMedical Primary Prevention\nOxford\nLoE GR AGO\n\u00a7ASS ( especially forpostmenopausal women with\nregard toDCIS and ER-positive invasive breast\ncancer )\nSee slide 94d D +/-\n\u00a7Bisphosphonates 2b B +/-\n\u00a7Statins (noeffect ) 2b B -\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.de\nMedical Prevention \nKehm RD et al., Regular useofaspirin and other non- steroidal\nanti-inflammatory drugs and breast cancer risk forwomen at familial or\nGenetic risk: a cohort study , Breast Cancer Res. 2019 Apr. 18;21(1):52\nProspective multinational cohort study , n=5606, healthy women questionaire , \nregular intake ofASS, NSAID, COX2- inhibitors\nRegular ASS -intake : HR 0.61, CI 0.33 -1.14, breast cancer incidence\nRegular COX2 -inhibitors : HR 0.39, CI 0.15 -0.97, breast cancer incidence other\nNSAIDs: n.s.\n[independent ofBRCA -status]\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.dePrevention by Changing Lifestyle Factors: \nBody Mass Index / Diet\nOxford\nLoE GR AGO\n\u00a7Maintaining normal weight \n(BMI at 18.5 \u201325 kg/m\u00b2)*2a B ++\n\u00a7Premenopausal 3a B +/-\n\u00a7Postmenopausal 2a B ++\n\u00a7Prevention/screening and treatment of diabetes mellitus type II \n(reduction of breast cancer incidence and mortality)2b B ++\n* Amount ofbody fatcanbeincreased in people with normal BMI andcorrelates with breast cancer risk\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.de\n\u00a7Meta -analysis, ofatotal of150, 537 patients inthe bariatric surgery arm\nand 1,461, 938 women inthecontrol arm.\n\u00a7The risk ofbreast cancer was reduced by49% [RR:0.39(95%CI [0.31to\n0.56];I2=90%; 7studies) .\n\u00a7The risk ofovarian cancer was reduced by53% [RR:0.47(95%CI [0.27to\n0.81];I\u00b2=0%;3studies) .\n\u00a7The risk ofendometrial cancer was reduced by67% [RR:0.33(95%CI [0.21\nto0.51];I2=88%; 7studies) .The risk of breast, ovarian and endometrial cancer in obese women \nsubmitted to bariatric surgery: a meta-analysis \nBIshihara , DFarah, M Fonseca and A Naz\u00e1rio, Surg Obes Relat Dis2020;16(10):1596 -1602\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.de\nAssociation of Body Fat and Risk of Breast Cancer in Postmenopausal Women \nWith Normal Body Mass Index: A Secondary Analysis of a Randomized Clinical \nTrial and Observational Study.\nIyengar NM et al.: JAMA Oncol . 2019 Feb1;5(2):155 -163\n\u00a7WHI substudy\n\u00a7Among the 3460 women included in the analysis (mean [SD] age, 63.6 [7.6] \nyears), multivariable -adjusted hazard ratios for the risk of invasive breast \ncancer were 1.89 (95% CI, 1.21 -2.95) for the highest quartile of whole -body \nfat and 1.88 (95% CI, 1.18 -2.98) for the highest quartile of trunk fat mass.\n\u00a7The corresponding adjusted hazard ratios for ER -positive breast cancer were \n2.21 (95% CI, 1.23- 3.67) and 1.98 (95% CI, 1.18 -3.31), respectively.\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.dePrevention by Changing \nLifestyle Factors: Diet\nOxford\nLoE GR AGO\n\u00a7Preference of a balanced diet* 2b B +\n\u00a7Mediterranean Diet 2a B +\n\u00a7Dietary components\n\u00a7 Olive oil (extra virgin olive oil), as part of Mediterranean diet 2b B +\n\u00a7 Fat reduced food 2a B +\n\u00a7 Reduced consumption of red meat 2b C +\n\u00a7 Supplementation ofvitamins , minerals , trace elements 2a B -\n\u00a7 Vitamin D substitution forprevention (MaCa HR1,02) 1b B +/-\n\u00a7 Vegetables / fruits**2a B +/-\n\u00a7 Phytoestrogens / soy 2a B +/-\n\u00a7 Fiber containing food 2a B +\n\u00a7 Vegetarian/ vegan diet (no significant risk reduction) 2b C +/-\n\u00a7 Coffee (no significant reduction) 2a B +/-\n\u00a7 nuts /peanuts (> 10g/d) (peanut butter without effect) 2b B +\n*As recommended by German Society of Nutrition (DGE)\n**Recommended as a part of healthy nutrition\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.de\nVitamin D Supplements and Prevention ofCancer and Cardiovascular\nDisease\nN Engl J Med. 2019 Jan 3;380(1):33 -44. doi : 10.1056/NEJMoa1809944. Epub 2018 Nov 10.\nrandomized, placebo -controlled trial, with a two -by-two factorial design, \nofvitamin D 3(cholecalciferol) at a dose of 2000 IU per day and marine n -3 \n(also called omega -3) fatty acids at a dose of 1 g per day\nPrimary end points were invasive cancer of any type and major \ncardiovascular events \n25,871 participants\nmedian follow -up of 5.3 years\n124 breast cancers (Vit D group) vs. 122 ( placebo group) Hazard Ratio: 1,02\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.dePrevention by Modifying \nLifestyle Risk Factors: Alcohol\nOxford\nLoE GR AGO\n\u00a7Reduction of alcohol intace reduces risk of breast \ncancer (ideal <10g/d, class II evidence)2a B +\nParticularly for\n\u00a7ER+/PR+ tumors 2a B\n\u00a7Invasive lobular tumors 2a B\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.de\nNature, Nurture and cancer risks : Genetic and nutritional contributions to\ncancer\nTheodoratou , E.: Annu Rev Nutr . 2017 August 21; 37: 293 \u2013320. \ndoi:10.1146/annurev -nutr -071715- 051004 \nNo association was classified as convincing (class I). The association between \nalcohol intake and ER+ breast cancer was classified as highly suggestive (Class II) \nbased on a meta -analysis of 20 prospective studies (\u2265 30g/d of alcohol \nconsumption versus non -drinkers \nRR (95% CI): 1.35 (1.23, 1.48, p -value=5.2 x 10-10, I2= 26%, \nPsmall effect bias = 0.184, Pexcess significance bias = 4 x 10-8)\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.dePrevention by Modifying \nLifestyle Risk Factors: Smoking\nOxford\nLoE GR AGO\n\u00a7Never smoking reduces risk of breast cancer\n\u223c15\u201324% reduction of lifetime risk)2a B ++\n\u00a7Young women smoking have a 60% increased risk of BC, \nif smoking > 10 years before first childbirth \n(vs. never smokers)\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.de\nSmoking and risk of breast cancer in the Generations Study cohort\nJones, M.E.: Breast Cancer Res. 2017 Nov 22;19(1):118. doi: 10.1186/s13058 -017- 0908- 4.\n102,927 women recruited 2003\u2013 2013\naverage of 7.7 years of follow -up\nThe HR (reference group was never smokers) was \n1.14 (95% CI 1.03\u2013 1.25; P\u2009=\u20090.010) for ever smokers, \n1.24 (95% CI 1.08\u2013 1.43; P\u2009=\u20090.002) for starting smoking at ages\u2009<\u200917 years\n1.23 (1.07 \u20131.41; P\u2009=\u20090.004) for starting smoking 1 \u20134 years after menarche\nWomen with a family history of breast cancer (ever vs never smokers HR 1.35; 95% CI 1.12\u2013 1.62; P\u2009=\u20090.002) had a significantly larger HR \u2026 than women without \n(ever smoker vs never smoker HR 1.07; 95% CI 0.96 \u20131.20; P\u2009=\u20090.22).\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.dePrevention by Modifying \nLifestyle Risk Factors: Physical Activity \nOxford\nLoE GR AGO\n\u00a7Physical exercise 2a(-) B ++\n(Metabolic equivalents to 3 \u20135 hrs \nmoderate pace walking per week)\nThese effects also apply to BRCA1/2 mutation carriers and to women \nwith an increased family risk.\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.de\n\u00a7Prospective cohort study \n\u00a7N=15550, women with  fam. Hx of breast cancer \n\u00a7multiplicative interactions of physical activity with predicted absolute \nbreast cancer familial risk based on pedigree data and with BRCA1 and \nBRCA2 mutation status\n\u00a7Higher physical activity => 20% reduction of breast cancer incidence\n\u00a7(HR0.80, CI 0.68 -0.93), independent of BRCA -status or pedigree riskRecreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult \nWomen at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and \nGenetic Risk. \nKehm RD et al.: Cancer Res. 2020 Jan 1;80(1):116 -125. doi: 10.1158/0008 -5472.CAN -19-1847. Epub 2019 Oct 2.\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.dePrevention by Modifying Lifestyle Risk Factors:\nHormone Therapy in Postmenopausal Women\nOxford\nLoE GR AGO\n\u00a7Avoiding hormonal therapy in \npostmenopausal women\n\u00a7 Avoiding estrogen / progestin combinations 1b A +\n\u00a7 Avoiding estrogens only\n(no increased, possibly even reduced breast cancer risk, but \nincreased risk for endometrial cancer, unless after \nhysterectomy)1b A +/-\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.de\nEpigenome -wide association study for lifetime estrogen exposure \nidentifies an epigenetic signature associated with breast cancer risk. \nJohansson A et al.: Clin Epigenetics. 2019 Apr 30;11(1):66.\nepidemiological data from EPIC -Italy (n\u2009=\u200931,864)\nStudy:  estimated lifetime estrogen exposure\nMethod : epigenome -wide association study , blood DNA samples, N=216 , \nand 440 healthy controls\nResults : an estimated 5% increase in breast cancer risk per 1 -year longer ELEE \n(OR\u2009=\u20091.05, 95% CI 1.04 -1.07, P =\u20093x10-12) in EPIC -Italy.\n694 CpG sites were associated with ELEE (FDR Q <\u20090.05)\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.de\nN MC-RR (95%CI) Further information\nWHI \nWHI: JAMA 2002,\nJAMA 2017\u223c27 000 1.3  \n(1,0- 1,6)1.3 (1.1 -1,6) coronary events \n1.4 (1,1 -1,9) insults \n2.1 (1,4 -3,3) pulmonary embolism\n2.1 (1,5 -2,9) deep vein thrombosis\nHERS\nHulley S: JAMA 2002 I 2763\nRCT, med. 4.1 J\nII 2321\nopen -label, 2.7J1.2\n(0.95 -1.5) med. age 67 J\nno secondary prevention\nside effects as comp. to WHI + cholcystectomy \u00e4\nMillion\nWomen \nBeral V: Lancet 20031.084 110\n\u223c50% HRT \n4.1 J. follow -up1.66 \n(1.6- 1.8)EPC > E\nmode of applic. not relevant\nduration > 5 yrs.Tibolon RR 1.45 (1.2 -1.7) \nEPIC\nInt J Cancer 2010 1.153 747 \nperson -years 1.4 (1.2- 1.6)\n1.8 (1.4- 2.2)E-Mono\nEPC > E\nMetaanalyse\nNelson HD: JAMA 200216 Studies 1.21 -1.40side effects as compared to WHI +Prevention of Hormones \nin Postmenopausal Patients\nChlebowski et al., Climacteric 2015, 18:336-8\nChlebowski et al., J Natl Compr Canc Netw 2015, 13:917-24\nManson JE et al., JAMA 2017; 318: 927 -938\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.de\nPrevention of Hormones (EGC) \nin Postmenopausal Patients \nN MC-RR (95% CI) Further statements\nCLEAR -study (NSW)\nCase -Control -Study,\nretrospect.\nAustralia1236 BC \ncases2.09  \n(1,57 -2.78)current user\n1.03\n(0.82 -1.28)past user\n2.62\n(1.56 -4.38)E/P combination\n1.80\n(1.21 -2.68)E only\nSalagame et al., Int J Cancer. 2016;138(8):1905 -14 \nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1\nwww.ago- online.dePrevention by Modifying \nLifestyle Risk Factors: Oral Contraception (OC)\nOxford\nLoE\n\u00a7OC does notincrease the risk of mortality \nfrom breast cancer1a\n\u00a7Risk of breast cancer slightly increased, \nrisk of ovarian or endometrial cancer is decreased1a(-)\nOptions for Primary Prevention: Modifiable Lifestyle Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 202.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1EBreast Cancer Risk \nand Prevention\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBreast Cancer Risk and Prevention\n\u00a7Versions 2003 \u20132020: \nSchmutzler mitAlbert / Bischoff / Blohmer / Ditsch /  Fasching / Fehm / \nKiechle / Maass / M\u00fcller -Schimpfle / Mundhenke / Rhiem / Rody / \nSchmidt / Schmutzler / Stickeler / Thomssen\n\u00a7Version 2021:\nPark -Simon / Witzel\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePrinciples of Prevention\n\u00a7Women at increased risk for breast cancer are not considered \npatients but healthy women or counselees\n\u00a7A comprehensive informed consent taking into consideration\nall potential side effects and risks is warranted prior to offering \npreventive measures\n\u00a7Highest priority: \u201eFirst, do no harm!\u201c \n(Primum nil nocere)\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deIndication for Genetic Testing of BRCA1/2 Genes\nand Possibly Further Risk Genes? \n(Part 1 of 2 \u2013testing according to family history)\nFamilies with (each from one family branch)*\n\u00a7at least three women with breast cancer independent of age or\n\u00a7at least two women with breast cancer, one < 50 yrs. (before the 51stbirthday) or\n\u00a7at least one woman affected by breast and one by ovarian cancer or\n\u00a7at least one woman affected by breast and ovarian cancer or\n\u00a7at least two women affected by ovarian cancer or\n\u00a7at least one woman affected by bilateral breast cancer, first before the 51stbirthday\n\u00a7at least one woman affected by breast cancer < 35 yrs. (before the 36thbirthday) or\n\u00a7at least one man affected by breast cancer and one additional relative affected by \nbreast or ovarian cancerOxford LoE: 2b      GR: B      AGO: ++\n*Inclusion criteria of the German Consortium of Hereditary Breast and Ovarian Cancer (GCHBOC) \nbased on a BRCA1/2 mutation prevalence \u2265 10% tested in 21,401 families. All mutation carriers should be registered in \nscientific databases, to validate the inclusion and exclusion criteria (including population -based studies). \nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deIndication for Genetic Testing of BRCA1/2 Genes\nand Possibly Further Risk Genes? \n(Part 2 of 2 -testing according to disease)\n\u00a7Other recommended criteria:\n\u00a7own disease of triple negative breast cancer \u2264 60 yrs. of age\n\u00a7own disease of ovarian cancer\n\u00a7if therapeutically relevant (e.g. PARPi )Oxford LoE: 2b      GR: B      AGO: ++\n*Inclusion criteria of the German Consortium of Hereditary Breast and Ovarian Cancer (GCHBOC) \nbased on a BRCA1/2 mutation prevalence \u2265 10% tested in 21,401 families.  All mutation carriers should be \nregistered in scientific databases, to validate the inclusion and exclusion criteria (including population -based \nstudies). \nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nChecklist according to Public Health \nInsurance Policies (German GKV)\nonline tool provided by the GC -HBOC , V2_05.08.2020\nhttps:// familiaerer -brust -und-eierstockkrebs.uk -koeln.de /informationen /downloads /\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nState of research: Relevance of genetic and \nnon- genetic risk factors\nallele frequency (genetic variants)disease riskmoderately penetrant risk genes \n(e.g. CHEK2, BARD1, ATM, RAD51C, RAD51D)\nlow risk variants / modifiers \n(>300)high risk genes (e.g. BRCA1, BRCA2, PALB2)\nlowhigh\nVery \nrarecommon\nBRCA1/2\nMod. penetrant risk genes\nOther genes/genet. risk factors\nLow risk variants/modifiers\nSingle genes\ngeneticnon-genetic\nreduced penetrance\nmultifactorial\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deGenes with Moderate to High Lifetime Risk for \nBreast Cancer\n* Efficacy of preventive strategies.\n\u00b0Participation in prospective registries orstudies ishighly recommended .Oxford\nLoE GR AGO\nCumulative risk for breast cancer \n\u00a7high: BRCA1, BRCA2, PALB2 1b A ++\n\u00a7moderate: ATM, CHEK2, BARD1, RAD51C, RAD51D 1b B +\nClinical benefit* of a genetic test\n\u00a7BRCA1, BRCA2 1b A ++\u00b0\n\u00a7PALB2 3a B +\u00b0\n\u00a7ATM, BARD1, CHEK2, RAD51C, RAD51D 3a B +/-\u00b0\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nEstimated Cumulative Risk ofBreast Cancer \nwith Protein -Truncating Variants in 8 Genes\nShown arecumulative risks ofbreast cancer through 80 years ofageforprotein-truncating variants in 8 genes that had significant\nevidence ofan association with breast cancer overall , on thebasis ofestimated odds ratios from population-based studies . Baseline \nabsolute risks were derived from population incidences in theUnited Kingdom in 2016. The I bars indicate 95% confidence intervals . \nDorling L, Carvalho S, Allen J et al. Breast -Cancer Risk Genes \u2014Association Analysis in More than 113,000 Women. January 20, 2021 DOI: 10.1056/NEJMoa1913948\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deCurrent Clinical Impact of Further Risk Genes\n\u00a7Further moderate and low -risk gene variants are most likely transmitted by an oligo -or \npolygenic trait.\n\u00a7The penetrance of such genes depends on the own and family cancer history.\n\u00a7Single low -risk variants confer only small risk elevations and also seem to be associated with \nspecific tumor subtypes. Potential multiplicative effects that may be relevant for risk \nstratification and provision of clinical prevention strategies remain to be elucidated. \nTherefore, analysis of multiple gene regions may be of clinical relevance in the future. \n\u00a7* Therefore,  genetic testing of moderate and low -risk genes and variants should only be \nperformed within large prospective cohort studies like the German Consortium for \nHereditary Breast and Ovarian Cancer (GC- HBOC).\nOxford\nLoE GR AGO\n\u00a7Clinical genetic testing of moderate -risk genes, \ne.g. gene panels1b B +\n\u00a7Clinical genetic testing for low -risk variants (polygenic risk score) 2b B +/-*\n\u00a7Referral to centers of the GC -HBOC or cooperating centers 5 D +\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nNon BRCA -associated Hereditary Cancer \nSyndromes with Increased Risk for Breast Cancer \nSyndrome Gene Risk for malignancy \nLi Fraumeni TP53 Breast, endometrium, colorectal, small intestine, stomach, hepato biliary, \nskin, osteosarcoma, soft tissue sarcoma, urogenital, CNS, ACC, leukemia, \nlymphoma, lung\nCowden PTEN breast, endometrium, thyroid, colorectal, kidney, melanoma\nHereditary diffuse gastric cancer \nsyndromeCDH1 Hereditary diffuse gastric cancer, lobular invasive breast cancer\nPeutz -Jeghers Syndrome STK11/ LKB1 Colorectal, small intestine, stomach, pancreas, testicle, endometrium\nLynch MLH1, MSH2, MSH6, \nPMS2, EPCAMEndometrium, ovary, colorectal, small intestine, stomach, hepato biliary, \npancreas, kidney, urogenital, CNS\nAtaxia telangiectasia \n(AT-Syndrome)ATM breast cancer, leukemia, stomach, melanoma, sarcoma\nFranconi An\u00e4mie BRCA2, BRIP1, RAD51C, \nPALB2AML, MDS, SCC, medulloblastoma , nephroblastoma , breast , pancreas , ovary\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nCurrent version of the TruRisk\u00aeBC/OC* Gene Panel \nby the German Consortium (GC-HBOC )\nSelection of genes: 11 BC/OC \u2018core genes\u2019 (Data on risk increase)\n7 other syndrome -associated genes (Lynch, Cowden, Peutz -Jeghers) with suspected \nBC/OC association\n16   BC/OC candidate genes from scientific projects (validation in the GC -HBOC)\nStrategy: Validation in prospective cohort, continuous expansion and improvement\n*BC=breast cancer, oc=ovarian cancer\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nDistinct genetic subtypes of breast cancer may show distinct clinical features. \nPrior to the offer risk reducing clinical procedures the following facts and data \nshould be addressed:\n\u00a7Age related disease penetrance?\n\u00a7Typical histopathological features? \n\u00a7Sensitivity to current screening modalities?\n\u00a7Better survival of early detected tumors?\n\u00a7Natural disease course?\n\u00a7Response to anti -tumor therapy?Distinct Genetically Subtypes \nDefines Distinct Tumor Entities\nGenotype -phenotype -correlations must be known before performing \npreventive clinical measures\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7\u201eA Variant of Unknown Significance (VUS IARC class 3) is a genetic variant \nwith unknown clinical relevance.\u201c  (Plon et al. Hum Mutat 2008)\n\u00a7Most VUS are extremely rare (\u22643 variants in >80% of families)\n\u00a7Classification of sequence variants should be performed according to the IARC classification system\n\u00a7Frequency of VUS (IARC class 3) increases with numbers of tested genes\n\u00a7Clinical interpretation and decision making depending on the IARC \nclassification system is not standardized yet\n\u00a7In silico prediction tools (PolyPhen2, SIFT) are not adequate or sufficient \nfor clinical decision making\n\u00a7Additional analyses are required, e.g. in vitro splicing assay, functional \nassay, segregation analysis, co -occurence analysis, large case / control \nstudiesVUS: Problems and Questions\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deVariant classification proposed by IARC\n(Plon et al., Human Mutation, 2008)\nProposed Classification System for Sequence \nVariants Identified by Genetic Testing\nClass Discription Probabilty of being \npathogenic\n5 Definitly pathogenic > 0,99\n4 Likely pathogenic 0,95 \u20130,99\n3 Uncertain 0,05 \u20130,949\n2 Likely not pathogenic or of little clinical \nsignificance0,001 \u20130,049\n1 Not pathogenic orofnoclinical\nsignificance< 0,001\nOnly class 4 and 5 variants areconsidered clinically relevant.\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nRequires additional information and analyses, e.g.\n\u00a7Co-occurence data from large data banks\n\u00a7Segregation analysis\n\u00a7Functional analysis etc. \n\u00a7Data should be pooled in large study groups (e.g. ENIGMA)Classification of IARC Class 3 Variants\n*Most class 3 variants can be downgraded to clinically irrelevant classes 1 or 2 by these analyses. \nFew are upgraded to the clinically relevant classes 4 or 5. Any re -evaluation of the IARC class should \nbe communicated to the tested persons (see for example the concept of supervision in centres of \nthe German Consortium/GC- HBOC).\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7The risk collective is clearly defined by risk criteria.\n\u00a7The positive predictive value of risk critiera with respect to the \nidentification of the genetic risk factor is known.\n\u00a7The cut -off values for genetic testing evolved through a transparent \nconsensus process. \n\u00a7The genetic test is valide and reliable.\n\u00a7A spectrum bias is excluded or defined.\n\u00a7A clinical prevention strategy exists that leads to early detection or prevention and mortality reduction of the genetically defined subset of \nthe disease.Requirements for the Introduction of New \nDiagnostic or Predictive Genetic Testing*\n*Acc. to the position paper on risk -adjusted early detection of cancer of the German National Cancer Plan \ndeveloped under the Federal Ministry of Health, e.g. \"Pr\u00e4ventive Gendiagnostik -Hoffnung und Fluch der \nGenanalyse\", Heft 26 des Deutschen \u00c4rzteblattes vom 29.06.2012; Dtsch. \u00c4rztebl. 2012; 109(26): A -1371 / B -\n1183 / C -1163)\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deNon -Directive Counseling regarding Preventive \nMeasures\n\u00a7According to the Genetic Diagnostic Law\n\u00a7According to the Medical Devices Act, \ne.g. risk assessment  requires  professional training  and expertise\n\u00a7Application of software for risk calculation requires professional training \nand experience\n\u00a7Communicate absolute risks within a manageable timeframe\n\u00a7Communicate risk and benefit of a multimodal intensive surveillance \nprogram \n\u00a7Communicate risk and benefit of preventive clinical methods \n\u00a7Communicate competing risks, e.g. risk of disease progression in relation to \nrisk of a secondary primary in women already affected by primary breast \ncancer\n\u00a7Allow appropriate time for considerationOxford\nLoE GR AGO\n5 D ++\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMultimodal Intensive Surveillance Program*\nOxford\nLoE GR AGO\n\u00a7Program f\u00fcr BRCA -Carriers\n\u00a7For the detection of early stage cancers 2b B ++\n\u00a7Clinical breast exam > = 25 Jahre Semi -annually\n\u00a7Sonography > = 25 Jahre Semi -annually\n\u00a7Mammogram > = 40 Jahre Bi-annually\n\u00a7Breast MRI > = 25 Jahre Annually\n\u00a7For improvement of metastasis -free interval 2b B +\n\u00a7Survivors after tumors in childhood and radiotherapy of \nthoracic wall ( e.g. M. Hodgkin)2a B ++\n*The multimodal intensified early detection program should be carried out within the framework of transparent \nquality assurance and appropriate evaluation.\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nHigh -risk breast cancer surveillance with MRI\nBick U, Engel C, Krug B, et al. High -risk breast cancer surveillance with MRI: 10 -year experience from the German consortium for hereditary breast and \novarian cancer. Breast Cancer Res Treat . 2019;175(1):217 \u2013228. doi:10.1007/s10549 -019- 05152- 930-39 years 40-49 years >50 years\nDetection \nrate (\u2030)PPV (%) Detection \nrate (\u2030)PPV (%) Detection \nrate (\u2030)PPV (%)\nBRCA1 43.2 29.4 21.8 25.5 30.5 33.3\nBRCA2 22.7 23.3 24.3 27.5 16.3 23.5\nBRCA1/2 -non \ncarriers with\nhigh risk2.9 2.8 7.4 6.8 10.9 13.8\nDetection performance ofannual multimodality screening rounds with MRI byrisk group and agePPV: Positive predictive value\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSurveillance Program for Female Carriers of Pathogenic BRCA \nMutations after Primary Breast Cancer acc. to GC -HBOC *\nOxford\nLoE GR AGO\n\u00a7Multimodal intensive lifelong surveillance program\n\u00a7For detection of early stage breast cancers 2a B ++\n\u00a7Clinical breast exam > = 25 Jahre Semi -annually\n\u00a7Sonography > = 25 Jahre Semi -annually\n\u00a7Mammogram > = 40 Jahre Biannually\n\u00a7Breast MRI (until ACR1) > = 25 Jahre Annually\n\u00a7For mortality reduction (10- year survival) 3a C +/-*\n*Follow -up care should be carried out as part of transparent quality assurance and appropriate evaluation.\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSurveillance for male carriers of pathogenic \nBRCA Mutations*\nBRCA1 mutation carriers have a risk of breast cancer corresponding to the \ngeneral population (about 1%) and an up to 1.8 to 3.75 times higher risk for \nprostatic cancer </= 65y.\nBRCA 2 mutation carriers have an up to 5 \u20137% lifetime risk for breast cancer and \nan up to 2.5 to 8.6 times higher risk for prostatic cancer </= 65y.\n* Follow -up care /surveillance should be carried out as part of transparent quality assurance and \nappropriate evaluation.Oxford\nLoE GR AGO\nCurrently ,no specific surveillance is recommended\n\u00a7For breast cancer: \nself examination and watchful waiting5 D +\n\u00a7For prostate cancer:Compare German Guideline program5 D +\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nRationale: \n\u00a7Increased risk of breast cancer after chest irradiation because \nof Hodgkin lymphoma in childhood (9 \u201318 years)\n\u00a7Increased risk of breast or ovarian cancer in women from BRCA1/2 negative families at risk that is, however, lower than in women from \nBRCA1/2 positive families\n\u00a7Referral to centres of the GC -HBOC or cooperating centres for the \nevaluation of structured surveillance and follow -upModified Surveillance Program for \nBRCA -neg. Women at Moderate to High Risk \nor Survivors of Hodgkin Disease\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSurgical Prevention\nOxford\nLoE GR AGO\n\u00a7A secondary risk -reducing unilateral or bilateral \nmastectomy is not indicated without the presence \nof clearly defined genetic risk factors because it \ndoes not lead to a reduction in mortality.2a B +*\n*study participation recommended\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSurgical Prevention for Healthy\nFemale BRCA1/2 Mutation Carriers\nOxford\nLoE GR AGO\n\u00a7Risk- reducing bilateral salpingo- oophorectomy \n(RR-BSO)**2a B *\n\u00a7Reduces OvCa incidence and mortality ++*\n\u00a7Reduces overall mortality ++*\n\u00a7Risk- reducing bilateral mastectomy (RR-BM)\n\u00a7Reduces BC incidence 2b B +*\n\u00a7Reduces BC mortality in BRCA1 mutation carriers*** 2b B +*\n*      study participation recommended\n**    RR-BSO is recommended from about 35 years for BRCA1 and from about 40 years for BRCA2 mutation \ncarriers, taking into account the age of ovarian cancer diagnosis in the family and the family planning status.\n***   No reduction in mortality could be shown for BRCA2 mutation carriers. RRM counselling should be individualised .\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deRisk-reducing Interventions for BRCA1/2 Female \nMutation Carriers Affected by Breast Cancer\nOxford\nLoE GR AGO\n\u00a7Risk-reducing bilateral salpingo -oophorectomy \n(RR-BSO)2b B +*\n\u00a7 Reduces OvCa incidence and mortality\n\u00a7 Reduces overall mortality\n(contradictory results regarding reduction ofcontralateral BC incidence )\n\u00a7Prophylactic contralateral mastectomy (RR -CM)* 2b B +*\n\u00a7 Reduces BC incidence and mortality\n\u00a7Tamoxifen ( reduces contralateral BC incidence ) 2b B +/-*\n\u00a7Indication forRR-CM should consider ageat onset offirst breast\ncancer in affected gene2a B ++*\n\u00a7RR-BM after ovarian cancer 4 C +/-**\n*study participation recommended\n** Depends on tumor stage (FIGO I/II ), recurrence free interval (\u2265 5y), age\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nImproved Overall Survival After Contralateral \nRisk-reducing Mastectomy in BRCA1/2 Mutation Carriers with \na history of unilateral breast cancer: a prospective analysis.  \nAnalysisa Group Person years of \nobservationDeaths Mortalityb(95% CI) HR (95% CI)\n(a) Surveillance 3007 65 21.6 (16.9 -27.6) Ref\nCRRM 1975 19 9.6 (6.1 -15.1) 0.43 (0.26 -0.72)c\n0.49 (0.29 -0.82)d\n(b) Surveillance 2673 56 21.0 (16.1 -27.2) Ref.\nCRRM 1837 18 9.8 (6.2 -15.5) 0.46 (0.27 -0.79)c\n0.55 (0.32 -0.95)d\naAnalysis (a) is the main analysis with start of observation being either the date of primary breast cancer (PBC) diagnosis or the date of DNA diagnosis, whichever \ncame first. In the additional analysis (b), the observation starts either 2 years after PBC or at the date of DNA diagnosis, whichever came first, to exclude patients who \npresented with distant metastases or died within 2 years after PBC diagnosis ( n\u2009=\u200917). \nbPer 1000 person years of observation. \ncUnivariate analysis. \ndMultivariate analysis, adjusted for risk -reducing salpingo -oophorectomy. The following variables did not meet the criteria for incorporation in the multivariate Cox model \nas described in the Methods section, and were therefore not included in the multivariate analysis: type of mutation, year of birth, age at DNA diagnosis, age at PBC \ndiagnosis, T -status, presence of positive lymph nodes, differentiation grade, hormone receptor status, HER2 status and treatments administ ered for PBC. \nAbbreviations: CRRM, contralateral risk -reducing mastectomy; HR, Hazard ratio; CI, confidence interval. \nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deTherapy of Germline mutation- associated \nBreast Cancer\nOxford\nLimited prospective cohort studies with \nshort follow -up timeLoE GR AGO\n\u00a7Breast con serving surgery: adequate local tumor control \n(~10 years observation)2a B +\n\u00a7Systemic therapy according to sporadic breast cancer 3a B +\n\u00a7gBRCA mutation status is predictive for chemotherapy \nresponse in TNBC2b B +\n\u00a7Carboplatin (vs. Docetaxel) in metastatic breast cancer 2b B +\n\u00a7PARP inhibitor in metastatic breast cancer\n\u2022BRCA1/2 1b B +\n\u2022PALB2 2b B +/-\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMedical Prevention for \nWomen at Increased Risk\nOxford\nLoE GR AGO\n\u00a7Tamoxifen for women >35 years: reduction of \ninvasive BC, DCIS, and LN1a A +*\n\u00a7Raloxifen for postmenopausal women: reduction  of invasive BC only1b A +*\n\u00a7AI for postmenopausal women 1b A +#\n#Significant risk reduction was seen for anastrozole regarding ovarian and endometrial cancer, \nas well as skin, colorectal, hematologic, thyroid and urinary tract cancers. Chemopreventive\nregimes should only be offered after individual and comprehensive counseling. The net benefit \nstrongly depends on risk status, age and pre -existing risk factors for side effects.\n*Risk situation asdefined in NSABP P1- trial (1.66% in 5 years ) oraccording to#Tyrer -Cuzick model (IBIS -II)\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deRisk Reduction for Ipsi -and \nContralateral Breast Cancer \nOxford\nLoE GR AGO\n\u00a7Tamoxifen* 1a A +\n\u00a7Aromatase inhibitors * 1a A +\n\u00a7Suppression of ovarian function* + Tamoxifen 1b B +\n*Only proven for ER/PR -positive primary sporadic BCRationale: Women with breast cancer have an\nincreased risk for a second primary\nBreast Cancer Risk and Prevention\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deCooperation of Certified Breast Cancer (BC) \nCentres (Ctr) with Familial BC Ctr of the GC -HBOC*\n*trans- sectoral contract for integrated care, acc. to code of social law \u00a7140a since 2015Certified\nBC CenterFamilial\nBC CenterCommunication, \nExchange, Advice\nProphylactic surgery\nStratified therapyGenetic testingCheck list (inclusion criteria)\nCounseling for diagnostic genetic testing\nCounseling: Indication for surveillance \nand/or prophylatic surgery\nBreast Cancer Risk and PreventionDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1EEarly Detection and Diagnosis\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deEarly Detection and Diagnosis\n\u00a7Versions 2005 \u20132019:\nAlbert / Blohmer / Fallenberg / Fersis / Junkermann / \nMaass / M\u00fcller- Schimpfle / Scharl / Schreer\n\u00a7Version 2021\nFallenberg / Gerber\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deEarly Detection with Mammography\nOxford\nAge Interval LOE GR AGO\n< 40 na - - --\n40-44 na 1b B -\n45\u201349 24-36 1a B +#\n50\u201369* 24 1a A ++\n70\u201374 24 1a A +#\n> 75** 24 4 C +/-#\n*National Mammography -Screening -Program\n**health status + life expectancy more than 10 years\n# clear indication necessary\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deEarly Detection in Asymptomatic Women\nDigital Breast Tomosynthesis\nThe complete DBT dataset ofimages hastobeavailable forevaluation /reporting , the synthetic\nmammography only isnot sufficient . \n\u2022Sign. higher sensitivity , heterogeneous specificity , and higher costs [machine , evaluation , archiving ] \nofDBT in comparison toFull-Field Digital Mammography (FFDM) \n\u2022Dose reduction due to calculated synthetic 2D mammography (SM) instead ofFFDM\n** Evaluation forGermany in a randomized prospective trial (TOSYMA)Oxford\nLOE GR AGO\nDigital Breast Tomosynthesis (DBT in \naddition toFFDM orSM)*1a B +\nReplacing FFDM by synthetic MG in addition toDBT** 2a B ++\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deMeta -Analysis RR 95%CI\nIndependent UK Panel, 2012\n13-year metaanalysis 0.80 (0.73\u2013 0.89)\nCochrane Review, 2011\nFixed -effect metaanalysis of 9 RCT -trials 0.81 (0.74\u2013 0.87)\nAs above, but excluding women <50 years 0.77 (0.69\u2013 0.86)\nCanadian Task Force, 2011\nWomen aged 50 \u201369 years 0.79 (0.68\u2013 0.90)\nDuffy et al, 2012\nReview of all trials and age groups 0.79 (0.73\u2013 0.86)\nDuffy et al, 2020\nReview of549,091 Women (30% eligible Swedish screening population)0.59 (0.51- 0.68) mortality\n0.75 (0.66- 0.84) advanced BCBreast Cancer Mortality Reduction\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deMeta -Analysis RR 95%CI\nCase -Control Studies\nBroeders et al Screening Mx\nCorr. for  self selectionInvited for screening0.46  (0.4 \u20130.54)\n0.52  (0.42 \u20130.65)\n0.69  (0.57 \u20130.83)\nIncidence -based Mortality Studies\nBroeders et al Screening Mx\nInvited to screening0.62   (0.56 \u20130.69)\n0.75   (0.69 \u20130.81)\nRandomized Clinical Trials\nGotsche and Jorgenson Screening Mx 0.81   (0.74 \u20130.87)\nECIBC Screening MX\n45\u201349 0.88 (0.76 -1.02)\n50\u201369\n0.77 (0.66 -0.90)\n70\u201375 0.77 (0.54 -1.09)Breast Cancer Mortality Reduction\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.de\u00a7Annual incidence of breast cancer and mortality in theEU (GLOBOCAN \n2012)Breastcancer: incidence and mortality\nFrom: http:// gco.iarc.fr /Age Incidence/1000 Mortality/1000\n40 to44 1,2 0,1\n45 to49 1,7 0,2\n50 to69 2,7 0,5\n70 to74 3,0 0,8\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deMammography -Screening \nBenefit and Harm\nSiuAl  on behalf oftheUSPSTF 2016, 164:279 \u2013296Age 40-49 50-59 60-69 70-74\nBreast cancer death avoided (CI95%) 3 (0-9) 8 (2-17) 21 (11 -32) 13 (0 -32)\nFalse -positive  (n) 1212 932 808 696\nBreast biopsies (n) 164 159 165 175\nFalse -negative ( n) 10 11 12 13Data background : Breast Cancer Surveillance Consortium Registry Data\nper 10.000 Women screened over 10 years\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deEarly Detection (normal risk) Sonography /MRI\nOxford\nLoE GR AGO\n\u00a7Screening -Breast Sonography allone 5 D --\n\u00a7Automated 3D-Sonography 3a C --\n\u00a7Breast sonography asan adjunct :\n\u00a7Dense mammogram\n(heterogeneously dense , extremely dense )2a B ++\n\u00a7Elevated risk 1b C ++\n\u00a7Mammographic lesion 2b B ++\n\u00a7Second- look US (MRI -only detected lesions) 2b C ++\n\u00a7MRI ifscreening MG isnegative and breast\ncomposition : extremely dense* 50 \u201375 y1b B +\n* Definition ofextremely dense corresponds toBIRADS -density category D,  heterogeneously dense toBIRADS -category C \naccording toACR BI -RADS -Atlas  5th ed. 2013\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deEarly Detection (normal risk)\nClinical Breast Examination (CBE)\nOxford\nLoE GR AGO\nAs a stand -alone procedure\n\u00a7Self-examination 1a A -*\n\u00a7Clinical breast examination (CBE) by health \nprofessionals outside  checkup for cancer 1a C -*\n\u00a7Clinical breast examination (CBE) by health professionals during checkup for cancer 1a B ++\n\u00a7Medical palpation thru blind/ optically disabled\npersons3b C -\nCBE because of mammographic/sonographic lesion 5 D ++\nCBE in combination with imaging 1a A ++\n*May increase breast awareness\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deAssessment of Breast Symptoms or Lesions\nOxford\nLoE GR AGO\n\u00a7Clinical examination 3b B ++\n\u00a7Mammography 1b A ++\n\u00a7Tomosynthesis*** 2b B +\n\u00a7Contrast -enhanced mammography (alone or as an \nadjunct)2a B +\n\u00a7Sonography 2b B ++\n\u00a7Elastography (shear -wave ) * 2b B +\n\u00a7Automated 3D-sonography 3b B +/-\n\u00a7Minimally invasive biopsy 1b A ++\n\u00a7MRI** 3a B +\n*Adjunct assessment\n**If clinical examination, mammography and sonography incl. needle biopsy do not allow a definite diagnosis\n*** replacement of FFDM with SM\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.dePre-therapeutic Assessment \nof Breast and Axilla\nOxford\nLoE GR AGO\n\u00a7Clinical examination 5 D ++\n\u00a7Mammography 2b B ++\n\u00a7 + Tomosynthesis (DBT)*** 2b B +\n\u00a7 Contrast -enhanced mammography (alone or as adjunct) 2a B +\n\u00a7Sonography (breast and axilla ) 2b B ++\n\u00a7MRI* 1b B +\n\u00a7Minimally invasive biopsy ** 1b A ++\n\u00a7Axilla CNB, if lymph node issuspect 2b B ++\n\u00a7Breast -CT 5 D -\n* MRI -guided vacuum biopsy is mandatory in case of MRI -detected additional lesions (in house or with cooperations ). \nIndividual decision for patients at high familiar risk, with dense breast (density C/D), lobular invasive tumors, suspicion o f  \nmultilocular disease. No reduction in re -excision rate. \n** Histopathology of additional lesions if relevant for treatment\n*** replacement of FFDM with SM\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deSensitivities CESM\n* Recall from Screening CESM is comparable to MRI regarding index, a bit inferior for additional lesions Author n MG CESM MRI US Analyse\nDromain 2011 110 78 92 Per patient\nFallenberg 2014 118 77.9 94.7 Per patient\nMokhtar 2014 60 93.2 97.7 Per patient\nLobbes 2014* 113 96.9 100 Per patient\nPerez 2015 ECR 98 78 66 Per lesion\nLuczinska 2014 152 91 100\nJochelson 2012 52 81\n5996839693Per patientPer lesion\nFallenberg 2013 80 81 100 97 Per patient\nFallenberg 2016 155 815594729576IndexPer Lesion\nLalji2016* 199 93 96,9 Per patient \n10 reader \nTennant 2016 100 84 95\nLuczynska 2016 116 90 100 92\nXing 2019 235 91,5 91,5Per lesion\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.dePre-therapeutic Staging\nOxford\nLoE GR AGO\n\u00a7History and clinical examination 5 D ++\nAdditional diagnosis forpatients with tumors ofhigh metastatic potential \nand/orsymptoms and/orindication for(neo -)adjuvant chemotherapy\nand/orantibody -therapy ):\n\u00a7CT scan ofthorax/ abdomen 2a B +\n\u00a7Bone scan 2b B +\n\u00a7Chest X-ray 5 C +/-\n\u00a7Liver ultrasound 5 D +/-\n\u00a7In case ofsuspicious lesions further diagnosis (e.g. \nliver -MRI, CEUS*, biopsy etc.)2a B +\n\u00a7FDG -PET orFDG -PET /CT** 2b B +/-\n\u00a7Whole body MRI 4 C +/-\n* Contrast enhanced ultrasound **especially in patients with high tumor stage (III) ifavailable\nEarly Detection and Diagnosis\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\nPathology\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePathology\n\u00a7Versions 2004 \u20132020: \nBlohmer / Costa / Fehm / Friedrichs / Harbeck / Huober /                \nKreipe / L\u00fcck / Maass /Schneeweiss / Sinn / Thomssen / Schmidt\n\u00a7Version 2021: \nKreipe / Sinn / K\u00fchn\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePreanalytics: Fixation\nOxford\nLoE GR AGO\n\u00a7Minimize time to fixation (cold ischemia time) 5 D ++\n\u00a7Minimal fixation time of 6 hours for\noptimal antigen preservation5 D ++\n\u00a7Optimal fixation time 6 -72 h for core biopsies 5 D ++\n\u00a7Optimal fixation time for resection specimens:12 -72 h5 D ++\n\u00a7Use of neutral buffered formalin 5 D ++\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deUse of Breast Cytology*\nOxford\nLoE GR AGO\n\u00a7Nipple secretion 5 D +\n\u00a7Tumor 5 D -\n\u00a7Cyst 5 D +/-\n\u00a7Lymph node 5 D +/-\n*Ultrasound -guided core biopsy recommended\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deWorkup: Core Needle Biopsies \n(US-guided or stereotactic)\nOxford\nLoE GR AGO\n\u00a7Routine workup in step sections\n(14G: 1\u20133 step sections / 11G, 8G: 6 \u20138 step\nsections)5 D ++\n\u00a7Correlation with imaging (density, calcifications), use of B -classification1b B ++\n\u00a7Frozen section diagnosis on core biopsies 5 D --\n\u00a7Routine evaluation of ER/PR and HER2 status 3b C ++\n\u00a7Turn -around time < 24 h (histology) 5 D +\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deWorkup: Breast -Conserving Specimens\nOxford\nLoE GR AGO\n\u00a7Slicing perpendicular to the longitudinal axis\n(or perpendicular to the nipple -peripheral axis\nin case of spherical specimens)5 D ++\n\u00a7Systematic sampling, at least 1 tissue block \nevery 1 cm5 D ++\n\u00a7Inking of resection margins. Sampling of resection margins5 D ++\n\u00a7Documentation after slicing using specimen radiography, photo documentation or diagram5 D +\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deWorkup: Mastectomy Specimens\nOxford\nLoE GR AGO\n\u00a7Margins always to be sampled 5 D ++\n\u00a7Skin close to tumor\n\u00a7Deep margin\n\u00a7Other margins, if close (< 1 cm)\n\u00a7Attention to soft tissue margins in skin \nsparing mastectomy5 D ++\n\u00a7Routine sampling of uninvolved quadrants,skin above tumor, and retroareolar region5 D ++\n\u00a7Systematic sampling in prophylactic \nmastectomies ( patients with BRCA -1/2 mutation ) 5 D ++\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deWorkup: Sentinel Node Biopsy\nOxford\nLoE GR AGO\n\u00a7Full workup using step sections of \u2264 500 \u00b5m on paraffin embedded tissue 5 D ++\n\u00a7Cytokeratin immunohistochemistry\n\u00a7 If suspicious, to detect micrometastases 2b B +\n\u00a7 Formicrometastasis detection after NACT 2b B +\n\u00a7 As a routine procedure 5 D +/-\n\u00a7Frozen section (compromises paraffin histomorphology)\n\u00a7 Ifclinical consequences 5 D +\n\u00a7 If no clinical consequences from frozen section\n(e.g. cT1 or cT2 and cN0 and BCT) 5 D -\n\u00a7Imprint cytology instead of, or in addition to frozen section 3b C +/-\n\u00a7RT-PCR for epithelial genes 4 D -\n\u00a7 OSNA 3b B -\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deWorkup: Intraoperative pathological evaluation\nand frozen sections\nOxford\nLoE GR AGO\n\u00a7Sentinel node biopsy for invasive cancer\n(compromises final paraffin histomorphology )\n\u00a7If clinical consequences 5 D +\n\u00a7No clinical consequences 5 D -\n\u00a7Closest margin of resection\n\u00a7If macroscopically < 1 cm 5 D +\n\u00a7If macroscopically > 1 cm 5 D -\n\u00a7Lesions \u2265 1 cm, without core biopsy 5 D +\n\u00a7Non -palpable lesions or lesions < 1 cm 5 D --\n\u00a7Conservation of fresh tissue (tumor banking) 5 D +\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deReporting: Histologic Tumor Type\nOxford\nLoE GR AGO\n\u00a7Histologic tumor typing according to \nWHO -Classification, ( 5th ed., 2019)3b C ++\n\u00a7Partial special differentiation: \n> 50% NST component\nand < 50% special tumor type (minor component)\n\u00a7Mixed differentiation: \n> 50% special tumor type \nand < 50% NST componentExample: mucinous breast cancer, mixed type\n\u00a7Pure types: \n> 90% special tumor type \nExamples: tubular or cribriform Ca.\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deReporting: Grade of Malignancy\nOxford\nLoE GR AGO\n\u00a7Use of Nottingham grading system (Elston & Ellis \n1991) for all types of invasive breast cancer5 D ++\n\u00a7In case of very little tumor tissue, pure nuclear \ngrading or additional criteria, such as Ki- 67 \nproliferation fraction, may be used5 D ++\n\u00a7Grading of DCIS, e.g. according to WHO -\nClassification, ( 5th ed., 2019)5 D ++\n\u00a7Reporting of tumor grade in numeric form \n(e.g. G3)5 D ++\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deReporting: Tumor Size \nand Total Extent of Tumor\nOxford\nLoE GR AGO\n\u00a7Reporting of invasive tumor size taking into \naccount macroscopic and histologic findings \nand clinical imaging results5 D ++\n\u00a7Additional reporting of total extent of invasivecarcinoma in case of satellite nodules or \nmultifocality5 D ++\n\u00a7Reporting of size of non -invasive component \n(DCIS or LCIS) when DCIS or LCIS component is \nextensive  (more than 2x invasive Ca ) 5 D ++\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deReporting: pTNM\nOxford\nLoE GR AGO\n\u00a7Use of current UICC classification ( 8th ed.) 5 D ++\npT 1 -3:   Invasive tumor size (largest focus in \ncase of multifocality or multicentricity)\npT4:       Invasion of dermis alone does not qualify \nas pT4. Criteria for pT4a/b/c/d must be met.\npT4d:     Negative skin biopsy does not rule out pT4d\n(inflammatory carcinoma).\npM:        pM1 indicates any non -regional disease, except \n2ndprimary contralateral. \nUse of MX is not recommended.\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deReporting: Margins of Resection \nand R -Classification\nOxford\nLoE GR AGO\n\u00a7Evaluation of distance to all resection margins \nmacroscopically and close margins histologically \n(< 1 cm)5 D ++\n\u00a7Reporting of minimal distance to resection margin and its\ntopography5 D ++\n\u00a7R-Classification 5 D ++\nR0: No residual tumor\nR1: Microscopic invasive or noninvasive carcinoma involving resection margin\nRX: Presence of residual tumor cannot be assessed (e.g. tumor in multiple specimens)\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deReporting: Lymphovascular Invasion\nOxford\nLoE GR AGO\n\u00a7L1: Lymphovascular invasion\nL0: No lymphovascular invasion5 D ++\n\u00a7IHC for evaluation of lymphovascular invasion 3b C -\n\u00a7Differentiation of peritumoral and extensive lymphovascular invasion3b C ++\n\u00a7Reporting of venous invasion (V0/V1) optional, prognostic significance not established5 D +\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deReporting: Evaluation of \nTumor -Infiltrating Lymphocytes (TIL)\nOxford\nLoE GR AGO\n\u00a7Identification of tumors with predominant \nlymphocytic infiltrate (> 50%) in tumor stroma (according to Salgado et al.*)5 D +/-\nConsider only lymphocytic infiltrate in tumor stroma and not at the invasion front\nDo not consider central fibrosis and necrotic areas\nReport average of lymphocytic infiltrate as percentage\n*Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., et al. \n(2014). The evaluation of tumor -infiltrating lymphocytes (TILs) in breast cancer: \nrecommendations by an International TILs Working Group 2014. Annals of Oncology\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deReporting: Evaluation after \nNeoadjuvant Chemotherapy\nOxford\nLoE GR AGO\n\u00a7Identification of tumor bed, otherwise ypTX 4 D ++\n\u00a7Reporting of tumor size as total extent of tumor bed area \ninvolved by infiltrates of residual vital invasive carcinoma4 D ++\n\u00a7pCR if absence of invasive Ca. and absence of \nangioinvasion or LN metastases.\nPresence of ypTis should be recorded2b D +\n\u00a7Use of IHC to identify tumor residues (lymphnodes) 2b B +/-\n\u00a7Reporting of ypTN after therapy 5 D ++\n\u00a7Repeat IHC forER, PR, and HER2 5 D +/-\n\u00a7Intraoperative frozen section (reduced sensitivity) 5 D -\n\u00a7Tumorregression -Scores : RCB -Score orSataloff -Score 4 D +/-\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSpecial Studies:\nER-Testing by IHC\nOxford\nLoE GR AGO\n\u00a7Immunohistochemical detection on paraffin\nembedded (FFPE) tissue1a A ++\n\u00a7Reporting percentage of pos. tumor nuclei\n(pos. if \u2265 10%, low pos. if \u2265 1%\u2013 10%)1a A ++\n\u00a7Staining intensity 4 D +\n\u00a7Only Allred Score (0 \u20138) orRemmele Score (0 \u201312) 4 D -\n\u00a7Re-evaluation on excision specimen if uncertain or\ntriple -negative on core biopsy5 D +\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nLow ER+ (1\u2013 10%)\nSanford AS et al.\nCancer 2015High Incidence of Germline BRCA \nMutation in Patients with ER\nLow-Positive/PR Low -Positive/HER -2 neu \nNegative Tumors314 Pat. 1 \u20139% ER, Anteil \nBRCA mutierter F\u00e4lle wie \nbei ER -\nDeyarmin B et al. \nAnn Surg Oncol (2013) 20:87 \u201393Effect of ASCO/CAP Guidelines for \nDetermining ER Status on Molecular \nSubtype26 Pat. 1 \u201310% ER, \nGenexpression  eher wie \nTN oder HER2 enr\nPrabhu YS et al. 2014; J Cancer \n5(2): 156 \u2013165.A Majority of Low (1 \u201310%) ER Positive \nBreast Cancers\nBehave Like Hormone Receptor Negative \nTumors21 Pat. 1 \u201310% ER, \nGenexpression wie ER -, \n\u00dcberleben < ER+\nYi et al. Annals Oncol. 2014 Which threshold for ER positivity? a \nretrospective study based on 9639 \npatients251 Pat. 1 \u20139% ER\n\u00dcberleben = ER -\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSpecial Studies:\nPR-Testing by IHC\nOxford\nLoE GR AGO\n\u00a7Immunohistochemical detection on paraffin\nembedded (FFPE) tissue1a A ++\n\u00a7Reporting percentage of pos. tumor nuclei\n(pos. if \u2265 10%)1a A ++\n\u00a7Only Allred Score (0 -8) orRemmele Score (0 -12) 4 D -\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAdditional Special Studies:\nMolecular Analysis of ER/PR Status\nOxford\nLoE GR AGO\n\u00a7Evaluation of hormone receptors using\nvalidated gene expression test kits3b A +/-\n\u00a7Exclusive evaluation of hormone receptors by \nRNA -quantification5 D -\n\u00a7Use of molecular receptor analysis for subtyping 3b A +/-\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deHER2- Analysis by IHC\nOxford\nLoE GR AGO\n\u00a7Reporting ofimmunohistochemistry (IHC): 1a A ++\n\u00a73+ staining pattern: HER2+ if strong complete \ncircular membrane staining of > 10% invasive \ncells\n\u00a72+ staining pattern: If > 10% circular but \nmoderate/weak membrane staining or \u2264 10% \nstrong staining, U -shaped staining in \nmicropapillary carcinoma :ISH required (CISH, \nSISH, FISH)1a A ++\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deHER2- Analysis by ISH when IHC 2+\nOxford\nLoE GR AGO\n\u00a7Single -Color In -Situ-Hybridisation (ISH): 3a C ++\n\u00a7HER2+ if signal counts \u2265 6 in at least 20 cohesive cells\n\u00a7negative if signal counts < 4 signals/nucleus\n\u00a72-Color ISH recommended for\u2265 4 and < 6 signals/nucleus\n\u00a7Two -Color In -Situ-Hybridisation (ISH): 3a D ++\n\u00a7Group 1: Ratio \u2265 2.0 and signals/nucleus \u22654.0 -> HER2+\n\u00a7Group 2: Ratio \u2265 2.0 and signals/nucleus <4.0\n-> HER2 -(no benefit of anti -HER2 therapy)\n\u00a7Group 3: Ratio < 2.0 and signals/nucleus \u22656.0 \n-> HER2+ (but benefit of anti -HER2 therapy not certain)\n\u00a7Group 4: Ratio < 2.0 and signals/nucleus \u22654.0 und < 6\n-> HER2 -(no benefit of anti -HER2 therapy)\n\u00a7Group 5: Ratio < 2.0 und signals/nucleus <4.0 -> HER2 -\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nBatch controls and on- slide controls show appropriate hybridization\nHER2/CEP17 ratio \u2265 2.0HER2/CEP17 ratio < 2.0\nGroup 1\nAverage HER2 \ncopy number \u2265 4.0 \nsignals/cellGroup 2\nAverage HER2 \ncopy number < 4.0 \nsignals/cellGroup 3\nAverage HER2 \ncopy number \u2265 6.0 \nsignals/cellGroup 4\nAverage HER2 \ncopy number \u2265 4.0  \n-< 6.0 signals/cellGroup 5\nAverage HER2 \ncopy number <4.0 \nsignals/cell\nHER2\nnegativemostly mostly mostly\nHER2\npositive\nHER2\nnegative\nHER2\npositive\nHER2\nnegativeHER2 testing by validated dual -probe ISH assay\nwhen IHC = 2+\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nFalse positive immunohistochemical labeling may occur in core biopsies. \nTherefore, methods of individual laboratories should be validated by comparison of core biopsies and resection specimens. Background staining should be evaluated by \ncomparison with normal duct epithelium.\nAlternatively, all G1 and G2 cases with HER2 3+ in core biopsies may be analyzed by \nISH or may be re- evaluated in the resection specimen.\nFalse positivity is likely when HER+ was reported in G1 tumors of the following types:\nInfiltrating ductal or lobular carcinoma, ER and PR positive, Tubular (at least 90% \npure), Mucinous (at least 90% pure) Cribriform (at least 90% pure), Adenoid cystic \ncarcinoma (90% pure).\nIn case of discrepancy between core biopsy and specimen, the HER2 overexpressing \nsample should be re -evaluated by a different method. If still discrepancy \u2013anti-HER2 -\ntreatment if amplified in one of both samples. Expected rate of HER2 -overexpression: \n15% HER2 positiveHER2 Testing on Core Biopsies\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAdditional Special Studies:\nMolecular Analysis of HER2 Status\nOxford\nLoE GR AGO\n\u00a7Therapy decisions should only be based on IHC and \nISH1a A ++\n\u00a7Evaluation of HER2 using validated gene \nexpression test kits3b B -\n\u00a7Evaluation of HER2- amplification by RNA -\nsequencing5 D -\n\u00a7Use of molecular HER2 -testing for subtyping 3b B +/-\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSpecial Studies:\nEvaluation of Ki -67 Score\nOxford\nLoE GR AGO\n\u00a7Counting of tumor nuclei at the invasion front 5 D ++\n\u00a7Semiquantitative eyeballing or counting of labelled \ncells in core needle biopsies2 A ++\n\u00a7Consideration of weakly stained tumor nuclei 5 D ++\n\u00a7Reporting of Ki -67 positive nuclei as percentage 5 D ++\n\u00a7Establishing of laboratory standards and cut -off values 5 D ++\n\u00a7Use of image analysis for objective Ki -67 evaluation 5 D +\n\u00a7Determination of Ki -67 dynamics after short term (2 -4 \nweeks) endocrine therapy*1b B +\n* See chapter Neoadjuvant Systemic Therapy\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePredictive PD- L1 Assay\nOxford\nImmunohistochemical assay LoE GR AGO\nImmune Score (IC): Cytoplasmic staining of at least 1% of the leucocyte stromal \ninfiltrate (lymphocytes, macrophages, plasma cells, granulocytes outside of \nabscesses) for prediction of atezolizumab efficacy in triple- negative metastatic \nbreast cancer2 A ++\nMetastatic or primary tumor tissue 2 A ++\nDetection with antibodies equivalent to Impassion 130 study reagents 3 B +\nCombined positive score (CPS): positive cells ( tumor cells, lymphocytes, and \nmacrophages) divided by the total number of tumor cells multiplied by 100; \u226510 \n= positive) for prediction of pembrolizumab efficacy in metastatic triple -negative \nbreast cancer (FDA approval, EMA pending)3 B +/-\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMutational studies in mBC :\n\u201ePrecision medicine \u201c fortargeted therapies\nGene Therapeutic\nRelevanceGene region Source Oxford\nLoE GR AGO\nBRCA1, BRCA2 PARP Inhibitor all exons Germ line: blood cells\nSomatic: tissue1b\n2bA\nB++\n+/-\nPIK3CA Alpelisib exons 7,9 and 20 Primary tumor, \nmetastases, plasma1b A ++\nHER2 -mutation \n(irrespective of HER2 -\nstatus)Neratinib , \nLapatinibkinase and extracellular\ndomain ; S310, L755, \nV777, Y772_A775dup Primary tumor , \nmetastases , plasma4 C +/-\nESR1 Resistance vs \naromatase inhibit.exons 4,7 und 8 metastases, plasma 2b B +/-\nNTRK gene fusion Larotrectinib, \nEntrectinibGene fusions and splice \nvariantsTumor tissue, in \nparticular secretory \nbreast caner2a B +\nMSI Pembrolizumab Mikrosatellite instability tissue 2a B +\nPathology\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1EPrognostic and\nPredictive Factors\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePrognostic and\nPredictive Factors\n\u00a7Versions 2002 \u20132020: \nCosta / Fasching / Fersis / Friedrichs / Gerber / G\u00f6hring / Harbeck / Janni / \nKolberg -Liedtke / Kreipe / Loibl / L\u00fcck / Mundhenke / Nitz / Rody / \nSchaller / Schmidt / Schmutzler / Schneeweiss / Simon / Solomayer / Thill\n/ Thomssen / Witzel / W\u00f6ckel\n\u00a7Version 2021: \nHarbeck / Untch\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deDefinition\nA Prognostic Factors is associated with the probability of the course of the \ndisease (e.g. disease -free or progression -free survival, overall survival). The \nprobability can be influenced by therapy. \nA Predictive Factor is associated with the probability of the effect of a given \ntherapy.\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u201cLow absolute risk implies \nlow absolute benefit\u201d\nEarly Breast Cancer Trialists' Collaborative Group (EBCTCG), Lancet 379: 432 -444, 2012\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7Biological hypothesis\n\u00a7Simple and standardized assessment method, quality assurance (QA) of \nthe test\n\u00a7Prospectively planned statistical evaluation (primary goal)\n\u00a7Validation of clinical significance according to\n\u00a7\u201eOxford Level of Evidence (LoEOx2001)\u201c criteria and \u201eGrades of \nRecommendation (GR)\u201c \n\u00a7\u201eGrades of Recommendation (GR)\u201c as well as modified LoE criteria for the use \nin archived specimen (LoE2009) and category of tumor marker study (CTS) \n\u00a7Clinical relevance for treatment decisionsQuality Criteria\n1Simon et al, J Natl Cancer Inst 101: 1446 -1452, 2009\n2Febbo et al, J Natl Compr Canc Netw 9 Suppl 5: S1 -32, 2011\n3McShane, Hayes, J Clin Oncol  30: 4223 \u20134232, 2012\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEarly Breast Cancer (M0) \u2013eBC\nPrognostic Factors I\nOxford\nFactor LoEOx2001 GR AGO\n\u00a7Tumor size \u2013 pT 1a A ++\n\u00a7Axillary lymph node status \u2013pN 1a A ++\n\u00a7Histological tumor type (mucinous, tubular etc.) 2b B ++\n\u00a7Grade (Elston & Ellis) \u2013G 2a B ++\n\u00a7Age 2a B ++\n\u00a7Histologically proven peritumoral lymphatic vessel \nand vascular invasion (L1 V1) 1b B ++\n\u00a7pCR after NACT* in (luminal -B-like, HER2+, TN) 1a A ++\n\u00a7Increased risk ofrecurrence in invasive -\nlobular BC, cT3/4, N+2a B +/-\n\u00a7Obesity (BMI > 30 kg/m\u00b2) 1b B +\n\u00a7Margins (resection status ) \u2013R0/R1 1a A +\n*NACT = Neoadjuvant Chemotherapy\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEarly Breast Cancer (M0) -eBC\nPrognostic Factors II\nOxford\nFactor LoE GR AGO\n\u00a7ER / PR 2a B ++\n\u00a7HER2 (IHC, ISH) 2b B ++\n\u00a7ER / PR / HER2/ Ki -67 to assess the \nmolecular type2b B ++\n\u00a7uPA / PAI -1 (Femtelle\u00ae ELISA) in N0 1a A +\n\u00a7Proliferation markers\n\u00a7Ki-67 before, during, or after treatment 1a B +\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7ER/PR: concordance central vslocal ishigh (97%; Plan B, SABCS 2014)\n\u00a7Grade: concordance central vslocal is68% ( PlanB , JCO 2016)\n\u00a7HER2: frequency offalse -positive test results 6% (ASCO /CAP JCO 2013)\n\u00a7Impact ofroutine pathologic review in N0 BC: 20% changes : grade 40%, LVI  26%, N \n15%, margin 12% (JCO 2012)\n\u00a7pN0 from MIRROR study : pN0 was upstaged in 22%, in central pathology review\n(Ann Oncol 2012)\n\u00a7Ki67: \n\u00a7Inter -and intraobserver variability in measurement ofKi-67 is high (J Nat. \nCancer Institute 2011)\n\u00a7High reproducibility forlow and high Ki67 levels (J Pathol 2002)\n\u00a7Standardized methodology improves analytical validity (JNCI 2020)Reproducibility \u2013Quality assurance iskeyfor\nclinical decision making\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEarly Breast Cancer (M0) -eBC\nPrognostic Factors III\nFactor LoE GR AGO\n\u00a7 Gene expression profiles (GEP, multigene assays , gene signatures)\n\u00a7 MammaPrint \u00ae (N0- 1) 1b A +*\n\u00a7 Oncotype DX\u00ae  (N0 -1, HR+ HER2 -) 1b A +*\n\u00a7 EndoPredict \u00ae (N0 -1, HR+, HER2 -) 2b B +*\n\u00a7 Prosigna \u00ae (N0 -1, HR+, HER2 -) 2b B +*\n\u00a7 Breast Cancer IndexSM(N0-1, HR+ HER2 -)** 2b B +/-*\n\u00a7 PREDICT\u00ae algorithm (https:// breast.predict.nhs.uk /) 1b A +\n\u00a7 Clinical -pathological score forlobular breast cancer (nodal status , tumor size, \nlymphovascular invasion LVI)2b B +/-\n\u00a7 CTS5 Clinical Treatment Score** 2b B +\n\u00a7 CPS-EG Score 2b B +\n*Should only be used in the context of clinical -pathological criteria (tumor size, nodal involvement, grade, Ki -67, ER, \nPR, HER2)\n** estimation oflate recurrenceOxford\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEarly Breast Cancer (M0) -eBC\nPrognostic Factors IV\nFactor LoE GR AGO\n\u00a7Disseminated tumor cells (DTC, in bone marrow) 1a A +/-\n\u00a7Circulating tumor cells (CTC, in blood, Cell Search \u00ae)$ 1b A +/-\n\u00a7CTC before NACT (regarding OS, DDFS, LRFI) 1b B +/-\n\u00a7Therapy decisions based on CTC phenotypes 3a C -\n\u00a7Cell-free DNA ( cfDNA, in blood, for DFS, PFS, OS) 2ba B +/-\n$Validated clinical data only available for this assayOxford\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nCommercially available molecular tests\n70 gene signature\n(MammaPrint\u00ae) $21 gene Recurrence score(Oncotype DX\u00ae) \n$8 gene signature\n(Endopredict \u00ae)$PAM 50(Prosigna\u00ae)\n$Breast Cancer \nIndex \u00ae (BCI)$\nProvider Agendia Genomic Health Sividon (Myrirads) NanoString Biotheranostics\nType of assay 70-gene assay 21-gene recurrence score 11-gene assay 50-gene assay 5 + 2  (MGI+H/I)\nType of tissue fresh frozen\n(technical validation for \nFFPE available)FFPE FFPE FFPE FFPE\nTechnique Microarrays for RNA qRT-PCR q-RT-PCR Direct hybridization \n(nCounter\u00ae)q-RT-PCR\nCentral lab yes yes no no yes\nIndication and \npopulation \nstudiedprognostic\nN-/+, < 70 JahreprognosticN-/+, ER+ \nendocrine treatedprognostic (pre-) postmenopausal \nN-/+, ER+ HER2 -\nendocrine treatedprognostic postmenopausal \nN-/+, ER+ HER2 -\nendocrine treatedPrognostic\npT1-3pNo \u2013pN1\nER+ / HER2 \u2013\nEndocrine treated\nRisk classes Low -high RS (Low \u2013intermediate \u2013high) Low -high ROR (Low \u2013inter -\nmediate \u2013high), \nmolecular typesLow -high\nClinical \nValidationyes yes yes yes Yes\nRegistration FDA clearance as \u201c In Vitro \nDiagnostic Multivariate \nIndex Assay (IVDMIA)\u00ab\nCE-Mark\n(fresh tissue and FFPE)Clinical Laboratory Improvement Amendments\n(CLIA) + College ofAmerican \nPathologists (CAP)- accredited\nreflabCE-Mark\nCE-Mark\nFDA 510(k) \nClearance Service Mark (SM)\n$Validated clinical data only available for this assay\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n70 gene signature\n(MammaPrint\u00ae) $21 gene Recurrence score(Oncotype DX\u00ae) \n$8 gene signature(Endopredict\u00ae)\n$PAM 50(Prosigna\u00ae)\n$Breast Cancer Index\u00ae (BCI)\nPrognosis after 5 yrs (late \nrecurrences) not separately\nshownyes yes yes yes\nPredictive impact\n(chemotherapy\nbenefit )poorly validated yes not shown not shown EAT after 5 yrs\nProspective -\nretrospectiveevidence\n(% ofrecruited\npatients )MulticentervalidationNSABP B -14 (14%)\nNSABP B -20 (28%)\nECOG 9127\nSWOG 8814 (40%)\nATAC (30%)ABCSG 6 (19%)\nABCSG 8 (36%)\nGEICAM -9906 (45%)\nATAC (10%)MA.12 (59%)\nMA.5 (66%)\nABCSG 8 (44%)\nATAC (16%)TransATTOM (11%)\nProspective \nevidenceMINDACT (N0, N1)  \n(8y DFS, OS)TAILORx (9y DFS, OS), \nN0, RS\u2264 25 vs. \u2265 \n26)   \nPlanB (N0 highrisk /N+) (5y DFS, OS)\nRxPONDER (5y DFS, OS), N1, RS\u2264 25 vs. \n\u226526)   \nADAPT (5y DFS, OS), N0 -1, RS 0 -11; RS12 -\n25/Ki67 response\u2013\u2013 --\n$Validated clinical data only available for this assayCommercially available molecular tests\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nProspective clinical trials (Oncotype DX\u00ae [ TAILORx , PlanB , \nRxPONDER, ADAPT], MammaPrint \u00ae [MINDACT])\nTailorX RxPONDER PlanB ADAPT MINDACT\nFollow -up Median 90 months Median 5.1 years 5-J-DFS Median 60 months Median 8.7 years (ASCO 2020)\nTrial design (biomarker \nquestion)pN0; Randomization RS \n11-25 (+/ -CTX)pN1; Randomization RS0-25 (+/ -CTX)Prospective ODX testing: ET alone \nin RS 0 -11 pN0 -1Non -inferiority (iDFS) ET alone: \nRS 0 -11 vs  RS12 -25/ET \nresponseProspectively defined 5y-\nDMFS threshold for ET alone\nPercentage  clinically defined low -risk group6615/9427 (70.2%, adj -\nonline)all 1-3 involved \nlymph nodesall clincial CTX indication (pN0 -1)all clincial chemotherapy (CTX)  indication (c/pN0 -1)3336/ 6693 (49.8%, adj- online)\nPercentage high clinical risk and low genomic risk \n(clinical CTX  indication)16.7% (RS 0 \u201310) 42.8% (RS 0 -13) 15.3% (RS 0 \u201311) ET-trial (pN0 -1): all RS 0 -25, i.e. \nlow genomic risk with ET alone23.2% \n(high clinical/low genomic risk)\nTest failure rate n.r. n.r. 2.9% n.r. 26% (fresh frozen)\nPercentage genomically \nintermediate -risk group \n(only for Oncotype DX, ODX)69.1% (RS 11 \u201325) 57.2% (RS 14 -24) 60.4% (RS 12 \u201325) Included only RS 0 -11 (37.9%) \nor\nRS 12 -25/ET response (62.1%)n.a.\nPercentage genomically high -risk group (only for \nOncotype DX)14.3% (RS \u2265 26) n.a. 24.3% (RS \u2265 26) n.a. 27.0% (high clinical and\nhigh \ngenomic risk)\n10-year follow -up n.r. n.r. n.r. n.r. n.r.Prognosis in low-riskgroups excellent forboth tests : ~94% 5J. DFS with only adjuvant endocrine therapy (ET)\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAdjuvant endocrine therapy\nPredictive factors for DFS\nOxford\nTherapy Factor LoE GR AGO\n\u00a7 Endocrine therapy \u00a7 ER/PR status [%] 1a A ++\n\u00a7 IHC staining intensity (ER/PR) 1a A -\n\u00a7 Ki-67 after 2 -4 weeks ofpreoperative endocrine\ntherapy1b A +\n\u00a7 Extended endocrine therapy \n(EAT)\u00a7 Breast Cancer IndexSM(5y Let(MA.17) or5y Tam \n(aTTOM ), resp., after 5y Tam)2b B +\n\u00a7 Tamoxifen \u00a7 CYP2D6 -polymorphism 2b B -\n\u00a7 Ovarian ablation or\nsuppression\u00a7 Menopausal status 1c A ++\n\u00a7 Aromatase inhibitors vs. tamoxifen\u00a7 Menopausal status 1c A ++\n\u00a7 ER / PR / HER2 assingle factors 1c A -\n\u00a7 Invasiv -lobular breast cancer 2b B +\n\u00a7 Ki-67 high 2b B +/-\n\u00a7 Obesity (BMI > 30 kg/m\u00b2) 2b B +/-\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAdjuvant Chemotherapy and Targeted Therapy \nPredictive Factors for DFS\nTherapy FactorOxford\nLoE GR AGO\n\u00a7Adjuvant\nChemotherapyuPA / PAI -1 (ELISA, Femtelle \u00ae) 1a A +/-\n70-Gene -signature (Mammaprint \u00ae) 1b A +\n21-Gene -signature (Oncotype DX RS\u00ae) 1b A +\nEPclin (Endopredict\u00ae) 2b B +\nPAM -50 (Prosigna\u00ae) 2b B +\nHistological type ( lobular vs. NST) 2b B -\n\u00a7Anti -HER2 -Therapy HER2 (IHC, ISH) 1a A ++\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deNeoadjuvant Systemic Chemotherapy  (NACT) \nPredictive Factors for pCR I\nFactorpCR*\nProbabilityOxford\nLoE GR AGO\n\u00a7Young age \u00ad 1a A +\n\u00a7cT1 / cT2 tumors o. N0 o. G3 \u00ad\u00ad 1a A ++\n\u00a7Negative ER -and PR-status \u00ad\u00ad 1a A ++\n\u00a7Triple negative breast cancer (TNBC) \u00ad\u00ad 1a A ++\n\u00a7Positive HER2 -status \u00ad\u00ad 1a A ++\n\u00a7Early response, clnically \u00ad 1b A +\n\u00a7Invasive -lobular breast cancer \u00af 1a A +\n\u00a7Metaplastic breast cancer \u00af\u00af 4 C +\n*   High ( \u00ad) or very high ( \u00ad\u00ad) probabililty of pCR, low ( \u00af) or very low ( \u00af\u00af) probabililty of pCR\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deNeoadjuvant Systemic Chemotherapy  (NACT) \nPredictive Factors for pCR II\npCR*\nProbabilityOxford\nFactor LoE GR AGO\n\u00a7Gene expression profiles (gene signatures ) \n(Mammaprint \u00ae, Endopredict \u00ae  Oncotype DX\u00ae, \nProsigna \u00ae, Breast Cancer IndexSM)\u00ad 2b B +/-\n\u00a7Ki-67 \u00ad 2b B +\n\u00a7Tumor infiltrating lymphocytes ** \u00ad 2a B +\n\u00a7PIK3CA mutation (for HER2 -positive BC) \u00ad 2a B +/-\n\u00a7gBRCA- mutation (for the effect of chemotherapy) \u00ad 2b B +\n\u00a7gBRCA- mutation ( fortheeffect ofplatinum ) \u2194 2b B +/-\n** Defined as dense lymphocytic infiltration of inner peritumoral stroma outside of the invasion front (lymphocytes make up >50% \nof  stroma area)*   High ( \u00ad) orvery high ( \u00ad\u00ad) probabililty ofpCR, low(\u00af) orvery low(\u00af\u00af) probabililty ofpCR\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMetastatic Breast Cancer ( mBC )\nPrognostic Factors\nFactorOxford\nLoE GR AGO\n\u00a7Circulating tumor cells (CTC in blood, Cell Search\u00ae)\n\u00a7Prognosis 1a A +\n\u00a7Early response assessment (3w) 1b B +\n\u00a7Therapy decision solely based on dynamics\nof CTC numbers over time or CTC phenotype1b A -*\n\u00a7Cell-free DNA (cfDNA in blood) 2a A +/-\n*Study participation recommended\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deTreatment of Metastatic Breast Cancer\nPredictive Factors for response\nOxford\nTherapy Factor LoE GR AGO\n\u00a7 Endocrine therapy ER / PR (prim. tumor , better : metastasis ) 1a A ++\nResponse toprior therapy 2b B ++\nAutocrine receptor mutation (ESR1) 2b B +\n\u00a7 Alpelisib PIK3CA mutation (prim. tumor , metastases , \nplasma )1b A ++\n\u00a7 Chemotherapy Response toprior therapy 1b A ++\n\u00a7 Anti -HER2 -therapy HER2 (prim. tumor , better : metastasis ) 1a A ++\n\u00a7 Checkpoint -Inhibitors PD-L1 positivity#(PD-L1ic, CPS) in TNBC \n(primary tumor ormetastasis )1b B ++\n\u00a7 PARP- Inhibitors gBRCA1/2 -mutation 1a A ++\n\u00a7 Bone modifying drugs Bone metastasis 1a A ++\n\u00a7 Any therapy CTC  monitoring 1b A +*\n* In clinical trials ; # seechapter \u201epathology \u201c\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMutation diagnostics* in mBC :\n\u201ePrecision medicine \u201c fortargeted therapies\nAltered genes Therapeutic\nrelevanceGene region Material Oxford\nLOE GR AGO\nBRCA1, BRCA2 PARP Inhibitors All exons Germline : Blood cells\nSomatic : Tissue1b\n2bA\nB++\n+/-\nPIK3CA Alpelisib Exons 7,9 and 20 Primary tumor , \nmetastases , plasma1b A ++\nHER2 -mutation \n(independent ofHER2 -\nstatus)Neratinib , \nlapatinibKinase -and extracellular\ndomains ; S310, L755, \nV777, Y772_A775dup Primary tumor , \nmetastases , plasma\nparticul . lobular BC4 C +/-\nESR1 Resistance \nagainst AIExons 4,7 und 8 Metastases , plasma 2b B +/-\nNTRK gene fusion Larotrectinib, \nentrectinibFusion -and splice \nvariantsTumor tissue , particul . \nsecretory breast cancer2a B +\nMSI Pembrolizumab Microsatellite -instability Tissue 2a B +\n* Ideally panel diagnostics\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deTherapy -relevant mutational analysis for \n\u201eactionable\u201c genomic alterations in BC\nFactor * Outcome LoE GR AGO\nEvidence from studies with other cancer patients (\u201etumor -agnostic testing \u201c)\n\u00a7Companion Diagnostics fortherapies ofother\ntumor entities (z.B. BRAF, FGFR1, \u2026)Efficacy ofdiverse \ntherapies4 D +/-**\n\u00a7Large Panel Gene Analysis (e.g. FoundationOne, \nGPS Cancer, NeoSelect, Molecular Health Guide, \nlocal \u201ehand -selected\u201e panels) Efficacy ofdiverse \ntherapies , prognosis3a C +/-**\n*    Assessment method forsomatic mutations (tumor tissue , cf-DNA) isnot taken into consideration forLoE\n**Participation in clinical trials orstructured registries recommendedOxford\nPrognostic and Predictive Factors\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1ELesions of Uncertain \nMalignant Potential (B3)\n(ADH, LIN, FEA, Papilloma, Radial Scar) \nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deLesions of Uncertain Malignant Potential (B3)\n(including \u201cPrecursor Lesions\u201d)\n\u25aaVersions 2005 \u20132020: \nAlbert / Audretsch / Brunnert / Ditsch / Fallenberg / Fersis / Friedrich /  \nFriederichs / Gerber / Huober / Kreipe / Nitz / Rody / Schmidt / Schreer / \nSinn / Thomssen\n\u25aaVersion 2021:\nKreipe / Maass\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePathology Reporting for Minimal \nInvasive Biopsies\nB-Classification* \nB1 = Unsatisfactory or normal tissue only\nB2 = Benign lesion\nB3 = Lesion of uncertain malignant potential\nB4 = Suspicion of malignancy\nB5 = Malignant\nB5a = Non -invasive\nB5b = Invasive\nB5c = In situ/invasion not assessable\nB5d = Non epithelial, metastatic\n*National Coordinating Group for Breast Screening Pathology (NHSBSP), \nE.C. Working Group on Breast Screening Pathology, S3 -Leitlinie Mammakarzinom der DKG\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nB3-Lesions\n1. Lesions with increased risk of associated DCIS or invasive carcinoma  \n\u00a7Atypical ductal hyperplasia (ADH) or atypical epithelial proliferation of ductal type (classification \npossibly as B4, depending on extent of lesion)\n\u00a7Flat epithelial atypia (FEA)\n\u00a7Lobular neoplasia (LIN; LN; now subdivided into ALH and LCIS, no differentiation according to \nolder nomenclature) classical and non -classical type \n\u00a7Atypical apocrine adenosis\n2. Potentially heterogeneous lesions with risk of incomplete sampling\n\u00a7Cellular fibroepithelial lesion or phyllodes tumour without evidence of malignancy\n\u00a7Intraductal papilloma with/without atypia (possibly also B4, depending on the extent of the \nlesion)\n\u00a7Radial scar or complex sclerosing lesion (unless the radial scar only microscopically, not \nradiologically detected: B2)\n\u00a7Hemangioma\n3. Rare Lesions\n\u00a7Adenomyoepithelioma, microglandular adenosis, mucocele -like lesion, nodular fasciitis, \ndesmoid- type fibromatosis, spindle cell lesion of unknown significance\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deManagement after \nMinimally Invasive Biopsy\nOxford\nLoE GR AGO\n\u00a7Interdisciplinary conference: \nConcordant findings in pathology and imaging? \n\u00a7yes: proceed according to histologic type 3a C ++\n\u00a7no: open biopsy 3a C ++\nVacuum -assisted biopsy (after core biopsy) 5 D +\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7Synonyms: Atypical intraductal epithelial proliferation (AIDEP), \natypical epithelial proliferation of ductal type\n\u00a7Definition: Atypical intraductal proliferations with cytological and structural features \nof well differentiated DCIS, such as rigid bridging or micropapillae, well demarcated \ncell borders and occupy less than two separate duct spaces. The extension of all \ninvolved lumens within one ductulo -lobular unit is less than 2 mm. Atypical ductal \nproliferations larger than 2 mm or in at least two ductules are classified as DCIS (low -\ngrade).\n\u00a7Indicator/Precursor lesion: Ipsi-and contralateral breast cancer risk: \nRR 3 -5 x after 3 -5 years.\n\u00a7Particularly high risk for breast cancer when combined with BIRADS IV / V and high \nbreast volume.Atypical ductal Hyperplasia (ADH) \nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deStrategy after Diagnosis of ADH\nin Biopsy Sypecimen\nOxford\nLoE GR AGO\nADH in core -/ vacuum -assisted biopsy:\n\u00a7Open excisional biopsy 3a C ++\n\u00a7Open excisional biopsy may be omitted, if: 5a C +/-\na) No mass -lesion radiologically, and\nb) a small lesion (\u2264 2 TDLU*) in vacuum biopsy, and\nc) complete removal of imaging abnormality \nADH at margins in open biopsy specimen:\n\u00a7No further surgery, if incidental finding \naccompanies invasive or intraductal\ncarcinoma3a C ++\n*Terminal ductal -lobular unit\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7Includes:\n\u00a7Atypical lobular hyperplasia\n\u00a7Classical lobular carcinoma in situ (LIN, classical variant)\n\u00a7Non -Classical lobular carcinoma in situ (LIN, classical variant)\n\u00a7LIN 1 \u20133 classification is not sufficiently validated prognostically\n\u00a7Non -Classical LIN (pleomorphic LIN, florid LIN) are classified as \npremalignant \u2192 B5a\n\u00a7Indicator/Precursor lesion:\nIpsi-and contralaterally increased breast cancer risk: \n7 x after 10 yearsLobular Intraepithelial Neoplasia (LIN) \nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nClassical LIN and Variants \nof LIN (non -classical LCIS)\nClassical LIN LIN  with comedo type necrosis\nFlorid LIN Pleomorphic LIN\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7Non -Classical LCIS:\n\u00a7Pleomorphic LCIS: high grade cellular atypia, frequent involvement of \nductules, comedo- type necrosis, microcalcifications\n\u00a7Florid LCIS: Involvement of numerous lobuli with distension and near \nconfluence, extension to ductules and neighboring TDLU\n\u00a7LCIS with microinvasion*:\n\u00a7classical LCIS: n = 11\n\u00a7florid LCIS: n = 4\n\u00a7pleomorphic LCIS: n = 1LIN with High Risk\n*Ross DS. Am J Surg Pathol 2011 35: 750 \u20136. \nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deStrategy after Diagnosis of LIN\nOxford\nLoE GR AGO\n\u00a7LIN in core -/ vacuum -assisted biopsy:\n\u00a7 No further measures if LIN (LCIS, classical variant) \nwith involvement of \u2264 3 TDLU (terminal ductulo- lobular unit) in \nvacuum biopsy and concordant with imaging 2b C ++\n\u00a7 Open excisional biopsy, with pleomorphic LIN,florid LIN (LIN 3), or LIN with comedo type necrosis\nor if not concordant with imaging findings2b C ++\n\u00a7LIN at margins of resection specimen (BCT):\n\u00a7 No further surgery 2a C ++\nExceptions:\na) Pleomorphic LIN, florid LIN, or LIN with necrosis\na) Imaging abnormality is not removed\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7Synonyms: Columnar cell hyperplasia with atypia, \ncolumnar cell metaplasia with atypia, \nductal intraepithelial neoplasia grade 1A (DIN 1A)\n\u00a7Differential diagnosis:\n\u00a7ADH is discriminated by architectural features (micropapillary, cribriform) \u2192 B3\n\u00a7Clinging carcinoma is discriminated by high grade nuclear atypia (G2/G3) and classified as ductal carcinoma in situ \u2192 B5a\n\u00a7Marker lesion:FEA frequently is associated with calcifications and may be associated with low -\ngrade intraductal carcinoma. Frequent occurrence in combination with high density of the breast (OR1.3).  High risk for associated breast cancer in the presence of \nextensive calcifications (also when 75% of calcification remained after biopsy), age > \n= 57J, > 1 cm in imaging, > = 4 foci.Flat Epithelial Atypia (FEA)\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deStrategy after Diagnosis of FEA\nOxford\nLoE GR AGO\n\u00a7FEA in core biopsy/vacuum -assisted biopsy:\n\u00a7 Open excisional biopsy may be omitted under the following \ncircumstances:3b C +\na. a small lesion (\u2264 2 TDLU* in vacuum biopsy) \nand \nb. Complete or near complete removal of imaging abnormality \n\u00a7 Representative open excisional biopsy in radiologically extensive \nmicrocalcifications or discordance to the radiological result5 C +\n\u00a7FEA at margins in resection specimen: \n\u00a7 No further surgery, unless calcifications have not been completely removed 3b C ++\n*TDLU = Terminal ductal- lobular unit\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7Includes: Central and peripheral papilloma > 2 mm, \natypical intraductal papilloma (B3)\n\u00a7To be distinguished from peripheral micropapilloma arising in the TDLU, \nsize \u2264 2 mm, may be multiple\n\u00a7To be distinguished from papilloma with DCIS, from intraductal papillary \ncarcinoma, and from encapsulated papillary carcinoma\n\u00a7Precursor lesion:\nMay be associated with in -situ or invasive cancer (up to 6% without atypia \nif concordant imaging, up to 30% with atypia), increased ipsilateral risk for cancer (up to 4.6% and up to 13% in case of atypical papilloma) .Papilloma \nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deStrategy after Diagnosis of \nPapilloma\nOxford\nLoE GR AGO\n\u00a7Papilloma without atypia in core needle or \nvacuum biopsy:\n\u2192no further therapy , if biopsy  sufficiently representative \n(100 mm2) and concordant with imaging3a C +\n\u00a7Multiple papillomas\n\u2192open biopsy 3a C ++\n\u00a7Papilloma with atypia in core needle or vacuum biopsies:\n\u2192open biopsy 3a C ++\n\u00a7Papilloma at resection margin:\n\u2192no published data available\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7Benign pseudoinfiltrative lesion with central fibroelastic core and \nradical configuration. \n\u00a7Includes:\n\u00a7radial scar\n\u00a7complex sclerosing lesion (> 1 cm)\n\u00a7Additional risk factor in patients with benign epithelial hyperplasia (proliferating breast disease)\n\u00a7Risk for upgrade in open biopsy after diagnosis of a radial sclerosing lesion, depending on the size of the needle (CNB) or method (VAB) and additional atypia: 1 \u201318%Radially Sclerosing Lesion\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deStrategy after Diagnosis of Radial Scar, \nComplex Sclerosing Lesion (CSL)\nOxford\nLoE GR AGO\n\u00a7Radial scar / CSL in core -/ vacuum -assisted\nbiopsy:\n\u2192Open excisional biopsy may be omitted with a small \n(< 5mm) lesion or complete removal or near \ncomplete removal of imaging abnormality 5a C +\n\u00a7Radial scar / CSL at margins in resection specimen:\n\u2192No further surgery 3b C ++\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nManagement Radial Scar \n\u00a7\u201cWhen RS (radial scar) is associated to atypia (such as flat epithelial atypia \n(FEA), atypical ductal (ADH), or lobular neoplasia (classical LN)), \nmanagement can the same as recommended in cases of atypia alone.\u201d\nRageth CJ, O`Flynn EAM, Pinker K et al.: Second International Consensus Conference on lesions \nof uncertain malignant potential in the breast (B3 lesions). Review, Breast Cancer Res Treat, 2018, \ndoi: 10.1007/s10549 -018-05071- 1\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deFollow -up Imaging for Women Age\n50\u201369 Years with B3 -Lesions\nOxford\nLoE GR AGO\n\u00a7FEA, non -atypical papilloma\n\u00a7Screening mammography 5 C ++\n\u00a7LIN\n\u00a7Mammography (12 months) 3a C ++\n\u00a7ADH\n\u00a7Mammography (12 months) 3a C ++\n\u00a7Women with LIN and ADH should be \ninformed about their elevated risk of breast cancer 3a C ++\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMedical Prevention for Lesions with Uncertain \nBiological Behavior  (incl. LIN, ADH) \nOxford\nLoE GR AGO\n\u00a7Tamoxifen for women > 35 years 1a A +/-\n\u00a7Low -dose Tamoxifen 5mg (3 years) 2b B +/-\n\u00a7Aromatase inhibitors (Exemestan e, Anastrozole)                       \nfor postmenopausal women 1b A +/-\n\u00a7Raloxifen for postmenopausal women :Risk \nreduction of invasive BConly 1b A +/-*\nMedical prevention should only be offered after individual and \ncomprehensive counseling; overall benefit depends on classification, age, \nand pre -existing conditions that may influence occurrence of side effects.\n*Risk situation as defined in NSABP P1- trial (1,66% in 5 years)\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7500 women \u2264 75 with intraepithelial neoplasia (ADH, LCIS, DCIS)\n\u00a7Tamoxifen 5 mg/d for 3 years vs. placebo \n\u00a7Breast cancer events: 14 vs. 28 \n\u00a7invasive: 11 vs. 19\n\u00a7HR 0,48; 95% CI 0,26- 0,92; P = 0,02\n\u00a7NNT 22\n\u00a7PROM comparable except for hot flushesLow-dose Tamoxifen\nDeCensi et al. J Clin Oncol  37:1629 -1637, 2019\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nPlacebo Verum\nParticipants 18.322 18.355\nInvasive breast \ncancer805 537\nER-positive 632 350\nER-negative 144 173\nBreast cancer -\nrelated death48 60Tamoxifen Chemoprevention \u2014\nEnd of the Road?\nNarod. JAMA Oncol 1:1033 -4, 2015\nLesions of Uncertain Malignant Potential (B3)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer \nDuctal Carcinoma in Situ\n(DCIS) \nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deDuctal Carcinoma in situ\n(DCIS)\n\u00a7Versions 2002 \u20132020: \nAudretsch / Bauerfeind / Blohmer / Brunnert / Budach / Costa/ Fersis / \nFriedrich / Gerber / Hanf / Junkermann / K\u00fchn / Lux / Maass / M\u00f6bus / \nMundhenke / Nitz / Oberhoff / Scharl / Sch\u00fctz / Solomayer / Souchon / \nThill / Thomssen / Wenz\n\u00a7Version 2021: \nBudach / Lux / Solbach\nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePretherapeutic Assessment of\nSuspicious Lesions (BIRADS 4 -5)\nOxford\nLoE GR AGO\n\u00a7Mammography 1b B ++\n\u00a7 Magnification view of microcalcifications 4 C ++\n\u00a7 Increas eddetection rate of G1/G2 DCIS by full -field digital \nmammography (versus screen -film)2b B +\n\u00a7Stereotactic core needle / vacuum biopsy (VAB) 2b B ++\n\u00a7 Specimen radiography 2b B ++\n\u00a7 Marker (clip) left at biopsy site for localization if lesion is completely \nremoved5 D ++\n\u00a7Assessment of extension and planning of surgery\n\u00a7 MRI 1b B +/-\n\u00a7Clinical examination 5 D ++\n\u00a7FNA / ductal lavage 5 D -\n\u00a7Interdisciplinary board presentation 5 D ++\nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1DE\nwww.ago- online.de\nRisk factors forupstaging from DCIS to\ninvasive cancer in final surgical specimen\nOxford\nLoE\nHigher risk\n\u00a7 DCIS without microcalcification in core needle orvaccum biopsy 3b\n\u00a7 Microcalcification \u2265 11,5 mm 3b\n\u00a7 Presentation astumor in MRI 3b\n\u00a7 Increased Ki-67 (\u226520%) 3b\n\u00a7 PR negative 3b\n\u00a7 High peak contrast enhancement on MRI 3b\n\u00a7 Irregularly shaped , non -circumscribed , heterogeneous ormargin -enhancing\ntumors with intratumoral high signal intensity orperitumoral edema on MRI3b\n\u00a7 Biopsy technique: diagnosis bycore needle biopsy versus vacuum biopsy\n(smaler sampling volume )3b\n\u00a7 High platelet -lymphocyte ratio 3b\nLower risk\n\u00a7 Removal \u2265 90% ofthemicrocalcifications byvacuum biopsy 3b\nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1DE\nwww.ago- online.de\n\u00a7108.196 patients from the SEER data base,\n\u00a7retrospective analysis,\n\u00a7breast cancer specific mortality 3,3 %,\n\u00a7results:\n\u00a7risk is greater for young and black women,\n\u00a7therisk ofdying from breast cancer isincreased after ipsilateral invasive \nrecurrence [HR 18.1 (95% CI 14.0- 23.6); P<0.001] orcontralateral invasive \nrecurrence [HR 13.8 (95% CI 11.5- 16.6); P<0.001), but not after a DCIS \nrecurrence (ipsilateral orcontralateral ),\n\u00a7theuseofradiotherapy reduced therisk ofdeveloping an ipsilateral invasive \nrecurrence from 4.9% to2.5% but didnot reduce breast cancer -specific\nmortality at 10 years (0.9% vs0.8%).Original Investigation\nBreast Cancer Mortality After a Diagnosis  of Ductal Carcinoma In Situ\nNarod A. et al.: JAMA Oncol . 2015 Oct;1(7):888 -96\nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nOriginal Investigation\nBreast Cancer Mortality After a Diagnosis of Ductal \nCarcinoma In Situ\nNarod A. et al.: JAMA Oncol. 2015 Oct; 1(7): 888 -96\nTreatment Cases, No 10\u2013Year BCS \nMortality (95%CI), \n% Univariate HR\n(95% CI)P Value Multivariate3\nHR\n(95%)P Value\nLumpectomy\nWithout\nradiotherapy19762 0.9 (0.7 -1.1) 1[Reference] 1[Reference]\nWith radiotherapy 42250 0.8 (0.7 \u20131.0) 0.86 (0.67 \u20131.10) 0.22 0.81 (0.63 \u20131.04) 0.10\nall 63319 0.8 (0.7 \u20131.0) 1[Reference] 1[Reference]\nUnilateral \nmastectomy19515 1.3 (1.1 \u20131.5) 1.45(1.18 \u20131.79) < 0.001 1.20(0.96 \u20131.50) 0.11\n3Adjusted for year of diagnosis, age of diagnosis, ethnicity, income, \nER-status, tumor size and grade\nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1DE\nwww.ago- online.de\n\u00a7144,524 women treated for DCIS, 1,540 women died of breast cancer,\n\u00a7cohort study included data for women who had first primary DCIS diagnosed \nbetween 1995 and 2014 from the SEER registries database (use of ET is not \nreported),\n\u00a7retrospective analysis,\n\u00a7results:\n\u00a7standardized mortality ratio for death from breast cancer among women with \nDCIS was 3.36 (95% CI, 3.20 -3.53),\n\u00a7risk is greater for young and black women,\n\u00a74,502 (3.1%) ipsilateral invasive recurrences, resulting in a 20 -year actuarial \nrisk of 13.9%,\n\u00a75,527 (3.8%) contralateral invasive breast cancers, resulting in a 20 -year \nactuarial risk of 11.3%,\n\u00a7women with DCIS had a 3 -fold increased risk of death from breast \ncancer compared to women without DCIS.Association of a Diagnosis of Ductal Carcinoma In Situ With Death\nFrom Breast Cancer\nGiannakeas V, Sopik V, Narod SA. JAMA Netw Open. 2020 Sep 1;3(9):e2017124\nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deGood Clinical Practice (GCP)\nSurgical excision (BCS or mastectomy) is the standard\ntreatment for DCIS.\nAdjuvant treatment (radiotherapy, endocrine treatment)\nmust be discussed with the patient individually. Adverse \neffects should be weighted against risk reduction.\nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSurgical Treatment for \nHistologically Proven DCIS I \nOxford\nLoE GR AGO\n\u00a7Excisional biopsy (wire guided) 2b B ++\n\u00a7 Localization with wire -free procedure 3b C +/-\n\u00a7Bracketing wire localization in large lesions 3a C +\n\u00a7Specimen radiography 2b B ++\n\u00a7Intraoperative ultrasound (visible lesion) 3a C +/-\n\u00a7Immediate re -excision for close margins (specimen \nradiography)1c B ++\n\u00a7Intraoperative frozen section (in individual cases for \nmargin assessment)3a D +/-\n\u00a7Interdisciplinary board presentation 2b C ++\nOpen biopsy in suspicious lesions (mammographic microcalcifications , suspicious US, MRI etc.) without preoperative\nneedle biopsy should beavoided\nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSurgical Treatment for \nHistologically Proven DCIS II\nOxford\nLoE GR AGO\n\u00a7Histologically clear margins (Ris0) 1a A ++\n\u00a7Multifocal DCIS: BCS if feasible 2b B +\n\u00a7Re-excision required for close margin (\u2264  2 mm in paraffin section)* 2b C +\n\u00a7Mastectomy** \n\u00a7 Large lesions confirmed by multiple biopsies; no clear margins after re -excision 2a B ++\n\u00a7SLNE\n\u00a7 Mastectomy 3b B +\n\u00a7 BCS 3b B --\n\u00a7 In case of DCIS in the male breast 5 D +/-\n\u00a7ALND 2b B --\n* Individual approach taking into account age, tumor size, grading and implementation of radiation, especially in case of no subsequent radiation\n** Patients who present with a palpable mass have a significantly higher potential foroccult invasion (26%), multicentricity and local recurrence . \nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePrognostic Factors for an \nIpsilateral Recurrence after DCIS\nLoE\n\u00a7 Rese ction margins 1a\n\u00a7 Age 1a\n\u00a7 Size 1a\n\u00a7 Grade 1a\n\u00a7 Growth pattern (cribriforme / solid versus \u201e clinging \u201c/ micro -papillary ) 2b\n\u00a7 Comedo necrosis 1a\n\u00a7 Method of diagnosis 1a\n\u00a7 Focality 1a\n\u00a7 HER2 -overexpression 1a\n\u00a7 ER/PR (positive vs. negative) 1a\n\u00a7 Residual tumor -associated microcalcifications 2b\n\u00a7 Architecture 2b\n\u00a7 (modified) Van Nuys Prognostic Index/ mitotic rate 2b\n\u00a7 Palpable DCIS 2b\n\u00a7 ER-, HER2+, Ki-67+ 2b\n\u00a7 Scores : DCIS  (9 gene recurrence score), CCP (23 genes) 2b\n\u00a7 MSKCC Nomogram 2b\n\u00a7 Intrinsic subtypes (luminal A, B, HER2+, triple negative) 2b\n\u00a7 Hereditary breast cancer risk 2a\n\u00a7 Premenopausal at time ofDCIS diagnosis 2a\n\u00a7 High BMI 2a\n\u00a7 High breast density 2a\n\u00a7 DCIS compared to invasive carcinoma with higher risk of contralateral BC 2b\nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deDCIS Radiotherapy \nStatements\n\u00a7Radiotherapy has no impact on survival LoE1a\n\u00a7Radiotherapy reduces the risk of ipsilateral  (invasive and non \ninvasive) recurrences by 50 %LoE1a\n\u00a7Avoidance of invasive recurrence is probably not associated \nwith survival benefitLoE2b\n\u00a7The absolute (individual) benefit of radiotherapy depends on \nthe individual risk of local recurrence\n\u00a7The number needed to treat (for ipsilateral breast recurrence)\nis 9 (across all risk groups)\nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deDCIS \nAdjuvant Radiotherapy\nSide effects and disadvantages must beweighed against riskreduction . Omitting radiotherapy implies elevated risk forlocal recurrence without\neffect foroverall survival even in thesubset of\u201egood risk\u201d patients . Lack oflevel- 1 evidence supporting theomission ofadjuvant radiotherapy in \nselected low-riskcases: < 2.5 cm, low and intermediate nuclear grade, mammographically detected\n* <50 years or \u2265 50 years and diagnosis based on symptoms, \u2265 15 mm, multifocality, palpable tumor, resection margins <10 mm, G2 / 3, central \nnecrosis, comedo typeOxford\nLoE GR AGO\nRadiotherapy after:\n\u00a7Breast conserving surgery (BCS) 1a A ++\n\u00a7Mastectomy 2b B --\nRadiotherapy procedure:\n\u00a7Conventionally fractionated radiotherapy (50 Gy in 25 fract .) 1a A +\n\u00a7Hypofractionated radiotherapy (40-42,5 Gy in 15 -16 fract .) 1a A +\n\u00a7Radiotherapy boost ofthetumor bed 1b B +/-\n\u00a7in case ofrisk factors * (absolute benefit 5-y-RFS 4%, rate of\nfibrosis significant increased )1ba B +/-\n\u00a7without risk factors 2b B -\n\u00a7Partial breast irradiation [age\u226550y, DCIS \u2264 3 cm, G1- 2, R0 ( \u2265 5 mm), \nunifocal / unicentric ]1b B +\nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deDCIS \u2013\nAdjuvant Systemic Treatment\n\u00a7Adjuvant endocrine treatment has no impact on survival LoE1a\n\u00a7Endocrine treatment may have a small effect on ipsilateral \ninvasive and DCIS recurrencesLoE1a\n\u00a7Endocrine treatment for DCIS has an effect on contralateral \ninvasive and non -invasive cancerLoE1a\n\u00a7The number needed to treat for any ipsilateral breast event is \n15LoE1a\n\u00a7The number needed to treat to prevent invasive breast cancer is 29 for anastrozole vs. 59 for tamoxifen*LoE1b\n* within 12 years; according to IBIS II -trial\nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deDCIS \u2013\nAdjuvant Systemic Treatment\nOxford\nLoE GR AGO\n\u00a7Tamoxifen (only ER+) 20mg 1a A +/-*\n\u00a7Tamoxifen (only ER+) 5mg (long -term data missing) 2ba B +/-*\n\u00a7Aromatase inhibitor (only ER+) in postmenopausal \nwomen only1b A +/-*#\n\u00a7Trastuzumab (only H ER2+) 5 D --\n* Indication fortreatment depends on risk factors , side effects and patient preference\n# Anastrozole versus Tamoxifen: Anastrozole higher fracture rate (OR 1.34), Tamoxifen higher rate ofstroke\n(OR 3.10) and TIA (OR 3.10)\nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1DE\nwww.ago- online.de\nUse ofanastrozole forbreast cancer prevention (IBIS -II):\nlong- term results ofa randomised controlled trial\nCuzick J et al, Lancet 2020\n\u00a7N = 3,864 postmenopausal women at inceased risk forbreast cancer ,\n\u00a7median follow -upof131 months ,\n\u00a7results :\n\u00a749% reduction ofall breast cancers with anastrozole (HR 0.51, 95% CI 0.39 \u20130.66, \np<0.0001),\n\u00a7significant reduction in incidence foranastrozole forductal carcinoma in situ (HR 0.41, \n0.22\u2013 0.79, p=0.0081), especially foroestrogen -positive (HR 0.22, 0.07 \u20130.65, p=0.0062),\n\u00a75-year adherence anastrozole 74.6% vs. 77.0% forplacebo ,\n\u00a7nodifference in major side effects (fractures , mycardial infarctions , deep vein thrombosis , \npulmonary embolism ),\n\u00a7NNT toprevent one breast cancer during 12 years : 29 ( anastrozole ) vs. 59 (tamoxifen ).3864 postmenopausal \nwomen RN=1,920 anastrozole 1mg, 5y\nN= 1,944 placebo\nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1DE\nwww.ago- online.de\nLow dose Tamoxifen (5mg) in premalignant lesions\nLazzeroni M et al: Breast 2019\n\u00a7N = 500,\n\u00a7follow -up5.69 years ,\n\u00a7results:\n\u00a7EFS: Tam 5.5% (14/253) vs. Pacebo 11.3% (28/247),\n\u00a7severe adverse event with same incidence (endometrial cancer\nTam 1 vs. PLAC 0, thrombo -embolic event Tam 1 vs. PLAC 1)\n\u00a7adherence Tam 65% vs. PLAC 61%. DCIS (69%), LCIS (11%), \nADH (20%)RTamoxifen 5 mg 3y\nPlacebo\nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deTherapy of Local DCIS Recurrence  \nafter Tumorectomy\nOxford\nLoE GR AGO\nAfter Radiation:\n\u00a7Simple Mastectomy 3a C +\n+ SLNE 5 D +\n\u00a7Secondary breast conserving surgery 5 D +/-\nWithout radiation after first tumorectomy\n\u00a7Treatment like primary disease 3 C ++\nPrognosis seems tobebetter forinvasive recurrences than forprimary\ninvasive breast cancer . About 50% ofrecurrences areinvasive.\nDuctal Carcinoma in Situ (DCIS)\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.deDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer \nBreast Cancer Surgery\nOncological Aspects\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBreast Cancer Surgery\nOncological Aspects\n\u00a7Versions 2002 \u20132020: \nBauerfeind / Blohmer / B\u00f6hme / Brunnert / Costa / Fersis / Gerber / \nHanf / Janni / Junkermann / Kaufmann / K\u00fchn / K\u00fcmmel / M\u00f6bus / Nitz / \nRezai / Simon / Solomayer / Thomssen / Thill / Thomssen / Untch / \nW\u00f6ckel\n\u00a7Version 2021:\nDitsch /Fallenberg / Friedrich\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBreast Cancer Surgery\nOncological Aspects\nAGO: ++\nSurgery is one sub -step out of multiple steps in breast cancer\ntreatment. Thus, both diagnostic and oncological\nexpertise are an essential requirement for every breast surgeon.\nAGO: +\nAvoidance ofa significant delay in cancer treatment\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePre-therapeutic Assessment \nofBreast andAxilla\nOxford\nLoE GR AGO\n\u00a7Clinical examination 5 D ++\n\u00a7Mammography 2b B ++\n\u00a7 Tomosynthesis (DBT)*** 2b B +\n\u00a7 Contrast -enhanced mammography (alone or as adjunct) 2a B +\n\u00a7Sonography (breast and axilla) 2b B ++\n\u00a7MRI* 1b B +\n\u00a7Minimally invasive biopsy ** 1b A ++\n\u00a7Axilla CNB, iflymph node issuspect 2b B ++\n\u00a7Breast -CT 5 D -\n* MRI -guided vacuum biopsy is mandatory in case of MRI -detected additional lesions (in house or with cooperations ). \nIndividual decision for patients at high familiar risk, with dense breast (density C/D), lobular invasive tumors, suspicion \nof  multilocular disease. No reduction in re- excision rate. \n** Histopathology of additional lesions if relevant for treatment\n*** replacement of FFDM with SM\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.dePre-therapeutic Staging\n* Contrast enhanced ultrasound **especially in patients with high tumor stage (III) ifavailableOxford\nLoE GR AGO\n\u00a7History and clinical examination 5 D ++\nAdditional diagnosis forpatients with tumors ofhigh metastatic potential and/or\nsymptoms and/orindication for(neo -)adjuvant chemotherapy and/orantibody -\ntherapy ):\n\u00a7CT scan ofthorax /abdomen 2a B +\n\u00a7Bone scan 2b B +\n\u00a7Chest X-ray 5 C +/-\n\u00a7Liver ultrasound 5 D +/-\n\u00a7In case ofsuspicious lesions further diagnosis (e.g. liver -\nMRI, CEUS*, biopsy etc.)2a B +\n\u00a7FDG -PET orFDG -PET /CT ** 2b B +/-\n\u00a7Whole body MRI 4 C +/-\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEvidence of Surgical Procedure\nOxford\nLoE GR\n\u00a7Survival rates after lumpectomy + RT are \nequivalent to those after (modified) radical \nmastectomy1a A\n\u00a7Local recurrence rates after skin sparing \nmastectomy are equivalent to those after \nmastectomy 2b B\n\u00a7Conservation of the NAC (nipple areola complex) is \nan adequate surgical procedure if R0 resection is \nachieved2b C\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBreast Conservation:\nSurgical Technical Aspects\nOxford\nLoE GR AGO\n\u00a7Wire guided localization 2b B ++\n\u00a7Wireless intraoperative ultrasound localization * 2b B +\n\u00a7Other procedures (Radionuclide guided localization /RADAR \nreflection , Magnetic Seeds **, RFID )2a B +/-\n*The lesion must bevisualized bythesame examiner pre-and intraoperatively in itswhole extension. Adequate equipment and training\nofthesurgeon aremandatory\n**not adequate forMRI-FU under NACT\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBreast Conservation:\nSurgical Technical Aspects\nOxford\nLoE GR AGO\n\u00a7Tumor -free margins required\n(also in unfavorable biology, \u201eno ink on tumor\u201c is sufficient)2a A ++\n\u00a7Re-excision required for involved margins (paraffin \nsection )3b C +\n\u00a7Therapeutic stereotactic excision alone 4 D --\n\u00a7Ultrasound guided surgery to prevent re -excision 2a B +\n\u00a7Intraoperative margin evaluation (with Margin Probe\u00ae) 1b A +/-\n\u00a7Specimen radiography orultrasound 2b B ++\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBreast Conservation Surgery (BCS)\nOxford\nLoE GR AGO\n\u00a7Multicentric disease (MF/MZ)\n(R0-resection ofall lesions )2b B +\n\u00a7Positive microscopic margins after repeated \nexcision2b B --\n\u00a7Inflammatory breast cancer 2b B --\nForsurgery after neoadjuvant chemotherapy \nsee chapter \u201eneoadjuvant chemotherapy\u201c\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePrimary Axillary Lymph Node Dissection\n(ALND) I\nOxford\nLoE GR AGO\n\u00a7 Endpoint : Survival 3 D -\n\u00a7 Endpoint Staging 3 A -\n\u00a7 Endpoint : Locoregional control 2a A +/-\n\u00a7 pN+ (pre-surgery )without neoadjuvant systemic therapy 2a B +\n\u00a7 cN0 pN0(sn)(i+) 1b A --\n\u00a7 cN0 pN1(mi) 2b B --\n\u00a7 cN0 pN 1(sn) ( cT1/2 , < 3 SN +, BCS + tangential radiation field, adequate \nsystemic therapy) 1b A -\n\u00a7 cN0 pN1 (sn) and mastectomy (no chestwall radiotherapy) 1b B +*\n\u00a7 cN0 pN1( sn)  and mastectomy (T1/2, <3SN+)  ( chestwall radiotherapy) 5 D +/-*\n\u00a7ALND indicated, but not feasible\n\u00a7 Radiotherapy according to AMAROS -trial (validated for cN0 pN1sn) 1b B +\n* Study participation recommended\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n*Study participation (Axsana ) recommended ; ** s. Recommendations chapter Radiotherapy , irradiation alone isnot recommended in case ofpN1( sn)        \nand pN+ ; ***recommendation grade concerning tostaging at cN0 and cN+ ypN0  Axillary Surgery and NACT Oxford\nLoE GR AGO\nSLNE after NACT  \nSLNE before NACT2b\n2bBB++\n-\ncN-Status\n(before NACT)pN-Status\n(before\nNACT)cN-Status\n(after NACT)Surgical procedure\n(after NACT)pN-Status (after \nNACT and Surgery )Surgical\nconsequence from\nhistology **\ncN0 __ ycN0 SLNE aloneypN0 ( sn) __ 2b B ++***\nypN0 (i+)\nypN1 mic (sn)ALND 2b C + (+/ -at i+)\nnone ** 5 D +/-\nypN1 ( sn)ALND 2b C ++\nnone ** 5 D +/-\ncN+ pN+ CNB ycN0SLNE alone *\nTAD (TLNE + SLNE)*\nALND*ypN0\nypN0\nypN0__2b\n2b\n2bB\nB\nB+/-***\n+***+***\nSLNE alone *\nTAD (TLNE + SLNE)*ypN+ incl. ypN0 (i+) ALND 2b B + (+/ -at i+)\nALND ypN+ __ 2b B ++\nnone n.d. none ** 5 D -\ncN+ pN+\nCNB ycN+ALND ypN+ incl. ypN0 (i+) __ 2b B ++\nnone n.d. none ** 5 D -\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deImprovement of the False -Negative Rate of SLNE \nin Patients with pN+CNBbefore NACT and ycN0 after NACT\nOxford\nLoE GR AGO\n\u00a7Removal of> 2 SLNs\n(SLNE, no untargeted axillary sampling )2a B +\n\u00a7Combined tracer 2a B +/-\n\u00a7IHC and serial sections todetect ITC ormicrometastases 2b B +\n\u00a7Localization ofpos. LN before NACT 2b B +*\n\u00a7Targeted Axillary Dissection (TAD = TLNE + SLNE) 2b B +*\n\u00a7TLNE only 2b B +/-*\n* Study participation recommended\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.de\n\u00a7Predictive factors for axillary remission\npN1 (before NACT) to ypN0sn/TAD (after NACT)\n\u00a7Young age\n\u00a7Intrinsic Subtype (ER neg, HER 2 pos)\n\u00a7Grade 3\n\u00a7N1 (vs N2)\n\u00a7pCR (breast)Reduction of individual failures \nfor SLNB in pN1 ypN0\nKantor et al. Ann Surg Oncol 2018\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSentinel Lymph Node Excision (SLNE) \nIndications I\nOxford\nLoE GR AGO\n\u00a7Clinically / sonographically negative axilla (cN0) 1b A ++\n\u00a7 Add CNB in cN1 (clinically/ sonographically suspicious) in order to enable SLNB 2a B +\n\u00a7cT 1\u20132 2b A ++\n\u00a7cT 3\u20134c 3b B +\n\u00a7Multifocal / multicentric lesions 2b B +\n\u00a7DCIS\n\u00a7 Mastectomy 3b B +\n\u00a7 BCT 3b B -\n\u00a7 DCIS in male 5 D +/-\n\u00a7Male breast cancer 2b B +\n\u00a7In elderly patients 3b B +\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSentinel Lymph Node Excision (SNLE)\nIndications II\nOxford\nLoE GR AGO\n\u00a7During pregnancy and / or breast feeding \n(only99mTc-colloid, no blue dye )3 C ++\n\u00a7After prior tumor excision 2b B +\n\u00a7After prior major breast surgery\n(e.g. reduction mammoplasty )3b C +/-\n\u00a7Ipsilateral breast recurrence after prior BCS and prior SNLE4 D -\n\u00a7SLNE in the mammary internal chain 2b B -\n\u00a7After axillary surgery 3b B +/-\n\u00a7Prophylactic bilateral / contralateral mastectomy 3b B --\n\u00a7Inflammatory breast cancer 3b C -\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSentinel Lymph Node Excision (SLNE)\nMarking\nOxford\nLoE GR AGO\n\u00a799mTc colloid 1a A ++\n\u00a7Preoperative lymphoscintigraphy (added infomation\nlimited, but mandatory bylegal regulations )*1b A +\n\u00a7Patent blue dye 1a A +/-\n\u00a7Methylen blue    4 D -\n\u00a7Indocyanin green (ICG) 2a B +/-\n\u00a7SPIO#2a B +/-\n*  In Germany required forquality assurance ofnuclear medicine\n#    SPIO: Superparamagnetic Iron Oxide\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deProcedure after Neoadjuvant Therapy\nOxford\nLoE GR AGO\n\u00a7Early marking of tumor (incl. detailed topographic \ndocumentation)5 D ++\n\u00a7Surgical removal oftumor / representative excision of\npost -therapeutic , marked tumor area2b C ++\n\u00a7Tumor resection in new margins 2b C ++\n\u00a7Microscopically clear margins 2a B ++\nFor \u201eSurgery after neoadjuvant chemotherapy\u201c \nsee chapter \u201eNeoadjuvant chemotherapy\u201c\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAdjuvant Therapy after Primary Surgery\nOxford\nLoE GR AGO\n\u00a7Start adjuvant systemic therapy and radiotherapy (RT) as \nsoon as possible (asap) after surgery 1b A ++\n\u00a7Start of adjuvant chemotherapy +/ -HER2 therapy  asap \nafter surgery, prior to RT1b A ++\n\u00a7Without cytotoxic therapy +/ -anti-HER2 therapy:\n\u00a7Start RT 6 \u20138 weeks after surgery 2b B ++\n\u00a7Start endocrine therapy asap after surgery 5 D ++\n\u00a7Endocrine therapy concurrent with radiotherapy 3b C +\nBreast Cancer Surgery Oncological Aspects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1EOncoplastic and\nReconstructive Surgery\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePlastic -reconstructive aspects after \nmastectomy\n\u25aaVersions 2002 \u20132020: \nAudretsch / Bauerfeind / Blohmer / Brunnert / Dall / Ditsch / Fersis / \nFriedrich/ Gerber / Hanf / K\u00fchn / K\u00fcmmel / Lux / Nitz / Rezai / Rody / \nScharl / Solbach / Thomssen\n\u25aaVersion 2021:\nThill / Heil\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deUse ofplastic surgical techniques at thetime oftumor\nremoval toenable safe resection margins and topreserve\naesthetic breast contour .\nFocus on favorable scar placement , adequate soft tissue\nformation , choice ofproper reconstruction procedure\n(including in thecontext ofradiation ) and reconstruction\nofthecontralateral side toachieve symmetric results . Definition ofoncoplastic surgical procedures\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de1. ByHoffmann/Wallwiener: \nClassification byreconstructive surgery complexity with respect to\nbreast conservation and mastectomy : PubMed Central, Figure 1: \nBMC Cancer. 2009; 9: 108. Published online 2009 Apr 8. \ndoi:10.1186/1471-2407-9 -108 ( nih.gov )\n2. By Clough: \nOncoplastic classifcation forbreast conservation according to\nrelative resection volume : Level 1: < 20% ofbreast volume resection\n(\u201esimple oncoplastic surgery \u201c) and Level 2 > 20% ofbreast volume\nresection with quadrant per quadrant techniques ofmastopexy . Classifications\nHoffmann D et al., BMC 2009; Clough KB et al., Ann Surg Oncol 2010\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deOncoplastic breast conserving surgery (OPS) \nOxford\nLoE GR AGO\n\u25aaOPS may replace mastectomy in selected patients 2b B +\n\u25aaOPS and BCS areoncologically equivalent 2b B +\n\u25aaAesthetic outcome ofOPS might bebetter in \nselected cases2b B +\n\u25aaComplication rates ofOPS and BCS aresimiliar 3b C +\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAlgorithm ofBreast Reconstruction\nPatient wishes to undergo breast reconstruction\nN.B.: Habitus, breast volume, wishes, previous surgery \nSSM/NSM and implantation\nor\nMRM + tissue expander \u00e0 Implant\nor\nnot suitable foralloplastic\nreconstruction orwish ofpatient\n\u00e0 autologous reconstructionPostmastectomy radiotherapy indicated\nMastectomy\n\u00e0 Radiotherapy \n\u00e0 Delayed autologous\nreconstructionNot suitable forautologous\nreconstruction\nE.g. toolittle subcutaneous fat,\nwishes ofpatient\nDirect prosthesis reconstruction or\ntwo-staged implant -based\nreconstruction : \nMRM\u00e0 Tissue expander \u00e0\nImplant\n+ Radiotherapy\nN.B.: Increased complication rate, \nparticularly capsular fibrosisTobediscussed in individual cases :\nImmediate autologous reconstruction\nN.B.: Increased fibrosis rate\nDelayed prothesis reconstruction\nN.B.: Increased complication rateNo postmastectomy radiotherapy\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\u00a7Planning ofreconstructive procedure byinterdisciplinary tumor board before mastectomy\n\u00a7Counseling regarding all surgical techniques , including advantages and disadvantages\n\u00a7Preference forautologous reconstruction after radiotherapy orifradiotherapy isplanned\n\u00a7Offer second opinion\n\u00a7Discussion ofneoadjuvant treatment ifunfavorable tumor -breast -relation\n\u00a7Consideration ofcontralateral breast ; \n\u00a7discuss possible alignment / sequencing surgical procedures toproduce symmetry ; \nusually after at least 3 -6 months (Caveat : need forpost -resections , consider effects\nofradiotherapy foraffected side)\n\u00a7Preference forless stressful surgical technique with stable long -term aesthetic result\n(prefer BCS / OPS over mastectomy)\n\u00a7Avoid delay ofadjuvant therapy due toreconstruction\n\u00a7Assessment ofoutcome (e.g. PROM)\n\u00a7Ensure that oncologic safety isnot impairedBreast Reconstruction Principles\nGood Clinical Practise\nAGO: ++ \nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePostmastectomy Reconstruction\nOxford\nLoE GR AGO\n\u00a7Use ofsilicone gelfilled breast implants\none step ortwo steps after expander2a B +\n\u00a7Safety comparable tosaline implants 2b B\n\u00a7Autologous tissue reconstruction 2a B +\n\u00a7Pedicled tissue reconstruction 2a B +\n\u00a7Free tissue reconstruction\n(including vascular anastomoses )2a B +\n\u00a7Autologous tissue procedure plus implants 3a C +/-\nCaveat : BMI >30, smoking status , diabetes, radiotherapy , age, bilateral mastectomy\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deTiming of Reconstruction\nOxford\nLoE GR AGO\n\u25aaImmediate breast reconstruction 3b B ++\n\u25aaMandatory : SSM/NSM\n\u25aaAvoidance ofa postmastectomy syndrome\n\u25aaDelayed breast reconstruction (2-step) 3b B ++\n\u25aaNointerference with adjuvant procedures (CHT, RT) \n\u25aaDisadvantage : loss ofskin envelope\n\u25aa\u201eDelayed -immediate\u201c breast reconstruction\n(placeholder before definitive reconstruction )3b B +\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deTiming of implant Based Reconstruction \nand Radiotherapy\nOxford\nLoE GR AGO\n\u00a7Implant reconstruction (IR) 2a B +\n\u00a7IR without radiotherapy 2a B ++\n\u00a7IR prior toradiotherapy 2a B +\n\u00a7IR following radiotherapy 2b B +/-\n\u00a7IR following secondary mastectomy\n(after BCS* with radiotherapy )2a B +/-\n\u00a7Perioperative antibiotic prophylaxis (max. 24 hours ) 2a B +\n*BCS: Breast Conserving Surgery\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\u25aa11 studies (15,966 mastectomy procedures) \n\u25aaThree studies comparing topical antibiotics with no topical \nantibiotics demonstrated statistical significance (RR= 0.26, 95% CI: 0.12 \u20130.60, P = 0.001)\n\u25aa8 studies comparing extended systemic antibiotics with standard of care found no statistical significance (RR = 0.80, 95% CI: 0.60\u2013 1.08, P\n= 0.13).\nLoE2a B\nIn the setting of immediate breast reconstruction (IBR) following mastectomy, there is insufficient evidence for \nthe use of extended prophylactic antibiotics to reduce surgical site infection (SSI) rates. Welldesigned\nrandomized controlled trials in patients undergoing IBR should be conducted to determine the appropriate regimen and/or duration of prophylactic antibiotics on SSI outcomes .\nHai Y et al. Plast Reconstr Surg Glob Open 2020;8:e2613; doi: 10.1097/GOX.0000000000002613 , Metaanalysis ofProphylactic Antibiotics >24h in \nImplant -based Immediate Breast Reconstruction (IBR)\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deCave: High complication rate in combination with\nradiotherapy (capsular contracture , revision surgery , \nreconstruction failure , reduced cosmetic outcome and\npatient satisfaction ) \nCave: Lower patient satisfaction with implant -based\nreconstruction plus radiotherapy compared toautologous\nreconstruction plus radiotherapy\nLoE2b BRadiotherapy and\nImplant -based Reconstruction\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\u00a7US FDA Breast Implant Postapproval Studies (LPAS)\nLong -term Outcomes in 99,993  Patients\n(Primary Augmentation: N= 71.937 / Primary Reconstruction : N= 9942)\n-56% ofimplants were silicone implants\n\u00a7Possible Associations :\n-Sjogren syndrome : (SIR*8.14)\n-scleroderma : (SIR 7.00)\n-rheumatoid arthritis : (SIR5.96)\n-stillbirth : (SIR4.50)\n-melanoma : (SIR3.71)\n\u00a7At 7 years , reoperation rate is11.7% forprimary augmentation , and 25%  for\nprimary /revision reconstruction .\n\u00a7One case ofBIA-ALCLPossible Associations between Implants \nand rare Diseases\n*Standardized incidence ratio Associations need to be further analyzed with \npatient -level data to provide conclusive evidence !\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deRare Systemic Harms Compared With the General Population:\nAllergan follow -up 2 years\nMentor follow -up 7 yearsPossible Associations between Implants \nand rare Diseases\nManufacturer ,yStudy \nEventsStudy Event Rate\n(Per 10,000 Person\nYr)General Population Event \nRate\n(Per 10,000 Person Yr) SIRSIR 95% CIP Value\nFibromyalgia Allergan 9 1.8 112.8 0.02 0.01\u2013 0.03 <0.001\nMentor 307 28.4 112.8 0.25 0.22\u2013 0.28 <0.001\nRheumatoid arthritis Allergan 4 0.8 5.4 0.15 0.04\u2013 0.38 <0.001\nMentor 349 32.2 5.4 5.96 5.35\u2013 6.62 <0.001\nScleroderma Mentor 46 4.2 0.6 7.00 5.12\u2013 9.34 <0.001\nSjogren syndrome Mentor 62 5.7 0.7 8.14 6.24\u2013 10.44 <0.001\nSystemic lupus erythematosus Allergan 3 0.6 5.4 0.11 0.02\u2013 0.32 <0.001\nMentor 66 6.0 5.4 1.11 0.86\u2013 1.41 0.398\nCancer Allergan 80 16.0 41.3 0.39 0.31\u2013 0.48 <0.001\nMentor 532 63.8 41.3 1.54 1.42\u2013 1.68 <0.001\nBreast cancer Mentor 116 13.9 12.5 1.11 0.92\u2013 1.33 0.26\nLung cancer Mentor 5 0.6 5.2 0.12 0.04\u2013 0.27 <0.001\nBrain cancer Mentor 3 0.4 0.6 0.67 0.14\u2013 1.95 0.639\nMelanoma Mentor 65 7.8 2.1 3.71 2.87\u2013 4.73 <0.001\nNeurological disorder Allergan 18 3.6 22.5 0.16 0.09\u2013 0.25 <0.001\nMentor 394 35.8 22.5 1.59 1.44\u2013 1.76 <0.001\nMultiple sclerosis Mentor 47 4.3 2.5 1.72 1.26\u2013 2.29 0.001\nMyositis Mentor 17 1.5 0.8 1.88 1.09\u2013 3.00 0.018\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBreast Implant Associated Anaplastic Large Cell\nLymphoma (BIA -ALCL)\n\u00a7Approximately 10.000.000 implant carriers\n\u00a7Rare disease , 3 % ofNon -Hodgkin Lymphomas, 0.04 -0.5 % ofall malignant\nbreast diseases\n\u00a71:3.000 \u201330.000 in women with textured implants (caveat : underreporting !)\n\u00a7Estimated incidence 0.6-1.2 / 100.000 women with implants (median age: 54 y)\n\u00a7Mainly associated with textured implants\n\u00a7Interval todiagnosis : 8 years (median )\n\u00a7Clinical symptoms\n\u00a7Swelling and seroma . (60 %)\n\u00a7Solid tumor (17 %)\n\u00a7Seroma and solid tumor (20 %)\n\u00a7Histology : CD30+ / ALK -T-Cell Lymphoma\n\u00a7Mandatory registration asSAE ( \u00a73 MPSV to BfArM )\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\u00a7The cause ofBIA-ALCL isnot established ; however , ithasbeen proposed that lymphomagenesis may\nbedriven bya chronic in\ufb02ammatory reaction induced bycapsule contents orsurface . The risk for\nBIA-ALCL hasbeen shown tobesignificantly higher forimplants with grade 3 and 4 surfaces.BIA-ALCL -Surfaces ofBreast Implants\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBIA-ALCL \u2013Diagnosis \nOxford\nLoE GR AGO\n\u00a7Breast US (assessment ofnew seromas > 1 year after implant\ninsert , solid lesion (sensitivity : 84%, specificity : 75%)3a D ++\n\u00a7Breast- MRI in confirmed cases 3a D ++\n\u00a7Staging (Imaging, e.g. CT, PET -CT) 3a D ++\n\u00a7Cytology oflate seromas\n\u00a7-> 50 ml \n\u00a7-Complete assessment\n\u00a7-flow -cytology (T-cellclone )\n\u00a7-BIA- ALCL specific cytologic diagnostic (CD 30+)3a D ++\n\u00a7Core needle biopsy in solid lesions\n\u00a7Lymphoma assessment ofresected tissue and histologic staging3a D ++\n\u00a7Documentation oftheimplant (manufacturer , size, volume, \nsurface, Batch -number ) and entry in registry5 D ++\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBIA-ALCL \u2013Therapy\nOxford\nLoE GR AGO\n\u00a7Implant resection and complete capsulectomy including\ntumorectomy3a C ++\n\u00a7Resection ofsuspicious lymph nodes , noroutine useof\nsentinel -node -biopsy , noaxillary dissection4 D ++\n\u00a7Polychemotherapy ( e.g. CHOP) in cases of extra capsular \nextension4 D +\n\u00a7Radiotherapy in unresectable tumors 5 D +/-\n\u00a7Case discussion in an interdisciplinary tumor board in the\npresence ofa lymphoma specialist5 D ++\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deDiagnostic Pathways and Assessment\nLate Seroma\n>12 months since \n1stimplant\nUltrasound\nBreast + Axilla\nMass\nCore biopsy\n(any solid mass)\nHistology\nImmunohistology\nCapsule -related \nsolid tumor mass\n+/-\nMammogram\n(not useful if age < 40 yrs)\nEffusion\nFNA fluid\n(take > 50 ml)\nCytology\nimmune -cytology \nfor CD30\nPathological\nskin lesion\nPathological\nlymph nodes\nLymphomata\nB-SymptomsSuspicion Imaging\nSkin biopsy\nPET CT\n(r/o systemic disease)\nMRI Breast\n(if diagnosis is \nindeterminate)\nFindings Samples Assessment\nFlow -Cytometry\nClonality studies\n(for T -cell rearragenemnts)\nIndeterminate?\nSuspicious?\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBIA-ALCL Treatment Pathways\nBIA-ALCL\nconfirmed\nReferral to\nexperienced\nbreast cancer \ncenter\nEn-bloc \ncapsulectomy and  \ncomplete excision \n(mass)\nStage I : No further \ntreatment\nClinical follow -up \n(ultrasound /CT \nscan) 3 \u20136 m for 2y, \nafterwards for 5y\nIndeterminate\nPET-CT & \nbreast MRI\n+/-other breast\n+/-axilla biopsy \n(SNB not recommended)\nStage II -IV:\nConsider adjuvant \ntreatment\nPET-CT if\nsymptomatic\nNegative for \nBIA-ALCLOutcome Workup\nClinical suspicion \nremains\nChemo -\nimmunotherapySurgery Adjuvant Therapy Follow -up\nTreatment of infection/ \nbenign seroma (serial \naspiration, implant \nexchange with \ncapsulectomy)Options: Further \nimaging US/MRI/Repeat \nFNAC , Tertiary referral\nRoutine bloods\n(+/-bone marrow bx)\nMTD Discussion\nConsider diagnostic \ncapsulectomy\nRadiotherapy for \npositive margins / \nirresectable  thoracic \nwall infiltration but \nN0/M0Histological Staging \n(Clemens et al. 2016)\nMTD \nDiscussion\nReports to  BfArM, \nmanufacturer, DGPR\u00c4C, \nPROFILE database (FDA)\nTreatment as per \nsystemic ALCL regimes\n24 -36 Gy in 15 \nfractions\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deTNM Staging of BIA -ALCL\nTNM -\nKategorieDefinition\nTumor extent\n(cT/pT)T1 Confined to seroma or a layer on \nluminal side of capsule\nT2 Early capsule infiltration\nT3 Cell aggregates or sheets infiltrating \nthe capsule\nT4 Lymphoma infiltrates beyond the \ncapsule\nRegional lymph \nnodes (cN/pN)N0 No lymph node involvement\nN1 One regional lymph node positive\nN2 Multiple regional lymph nodes \npositive\nMetastasis\n(cM/pM)M0 No distant spread\nM1 Spread to other organs or distant sitesStage Definition\nIA T1 N0 M0\nTB T2 N0 M0\nTC T3 N0 M0\nIIA T4 N0 M0\nIIB T1-3 N1 M0\nIII T4 N1 -2 M0\nIV T any N any M1\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\u00a7Despite an increase ofBIA-ALCL in association with texture implants\ntheuseoftextured implants isstill permitted!\n\u201eForthemoment , textured implants cansafely continue tobeused with patient's fully informed\nconsent , and that women that have these type ofimplants already in place don't need toremove or\nsubstitute them , which would undoubtedly cause harm tomany tens ofthousands ofwomen , to\nprevent an exceptionally rare, largely curable and currently poorly understood disease .\"BIA-ALCL \u2013EUSOMA -Recommendation\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deTissue Replacement Techniques and Meshes\n(Details ofImplant Reconstruction )\n# Participation in registry studies recommendedOxford\nLoE GR AGO\n\u00a7The subcutaneous lodge is superior to the subpectoral\nlodge3b C +/-\n\u00a7Acellular dermal matrix (ADM) \n\u00a7subpectoral 1b A +/-#\n\u00a7subcutaneous 2b B +/-#\n\u00a7Synthetic meshes\n\u00a7subpectoral 2b B +#\n\u00a7subcutaneous 2b B +#\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deLipotransfer \nOxford\nLoE GR AGO\n\u00a7Lipotransfer following mastectomy and\nreconstruction2a B +\n\u00a7Lipotransfer after BCS* 2a B +\n\u00a7Autologous adipose derived stem cells (ASCs)-\nenriched fatgrafting vs. without stem cells2a B -\n*BCS: Breast Conserving Surgery\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePostmastectomy Pedicled Reconstruction\nOxford\nLoE GR AGO\nBreast reconstruction (BR) with autologous tissue\n\u00a7TRAM, latissimus- dorsi- flap (both canbe\nperformed asa muscle -sparing technique )2a C +\n\u00a7Delayed TRAM in patients at high -risk 3a B +\n\u00a7Ipsilateral pedicled TRAM 2a B +\n\u00a7Radiotherapy :\n\u00a7BR following radiotherapy 2a B +\n\u00a7BR prior toradiotherapy 2a B +/-\n\u00a7(higher rates offibrosis , wound healing problems , \nliponec rosisand reduced aesthetic outcome )\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deFree flaps forreconstruction\n*ICG: indocyanin greenOxford\nLoE GR AGO\nType of free flap\n\u00a7DIEP 2a B +\n\u00a7Free TRAM 2a B +\n\u00a7SIEA 3a C +/-\n\u00a7Glutealis flaps (SGAP -/ IGAP, FCI) 4 C +/-\n\u00a7Free gracilis flap (TMG) 4 C +/-\n\u00a7 Use ofICG* toassess flap perfusion 2a B +\nAdvantages\n\u00a7DIEP and free TRAM are potentially muscle -sparing procedures. DIEP has a lower rate of \nabdominal hernias ,especially in obesity\nDisadvantages\n\u00a7Time -and personnel consuming microsurgical procedure s\n\u00a7Intensified postoperative monitoring\n\u00a7Pre-reconstruction radiotherapy increases rate of vascular complications\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePedicled versus free tissue transfer\nOxford\nLoE GR AGO\n\u00a7Muscle -sparing techniques and accuracy\nofabdominal wall closure lead tolow rates oflate\ndonor site complications independent ofmethod\nused3a A ++\n\u00a7Autologous abdominal -based reconstructions have\nhighest satisfaction rates (PROM)\n\u00a7Donor site morbidity (e.g. impaired muscle\nfunction ) hastobetaken into consideration forall \nflap technique s\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSkin-/nipple -sparing Mastectomy (SSM/NSM)\nandReconstruction\n*ICG = Indocyanine GreenOxford\nLoE GR AGO\n\u00a7Skin -/nipple -sparing Maste ctomy (SSM/NSM)\n\u00a7Safe (same recurrence rate as MX) 2b B ++\n\u00a7Higher QoL for patients 2b B ++\n\u00a7NAC can be preserved under special conditions 2b B ++\n\u00a7Feasible after mastopexy / reduction mammoplasty 4 C ++\n\u00a7Use of ICG* to predict necrosis of the skin 1b B +\n\u00a7Skin incisions -different possibilities:\n\u00a7Periareolar\n\u00a7Hemi -periareolar with/without medial/ lateral extension  \n\u00a7Reduction pattern: \u201einverted -T\u201c or vertical\n\u00a7Inferior lateral approach, inframammary fold\n\u00a7Lowest incidence of complications 2b B +\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePrevention and therapy of capsular contracture\nOxford\nLoE GR AGO\n\u25aaPrevention\n\u25aaTextured implantats (Caveat : BIA- ALCL) 1a A +\n\u25aaAcellular Dermal Matrix (ADM) vs. nil 2a B +\n\u25aaSynthetic mesh vs. nil 3a C +\n\u25aaTopical antibiotics /antiseptics 2a B +\n\u25aaPVP ( Povidone -Iodine ) 2a B +/-\n\u25aaLeukotriene -antagonists 2a B +/-\n\u25aaBreast massage 3a C -\n\u25aaSurgical interventions\n\u25aaCapsulectomy 3b C +\n\u25aaCapsulotomy (Caveat : exclusion ofBIA- ALCL) 3b C +\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSeroma after implant -based reconstruction I\nOxford\nLoE GR AGO\n\u00a7Incidence: around 5-10% (2 -50%) 2a B\nCo-variates :\n\u00a7History ofradiation increases therisk (RR ca. 3) 2a B\n\u00a7Obesity increases risk (e.g. BMI > 30 vs. < 30; RR ca. 3) 2a B\n\u00a7ADM increases risk (RR ca. 3) 2a B\n\u00a7Smooth expanders increase risk (RR ca. 5) 3b C\n\u00a7History ofneoadjuvant systemic chemotherapy does not \nincrease therisk2a B\n\u00a7Epipectoral pocket des not incurease therisk 2b B\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSeroma after implant -based reconstruction II\nOxford\nLoE GR AGO\nPrevention\n\u00a7Drain with no, little and much suction 3b C +\n\u00a7Drain removal at < 30ml per 24 hours 2b B +\nTherapy \n\u00a7Evacuation ofserma byFNA orre-insertion ofdrain 4 C +\n\u00a7Dressings 5 D +/-\n\u00a7Revision surgery with capsulectcomy (ultima ratio ) 5 D +\n\u00a7Revision surgery with implant removal (ultima ratio ) 5 D +\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deRisk-reducing bilateral mastectomy \nfor healthy women (RRBM)  \nOxford\nLoE GR AGO\n\u25aaRRBM reduces breast cancer incidence 2b B ++\n\u25aaRRBM in deleterious BRCA1/2 mutation 2a B +*\n\u25aaRRBM in hig h-risk situation without BRCA 1/2 mutation\n(individual decision depending on personal -family history and\nmutational status \u2013e.g. high and moderate -risk genes, Hodgkin \nlymphoma )4 D +/-*\n\u25aa High risk and noBRCA counselling in specialized centre * 5 D --\n\u25aa Non -directive counselling prior toRR-BM 2b B ++*\n\u25aa RR-BM should beconsidered with other risk- reducing surgical options incl. \nbilateral salpingoophorectomy (BSO) and in thecontext ofpre-existing diseases2a A ++*\n\u25aa Further need foreducation ofphysicians regarding possibilities and advantages\nofRRBM1b A ++\n*Counselling , risk prediction , and follow -upin specialized centers recommended\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSurgical Prevention for Healthy\nFemale BRCA1/2 Mutation Carriers\nOxford\nLoE GR AGO\n\u00a7Risk- reducing bilateral salpingo- oophorectomy \n(RR-BSO)**2a B *\n\u00a7Reduces OvCa incidence and mortality ++*\n\u00a7Reduces overall mortality ++*\n\u00a7Risk- reducing bilateral mastectomy (RR-BM)\n\u00a7Reduces BC incidence 2b B +*\n\u00a7Reduces BC mortality in BRCA1 mutation carriers*** 2b B +*\n*study participation recommended\n** The RR-BSO is recommended from about 35 years for BRCA1 and from about 40 years for BRCA2 mutation carriers, \ntaking into account the age of ovarian cancer diagnosis in the family and family planning status.\n*** No reduction in mortality could be shown for BRCA2 mutation carriers. RRM counselling should be individualised .\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deRisk-reducing Interventions forBRCA1/2 Female\nMutation Carriers Affected byBreast Cancer\nOxford\nLoE GR AGO\n\u00a7Risk-reducing bilateral salpingo- oophorectomy  (RR -BSO) 2b B +*\n\u00a7 Reduces OvCa incidence and mortality\n\u00a7 Reduces overall mortality\n(contradictory results forreduction ofcl BC incidence )\n\u00a7Prophylactic contralateral mastectomy  (RR -CM) reduces BC\nincidence and mortality2b B +*\n\u00a7Tamoxifen ( reduces contralateral BC incidence ) 2b B +/-*\n\u00a7Indication forRR-CM should consider ageat onset offirst breast\ncancer in affected gene2a B ++*\n\u00a7RR-BM after ovarian cancer 4 C +/-**\n*study participation recommended\n** Depends on tumor stage (FIGO I/II ), recurrence free interval (\u2265 5y), ageSynchronisierung \nzum Kapitel  Brustkrebsrisiko\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deForms ofrisk-reducing (bilateral) \nmastectomy (RR-BM)\nOxford\nLoE GR AGO\nRR-BM reduces breast cancer incidence ;**BC-specific\nmortality also likely reduced\n\u00a7Simple mastectomy 2b B +\n\u00a7RR-BM bySSM* 2b C +\n\u00a7RR-BM byNSM* (NAC#sparing ) 2b C +\n\u00a7Contralateral prophylactic mastectomy 4 C +/-\n*SSM / NSM: Skin -/Nipple -Sparing Mastectomy\n# NAC: nipple- areola complex\n**depending on prior illnesses, e. g. pre -existing ovarian cancer 1 -2% (stage III- IV)\nOncoplastic and Reconstructive Surgery\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2021.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1EAdjuvant Endocrine Therapy \nin Pre- and Postmenopausal Patients \nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAdjuvant Endocrine Therapy in \nPre-and Postmenopausal Patients \n\u00a7Versions 2002 \u20132020:\nBauerfeind / Dall / Diel / Fersis / Fehm / Friedrichs / Gerber / G\u00f6ring / \nHanf / Harbeck / Huober / Jackisch / Lisboa / L\u00fcck / Lux / Maass / von \nMinckwitz / M\u00f6bus / M\u00fcller / Nitz / Oberhoff / Schaller / Scharl / \nSchneeweiss / Sch\u00fctz / Solomeyer / Stickeler / Thomssen / \n\u00a7Version 2021: \nFasching / Loibl\nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAssessment of\nSteroid Hormone Receptor Status\nOxford LoE: 1 GR: A AGO: ++\nendocrine responsive \u2013hormone receptor positive\nImmunhistology (ER and/or PgR)\n0% pos. cells: endocrine resistant\n1\u201310% pos. cells: possibly endocrine sensitive\n> 10% pos. Zellen: endocrine sensitive\nUnknown hormone \nreceptor status:endocrine sensitive\nIF ER negative / PR positive (> 10% positive cells ): reassess IHC status\nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAdjuvant Endocrine Therapy\nAssessment of Menopausal Status\nOxford\nLoE GR AGO\nAssessment ofmenopausal status :\n\u00a7Menstruation history ++\n\u00a7FSH, E2 ++\nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAdjuvant Endocrine Therapy\nOxford\nLoE GR AGO\nEndocrine therapy: \n\u00a7Endocrine responsive 1a A ++\n\u00a7endocrine doubtful responsiveness 3b D +\n\u00a7Endocrine therapy \nsequentially after CT5 D +\n\u00a7Endocrine therapy concurrent with T -DM1 /anti -HER2 \ntherapy (w/o chemotherapy)5 D +\n\u00a7Non -responsive: No endocrine therapy 1a A ++\nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deGeneral Principles in \nAdjuvant Endocrine Therapy AGO ++\n\u00a7Adjuvant endocrine therapy is divided into initial therapy (years 1 -5) and \nextended adjuvant therapy (EAT, years 6 -10+).\n\u00a7Standard treatment duration is 5 years.\n\u00a7Extended therapy should be considered based on individual risks and \nbenefits.\n\u00a7Duration, choice & sequence of AI or Tam mainly depend on menopausal status, tolerability, and risk of recurrence.\n\u00a7Switch to another better tolerated endocrine treatment (Tam or AI) is \nbetter than stopping endocrine therapy altogether. \n\u00a7AI should be used as first treatment in patients, especially in case of lobular cancers and/or high risk of recurrence.\n\u00a7To date, there is no sufficiently validated biomarker for identification of patients at risk for early versus late recurrence.\nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePremenopausal Patients\nInitial Adjuvant Endocrine Therapy (Year 1- 5)\nOxford\nLoE GR AGO\n\u00a7Tamoxifen 5 years (low risk ofrelapse ) 1a A ++\n\u00a7Tamoxifen + OFS 2 -5 years (intermediate risk of relapse)* 2b C ++\n\u00a7AI +OFS#for 5 years (high risk of relapse)* 1b B +\n\u00a7GnRH alone\n(only, if relevant contraindication for Tam vs. no therapy at all)1a B +\nOFS: ovarian function suppression; \n*   aslong astolerated and thepatient isclearly premenopausal\nafter chemotherapy if ovarian function resumes within 24 months\nApplication of chemotherapy in the trials served as a surrogate for high recurrence risk\n#  in premenopausal women AI only in combination with OFS \nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nTEXT /SOFT Joint Analysis\nTamoxifen 20 mg/day\n+ OFS* (n = 1328)Premenopausal\nPatients with HR+ BC\n\u2264 12 wks after surgery(N = 2672)\n*OFS\n\u00a7TEXT: triptorelin 3.75 mg \nIM every 28 days for 6 \nmos, then optional \nbilateral oophorectomy \nor irradiation\n\u00a7SOFT: choice of methodTEXT\nExemestane 25 mg/day\n+OFS* (n = 1014)\nTamoxifen 20 mg/dayPremenopausal\npatients with HR+ BC\n\u2264 12 wks after surgery\n(if no chemo) or\n\u2264 8 mos after chemo\n(N = 3066)SOFTTamoxifen + OFS*\n(n = 2344)\nTamoxifen 20 mg/day\n+ OFS* (n = 1016)Exemestane + OFS*\n(n = 2346)Exemestane 25 mg/day\n+OFS* (n = 1332)Joint Analysis\n5 yrs\nNach Pagani O, et al. N Eng J Med, 371(2) 2014Median follow -up: 5.7 yrs\nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nGnRH Analogue every 3 months\nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePostmenopausal Patients\nInitial Adjuvant Endocrine Therapy (Years 1 -5)\nOxford\nLoE GR AGO\n\u00a7Aromatase Inhibitor (AI) for first 5 years 1a A ++\n\u00a7Non steroidal -AI in lobular cancer 2b B +\n\u00a7High risk of recurrence 2b B +\n\u00a7Sequential therapy for first 5 years * 1a A ++\n\u00a7Tam (2 -3 yrs.) followed by AI to complete 5 years         1a A ++\n\u00a7AI (2 -3 yrs.)  followed by Tamoxifen to complete 5 years 1b C ++\n\u00a7Tamoxifen 20 mg/d for 5 years** 1a A +\n*   in postmenopausal patients , AI should beintegrated in thefirst five years\n** Tamoxifen may beoffered toindividual patients with very low risk ofrecurrence orifcontraindications forAI arepresent\nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nAromatase Inhibitor vs. Tamoxifen vs. \nSequentieller Therapie -5 Jahre Upfront Therapie \nAromatase inhibitors versus tamoxifen in early breast cancer: patient -level meta -analysis of the randomised trials. \nEarly Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet. 2015 Oct 3;386(10001):1341 -52.\nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAdjuvant therapy with CDK 4/6 inhibitors\nOxford\nLoE GR AGO\nIn patients at high- risk ofrelapse according totrial1,2,3\n\u00a7Abemaciclib for 2 years + standard endocrine therapy12b C +/-\n\u00a7Palbociclib for2 years + standard endocrine therapy22b C -\n\u00a7Palbociclib for1 year + standard endocrine therapy31b B -\n1MonarchE; \u00b2Pallas \u00b3PenelopeB\nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nCDK4/6 Inhibitoren zus\u00e4tzlich zu einer standardm\u00e4\u00dfigen \nendokrinen Therapie in der adjuvanten Situation\nPALLAS MonarchE Penelope\nTherapie Palbociclib for2years Abemaciclib for2years Palbociclib for1year\nN 5600 5637 1250\nMain Inclusion Criteria AJCC Stage II:\n\u2022 T0/T1 N1\n\u2022 T2 N0\n\u2022 T2 N1\n\u2022 T3 N0\norAJCC Stage III\n\u2022 T0/T1 N2\n\u2022 T2 N2\n\u2022 T3 N1/N2T1-T4and N1with one ofthefollowing criteria\n\u2022 \u22654 ipsilateral pos. axillary lymph nodes\n\u2022 1-3 ipsilateral pos. axillary lymph nodes and\none ofthefollowing criteria\n-G3\n-Tumor size \u22655cm\n-Ki-67\u226520%\u2022\u2265ypT 1or\n\u2022\u2265ypN 1\n\u2022CPS-EGscore >=3 pr2ypN+\n\u2022Neoadjuvant Chemotherapy ofatleast 16\nweeks\nEarly discontinuation of\ntherapy43% 27% 20%\nMedian follow up 24months 15months 43months\nResults (iDFS) HR: 0,93 (95%CI: 0,76 -1,15)\n3 year iDFS: 88.2% vs 88.5% HR = 0,713 (0.583 -0.871)\n2 year iDFS: 92.3% vs 89.3% HR=0,93 (95%KI: 0,74 -1,17)\n3year iDFS : 81.2% vs77.7% \nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePremenopausal Patients \nExtended Adjuvant Endocrine Therapy (EAT) (Years 6 \u201310)\nOxford\nLoE GR AGO\nIn case ofhigh risk ofrecurrence\n\u00a75 years Tamoxifen after 5 years Tamoxifen 1a A ++\n\u00a72\u20135 years AI after 5 years Tamoxifen in initially \npremenopausal patients who obtain validated \npostmenopausal status during course of therapy1b B +\n\u00a75 years Tamoxifen after 5 years of endocrine therapy + OFS5 D +\nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePostmenopausal Patients\nExtended Adjuvant Endocrine Therapy (EAT) (Years 6 \u201310)\nOxford\nLoE GR AGO\nIn case ofhigh risk ofrecurrence\n\u00a75 years Tamoxifen after 5 years Tamoxifen 1a A +\n\u00a72\u20135 years AI after 5 years Tamoxifen 1a A ++\n\u00a7After initial AI- containing therapy (upfront or switch),\nprolongation of endocrine therapy with AI for 2 \u20135 years*\n\u00a7 High -risk and good tolerabilty of AI 1a A +\n\u00a7 Low -risk, poor tolerabilty of AI 1a A -\n\u00a7Interruption of endocrine treatment up to 3 months during EAT \nwith AI1b B +/-\n*Up to date, no impact on OS\nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nExtended aromatase inhibitor treatment following 5 or more years of \nendocrine therapy: a metaanalysis of 22192 women in 11 randomised \ntrials (EBCTCG)\n1 (new primary breast cancer, local and distant recurrence)\nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nExtended adjuvant treatment , overiew\nbrown :Tamoxifen\ngreen : Tamoxifen orAI\nblue : AI\nstripes : Zeit der\nrandomisierten \nIntervention vskeine \nTherapie od. Plazebo\n*: randomisation\n\u00a7: MA17R after 5 years\nAI with / w/o Tam \nbeforeSt u d i e  Therapien  De-facto -\nVergleiche  \n(J ahre)  HR f\u00fcr \nDFS AI-Ther apie  \nJah r e 0-5  \n(%  ) \nJah r e n ach  \nDiagnose  1 2 3 4 5 6 7 8 9 10 15    \nSt udi e n  mit Tamoxifen nach 5 Jahren  Tamoxifen      \nATLAS      *       5 vs 10 0,75 \u2013 \n0,99 t 0 \nATTOM      *       5 vs 10 0,75 \u2013 \n0,99 t 0 \nSt udien mit AI nach 5 J ahren Tamoxifen      \nMA. 17      *       5 vs 10 0,57 0 \nNSAPB B -33     *       5 vs 10 0,68 0 \nABCSG 6a      *       5 vs 8 0,62 0 \nSt udi e n mi t  e r we iterter AI -Th. nach 5 Jahren  endokrin inkl. AI     \nDATA    *         6 vs 9 0,79 100 \nNSABP B -42     *       5 vs 10 0,85 100 \nMA.17R           \u00a7  10 vs 15 0,66 100 \nSt udi e n bzgl .  opt i mal e r  Dauer in Ja hr  5-10      \nBOOG  \n2006 -05 \nIDE AL      *        7,5 vs 10 0,92 88 \nABCSG 16      *       7 vs 10 1,007  49 \nSOLE                 Cont vs \nunterbr  1,08 81 \n \nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nFactors indicating a clinical benefit from EAT:\n\u00a7Adjuvant tamoxifen therapy only\n\u00a7Condition after chemotherapy  (indicating high risk)\n\u00a7Positive lymph node status and /or T2/T3 tumors\n\u00a7Elevated risk of recurrence  based on immunohistochemical criteria or based on \nmulti -gene expression assays\n\u00a7High CTS5 -score\n\u00a7BCI (H/I) ( Breast Cancer Index)\nFurther decision criteria:\n\u00a7Wish of patient\n\u00a7up to now well tolerated AI therapy,\n\u00a7good bone health\n\u00a7younger age\n\u00a7adherenceDecision criteria for extended therapy\nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deOxford\nLoE GR AGO\n\u00a7Fertility preservation counselling including referral of all \npotential patients to appropriate reproductive specialists                                                                   ++\n\u00a7CTx + GnRHa\n(preservation of ovarian function)\n(GnRHa application > 2 weeks prior to chemotherapy , \nindependent of hormone receptor status )1a A +\n\u00a7CTx + GnRHa\n(preservation of fertility)1b A +/-Ovarian Protection and Fertility Preservation in Premenopausal Patients \nReceiving (Neo)-Adjuvant Chemotherapy (CT) \nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nGonadotropin -Releasing Hormone Agonists During Chemotherapy for Preservation \nof Ovarian Function and Fertility in Premenopausal Patients With Early Breast \nCancer: A Systematic Review and Meta -Analysis of Individual Patient \u2013Level Data\nControl GnRH HR (95% -CI) P-value\nPOI1,2 30.9% 14.1% 0.38; \n0.26 to 0.57< 0.001N= 837 patients from 5 trial, median follow -up time 5.0 years (IQR, 3.0 -6.3 years)\nNo significant differences in disease -free survival and overall survival \nwere observed between groups.\nLambertini M et al. J Clin Oncol 20181premature ovarian insufficiency, 2different definitions and time points were used\n3 i  n most trials POI and not pregnancy was defined as the primary endpoint\nAdjuvant Endocrine Therapy in Pre- and Postmenopausal Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1 \nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E Adjuvant Cytotoxic and \nTargeted Therapy\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.deAdjuvant Cytotoxic and Targeted Therapy\n\u00a7Versionen 2002 \u20132020: \nDall / Fehm / Harbeck / Jackisch /Janni / Loibl / Lux/ \nvon Minckwitz / M\u00f6bus / M\u00fcller / Nitz / Schmidt / \nSchneeweiss / Simon / Sch\u00fctz / Solomayer / \nStickeler / Thill / Thomssen / Untch \n\u00a7Version 2021: \nAlbert / K\u00fcmmel\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.deSubtype -specific Strategies\nfor Systemic Treatment\n* Study participation recommendedAGO\nIf chemotherapy is indicated systemic treatment before surgery (neoadjuvant) should be preferred\nHR+/HER2 -and \u201elow-risk\u201d\n\u00a7 Endocrine therapy without chemotherapy ++\nHR+/HER2 -and \u201ehigh -risk\u201d\n\u00a7 Conventionally dosed AT-based chemotherapy (q3w) +\n\u00a7 Dose dense chemotherapy (including weekly schedule) ++\n\u00a7 Followed byendocrine therapy ++\nHER2+\n\u00a7 Trastuzumab (plus Pertuzumab in N+ orNACT) ++\n\u00a7 Sequential AT-based chemotherapy with concurrent T + anti -HER2 therapy ++\n\u00a7 Anthracycline -free chemotherapy +  anti -HER2 therapy ++\nTriple -negative (TNBC)\n\u00a7 Conventionally -dosed AT-based chemotherapy +\n\u00a7 Dose -dense chemotherapy (AT-based including weekly schedule ) ++\n\u00a7 Neoadjuvant platinum -containing chemotherapy +\n\u00a7 Neoadjuvant chemotherapy +  ICPi (immune checkpoint -inhibitors) +/-*\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.deAdjuvant Chemotherapy: \nTNBC\n\u00a7Indication forchemotherapy in node -negative \ndisease\n\u00a7> 10 mm 2b B ++\n\u00a7> 5\u201310 mm 2b B +\n\u00a7\u2264 5 mm 2b B -Oxford\nLoE GR AGO\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.deAdjuvant Chemotherapy \nwithout Trastuzumab: Overview\nOxford\nLoE GR AGO\n\u00a7Dose -dense anthracycline / taxane based (incl. weekly ) \nchemotherapy1a A ++\n\u00a7Conventional anthracycline -/taxane- based (q3w) 1a A +\n\u00a7\u201eTailored \u201canthracycline -/taxane- based 1b B +/-\n\u00a7If anthracyclines cannot be given\n\u00a7Docetaxel plus cyclophosphamide 1b B +\n\u00a7Paclitaxel mono weekly 1b B +/-\n\u00a7CMF 1a A +/-\n\u00a7Low -dose maintenance chemo 1b B -\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.de\nGray R et al., Lancet 2019\nEarly Breast Cancer Trialists\u2018 Cooperative Group (EBCTCG)\nIncreasing the dose -density of adjuvant chemotherapy: an EBCTCG meta- analysis\nSame chemotherapy drugs and doses (n = 10,004)\nRecurrence -free survival: 10 -y Gain 4.3% (95% -C.I. 2.2 \u20136.5)\n(RR = 0.83; 95%- C.I. 0.76 \u20130.91; p<0.0001)\nOverall survival: 10 -y Gain 2.8% (95% -C.I. 0.8 \u20134.8)\n(RR = 0.86; 95%- C.I. 0.77 \u20130.96; p=0.0054)\nER negative: 10-y Gain 4.7% (95%-C.I. 2.3 \u20137.1)\nER positive:  10-y Gain 3.1% (95%-C.I. 1.5 \u20134.7)\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.deRecommended Dose -dense and / or Dose- escalated, \nSequential Adjuvant Chemotherapy \nOxford\nLoE GR AGO\nDose -dense regimen \n\u00a7A60X4\u00e0Pac 175 x4\u00e0C600x4 q2w 1b A ++\n\u00a7A60C q2w x4 \u00e0Pac 175q2w x 4 1b B ++\n\u00a7E90C q2w x4 \u00e0Pac 175q2w x 4 1b A ++\n\u00a7E90C q2w x4 \u00e0Pac 80q1w x 12 1b B ++\n\u00a7NabPac 125 x8-12\u00e0E90C q2 (3)w x4 1b B +\nDose -dense and dose -escalated regimen  (N \u2265 4+)\n\u00a7E150\u00e0Pac 225\u00e0C2000q2w 1b A ++\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.deRecommended Conventional Regimens \nfor Adjuvant Chemotherapy\n*Extrapolation from doxorubicin trials Oxford\nLoE GR AGO\nAnthrazycline -/ taxane -based regimen\n\u00a7 *EC q3w x 4 \u00e0Pac q1w x 12 2b B ++\n\u00a7 AC q3w x 4 \u00e0Pac q1w x 12 1b A ++\n\u00a7 AC \u00e0Dqw3 A60C q3w x 4 \u00e0D100x 4 1b A +\n\u00a7 *EC \u00e0Dqw3 E90C q3w x 4 \u00e0D100x 4 1b B +\n\u00a7 DAC D75A50C q3w x 6 1b A +\nAnthrazycline -free regimen\n\u00a7 DC similar efficacy as EC \u00e0D D75C600 x 6 1b B +\n\u00a7 DC >> 4 x AC D75C600 x 4 1b B +\n\u00a7 Pac mono P80q1w x 12 1b B +/-\n\u00a7 CMF 1a A +/-\nTaxane -free regimen (ifpN0)\n\u00a7 FE100C x 6 F500E100C500x 6 2b(a)B +\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.deAdjuvant Chemotherapy\nOther Drugs\nOxford\nLoE GR AGO   \n\u00a7Capecitabine -containing regimen in TNBC                            1a B +/-\n\u00a7adjuvant /neoadjuvant 1aaA +/-\n\u00a7postneoadjuvant in non -pCR patients * 1aaA +\n\u00a7Platinum- containing regimen\n\u00a7Anthracycline -free adjuvant therapy in TNBC 1b B +\n\u00a7Anthracycline -based adjuvant therapy in TNBC 5 D +/-\n\u00a75-fluorouracile added to EC/AC 1b A --\n*no platinum pretreatment\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.de\nVan Mackelenbergh M et al., SABCS 2019, \nabstr. GS1 -07\nEffects of capecitabine as part of neo -/adjuvant chemotherapy\nMeta -analysis of individual patient data from 12 randomized trials (n=15,457) \nHR for DFS overall    0.952 (95%- C.I. 0.895- 1.012, p=0.115)\nX add.      0.888 (95%- C.I. 0.817- 0.965, p=0.005)\nX instead 1.035 (95%- C.I. 0.945- 1.134, p=0.455)\nHR for OS   overall    0.892 (95%- C.I. 0.824- 0.965, p=0.005)\nX add.      0.837 (95% -C.I. 0.751- 0.933, p=0.001)\nX instead 0.957 (95%- C.I. 0.853- 1.073, p=0.450)\nSignificance only for TNBC overall  DFS 0.886 (95%- C.I. 0.789- 0.994, p=0.040)\nOS  0.828 (95% -C.I. 0.720- 0.952, p=0.008)\nX add.: DFS 0.818 (95% -C.I. 0.713- 0.938, p=0.004)\nOS  0.778 (95% -C.I. 0.657- 0.921, p=0.004)\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.deAdjuvant Treatment\nwith Trastuzumab +/ -Pertuzumab\nOxford\nLoE GR AGO\n\u00a7Trastuzumab + Pertuzumab\n\u00a7pN+ 1baB +\n\u00a7pN- 1baB +/-\n\u00a7Trastuzumab in node -negative disease\n(ifchemotherapy isindicated)\n\u00a7>10 mm 1a A ++\n\u00a7> 5\u201310 mm 2b B +\n\u00a7\u2264 5 mm 2b B +/-\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.deAdjuvant treatment\nwith Trastuzumab /Pertuzumab\nOxford\nLoE GR AGO\nStart oftreatment\n\u00a7Simultaneously with taxanes 1a A ++\n\u00a7Sequentially up to 3 months after chemotherapy 1b B +\n\u00a7s.c. = i.v. 1a A ++\nDuration\n\u00a7For 1 year 1a A ++\n\u00a7For 0.5years (Trastuzumab ) 1a A +\n\u00a7For2 years 1b A -\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.deAdjuvant Treatment with Trastuzumab +/ -\nPertuzumab: Chemotherapy regimen\nOxford\nLoE GR AGO\nTrastuzumab simultaneously with\n\u00a7paclitaxel / docetaxel after AC / EC 1a A ++\n\u00a7P q1w 12 x in pT< 2 cm, pN0 2b B +\n\u00a7docetaxel and carboplatin 1b A +\nTrastuzumab + Pertuzumab simultaneously with\n\u00a7paclitaxel q1w (or docetaxel q3w) after EC/AC 1b B ++\n\u00a7docetaxel+ carboplatin 1b B +\n\u00a7taxan esdose-dense 2b B +\nRadiotherapy concurrently with Trastuzumab /Pertuzumab 2b B +\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.deAdjuvant Therapy With \nOther Targeted Agents\nOxford\nLoE GR AGO\n\u00a7Lapatinib 1ba B -\n\u00a7(delayed adjuvant treatment) 1b B -\n\u00a7Lapatinib + Trastuzumab 1ba B -\n\u00a7Neratinib * (one year) after completing a year of \nadjuvant trastuzumab (if HR -positive)1b B +\n\u00a7Bevacizumab 1b B --\n* In addition to standard endocrine treatment\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.dePost -neoadjuvant therapy : HER2- negative\nOxford\nLoE GR AGO\nHR positiv (pCR and non -pCR)\n\u00a7Endocrine therapy according to menopausal status (s. chap. 10) 1a A ++\n\u00a7Capecitabine (in case ofnon- pCR) 3b C +/-\n\u00a7Endocrine therapy + Abemaciclib 2b B +/-*\n\u00a7Endocrine therapy + Palbociclib 1ba B -*\nTriple negative (TNBC) (in case ofnon- pCR)\n\u00a7Capecitabine (up to 8 cycles)** 1b B +\n\u00a7Experimental  post -neoadjuvant therapies within clinical trials 5 D +*\n*Study participation recommended\n** without prior platinum -based therapy\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.dePost -neoadjuvant therapy : HER2- positive\nOxford\nLoE GR AGO\npCR\n\u00a7Low risk: Trastuzumab (to complete 12 mths) 2a C ++\n\u00a7High risk (cN+): Trastuzumab + Pertuzumab (to complete 12 mths) 2b C +\n\u00a7Neratinib after 1 year  Trastuzumab (HR -positive)* 2b B -\nnon-pCR\n\u00a7T-DM1 1b B +\n\u00a7Neratinib after 1 year* Trastuzumab (HR -positive)* 2b B +/-\n\u00a7Trastuzumab + Pertuzumab (tocomplete 12 mths ) 2b C +/-\n*In combination with standard endocrine treatment\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E \nwww.ago- online.deBiosimilars \nGenaral Considerations\nBiosimilars that are used for treatment (i.e. trastuzumab) and supportive \ncare of breast cancer (i.e G -CSF) must be approved by the respective \nregulatory authorities (EMA, FDA ) after passing the stringent \ndevelopment and validation processes required before being used in daily \npractise.*\n*Thill M et al. Einf\u00fchrung und Verwendung von biosimilaren Antik\u00f6rpern in der Therapie des Mammakarzinoms. \nGeburtshilfe Frauenheilkd 2018; DOI: 10.1055/s -0043- 118761\nAdjuvant Cytotoxic and Targeted Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1ENeoadjuvant \n(Primary) Systemic Therapy\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deNeoadjuvant Systemic Therapy\n\u00a7Versions 2002 \u20132020: \nBauerfeind / Blohmer / Costa / Dall / Fersis / Friedrich / G\u00f6hring / \nHarbeck / Heinrich / Huober / Jackisch / Kaufmann / Liedtke / Loibl /    \nLux / von Minckwitz / M\u00fcller / Mundhenke / Nitz / Schneeweiss /    \nSch\u00fctz / Solomayer / Untch\n\u00a7Version 2021:\nFehm / Stickeler\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSubtype -specific Strategies\nfor Systemic Treatment\n*study paticipation recommendedAGO\nIf chemotherapy is indicated systemic treatment before surgery (neoadjuvant) should be preferred\nHR+/HER2 -and \u201elow-risk\u201d\n\u00a7 Endocrine therapy without chemotherapy ++\nHR+/HER2 -and \u201ehigh -risk\u201d\n\u00a7 Conventionally dosed AT-based chemotherapy (q3w) +\n\u00a7 Dose dense chemotherapy (including weekly schedule) ++\n\u00a7 Followed byendocrine therapy ++\nHER2+\n\u00a7 Trastuzumab (plus Pertuzumab in N+ orNACT) ++\n\u00a7 Sequential AT-based chemotherapy with concurrent T + anti -HER2 therapy ++\n\u00a7 Anthracycline -free chemotherapy +  anti -HER2 therapy ++\nTriple -negative (TNBC)\n\u00a7 Conventionally -dosed AT-based chemotherapy +\n\u00a7 Dose -dense chemotherapy (AT-based including weekly schedule ) ++\n\u00a7 Neoadjuvant platinum -containing chemotherapy +\n\u00a7 Neoadjuvant chemotherapy +  ICPi (immune checkpoint -inhibitors) +/-*\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nAnthracycline -free Taxan /Carboplatin\nbased regimen forHer2+ \nT Docetaxel, Tx Paclitaxel, C Carboplatin, H Trastuzumab, P PertuzumabRegimen Pts. (n=) pCR rate (%) OUTCOME\n6 x TCH (TRIO B07) 34 47 Not published\n6 x TCHP (TRYPHAENA) 75 64 3-yr-DFS: 90%\n6 x TCHP (KRISTINE -TRIO -021) 221 56 3-yr-EFS: 94.2\n4 x TCHP (NSABP -B52; nur HR+) 155 41 Not published\n9 x TxCHP (TRAIN -2) 206 68 3-yr-EFS: 93.5%\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nHER2+ Early Breast Cancer\nNeo -/adjuvant and postneoadjuvant Therapy\nAdjuvant Therapy:\nlow risk of recurrence \nRezidivrisiko\nPaclitaxel weekly x 12 + Trastuzumab1\n\u2022 elderly or fragile patients\nor\n\u2022 pT1, pN0 \nAdjuvant Therapy:\nhigh risk of recurrence\nCHT + Trastuzumab + Pertuzumab\u00b2\n\u2022 Node -positive  (pN+)\n\u2022 Irrespective of ER -status5Neoadjuvant Therapy\u00b3\nTrastuzumab  + Pertuzumab\n\u2022 Node -positive (cN+/pN+)\nor\n\u2022 cT >2Postneoadjuvant Therapy4\nTrastuzumab +/-Pertuzumab\norT-DM1\nIn case ofpCR:\n\u2022 Trastuzumab\n\u2022 Trastuzumab + Pertuzumab\n-Node -positive prior NACT \n-Irrespective ofER-status\nIn case ofnon- pCR:\n\u2022 T-DM1\nTotal duration  of anti -HER2 -therapy: 1 year\n1.Tolaney SM, et al .J Clin Oncol April 2019; 2. von Minckwitz G, et al. N Engl J Med 2017; 377:122 \u2013131 (inkl. Suppl.);  3. Gianni L, et al. Lancet Oncol 2012;13:25 -32; \n4. von Minckwitz G, et al . N Engl J Med 2019; 380:617 -628, 5. Piccart M, et al. SABCS 2019 (abs GS1 -04)\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deNeoadjuvant Systemic Chemotherapy\nClinical Benefit\nOxford\nLoE GR\n\u00a7Leads to improvement of prognosis by individualization of post -\nneoadjuvant therapy\n\u00a7Survival is similar after neoadjuvant (preoperative, primary) and \nadjuvant systemic therapy (with same regimen and number of \ncycles ), if the post -neoadjuvant therapy is not\nindividualized according to pathological response1b A\n1a A\n\u00a7Pathological complete response is associated with improved \nsurvival1b A\n\u00a7Can achieve operability in primary inoperable tumors 1b A\n\u00a7Improved options for breast conserving surgery 1b A\n\u00a7Decreases rate of axillary lymphadenectomies 2b B\n\u00a7Allows individualization of therapy according to mid -course \ntreatment effect 1b B\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deNeoadjuvant Systemic \nChemotherapy -Indications\nOxford\nLoE GR AGO\n\u00a7Inflammatory breast cancer 2b B ++\n\u00a7Inoperable breast cancer 1c A ++\n\u00a7Large operable breast cancer requiring mastectomy \nand adjuvant chemotherapy with the goal of breast \nconservation 1b B ++\n\u00a7If similar postoperative adjuvant chemotherapy\nis indicated1b A ++\n\u00a7Toallow a risk- adapted postoperative therapy 1b A ++\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deFactor pCR* \nProbabilityLoE GR AGO\n\u00a7Young age \u00ad 1a A +\n\u00a7cT1 / cT2 tumors o. N0 o. G3 \u00ad\u00ad 1a A ++\n\u00a7Negative hormone receptor status \u00ad\u00ad 1a A ++\n\u00a7Triple negative breast cancer \u00ad\u00ad 1a A ++\n\u00a7Positive HER2- status \u00ad\u00ad 1a A ++\n\u00a7Early clinical response \u00ad 1b A +\n\u00a7Lobular tumor type \u00af 1a A +\n\u00a7Metaplastic tumor type \u00af\u00af 4 C +Oxford\n*High ( \u00ad) orvery high ( \u00ad\u00ad) probability toreach pCR, low (\u00af) orvery low(\u00af\u00af) probability toreach pCR\nSee asochapter \u201ePrognostic and predictive factors \u201cNeoadjuvant Systemic Chemotherapy     \nResponse Prediction I\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deNeoadjuvant Systemic Therapy\nResponse Prediction II\nFactor LoE 2009 CTS GR AGO\n\u00a7Multigene signatures II B B +/-\n\u00a7Ki-67 I B A +\n\u00a7Tumor infiltrating lymphocytes* I B B +\n\u00a7PIK3CA mutation in HER2 positive BC I B B +/-\n\u00a7gBRCA II B B +\n\u00a7Homologous recombination deficiency IV C C +/-\n\u00a7PD-L1 status (TNBC) II B B +/-\n* LPBC isdefined as dense lymphocytic infiltration of inner peritumoral stroma outside of invasion front \n(> 50% of stromal area are covered by lymphocytes)\nSee also chapter  \u201ePrognostic and predictive factors\u201c\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deNeoadjuvant Systemic Chemotherapy\nRecommended Regimens and Schedules\nOxford\nLoE GR AGO\n\u00a7Use of adjuvant standard regimens for NACT* 1a A ++\n\u00a7Taxane followed by anthracycline (reverse order) 1a A +\n\u00a7Platinum in TNBC (irrespective of BRCA status) 1a A +\n\u00a7Nab-Paclitaxel weekly instead of Paclitaxel weekly 1a A +\n\u00a7Checkpoint inhibitors in combination with\nchemotherapy (TNBC)1b B +/-**\n*See chapter Adjuvant Chemotherapy ; ** Study participation recommended\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nICPi plus neoadjuvant chemotherapy for triple \nnegative breast cancer patients\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deNeoadjuvant Systemic Therapy\nRecommended Methods of Monitoring of Response\nOxford\nLoE GR AGO\n\u00a7Breast ultrasound 2b B ++\n\u00a7Palpation 2b B ++\n\u00a7Mammography 2b B ++\n\u00a7MRI 2b B +\n\u00a7PET( -CT) 2b B +/-\n\u00a7Pretherapeutic marking oftumor region 5 D ++\n\u00a7Pretherapeutic marking ofpN+ 2a B +*\n*study participation recommended (AXSANA / Eubreast 3 Trial)\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deOxford\nLoE GR AGO\n\u00a7Pertuzumab + trastuzumab in combination with \nchemotherapy  (high -risk defined as cT2 -4 and / or \ncN+)2b B ++\n\u00a7Trastuzumab in combination with standard \npolychemotherapy (low -risk)*1b A +\n\u00a7Anti -HER2 agents without chemotherapy 2b B +/-**\n*    Monochemotherapy and trastuzumab should preferably beused in theadjuvant setting\n** Study participation recommendedNeoadjuvant Targeted Therapy \nin HER2 Positive Tumors\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deOxford\nLoE GR AGO\nIn case of early response\n\u00a7 Completion of neoadjuvant chemotherapy 1b A ++\nIn case of no change:\n\u00a7 Completion of neoadjuvant chemotherapy (NACT) followed by surgery 2b C ++\n\u00a7 Continuation of NACT with non cross- resistant regimen 2b B +\n\u00a7 AC or EC x 4 \u2192 D x 4 or Pw x 12 2b B +\n\u00a7 DAC x 2 \u2192NX x 4 1b B +\nIn case of disease progression\n\u00a7 Re-evaluation of tumorbiological factors 5 D +/-\n\u00a7 Stop NACT and proceed to surgery or radiotherapy 4 D ++\n\u00a7 Additional adjuvant chemotherapy with non cross -resistant regimen 4 D +/-Neoadjuvant Chemotherapy\nTreatment strategies based on clinical response\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n*Study participation (Axsana ) recommended ; ** s. Recommendations chapter Radiotherapy , irradiation alone isnot recommended in case ofpN1( sn)        \nand pN+ ; ***recommendation grade concerning tostaging at cN0 and cN+ ypN0  Axillary Surgery and NACT Oxford\nLoE GR AGO\nSLNE after NACT  \nSLNE before NACT2b\n2bBB++\n-\ncN-Status\n(before NACT)pN-Status\n(before\nNACT)cN-Status\n(after NACT)Surgical procedure\n(after NACT)pN-Status (after \nNACT and Surgery )Surgical\nconsequence from\nhistology **\ncN0 __ ycN0 SLNE aloneypN0 ( sn) __ 2b B ++***\nypN0 (i+)\nypN1 mic (sn)ALND 2b C + (+/ -at i+)\nnone ** 5 D +/-\nypN1 ( sn)ALND 2b C ++\nnone ** 5 D +/-\ncN+ pN+ CNB ycN0SLNE alone *\nTAD (TLNE + SLNE)*\nALND*ypN0\nypN0\nypN0__2b\n2b\n2bB\nB\nB+/-***\n+***+***\nSLNE alone *\nTAD (TLNE + SLNE)*ypN+ incl. ypN0 (i+) ALND 2b B + (+/ -at i+)\nALND ypN+ __ 2b B ++\nnone n.d. none ** 5 D -\ncN+ pN+\nCNB ycN+ALND ypN+ incl. ypN0 (i+) __ 2b B ++\nnone n.d. none ** 5 D -\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deNeoadjuvant Systemic Therapy\nLoco -regional Surgery (Breast)\nOxford\nLoE GR AGO\n\u00a7Early marking of tumor (incl. detailed topographic \ndocumentation)5 D ++\n\u00a7Surgical removal oftumor / representative excision of\npost -therapeutic , marked tumor area2b C ++\n\u00a7Tumor resection in new margins 2b C ++\n\u00a7Microscopically clear margins 2a B ++\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deNeoadjuvant Systemic Therapy\nIndications for Mastectomy\nOxford\nLoE GR AGO\n\u00a7Positive margins after repeated excisions 3b C ++\n\u00a7Radiotherapy not feasible 5 D ++\n\u00a7In case of clinical complete response\n\u00a7Inflammatory breast cancer (in case ofpCR) 2b C +/-\n\u00a7Multicentric lesions 2b C +/-\n\u00a7cT4a -c breast cancer 2b B +/-\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deNeoadjuvant Systemic Therapy\nTiming of Diagnosis, Surgery and Radiotherapy\nOxford\nLoE GR AGO\nInitiation oftherapy\nDelay oftherapy (> 60 days ) associated with worse\nprognosis2b    B\nTiming of surgery\n4-8 weeks after last course of chemotherapy2b B ++\nRadiotherapy within 2 months after surgery 2b B ++\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deNeoadjuvant endocrine Therapy (NET)\n-Good clinical practice -\n\u00a7Suitable forpatients who are\n\u00a7inoperable \n\u00a7not able ornot willing toundergo chemotherapy\n\u00a7Limited dataforpremenopausal in contrast topostmenopausal patients is\nlimited\n\u00a7Optimal duration ofNET isat least 4 -6 months oruntil best response oruntil\nprogression\n\u00a7Choice ofendocrine therapy isbased on menopausal status\n\u00a7NET for2 upto4 weeks isable topredict response toendocrine treatment by\nKi-67 dynamics (prognostic / predictive evaluation )\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deNeoadjuvant Endocrine Therapy in Patients \nwith Endocrine -responsive Breast Cancer\naOptimal duration ofneoadjuvant endocrine therapy isunknown .\nNolong term results forneoadjuvant endocrine therapy (vs. adjuvant endocrine therapy )Oxford\nLoE GR AGO\n\u00a7 Postmenopausal patients :\n\u00a7 Optimizes the option for breast conserving  therapy 1b A +\n\u00a7 Aromatase inhibitors (at least 6 months) 1aa B +\n\u00a7 Aromatase inhibitor + lapatinib (HER2+ BC) 2b B +/-\n\u00a7 Premenopausal patients\n\u00a7 Tamoxifen 2b C +\n\u00a7 Aromatase inhibitors + LHRHa 1b C +/-\n\u00a7 Concurrent chemo -endocrine therapy 1b A -\n\u00a7 Preoperative ET (Tam/AI) + Ki- 67 after 2 -4weeks (prognostic /predicive\nevaluation )1b B +\n\u00a7 Prognostic score: \n\u00a7 PEPI: pTN -Stage, ER expression and Ki -67 expression after     \nneoadjuvant endocrine therapy1b B +\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePost -neoadjuvant therapy : HER2- negative\nOxford\nLoE GR AGO\nHR-positive (pCR and non- pCR)\n\u00a7Endocrine therapy according to menopausal status (s. chap. 10) 1a A ++\n\u00a7Capecitabine (in case ofnon- pCR) 3b C +/-\n\u00a7Endocrine therapy + Abemaciclib 2b B +/-*\n\u00a7Endocrine therapy + Palbociclib 1ba B -*\nTriple negative (TNBC) (in case ofnon- pCR)\n\u00a7Capecitabine (up to 8 cycles)** 1b B +\n\u00a7Experimental  post -neoadjuvant therapies within clinical trials 5 D +*\n*Study participation recommended\n** without prior platinum -based therapy\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nPost -neoadjuvant treatment with CDK 4/6i \nIDFS: invasive disease -free survival\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePost -neoadjuvant therapy : HER2- positive\nOxford\nLoE GR AGO\npCR\n\u00a7Low- risk: Trastuzumab (tocomplete 12 mths ) 2a C ++\n\u00a7High -risk (cN+): Trastuzumab + Pertuzumab (tocomplete 12 mths ) 2b C +\n\u00a7Neratinib after 1 year Trastuzumab (HR-positive)* 2b B -\nnon-pCR\n\u00a7T-DM1 1b B +\n\u00a7Neratinib after 1 year * Trastuzumab (HR-positive)* 2b B +/-\n\u00a7Trastuzumab + Pertuzumab (tocomplete 12 mths ) 2b C +/-\n*In combination with standard endocrine treatment\nNeoadjuvant (Primary) Systemic Therapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1EAdjuvant Radiotherapy \nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAdjuvant Radiotherapy (RT)\n\u00a7Versions 2002 \u20132020: \nBlohmer / Budach / Friedrichs / G\u00f6hring / Huober / Janni / K\u00fchn / M\u00f6bus \n/ Rody / Scharl / Seegenschmiedt / Souchon / Thomssen / Untch / Wenz \n\u00a7Version 2021:\nBudach / Friedrich / Krug\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePreliminary Note\n\u00a7The recommendations on adjuvant radiotherapy  for breast \ncancer are based on a consensus discussion between AGO and DEGRO experts\n\u00a7For technical radiotherapy details, we refer to the corresponding updated DEGRO practice guidelines\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deRadiotherapy (RT) after Breast Conserving Surgery \n(Invasive Cancer): Whole Breast Irradiation\nOxford\nLoE GR AGO\n\u00a7Radiotherapy of the affected breast 1a A ++\n\u00a7Hypofractionated radiotherapy (total dose approx. 40 Gyin 15 -16 \nfractions within 3 -5 weeks1a A ++\n\u00a7Conventionally fractionated radiotherapy (total dose about 50 Gy\nin approx. 25 -28 fractions in 5- 6 weeks)1a B +\n\u00a7Ultra -hypofractionated RT (total dose 26 or 28,5 Gy in 5 fractions\nin 1 or5 weeks )1b B +/-\n\u00a7In case of life expectancy <10 years and pT1, pN0, R0, ER/PR -\npositive, HER2- negative, endocrine therapy (all criteria), \nradiotherapy can be omitted after individual counseling, resulting \nin an increased risk for in -breast recurrence1a B +\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nFAST / FAST -Forward\nFAST FAST Forward\nTimeframe 2004 -2007 2011 -2014\nSample size 915 4096\nDosse/Fractionation 50 Gy/2 Gy/5 weeks\n30 Gy/6 Gy/5 weeks\n28,5 Gy/5,7 Gy/5 weeks40 Gy/2,67 Gy/3 weeks\n27 Gy/5,4 Gy/1 weeks\n26 Gy/5,2 Gy/1 weeks\nMedian follow -up 119.8 months 71.5 months\nPrimary endpoint change in photographic breast \nappearanceIpsilateral breast tumor \nrecurrence (non -inferiority \nmargin 1,6%)\nInclusion criteria pT1-2 (< 3 cm) pN0\nAge \u226550 years\nBreast conserving surgery\nNo chemotherapypT1-3 pN0- 1\nAge \u226518 years\nBreast -conserving surgery or \nmastectomy\nApprox. 25% adj. chemotherapy\nBoost No Approx. 25%, 5 -8x 2 Gy\nBrunt AM et al. J Clin Oncol . 2020 Oct1;38(28):3261 -3272. Brunt AM et al. Lancet. 2020 May 23;395(10237):1613-1626.\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nFAST / FAST -Forward\nFAST (10 year -data) FAST Forward (5 year -data)\nDose Frequency Hazard \nratio\n(95% -CI)Dose Frequency Hazard \nratio\n(95% -CI)\nIpsilateral in -breast \nrecurrence50 Gy 0.7% - 40 Gy 2.1% -\n30 Gy 1.4% HR 1.36 \n(0.3-6.06)27 Gy 1.7% HR 0.86 \n(0.51 -1.44)\n28.5 Gy 1.7% HR 1.35\n(0.3-6.05)26 Gy 1.4% HR 0.67 \n(0.38 -1.16)\nModerate/marked \nnormal tissue \neffects \nbreast/chestwall50 Gy 33.6% - 40 Gy 26.8% -\n30 Gy 50.4% HR 1.79 \n(1.37 -2.34)27 Gy 35.1% HR 1.41 \n(1.23 -1.61)\n28.5 Gy 47.6% HR 1.45 \n(1.10 -1.91)26 Gy 28.5% HR 1.09 \n(0.95 -1.27)\nBrunt AM et al. J Clin Oncol . 2020 Oct1;38(28):3261 -3272. Brunt AM et al. Lancet. 2020 May 23;395(10237):1613-1626.\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nBCS >=70y <4cm cN0 : Tamoxifen vs. Tamoxifen + RT\nTime:1994 -1999, since 8/1996 only pT1cN0 ER/PR+ or unknown allowed\n@10 yrs\n(95% C.I.)Tamoxifen Tamoxifen plus \nRadiotherapyHazard Ratio\nLocal recurrence -\nfree (D=8%)90%\n(85% -93%)98%\n(96% -99%)HR=0.18\n(95% CI, 0.07 to \n0.42; P < .001)\nMastectomy -\nfree96% \n(93% -98%)98%\n(96% -99%)HR=0.50\n(95% CI, 0.17 to\n1.48; n.s.)\nDistant \nmetastasis -free95%\n(91% -97%)95% \n(92% -97%)HR=1.20 \n(95% CI, 0.63 to \n2.32; n.s)\nOverall survival 66%\n(61% -71%)67%\n(62% -72%)HR=0.95\n(95% CI, 0.77 to \n1.18; n.s.)\nHughes KE et al J Clin Oncol 2013; 31:2382-2387\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deRadiotherapy (RT) after Breast Conserving Surgery \n(Invasive Cancer) \u2013Boost Irradiation \nOxford\nLoE GR AGO\n\u00a7Boost -RT (improves local control, no survival benefit)\n\u00a7 Premenopausal 1b B ++\n\u00a7 Postmenopausal, if >T1*,G3, HER2 -positive, triple negative, EIC \n(at least 1 factor) 2b B +\n\u00a7Techniques\n\u00a7 Percutaneous boost (photons, electrons) as sequential boost 1a A ++\n\u00a7 Multicatheter brachytherapy -boost 1a A ++\n\u00a7 Percutaneous boost as simultaneous integrated boost (with \nconventionally fractionated whole- breast irradiation)1b B +\n\u00a7 Percutaneous boost assimultaneous integrated boost (with\nhypofractionated whole -breast irradiation )2b B +/-\n\u00a7 Intraoperative boost irradiation (followed bywhole -breast irradiation ) 2b B +\n*continuous parameter with regard to risk of relapse\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nEORTC 22881 -10882: Boost vs no Boost \n(Endpoint: Ipsilateral Breast Recurrence)\n@20 yrs\n(95% C.I.)Boost  \n(n=2.661)No boost \n(n=2.657)Hazard Ratio\n(95% C.I.)\nOverall Survival\n(D=-1.4%)59.7%\n(56.3 \u201363.0)61.1%\n(57.6 \u201364.3)HR 1.05\n(0.92 \u20131.19) n.s.\nCumulative Risk of Ipsilateral Breast Tumour Recurrence\nAll patients 12.0%\n(9.8\u201314.4)16.4%\n(14.1 \u201318.8)HR=0.65 \n(0.52 \u20130.81); p<0.0001\n\u226440 years(\nD=11.6%)24.4%\n(14.9 \u201333.8)36.0%\n(25.8 \u201346.2)HR=0.56 \n(0.34 \u20130.92); p=0.003\n41\u201350 years\n(D=5.9%)13.5%\n(9.5\u201317.5)19.4%\n(14.7 \u201324.1%)HR=0.66 \n(0.45 \u20130.98); p=0.007\n51\u201360 years\n(D=2.96%)10.3% \n(6.3\u201314.3)13.2% \n(9.8\u201316.7)HR=0.69 \n(0.46 \u20131.04); p=0.020\n>60 years\n(D=3.0%)9.7% \n(5.0\u201314.4)12.7% \n(7.4\u201318.0)HR=0.66 \n(0.42 \u20131.04); p=0.019\nacc. to: Bartelink et al. Lancet Oncol 2015; 16: 47 \u201356 (Median F/U 17.2 y)\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nEORTC 22881 -10882: Boost vs no Boost \n(Endpoint: Any First Recurrence)\n@15 yrs/20 yrs\n(95% C.I.)Boost  \n(n=2.661)No boost \n(n=2.657)Hazard Ratio\n(95% C.I.)\nOverall Survival\n(D= -1.4%)59.7%\n(56.3 \u201363.0)61.1%\n(57.6 \u201364.3)HR 1.05\n(0.92 \u20131.19) n.s.\nCumulative Risk of Any First Recurrence\nAll patients(\nD\u22654%)@15y@20y28.1%\n32,8%32.1%38.7%HR=0.92\n(0.81 -1.04), n.s.\n\u226440 years\n(\nD>6%)@15y@20y41.5%49.5%48.1%56.8%HR=0.80 \n(0.56 -1.15) , n.s.\n41\u201350 years @15y\n@20y34.0%38.6%35.6%44.2%HR=0.91 \n(0.71 -1.16) , n.s.\n51\u201360 years @15y\n@20y28.5%34.7%28.7%36.2%HR=0.96 \n(0.76 -1.21) , n.s.\n>60 years @15y\n@20y27.4%32.1%29.1%32.8%HR=0.94 \n(0.74 -1.19), n.s.\nacc. Bartelink et al. Lancet Oncol 2015; 16: 47 \u201356. Suppl. (Median F/U 17.2 y)\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deRadiotherapy (RT) after Breast Conserving Surgery \n(Invasive Cancer) \u2013Partial Breast Irradiation (PBI) \nOxford\nLoE GR AGO\n\u00a7Intraoperative Radiotherapy (low -risk)*\n\u00a7 As sole radiotherapy , during first breast surgery (IORT 50 kV, IOERT)\n\u00a7 >50 years 1b A +/-\n\u00a7 >70 years 1b A +\n\u00a7Postoperative partial breast irradiation (low -risk)*\n\u00a7 Interstitial Multicatheter -Brachytherapy 1b A +\n\u00a7 Intracavitary balloon -technique 2b B -\n\u00a7 Intensity -modulated radiotherapy (IMRT) (5x6 Gy in 2 weeks ) 1b A +\n\u00a7 3D-conformal radiotherapy (15x2.67 Gy in 3 weeks ) 1b A +\n\u00a7 3D-conformal radiotherapy (10x3.8 Gy in 2 weeks ) 2b B +/-\n\u00a7 3D-conformal radiotherapy (10x3.85 Gy in 1 week) 1b A +/-\n* only for pT1 pN0 R0 G1 -2, HR+, non -lobular, >50 years, no extensive DCISFordefinition oftarget volume and practical conduct seeDEGRO practice guidelines\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nData on partial breast irradiation\nNSABP B -39/RTOG 0413 (Vicini FA et al. Lancet. 2019 Dec 14;394(10215):2155 -2164.)\n\u2022Randomised phase III equivalence trial, 4216 pat., 2005 -2013, DCIS or invasive carcinoma \u2264 3 \ncm, 0 -3 involved lymph nodes, age >18 y\n\u202250 Gy/25 fr. +/ -boost vs. APBI with \n\u202238.5 Gy/10 fr. in one week (external beam irradiation)\n\u202234 Gy/10 fr. in one week (Multicatheter -or Single lumen -Brachytherapy) \n\u2022\u201cWe observed an HR of 1.22 with a 90% CI of 0.94 \u20131.58, which did not meet the equivalence \ncriteria and favoured whole -breast irradiation. The 10 -year cumulative incidence of IBTR was \n3.9% (95% CI 3.1 \u20135.0) in the whole -breast irradiation group and 4.6% (3.7 \u20135.7) in the APBI group \nfor an absolute difference of 0.7%.\u201d\n\u2022\u201cSignificantly more evaluable patients in the APBI group had recurrence- free interval events \nthan patients in the whole -breast irradiation group (figure 3). The 10 -year point estimate of \nrecurrence -free interval for the whole breast irradiation group was 93\u00b74% (95% CI 92\u00b71\u2013 94\u00b76), \nand in the APBI group it was 91\u00b78% (90\u00b74 \u201393\u00b70; figure 3)\u201d.\n\u2022\"Our findings support whole -breast irradiation but the absolute outcome difference compared \nwith APBI is small, so partial breast irradiation might also be an acceptable treatment for some \npatients . \u201c\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nData on partial breast irradiation\nRAPID (Whelan TJ et al. Lancet. 2019 Dec 14;394(10215):2165 -2172.)\n\u2022Randomised phase III non -inferiority trial, 2135 pat., 2006 -2011, DCIS or invasive carcinoma \u2264 3 \ncm, pN0, age \u226540 y., no ILC\n\u202242.56/16 fr. or 50 Gy/25 fr. +/ -Boost vs. APBI 38.5 Gy/10 fr. in one week (external beam \nirradiation)\n\u2022\u201cIn patients treated with APBI, the 5 year cumulative rate of IBTR was 2\u00b73% (95% CI 1\u00b74 \u20133\u00b72) \nand the 8 year cumulative rate was 3\u00b70% (1\u00b79\u20134\u00b70). In patients treated with whole breast \nirradiation, the 5 year cumulative rate of IBTR was 1\u00b77% (0\u00b79\u20132\u00b75) and the 8 year cumulative \nrate was 2\u00b78% (1\u00b78\u20133\u00b79; figure 2). The HR for APBI versus whole breast irradiation was 1\u00b727 (90% \nCI 0\u00b784 \u20131\u00b791). Thus, the upper bound of the estimated 90% CI did not exceed the non -\ninferiority margin of 2\u00b702.\u201d\n\u2022\u201cLate radiation toxicity (grade \u22652 [\u2026]) was more common in patients treated with APBI (346 \n[32%] of 1070 patients) than whole breast irradiation (142 [13%] of 1065 patients; p<0\u00b70001). \nAdverse cosmesis [\u2026] was more common in patients treated with APBI than in those treated \nby whole breast irradiation at 3 years (absolute difference, 11\u00b73%, 95% CI 7\u00b75 \u201315\u00b70), 5 years \n(16\u00b75%, 12\u00b75 \u201320\u00b74), and 7 years (17\u00b77%, 12\u00b79 \u201322\u00b73).\u201d\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePostmastectomy Radiotherapy\n(PMRT)* to the Chest Wall\nOxford\nLoE GR AGO\n\u00a7> 3 tumor infiltrated lymph nodes (LN) 1a A ++\n\u00a71\u20133 tumor infiltrated LN (high -risk) 1a A +\n\u00a71\u20133 tumor infiltrated LN (low -risk*) 5 D +/-\n\u00a7T3 / T4 1a A ++\n\u00a7 pT3 pN0 R0 (and no additional risk factors) 2b B +/-\n\u00a7If R0 is impossible to reach (for invasive tumor) 1a A ++\n\u00a7In young pts with high -risk features 2b B ++\nThe indications for PMRT and regional RT are \nindependent of adjuvant systemic treatment1a A\n*For definition of low -risk, see next slide Radiotherapy of the Chest Wall After Mastectomy (PMRT)\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nRadiotherapy of the Chest Wall After Mastectomy (PMRT) in \nCase of 1 -3 Axillary Lymph Node Metastases\nER pos, G1, HER2 neg, pT1\n(at least 3 criteria present)\u226545 y. AND >25% pos. ax. Lnn  in case of axillary \ndissection  OR\n<45 y. AND (ER neg. OR>25% pos. ax. Lnn in case of axillary dissection OR medial tumor location)\n<40 y. OR\nHER2 pos. OR\nlymphovascular invasion\nG3 OR\nlymphovascular invasion OR\ntriple negativeKyndi et al. 2009\nTruong et al. 2005\nShen H et al. 2015\nDifferent publicationsPMRT \ncan be omitted\nLoE 3b B AGO +PMRT \nrecommended\nLoE 3b B AGO +\nPatients, who \ndon\u2018t fulfill\nthe mentioned \ncriteria for\nhigh or low\nriskPMRT\nto be discussed\nLoE 3b B AGO + /-\nComment: In case of an indication for radiotherapy of regional lymph nodes, \nradiotherapy of the chest wall should also be administered\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBoost in PMRT\n\u00a7An additional boost irradiation to a part of the chest wall has not \nbeen shown to improve DSS and overall survival\n\u00a7An additional boost irradiation to a part of the chest wall should be given in case of of R1/R2 -resection, if secondary resection is not \nfeasible\n\u00a7In case of tumor extention to the pectoral resection margin, but no \nclinical signs of extention beyond the fascia, the resection margin \nshould be regarded as R0 (provided, that the pectoral fascia was resected). A boost radiotherapy is not required in this situationOxford\nLoE GR AGO\n2a B\n5 D ++\n5 D ++\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deRadiotherapy of axillary lymph nodes in patients with positive \nsentinel- lymph nodes**, who did not undergo axillary dissection \nOxford\nLoE GR AGO\nBCS and ACOSOG Z0011 -criteria+met\n\u00a7Radiotherapy ofthebreast including LN level 1 + 2 to5 mm below\ntheaxillary vein (PTV)2b B +*\nBCS and ACOSOG Z0011 -criteria+notmet\n\u00a7Radiotherapy oftheaxillary lymph nodes (analog AMAROS)1b B ++*\nME and chest wall RT indicated and ACOSOG Z011 -criteria+notmet orME \nand chest wall RT not planned\n\u00a7Radiotherapy oftheaxillary lymph nodes (analog AMAROS) 1b B ++\n>=3 pos. SLN\n\u00a7Radiotherapy oftheaxillary lymph nodes (analog AMAROS) 1b B +\n*Study participation recommended\n** Macrometastases\n+<T3, nopalpable LN, R0, 1 -2 positive SN, noextracapsular extention , noNACT\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n1Incidental dose toparts oflevel i/II isinevitable . 2The indication forsupra -/infraclavicular and internal mammary node RT hastobeassessed\nseparately. 3Cranial border 5 mm below theaxillary vein . 4\u2264 T3, cN0, noNACT, always in conjunction with supra -/infraclavicular RTAdditional RT oftheaxilla after primary surgery\n(in case ofan indication forRT ofthebreast /chest wall1+/-supra -/infraclavicular\nand internal mammary node RT2)\nExpansion ofthePTV ( planning target volume ) tolevel I-II3Oxford\nLoE GR AGO\npN-status\npN0(sn)/pN1mic(sn) 1b B --\npN0/+ after ALND 1a A --\npN+(sn) in analogy to ACOSOG Z0011 (no ALND) 2b B +\npN+(sn) not fitting ACOSOG Z0011 -criteria \u00e0RT in analogy toAMAROS4 \n(noALND)1b B ++\nR2-situation in theaxilla 5 D ++\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n1Incidental dose toparts oflevel i/II isinevitable . 2The indication forsupra -/infraclavicular and internal mammary node RT hastobeassessed\nseparately. 3Cranial border 5 mm below theaxillary vein . 4Study participation recommended . Additional RT oftheaxilla after neoadjuvant therapy\n(in case ofan indication forRT ofthebreast /chest wall1+/-supra -/infraclavicular and\ninternal mammary node RT2)\nExpansion ofthePTV ( planning target volume ) tolevel I-II3Oxford\nLoE GR AGO\nN-status \npre/post\nNACTpN-status\ncN0 / ycN0 ypN0( sn) 5 D -\ncN0 / ycN0ypN1mic( sn)/ypN+(sn)\n(noALND)5 D +4\npN+ CNB/ \nycN0ypN0( sn/TAD) 5 D +/-4\npN+ CNB/\nycN0ypN1mic(sn/TAD)/ypN+(sn/TAD)\n(no ALND)5 D +4\ncN0/cN+ ypN0/+ after ALND 2b B -\nR2-situation in theaxilla 5 D ++\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deACOSOG Z0011 Trial\n45%  micrometast. in the exp. arm\n2% no RT\nData from 228/856 pat.\u201ehigh tangent\u201csupra -\nclavicularmean encompassed\nLN level 1 dose *     volume **\nAMAROS           >95% >95%\nhigh tangent 86% 79%\nstandard tangent 66%              51% \nIMRT+ 29% 1%\nLN-level 2\nAMAROS        >95% >95%   \nhigh tangent 71% 51%\nstandard tangent 44%              26% \nIMRT+ 7%               0%\n*   in relation totheprescribed dose in thebreast\n**  % volume receiving theprescribed dose\n+  Lee et al. Medicine 2016 (3)\u201estandard\ntangent\u201cDose in the axillary LN -levels I + II using different RT -\ntechniques\nAMAROS\nJagsi (2): \u201cThe results of Z0011 should not be extrapolated to patients who receive RT using \npartial -breast or prone techniques, in which substantially less of the axilla is included\u201d\nIII\n17%\n53%\n28%\naxillary vein\nRT-volume\n% of  patientis\nbreast\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deRadiotherapy (RT) of Other Locoregional \nLymph Node Areas (SCG/ICG)\nOxford\nLoE GR AGO\nRT to supra -/infraclavicular lymphatic regions\n\u00a7\u2265 4 positive axillary lymph nodes (LN) or involved LN in \nlevel III or in supra -/infraclavicular LN1b A ++\n\u00a71\u20133 positive axillary lymph nodes1in case of 2a B +\n-central or medial tumor and G2 -3 or ER/PR -negative\n-premenopausal patient and G2 -3 or ER/PR -negative\n\u00a7pN0 with central or medial tumors, if premenopausal and \nG2-3 and ER/PR -negative2a B +/-\n1not applicable for micrometastases\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deRadiotherapy (RT) of Other Locoregional \nLymph Node Areas  (IMN) \nOxford\nLoE GR AGO\nInternal mammary lymph node region (IMN)\n\u00a7pN0 high- risk with central or medial tumor 1b B +/-\nand premenopausal and G2 -3 and ER/PR -negative\n\u00a71\u20133 positive axillary lymph nodes1in case of 2a B +\n-central or medial tumor and G2 -3 or ER/PR -negative\n-premenopausal patient and G2 -3 or ER/PR -negative\n\u00a7\u2265 4 positive axillary lymph nodes 2a B +\n\u00a7involved internal mammary lymph nodes 2a B +\n\u00a7In case ofcardiac risk factors oriftrastuzumab isgiven 2b A --\n1not applicable for micrometastases\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deFractionation of Radiotherapy in Case of \nRegional Nodal Irradiation\nOxford\nLoE GR AGO\n\u00a7Conventionally fractionated radiotherapy\n(total dose about 50 Gyin approx. 25 -28 fractions\nwithin 5\u20136 weeks)1a A ++\n\u00a7Hypofractionated radiotherapy\n(total dose approx. 40\u201343.5 Gyin 15 -16 fractions within \n3\u20135 weeks)2b B +/-\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nHypofractionated post -mastectomy \nradiotherapy and regional nodal irradiation\nWang et al. Lancet Oncol. 2019 Mar;20(3):352- 360.\n\u2022Randomised phase III non -inferiority trial, 820 pat., 2008 -2016, T3/4 and/or \u22654 involved lymph \nnodes, 50 Gy/25 fr. vs. 43.5 Gy/15 fr.\n\u202298% 2D- planned radiotherapy, no treatment of the internal mammary lymph nodes\n\u2022\u201cThe 5 -year cumulative incidence of locoregional recurrence was 8.3% (90% CI 5.8 \u201310.7) in the \nhypo -fractionated radiotherapy group compared with 8\u00b71% (90% CI 5.4 \u201310.6) in the \nconventional fractionated radiotherapy group (absolute difference 0.2%, 90% CI \u20133.0 to 2.6; HR \n1.10, 90% CI 0.72 to 1.69; figure 2). \n\u2022\u201dIn conclusion, this study provides high -level evidence for the clinical use of hypofractionated \npostmastectomy radiotherapy for patients with high -risk breast cancer. It can be recommended \nin clinical practice to patients who do not plan breast reconstruction and will not receive \ninternal mammary node irradiation .\u201d\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nMultivariate Analysis of Overall Survival: Effect of \nRadiotherapy of the Internal Mammaria Lymph Nodes\n(median follow -up  10.9 yrs )\nAdjuvant treatment n* Hazard ratio (95%CI)\nNo adjuvant reported 625 0.91\n(0.59 -1.39)\nChemotherapy 954 1.05\n(0.84 -1.32)\nEndocrine therapy 1185 0.82\n(0.63 -1.06)\nBoth (endocrine th. and \nchemotherapy)1200 0.72\n(0.55 \u20130.94)\nTotal 4004 0.88\n(0.76 \u20131.01)\n* missing data on 40 patients\nPoortmans et al. ECCO Amsterdam 2013\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nRadiotherapy following NACT\nPretreatment Posttreatment RT-BCS PMRT RT-RN\nLocally advanced pCR / no pCR yes yes yes\ncT1/2  cN1+* ypT1+ o. ypN1\n+ (no pCR)yes yes yes\ncT1/2  cN1+* ypT0/is  ypN0 yes Increased risk of\nrelapse1\ncT1/2  cN0\n(Sonogr.bligat)ypT0/is  ypN0 Ja nein neinOxford\nLoE GR AGO\n1a/1a/1a A/A/A ++/++/++\n1a/2b/2b A/B/B ++/+/+\n2b/2b/2b B/B/B +/+/+\n2b/2b/2b A/B/B +/-/-\nLocally advanced : T3-4 or cN2-N3, \n1Criteria for increased risk of relapse: \n\u00a7 pN0 premenopausal high risk: central ormedium tumor localization, and (G2-3 and ER/PR -neg.) \n\u00a7 pretreatment pN1a/ cN +* high risk: central ormedium tumor localization and (G2 -3 or ER/PR -neg.) or \npremenopausal, lateral tumor localization and  (G2 -3 or ER/PR -neg.) \n* Regarding coverage ofaxilla level I/II please also seeslides \u201eAdditional RT oftheaxilla after primary surgery \u201c and\n\u201eAdditional RT oftheaxilla after neoadjuvant therapy \u201c\n** = confirmed bycore biopsy\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMolecular predictors and use of radiotherapy \nOxford\nLoE GR AGO\n\u00a7Results ofgene expression profiling should not be\nused forindication ofradiotherapy2b B ++\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deUse of concomitant systemic therapy\nwith adjuvant locoregional radiotherapy \nOxford\nLoE GR AGO\n\u00a7Trastuzumab /Pertuzumab * 1a A ++\n\u00a7T-DM1 1b A +\n\u00a7Tamoxifen 2b B +\n\u00a7Aromatase inhibitors 2b B +\n\u00a7Checkpoint inhibitors 2b C +\n\u00a7Capecitabine 2b B +**\n\u00a7CDK4/6 -inhibitors 4 C +/-***\n* concurrent Trastuzumab/ Pertuzumab and parasternal radiotherapy should be avoided  \n**     with hypofractionated RT approx . 40 Gy, consider dose reduction ofCapecitabine , Pat. at high -risk for\nlocoregional recurrence\n***   In currently available phase III-trials ( monarchE , PALLAS, Penelope -B) RT was given before initiation ofCDK4/6 -\ninhibitors . Nodefinitive signs ofsignificantly increased toxicity with concomitant RT in thepalliative setting .\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nSimultaneous Capecitabine with locoregional \nradiotherapy\nWoodward et al. Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):777 -783\n\u2022Prospective phase trial, 32 pat. with LABC, sim. def./neoadj. chemoradiotherapy, median total \ndose 66 Gy\n\u2022\u201cThe first 9 patients analyzed [\u2026] received CAP 825 mg/m2twice daily continuously beginning \non the first day of RT. Because of observed excess grade 3 toxicity the protocol was amended, \nand subsequent patients received CAP only on RT days (5 days per week).\u201d\n\u2022\u201cNoncontinuous CAP dosing was much better tolerated than continuous dosing. Thirteen of 26 \npatients (50%) had grade \u22653 and higher treatment -related dermatologic toxicity . \u201c\nAlhanafy et al. Menoufia Medical Journal 2015, 28:325 -332 \n\u2022Randomised phase II -trial, 100 pat., adj. Radiotherapy 40 Gy/15 fr. +/ -CAP 825 mg/m2 Mo- Fr, \nLABC\n\u2022\u201c [\u2026] concurrent capecitabine was feasible with a high percent of patients (96%), [\u2026] only two \nout of 50 (4%) patients had capecitabine dose modification \u2026\u201d.\n\u2022\u201cAll early toxicities were GI/GII. Radiation dermatitis had  a peak incidence in the last few \nfractions of the radiation therapy and the week after radiotherapy; no treatment interruption \nwas needed and the incidence was close in both groups\u201d. \n\u2022Radiation dermatitis grade I 14% vs. 18%; grade 2 4% vs. 4%\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSmoking and Risk\nof secondary lung cancer\nOxford\nLoE GR AGO\n\u00a7Increased risk of lung cancer secondary to breast \ncancer radiotherapy in smokers1a A\n\u00a7Inform patients about risk ++\n\u00a7Recommend to stop smoking ++\nAdjuvant Radiotherapy\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nwww.ago- online.de\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1ESupportive Care and\nManagement of Side Effects\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSupportive Care and\nManagement of Side Effects\n\u00a7Versionen 2002\u2013 2020: \nAlbert / Bauerfeind / Brunnert / Bischoff / Costa / Dall / Diel / Fersis / \nFriedrich / Friedrichs / Gerber / G\u00f6hring / Hanf / Harbeck / Heinrich / \nHuober / Jackisch / Lisboa / L\u00fcck / L\u00fcftner / von Minckwitz / M\u00f6bus\n/M\u00fcller / Nitz / Oberhoff / Rody / Schaller / Scharl / Schmidt / Schneeweiss\n/Sch\u00fctz / Solomayer / Souchon / Stickeler / Thomssen / Untch / \n\u00a7Version 2021: \nMundhenke /Nitz\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\u00a7Guideline -environment\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nSpecific national and international guidelines deal with various aspects of evidence -\nbased supportive therapy of cancer patients\nWithout claiming completeness, such guidelines will be quoted, with an emphasis on \nGerman guidelines.\nAspects concerning breast cancer patients will especially be highlighted.The \u201eArbeitsgemeinschaft Supportive Ma\u00dfnahmen in der Onkologie, Rehabilitation \nund Sozialmedizin der DKG\u201c should especially behighlighted\n(http:// www.onkosupport.de ).\nMultidisciplinary S 3 guidelines of the AWMF (Reg. -Nr. 032 -054OL): \n\u00a7S3-Leitlinie: Supportive Therapie bei onkologischen Patientinnen \nLangversion 1.3 \u2013Februar 2020 AWMF -Registernummer: 032/054OLGuideline Environment\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\u00a7Assessment oftoxicity\n\u00a7Acute toxicity (NCI -CTCAE)\n\u00a7Long -term toxicity (ICPC, ICD- GM)\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAssessment of toxicity\nAcute Toxicity (according to WHO1or NCI -CTC\u00b2)\nAcute toxicities should beasked forand documented after every\ntreatment courseLoE 5 D  AGO ++\nGrade Information required\n0 none organs involved\n1 mild type of toxicity\n2 moderate time interval after treatment\n3 severe effect on general health status\n4 life threatening treatment required\n5 death recovery achieved\nLong term toxicity (= secondary diseases after tumour therapy )\nLong term surveillance and documentation in regular intervals \n(acc. ICPC\u00b3 following symptoms or acc. ICD -10-GM4following  diagnoses)LoE5 D AGO ++\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7Grade 1 \nMild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not \nindicated.\n\u00a7Grade 2 \nModerate; minimal, local or noninvasive intervention indicated; limiting age -appropriate \ninstrumental ADL*.\n\u00a7Grade 3 \nSevere or medically significant but not immediately life -threatening; hospitalization or \nprolongation of hospitalization indicated; disabling; limiting self care ADL**.\n\u00a7Grade 4 \nLife-threatening consequences; urgent intervention indicated.\n\u00a7Grade 5 \nDeath related to AE.Acute Toxicity (NCI CTCAE vs 5.0, 2017)\nActivities of Daily Living (ADL)\n*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing \nmoney, etc.\n**Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and \nnot bedridden.\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\u00a7Incidence ofside effects\n(according totechnical product information by\nMedDRA * classification )\n*MedDRA -Medical Dictionary for Regulatory Activities\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deChemotherapy \u2013Acute Toxicities I\nListing and grading of side effects was performed according the MedDRA -classification with the following categories of frequency :1. Very rarely (<1/10,000); 2. rarely (\u2265 1/1,000 to < \n1/10,000); 3. occasionally (\u2265 1/1,000 to < 1/100);  4. frequently (\u2265 1/100 to < 1/10); 5. very frequently (\u2265 1/10).  -unknown ( based on available data incidence not assessable)SYSTEM ORGAN CLASS\nDRUGS\nINFECTIONS \nAND \nINFESTATIONS\nNEOPLASMS \nBEN.,ALIGNANT AND NSPECIFIED (INCL CYSTS & POLYPS)BLOOD & \nYMPH.  SYST. ISORDERS\nIMMUNE \nYSTEM DISORDERS (ALLERGIES)\nENDOCRINE \nDISORDERS\nMETABOLISM \nAND NUTRITION DISORDERS\nPSYCHIATRIC \nDISORDERS\nNERVOUS \nSYSTEM DISORDERS\nEYE \nDISORDERS.\nEAR AND \nLABYRINTH DISORDERS\nCARDIAC \nDISORDERS\nVASCULAR \nDISOR. INCL \nHOT FLUSHES\nAlkylating antineoplastic agent\nCyclophosphamide 4 2 5 5 1 - 1 3 2 3 3 3\nAnti-Metabolites\nMethotrexate 1 - 4 3 3 - 3 4 2 - 1 2\n5-Fluorouracil* 5 - 5 2 2 5 - 3 3 - 5 3\nCapecitabine 4 3 (Lipoma) 4 3 - 5 4 4 4 3 3 4\nGemcitabine 4 - 5 1 - 4 -: 4 - - 2 2\nPlatinum -complexes\nCisplatinum 4 2 5 3 2 5 - 4 2 5 4 4\nCarboplatin 4 - 5 4 - - - 4 4 4 4 -\nAnthracyclines / Anthrachinones\nEpi-/Doxorubicin 5 3 5 1-2 - 1-5 - - 4 - 4 5\nLiposom . Doxorubicin 5 - 5 - - 5 3 4 (4) - 4 4\nPEG -lipos . Doxorubicin 4 - 4 - - 5 - 4 4 - 4 -\nMitoxanthrone 5 3 5 3 - 4 - 4 3 3 4 3\nTaxanes\nPaclitaxel 5 1 5 5 - 1 1 5 1 1 4 5\nnab-Paclitaxel 4 - 5 3 - 5 4 5 4 4 4 4\nDocetaxel 5 - 5 5 - 5 - 5 - - 4 4\nFurther tubulin -targeting drugs\nVinorelbine IV (PO) 5(5) - -(5) 2(-) - - -(5) -(5) -(4) - 2(3) 3(4)\nEribulin 4 - 4 - -: 5 4 5 4 4 4 4\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deChemotherapy \u2013Acute Toxicities II\nListing and grading of side effects was performed according the MedDRA- classification with the following categories of frequency : 1. Very rarely (<1/10,000); \n2. rarely (\u2265 1/1,000 to < 1/10,000); 3. occasionally (\u2265 1/1,000 to < 1/100); 4. frequently (\u2265 1/100 to < 1/10); 5. very frequ ently (\u2265 1/10).\n-unknown (based on available data incidence not assessable)SYSTEM ORGAN CLASS\nDRUG\nRESPIRAT.,\nHORAC. & MEDIA -\nSTINAL DIS.\nGASTROINT.DISO\nRD. (NAUSEA, EMESIS)\nHEPATOBILIARY \nDISORDERS\nSKIN & SUBCUT. \nTIS. DISORD. (ALOPECIA)MUSCULOSKELE\nTAL & CONNECTIVE \nTISSUE \nDISORDERS\nRENAL& URINARY \nDISORDERS\nPREGN., \nPUERPER. & \nPERINATAL \nCONDIT.\nREPRODUCT. \nSYS. & BREAST \nDISORDERSGENERAL \nDISORD. & ADMINI -\nSTRATION SITE CONDITIONSCONGEN., \nFAMILIAL GENET. DISORDERS\nSPECIAL \nFEATURES\nAlkylating antineoplastic agent\nCyclophosphamide 2 4 4 5 - 5 - 4 5 - Hyponatriaemia\nAnti-Metabolitee\nMethotrexate 4 5 5 4 3 3 - 3 1 - Mucositis , risk of  \u201cthird space\u201d- toxicity\n5-Fluorouracil 5 5 3 5 - - - - 5 - Risk DPD- deficiency : light 5%, severe 0,1%; diarrhea , heart\nCapecitabine 4 5 4 5 4 3 - 3 5 - Hand -foot- syndrome (HFS), risk of DPD -deficiency; heart\nGemcitabine 5 5 5 5 4 5 - - 5 - Flu-like symptoms, edema, heart\nPlatinum -complexes\nCisplatinum 4 5 4 4 - 5 - 3 5 - Nephrotoxicity, ototoxicity, CIPN\nCarboplatin 4 5 - 4 4 4 - - 4 - Colitis (nephrotoxicity )\nAnthracyclines / Anthrachinones\nEpi-/Doxorubicin 2 5 - 5 1 4 1 5 - Cardiotoxicity (CHF),  sec. malign. diseases , extravasation\nLipo . Doxorubicin 4 5 4 5 4 3 - (4) 5 -\nPEG -lipo. Doxo . 4 5 - 5 4 - - 4 5 - Palmar and plantar erythema (PPE)\nMitoxanthrone 4 5 3 5 - 3 - 3 4 - Sec. AML, cardiomyopathy\nTaxanes\nPaclitaxel 2 5 1 5 5 - - - 5 - Peripheral neuropathy (CIPN); hypersensitivity, myalgia\nnab-Paclitaxel 4 5 3 5 5 3 - 3 5 - Peripheral neuropathy (CIPN)\nDocetaxel 5 5 - 5 5 - - - 5 - Fluid retention, paronychia, colitis, myalgie\nFurther tubulin -targeting drugs\nVinorelbine IV (PO) 3(4) 2 (5) 5(4) 2(5) -(4) 2(4) - - - - Phlebitis, GI -Tox(PO), CIPN\nEribulin 5 5 4 5 5 4 - - 5 - Constipation, CIPN\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEndocrine Therapy \u2013 Toxicities\nListing and grading of side effects was performed according the MedDRA -classification with the following categories of frequency :\n1. Very rarely (<1/10,000); 2. rarely (\u2265 1/1,000 to < 1/10,000); 3. occasionally (\u2265 1/1,000 to < 1/100); 4. frequently (\u2265 1/1 00 to < 1/10); 5. very frequently (\u2265 1/10). \n-unknown (based on available data incidence not assessable)DRUG\nINFECTIONS \nAND \nINFESTATIONS\nNEOPLASMS \nBEN.,\nMALIGNANT \nAND \nUNSPECIFIED \n(INCL CYSTS & POLYPS)\nBLOOD & \nLYMPH.  SYST. \nDISORDERS\nIMMUNE \nSYSTEM \nDISORDERS \n(ALLERGIES)\nENDOCRINE \nDISORDERS\nMETABOLISM \nAND NUTRITION \nDISORDERS\nPSYCHIATRIC \nDISORDERS\nNERVOUS \nSYSTEM DISORDERS\nEYE \nDISORDERS.\nEAR AND \nLABYRINTH \nDISORDERS\nCARDIAC \nDISORDERS\nVASCULAR \nDISOR. INCL \nHOT FLUSHES\nSERM\nTamoxifen - 3 4 - 3 5 - 4 4 - - 4\nAIAnastrozole - - - - - 4 5 5 4 - 4 5\nExemestane 4 4 5 4 5\nLetrozole 3 - 3 - - 5 4 4 3 - 3 5\nSERDFulvestrant 4 - 3 4 - 4 - 4 - - - 4\nDRUG\nRESPIR.., \nTHORAC. & \nMEDIASTIN. DIS.\nGASTROINT. \nDIS.. (NAUSEA, \nEMESIS)\nHEPATOBILIARY \nDISORDERS\nSKIN & \nSUBCUT.TIS. \nDIS. (ALOPECIA)\nMUSCULOSKEL\nETAL & \nCONNECTIVE \nTISSUE DISORDERS\nRENAL& \nURINARY \nDISORDERS\nPREGN., \nPUERPER. & \nPERINAT. COND.\nREPRODUCT. \nSYS. & BREAST DISORDERS\nGENERAL DIS. & \nADMINISTRATIO\nN SITE CONDITIONS\nCONGEN., \nFAMIL. &GENET. \nDISORD.\nSPECIAL \nFEATURES\nSERM\nTamoxifen 3 5 4 5 4 - - 5 5 1 Hot flushes ; rarely : endometrial Ca(>55y); thrombosis\nAI\nAnastrozole - 5 4 5 5 - - 5 5 - Hot flushes , arthralgia , osteoporosis; cognition\nExemestane 5 5 5 5 - Hot flushes , arthralgia , osteoporosis; cognition\nLetrozole 3 4 3 5 5 3 - 4 5 - Hot flushes , arthralgia , osteoporosis; cognition\nSERD\nFulvestrant - 5 5 4 4 4 - 3 5 - Hitzewallungen\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deKey- Toxicities \u2013Antibodies and\nAntibody -Drug- Conjugates (ADC)\nOxford\nLoE GR\nTrastuzumab\n\u00a7 Cardiotoxicity in the adjuvant setting (1.0 \u20132.0%) 1b A\n\u00a7 Troponin I may identify patients at risk for cardiotoxicity 2b B\nPertuzumab \n\u00a7 Skin rash, diarrhea, mucositis 1b A\nTrastuzumab -Emtansine (T -DM1)\n\u00a7 Thrombocytopenia , hepatotoxicity ,pyrexia , headache , pneumonitis , neuropathy 1b A\nBevacizumab\n\u00a7 Hypertonus, proteinuria , bleeding , leftventricular dysfunction 2b B\nTrastuzumab -Deruxtecan\n\u00a7 Interstitial lung disease (ILD), neutropenia , nausea 2b B\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deToxicities of new compounds: antiHER2 -TKI \n\u2013Neratinib, Lapatinib \u2013\nAE, % Alle Grade Grad >/=3\nDiarrhea 90 40,1\nNausea 43 2\nAbdominal pain 36 2\nFatigue 27 2\nEmesis 26 3\nExanthema 18 0,6\nStomatitis 14 0,6\nAppetite loss 12 0,2\nDyspepsia 10 0,4\nALAT elevated 9 1,2\nASAT elevated 7 0,7\nNail disorders 8 0,3\nDry skin 6 0Lapatinib Neratinib\nAE, % All grades Grade >/=3\nDiarrhea 61% 6%\nNausea 18% 4%\nRash 60% 6%\nFatigue 16% 4%\nCardiac 3% < 1% SAE\nHepatobiliary 8%\nAll AE % 92% SAE 6%\nLoE GR AGO\nPrimary Prophylaxis with \nloperamide2b B ++\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deCommon Toxicities with antiHER2 -TKI: \nTucatinib , Trastuzumab + Capecitabine\nEvent Capecitabine+Tucatinib+Trastuzumab\nAny grade (%)                                    \u22653 grade (%)\nAny adverse event 99.3 55.2\nDiarrhea 80.9 12.9\nPPE syndrome 63.4 13.1\nNausea 58.4 3.7\nFatigue 45.0 4.7\nVomiting 35.9 3.0\nStomatitis 25.5 2.5\nReduced appetite 24.8 0.5\nHeadache 21.5 0.5\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nToxicities ofNew Substances \u2013CDK 4/6 Inhibitors \n(Palbociclib /Ribociclib/ Abemaciclib )\nUE, % All Grades Grade 3 Grade 4\nNeutropenia 79,5/ 74,3/41,3 56,1/ 49,7/19,6 10,4/ 9,6/1,5\nLeukopenia 39,0/ 32,9/20,8 24,1/ 19,8/7,3 0,7/ 1,2/0,3\nAnemia 24,1/ 18,6/28,4 5,2/ 0,9/5,8 0,2/ 0,3/0\nThrombocytopenia 15,5/ 5,7/10,0 1,4/ 0,6/2,0 0,2/ 0/<1,0\nFatigue 37,4/ 36,5/40,1 1,8/ 2,1/1,8 0/0,3/ 0\nNausea 35,1/ 51,5/38,5 0,2/ 2,4/0,9 0/0/0\nVomiting 15,5/ 29,3/28,4 0,5/ 3,6/1,2 0/0/0\nDiarrhea 26,1/ 35,0/81,3 1,4/ 1,2/9,5 0/0/0\nAlopecia 32,9/ 33,2/26,6 - -\nExantheme 17,8/ 17,1/14,0 0,9/ 0,6/<1,0 0/0/0\nALT elevated 9,9/ 15,6/15,6 1,7/ 7,5/5,8 0,1/ 1,8/0,3\nAST elevated 9,7/ 15,0/15,0 2,5/ 4,8/3,0 0/0,9/0\nInfections 60/50,3/39,1 6,0/ 3,6/4,0 1/0,6/0,9\nQT-prolongation N.A./ 7,5/N.A. N.A./ 3,0/N.A. N.A./ 0/N.A.\nPalbociclib /Ribociclib /Abemaciclib\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deQT interval prolongation: \nRibociclib vs Placebo\n\u00a7Post -baseline QT interval prolongation > 480 msec:  6.9% vs1.2% \n(incidence Ribo vsPlacebo)\n\u00a7Post -baseline QT interval prolongation > 500 msec: 1.5% vs0.3%\n\u00a7Therapy discontinuation forQT interval prolongation:  \n0.3% vs0.6%\n\u00a7QT interval prolongation isnot associated with symptoms ; however , QT \ninterval prolongation stands foranelevated risk oflife-threatening \narrhythmia \u201ctorsades de pointes\u201d (TdP )\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nToxicities of new compounds: mTOR -Inhibitor \n\u2013Everolimus \u2013\nUE, % All grades (%) grade >/=3 (%)\nStomatitis 11,6 1,6\nExanthema 7,4 0,02\nAnemia 3,3 1,3\nFatigue 6,8 0,8\nNausea 5,6 0\nEmesis / Vomiting 2,9 0\nDiarrhea 6,2 0,02\nLoss ofappetite 6,0 0,02\nHeadache 3,9 0\nWeight loss 3,9 0\nDyspnea 3,8 0,08\nArthralgia 3,3 0\nEpistaxis 3,1 0\nEdema 2,9 0\nConstipation 2,6\nPyrexia 2,9 0\nCough 4,5 0\nALT Elevated 2,6 0\nPneumonitis 0,2 0\nAsthenia 2,4 0,04\nDysgeusia 4,3 0\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deToxicities of new compounds: PIK3CA -\nalpelisib \nUE, % All Grade Grad >/=3\nHypergycemia 63,7% 32,7%\nDiarrhea 57,7% 6,7%\nNausea 44,7% 2,5%\nDecreased appetite 35,6% < 1% SAE\nRush 35,5% 9,9%\nVomiting 27,1% < 1% SAE\nWeight loss 26,8% 3,9%\nStomatitis 24,6% 2,5%\nFatique 24,3% 3,5\nAsthenia 20,4% 1,8\nAlopecia 19,7% 0\nMucositis 18,3% 2,1Alpelisib+Fulvestrant\nConsider recommendations for \nmanagement of side effects (diabetes \nmellitus, hyperglycemia, insulin resistance \nand metabolic syndrome)\nAndre F, et al N Engl J Med 2019;380:1929 -1940LoE GR AGO\n2b B ++\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nToxicities of new compounds: PARP -Inhibitors\n\u2013Olaparib, Talazoparib \u2013\nAE. % all grades (%) grade >/=3 (%)\nAE, overall 97.1 36.6\nNeutropenia 27.3 9.3\nAnemia 40.0 16.1\nFatigue 28.8 2.9\nNausea 58.0 0\nEmesis 29.8 0\nDiarrhea 20.5 0.5\nAppetite loss 16.1 0\nHeadache 20.0 1\nPyrexia 14.1 0\nCough 17.1 0\nALT elevated 11.2 1.5\nAST elevated 9.3 2.4\nPPE 0.5\nTreatm. discontinuation 4.9Olaparib Talazoparib\nAE. % all grades (%) grade >/=3 (%)\nAE, overall 98,6 31,8\nneutropenia 34,6 20,9\nAnemia 52.8 39,2\nFatigue 50,3 1,7\nNuasea 48,6 0,3\nEmesis 24,8 2,4\nDiarrhea 22,0 0,7\nAppetite loss 21,3 0,3\nHeadache 32,5 1,7\nBack pain 21,0 2,4\nCough 22,7 0,7\nPleural effusion 2,1 1,7\nPPE 1,4 0,3\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deImmune Checkpoint Inhibitors\n\u00a7Therapeutic approaches (antibodies )\n\u00a7PD1 /PD -L1\nPD1\n\u00a7nivolumab\n\u00a7pembrolizumab\nPD-L1\n\u00a7atezolizumab\n\u00a7durvalumab\n\u00a7avelumab\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nImmune Checkpoint Inhibitors\nTime Course of Adverse Events, ex. Nivolumab\nrashpneumonitis\nhypothyroidism\nhepatitis\nHaanen J et al. Ann Oncol 2017; 28 ( suppl 4): 119- 142\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nImmune Checkpoint Inhibitors\n\u2013side effects \u2013\n\u00a7Adverse events \u2265 grade 3\n\u00a7diarrhea\n\u00a7fatigue\n\u00a7skin lesions (maculopapular exanthema, vitiligo, epidermolysis)\n\u00a7pneumonitis\n\u00a7colitis\n\u00a7hypophysitis\n\u00a7hepatitis\n\u00a7nephritis\n\u00a7thyreoiditis (hyper -/hypothyroidism)\n\u00a7Guillain -Barr\u00e9 syndrome\n\u00a7cardiomyopathy\n\u00a7myopathy \u2013myalgia \u2013rhabdomyolysis\n\u00a7uveitis\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nImmune Checkpoint Inhibitors\nToxicities (Total in %)\natezolizumab nivolumab pembrolizumab\ndiarrhea 18.6% 13% 18%\ncolitis 1.1% 2% 1% \nexanthema 18.6% 15% <1%\nhepatoxicity 0.3% 1% 0.5%\nhypophysitis <0.1% <1% 0.5%\npneumonitis 3.1% 3% 2.9%\nthyroid dysfunction hyper -1.7%\nhypo -4.7%hyper -1%\nhypo -4%hyper -1.2%\nhypo -8.3%\nnephritis <1% 1% 0.7%\nneuropathy 0.2% <1% <1%\nAtezolizumab technical product information 2018 ;Nivolumab, safety management BMS 2014 ;Pembrolizumab PI 2014 \nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nImmune Checkpoint Inhibitors\nPrinciples of Adverse Event Management\nCTC AE -Grade Management\n1 \u00a7 supportive therapy\n\u00a7 close examination\n\u00a7 exclusion of infective complications\n\u00a7 patient information\n2 Like grade 1 but\n\u00a7 intermission of therapy until recovery of all irAE to grades 0 -1\n\u00a7 consider corticosteroids\n3 \u00a7 supportive therapy\n\u00a7 IV steroids (e.g. 1 -2 mg/kg prednisolone)\nIn case of no improvement within 48 h:\n\u00a7 consider additional immunosuppressive therapy (infliximab, MMF)\n\u00a7 consider further organ specific diagnostics (eg. colonoscopy)\n\u00a7 consider specialists consultations\n\u00a7 exclusion or treatment of infection\n\u00a7 stop of treatment, re- initiation after recovery to CTC AE grades 0, 1 \n\u00a7 slow reduction of steroids (3 -6 weeks)\n4 Like grade 3 but persistent withdrawal of therapy\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nPneumonitis\nCourtesy ofAndreas Schneeweiss , NCI\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nNephrotoxizit\u00e4t\nCourtesy ofAndreas Schneeweiss , NCI\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nHypophysitis\nCourtesy ofAndreas Schneeweiss , NCI\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nDiarrhoe und Kolitis\nCourtesy ofAndreas Schneeweiss , NCI\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nHepatitis\nCourtesy ofAndreas Schneeweiss , NCI\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nThyreoditis\nCourtesy ofAndreas Schneeweiss , NCI\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSide effects according Organ Systems\nIncidence, Prevention, Therapy\n1.Infections\n\u00a7General prophylaxis forinfections\n\u00a7Hepatitis B virus screening\n\u00a7Covid -19 (seejoint guidelines with DGHO)\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deOxford\nLoE GR AGO\n\u00a7Avoidance of  behavior or situations that are \nassociated with high risk for infections5 D +\n\u00a7Prophylactic treatment in low -risk patients 1a B -\n\u00a7Prophylactic treatment in high -risk* patients \n(e.g. according to NCCN Guidelines) with\n\u00a7Antibiotics 1a A ++\n\u00a7Anti -fungal agents (triazole) 1a B +/-\n\u00a7Virostatics in solid tumors 5 D -\n\u00a7Granulocyte colony -stimulating factors 1a A ++\n*High -risk: estimated duration of neutropenia < 100/\u00b5l > 7d Prophylaxis of Infections\nrarely applicable to patients with solid tumors (e.g. BC)\nASCO Practice Guideline \u201eAntimicrobial Prophylaxis...\u201c 2018\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deOxford\nLoE GR AGO\n\u00a7Hepatitis B virus screening before adjuvant chemotherapy \n(HBsAG , anti -HBC)2c B +\nIn case ofpositive serology orreactivation :\n\u00a7Interruption ofchemotherapy 5 D ++\n\u00a7Prophylactic therapy with virustatic drugs ifHBV -DNA \ndetected (according AGIHO/DGHO \u2013 recommendations )1b A ++\n\u00a7Hepatitis C virus screening before chemotherapy 5 D +/-Hepatitis B virus screening before \nchemotherapy\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nAGIHO / DGHO \u2013recommendations on \nHepatitis B virus screening in oncology\nSandherr M et al. Ann Hematol. 2015 Sep;94(9):1441 -50\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSide Effects According Organ Systems\nIncidence , Prevention, Therapy\n2.Neoplasms benign, malignant and \nunspecified (incl. cysts and polyps)\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSecondary Malignancies I\nOxford\nLoE GR\n\u00a7With regard to solid tumors, chemotherapy induced secondary \nmalignancies are rare events2a\n\u00a7Alkylating agents increase the risk of leukemia dose -dependently to a \ntotal of 0.2 \u20130.4 % within 10\u2013 15 years2a\n\u00a7Anthracycline -containing regimens increase the risk of MDS and \nleukemia to 0.2 \u20131.7 % within 8 to 10 years2a\n\u00a7PARP- inhibitors are associated with an increased risk of AML and \nMDS to 0.5 \u20131%2b\n\u00a7Radiotherapy increases the risk of leukemia by 0.2 \u20130.4% in patients \ntreated with anthracycline -containing chemotherapy2b\n\u00a7Tamoxifen approximately doubles the risk for developing endometrial \ncancer (in pts. older than 55y at start of therapy)2b\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSecondary Malignancies II\n(After Radiotherapy)\nOxford\nLoE\n\u00a7Radiotherapy (PMRT, BET) may moderately enhance the risk of \nipsilateral lung cancer and angiosarcoma (10-15 / 10.000) 5 \u201310 \nyears after treatment1a\n\u00a7Enhanced risk especially among ever smokers 2b\n\u00a7No difference of secondary malignancy between PBI und WBI 2c\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n3.Blood and Lymphatic System Disorders \n\u00a7Anemia\n\u00a7Neutropenia\n\u00a7Febrile Neutropenia (FN)\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAnemia \u2013 Indications for Therapy with \nErythropoiesis -stimulating agents (ESAs)\nOxford\nLoE GR AGO\n\u00a7Indicated in asymptomatic anemia 1a B -\n\u00a7Therapy and secondary prophylaxis in CTx- induced \nanemia1a A +\n\u00a7 Adjuvant setting 1b A +\n\u00a7 Neoadjuvant/metastatic setting 1a A +/-\n\u00a7 In dose -dense / dose -escalated CTx (iddETC ) 1b A +\n\u00a7Treatment start at Hb -levels < 10 g/dL 1a A +\n\u00a7Target Hb 11 \u201312 g/dL 1a A +\n\u00a7Improvement of outcome (DFS, OS) 1a B --\n\u00a7Risk of thromboembolic events is increased by use of ESAs 1a A\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7Epoetin \u03b1 and Darbepoetin are equieffective\n\u00a7Dosage:\n\u00a7Epoetin \u03b1: 150 IU/kg 3 x weekly s.c. or\n40.000 IU 1 x /week s.c. or\n80.000 IU  q2w s.c. or\n120.000 IU q3w s.c.\n\u00a7Epoetin \u00df: 30.000 IE weekly s.c.\n\u00a7Darbepoetin: 2,25 \u00b5g/kg s.c. weekly or  500 \u00b5g s.c. q3w\n\u00a7Weekly hematologic blood controls\n\u00a7Dose reduction if Hb -increase > 1g/dl within 2 weeks\n\u00a7Dose increase if Hb -increase < 1g/dl  within 4 -6 weeks\n\u00a7In case of FID (\u201cfunctional iron deficiency\u201d) iron supplementation,    \npreferably i.v.\n\u00a7Stop ESA -treatment if there is no Hb increase after 9 weeksPractical Use of ESAs\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deGranulocyte Colony -stimulating Factors\nOxford\nLoE GR AGO\n\u00a7Primary prophylaxis for expected febrile neutropenia (FN)\n\u00a7 If expected risk for FN 10 \u201320% 1b B +/-\n\u00a7 In case of individual risk factors 3b C +\n\u00a7 If expected risk for FN >20% (e.g. DAC, dose -dense CT) 1a A ++\n\u00a7Secondary prophylaxis during chemotherapy \n(previous FN or neutropenia grade IV > 7 days)1b A ++\n\u00a7Therapeutic useforFN 1a A +/-\n\u00a7Start related to chemotherapy and duration\n\u00a7 Pegfilgrastim day 2 1b A ++\n\u00a7 Lipegfilgrastim day 2 1b A ++\n\u00a7 Filgrastim/ Lenograstim from day 2 \u20133 until ANC > 2 \u20133 x 1091b A ++\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deManagement of Febrile Neutropenia\nc.f. Recommendations by Arbeitsgemeinschaft Infektionen in der H\u00e4matologie und Onkologie \n(AGIHO) der Deutschen Gesellschaft f\u00fcr H\u00e4matologie und Onkologie e.V. (DGHO) www.dgho -\ninfektionen.de\nDefinition (oral temperature of > 38.5\u2103or two consecutive readings of >38 \u2103for 2 h in a patient with \nan ANC of <500 cells/mm3or expected to fall to <500 cells/mm3) Oxford\nLoE GR AGO\n\u00a7Clinical examination 5 D ++\n\u00a7Daily evaluation 5 D ++\n\u00a7Hospitalization of high -risk patients 1b A ++\n\u00a7Homecare in low -risk patients 1b A +\n\u00a7Differential blood count 5 D ++\n\u00a7Blood cultures 5 D ++\n\u00a7Imaging of lungs 3 C ++\n\u00a7Immediate initial lyempiric antibiotic therapy 1a A ++\n\u00a7Empiric antifungal therapy 4 \u20137d in case of failure of antibiotic therapy 1b A ++\n\u00a7G-CSF for treatment (not prophylactic) 2b B +/-\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nEORTC and ASCO G -CSF \nGuideline -Based FN Risk Assessment\nStep 1: Assess frequency of FN associated with the planned chemotherapy regimen\nHigh risk: Age >65 years\nIncreased risk: Advanced disease\n(level I and II evidence) History of prior FN\nNo antibiotic prophylaxis\nOther Factors: Poor performance (ECOG > 1)\n(level III and IV Female gender\nevidence) Haemoglobin <12 g/dL\nLiver, renal or cardiovascular disease\nNutritional status\nProphylactic G -CSF recommended G-CSF prophylaxis not indicatedFN risk 10 -20% FN risk \u226520% FN risk <10%\nOverall FN risk \u226520% Overall FN risk <20%Step 2: Assess factors that may increase the risk of FN:\nReass\ness at \neach \ncycle\nStep 3: Define the patient\u2019s overall FN risk for planned chemotherapy regimen\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de4. Toxicities /Ovaries\nTherapy -associated amenorrhea (CRA, CIA, TIA) Oxford\nLoE\n\u00a7CRA may be permanent or temporary (depending on patient age and type \nof chemotherapy)2b\n\u00a7The risk ofCRA increases with patient ageand duration ofthe\nchemotherapy2b\n\u00a7CRA is an imperfect surrogate for menopause and fertility 5\n\u00a7Adjuvant endocrine therapy with GnRHa induces reversible amenorrhea,  \nbut delays conception to a less fertile period5\n\u00a7Ovarian reserve of women who remain premenopausal \nafter CTX is reduced2b\n\u00a7CRA is associated with improved outcome (DFS/OS) 1b\nSynonyme : Chemotherapy related or induced / Treatment induced Amenorrhea (CRA, CIA, TIA)\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n5. Psychiatric Disorders \n\u00a7Depression\n\u00a7Fatigue\n\u00a7Cognitive impairment \n\u00a7Sleep disturbances\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de(Therapy -associated) \nDepression\nOxford\nLoE GR AGO\n\u00a7Depression is an often reported adverse event in breast cancer \npatients (20\u2013 30%)2a B\n\u00a7Psychological interventions are effective to improve mood, but \nnot survival in distressed and depressed patients1b A\n\u00a7Antidepressants have been shown to improve depression in \nbreast cancer patients1b A\n\u00a7Regular exercise participation can prevent depression in breast \ncancer survivors2b B +\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de(Therapy -related ) \nFatigue\nOxford\nLoE GR AGO\n\u00a7Fatigue frequent in breast cancer patients (30 \u201360%) 2a B\n\u00a7Exclusion of somatic reasons (anemia, tumor burden, \nco-morbidity, medication) for fatigue1a A ++\n\u00a7Psycho -social interventions specifically addressing \nfatigue efficient in reducing fatigue1a A ++\n\u00a7Physical exercise can improve fatigue 1b D +\n\u00a7Diet, Yoga can improve fatigue 2b B +\n\u00a7Methylphenidate can improve fatigue 1a D +\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de(Therapy -associated) \nCognitive Impairment\nOxford\nLoE GR\n\u00a7Therapy- related cognitive deficits (\u201c chemobrain \u201d) frequently \ndescribed (16 \u201375%)2a B\n\u00a7Cognitive -behavioral therapy beneficial for cognitive function 2b B\n\u00a7Methylphenidate may improve cognitive function in cancer \npatients3a C\n\u00a7On aromatase inhibitor therapy , deterioriation ofcognitive\nperformance was observed (espec . verbal memory ) 1a B\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de(Therapy -associated) \nSleep Disturbances\nOxford\nLoE GR AGO\n\u00a7Sleep disturbances are a common problem in breast \ncancer patients during and after therapy (20 \u201370%)2a B\n\u00a7Behavioral therapies have demonstrated efficacy in \ntreatment of insomnia and improved quality of life1b A ++\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n6. Nervous system disorders \n\u00a7Chemotherapy -Induced Peripheral Neuropathy \n(CIPN)\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deChemotherapy -Induced Peripheral \nNeuropathy (CIPN)\n\u00a7Incidence with taxanes :\n\u00a7Grade 1 \u20132:  20\u2013 50 %\n\u00a7Grade 3 \u20134: 6\u2013 20 %\n\u00a7Risk factors : type and dose ofchemotherapy , BMI, reduced physical activity\n\u00a7Individual risk factors\n\u00a7Diabetes mellitus\n\u00a7Nutritive -toxic compounds , particularly alcohol\n\u00a7Renal failure\n\u00a7Hypothyreosis\n\u00a7Collagenoses / vasculitis\n\u00a7Vitamine deficiency\n\u00a7HIV-Infection\n\u00a7CMT -Gen mutations\nUnclear :\n\u00a7Other genetic factors (SNPs, mutations )\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deChemotherapy -induced Peripheral Neuropathy\n\u2013Prevention \u2013\nOxford\nLoE GR AGO\nNon drug -based prevention\n\u00a7 Functional training (physical fitness , sensomotoric stimulation training etc.) 5 D +\n\u00a7 Compression treatment (tight surgical gloves, compression stockings) 2b B +\n\u00a7 Cooling gloves and stockings 2ba B +/-\n\u00a7 Elektro -acupuncture 1b B -\nDrug- based prevention\nThere isnodrug -based prophylaxis available\n\u00a7 Venlafaxine 2a C +/-\n\u00a7 Palmitoylethanolamine (PEA) topically orPO 5 D +/-\n\u00a7 \u0391-lipoic -acid (thioctic acid),amifostine, amitriptyline , acetyl -L-car-nitine, carbamazepine , electrolyte\nsolutions, glutathione , Goshajinkigan (GJG), oxcarbazepine , vitamine B, vitamine E,orother compounds11b A -\n1Forlistofnot recommended drugs, seeHershman et al. 2014\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deChemotherapy -induced Peripheral Neuropathy\n\u2013Therapy \u2013\n1For list of not recommended drugs, see Hershman et al. 2014Oxford\nLoE GR AGO\nNon drug -based therapy\n\u00a7 Functional training (physical fitness, sensomotoric stimulation\ntraining etc.)2a C +\n\u00a7 Physiotherapy / physical treatment 5 D +\n\u00a7 acupuncture 2b B +\nDrug -based therapy\n\u00a7 Menthol locally (1%), capsaicin /lidocain locally 5 D +\n\u00a7 Baclofen /amitryptiline /ketamin -gel  2b B +\n\u00a7 Duloxetine for therapy of CIPN -induced pain 1b B +\n\u00a7 Opioids for therapy of CIPN -induced pain 5 D +\n\u00a7 Palmitoylethanolamine (PEA) topically orPO. 5 D +/-\n\u00a7 Venlafaxine 5 D +/-\n\u00a7 Gabapentin , pregabaline 1b B +/-\n\u00a7 Amitryptiline / nortripyline , imipramine /desipramine 1b B +/-\n\u00a7 Acetyl -L-carnitine , lamotrigine , orother compounds11b B -\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n7. Cardiac Disorders\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deCardiotoxicity as Long -term Side Effect\nOxford\nLoE GR AGO\n\u00a7Equivalent cardiotoxicity of doxorubicin and epirubicin at recommended \ndose levels (450 \u2013500 and 900\u2013 1000 mg/m\u00b2 cum. dose, resp.)2b B\n\u00a7Liposome encapsulated anthracyclines (doxorubicin) induce less\ncardiotoxicity1b B\n\u00a7Anthracycline -or trastuzumab -associated cardiotoxicity may occur \nearlier/more frequently:2b B\n\u00a7 Elderly patients , obesity , hypertension, hypercholesterinemia , \u00fcre-existing cardiac\ndisease (incl. borderline LVEF), diabetes mellitus\n\u00a7Monitoring of cardiac function: \n\u00a7 Standardized echocardiography (LVEF or SF in %) 3b C +\n\u00a7 Troponin I asmarker ofcardiac toxicicty 2b B +/-\n\u00a7Betablocker -prohylaxis during anthracycline therapy 2a B +/-\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAdjuvant Trastuzumab \nCardiac Monitoring for CHF\nOxford LoE: 5 GR: D AGO: ++\nBefore start of trastuzumab\n\u00a7History, physical examination (edema, \nhepatomegaly)\n\u00a7Echocardiography (alternative to MUGA)\nDuring trastuzumab\nRegular assessment of\n\u00a7Heart rate increase > 15% above individual base level\n\u00a7Body weight increase \u2265 2 kg/week\n\u00a7Cardiac signs and symptoms\n3 monthly assessment of LVEFAssessment\nof LVEF\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deFeasibility of Treatment Combinations \nConsidering Toxicities \nOxford\nLoE GR AGO\nRegarding cardiac toxicity\n\u00a7Trastuzumab concurrent with radiotherapy 2b B +\n\u00a7Trastuzumab concurrent with epirubicin 2b B +/-\n\u00a7Trastuzumab concurrent with doxorubicin 2b B -\n\u00a7Anthracycline concurrent with radiotherapy 2c C -\nRegarding lung and breast fibrosis\n\u00a7Tamoxifen concurrent with radiotherapy 3 C +/-\n\u00a7Chemotherapy concurrent with radiotherapy 1b B -\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nSide Effects of Trastuzumab/Pertuzumab: \nAlgorithm in Case of Cardiac Toxicity \nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n8. Gastrointestinal Disorders\n\u00a7Nausea, Emesis\n\u00a7Mucositis\n\u00a7Stomatitis (Everolimus)\n\u00a7Diarrhea\n\u00a7Constipation\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAntiemetic Therapy\nhttp://www.mascc.org/antiemetic-guidelines\nwww.onkosupport.de\nOxford\nLoE GR AGO\n\u00a7Prior assessment of emetic potential of chemotherapy protocol 5 D ++\n\u00a7Neurokinin -1-receptor- antagonists 1b A ++\n\u00a7Dexamethasone (also in chemotherapy combinations with ICPi) 1a A ++\n\u00a75-HT3-antagonists 1b A ++\n\u00a7Fixed antiemetic combination therapy 1b A ++\n\u00a7Rescue Medication\n\u00a7Olanzapine 1b A +\n\u00a7Levomepromazine , benzodiazepines 3b C +\n\u00a7Cannabinoids , ginger 3b C +\nICPi=Immune Checkpoint inhibitor\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nAntiemetic Therapy\nhttps://www.mascc.org/antiemetic -guidelines\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nAntiemetic Therapy\nhttps://www.mascc.org/antiemetic -guidelines\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nSupportive Therapy\nAntiemetics\nWirkstoffgruppe Substanz Dosierung Nebenwirkungen Potenzial\nSerotonin -\nantagonistenOndansetron\nTropisetron\nGranisetron\nPalonosetron8 mg i.v., 2 x 4 -8 mg p.o\n5 mg i.v., 5 mg p.o.\n1-3 mg i.v.\n0, 25 mg i.v.Kopfschmerzen, Diarrhoe, Flushsymptomatik\nTransaminasenanstieg\nDarmatonie in hoher \nDosierungsehr hoch\nNK1-Antagonisten Aprepitant\nFosaprepitant\nRolapitant125 mg d1, \n80 mg d 2 -3 p.o.\n150 mg d1 i.v.\n180 mg  d1 p.o.Cytochrom- P-450- Aktivierung mit Dosis -reduktion von \nDexamethason (2 x 8 mg). \nKeine Kombination mit Astemizol, Terfenadin, Cisapridsehr hoch\nDopamin -\nantagonisten/ substituierte \nBenzamideMetoclopramid\nAlizapridbis zu 120 mg/24h als \nDauerinfusion od. als Tropfen\nbis zu 300 mg i.v. oder \np.o./24 h ( 6 Amp. od. 6 Tbl.)Dyskinesien\n(Antidot:Biperiden )\nAngstreaktion, Depressionen, \nDiarrhoehoch\nOxazapine Olanzepin 10mg/d for d1 -4\nGgf. 5mg/d for  d1 -4Sedation, weight gain hoch\nPhenothiazine/\nButyrophenoneHaloperidol 1-3 mg 4 x/d Sedation, Senkung der \nKrampfschwelle, transiente\nLeberwerterh\u00f6hungm\u00e4\u00dfig\nCorticosteroide Dexamethason\nPrednisolon8-20 mg i.v. 1 -3 x/d\n100- 250 mg i.v. 1 -3 x/dBlutzuckerentgleisung, \npsychotische Reaktionen, \nFlush, Blutdruckanstiegm\u00e4\u00dfig\nBenzodiazepine Diazepam\nLorazepambis zu 20 mg/d0,5-1,0 mg/dSedation, Atemdepressiongering\nNEPA ( Netupitant\nand Palonosetron )fixe Kombinations\npartner (oral)NE 300 mg PA 0,5 mg sehr hoch\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nMucositis Prevention\nhttp://www.mascc.org/assets/documents/MukositisGuidelinesMASCC2020(dtV).pdf\nMultidisciplinary S 3 guidelines of the AWMF (Reg. -Nr. 032 -054OL): \n\u201eSupportive Therapie bei onkologischen Patientinnen \u2013interdisziplin\u00e4re Querschnittsleitlinie\u201c,  released 11.11.2016\nOxford\nLoE GR AGO\n\u00a7Standardized mouth hygiene for prophylaxis of oral mucositis \nshould be adhered to by all age groups and during all cancer -\nrelated therapies with any risk for oral mucositis. 2b ++\nThis entails:\n1. Patient:\n\u00a7Regular mouth washs (H2O, NaCl)\n\u00a7Soft toothbrushes\n\u00a7Interdental care: flossing or using interdental brush\n\u00a7Avoidance of alcohol, tobacco, hot food, sour food\n\u00a7Regular screening forlesions\n2. Risk adjusted prophylaxis by dentist\n3. Continuous clinical control\nThere isnoevidence with regard totheuseofone ofthefollowing compounds : allopurinol , capsaicin , glutamine , honey , \ncamomile , camomile oilorextract , chewing gum , kefir , methadone , nystatin, pentoxifylline, povidone-iodine , vitamine\nA/E/ combinationes\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nPrevention of Everolimus -Induced Stomatitis \nUsing Dexamethasone Mouthwash\n\u00a7Study design: single arm phase II -trial (SWISH) \n\u00a7Cohort: 92 pts., treated with everolimus 10 mg and exemestane \n25 mg\n\u00a7Schedule: 10 mL of alcohol -free dexamethasone 15 mg per 5 mL \noral solution (swish for 2 min and spit) for at least 8 \u201312weeks*\n\u00a7Results: after 13 wks exposition all -grade incidence of stomatitis \n27% (BOLERO 67%), \u2265 grade 2 events 9% (BOLERO 27%)\nRugo et al., Lancet Oncol 2017, , Jones et al. Oncologist 2019*Alternatively Hydrocortison: Hydrocortisonacetat -Suspension 0,5 % with Lidocainhydrochlorid and \nDexpanthenol (Germany: Arzneibuchrezeptur NRF 7.14.) \nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7 Desinfecting / antiphlogistic measures: : \nMouth rinsing with infusions of chamomile or salvia, extracts of chamomile, etheric oils, polyvidon -iodine, \nhexetidine. Local therapy with crystal violet solution 0.5% or tinctura myrrhei, H. mometasonfuroate  + propylene \nglycol \n\u00a7 Mucosa protecting measures (during / after application of chemotherapy): Sucking ice cubes (especially from pineapple juice) during 5 -fluorouracile -or HD -melphalane. Calcium folinate \n(Leucovorin -mouth gel\u00ae) every 4 \u20136 hrs for HD -methotrexate:\ndo not start earlier than 24 hours after end of MTX -Infusion (otherwise potential loss of efficacy of MTX!). \nDexpanthenole (Panthenol\u00ae -Solution. 5%) mouth rinsing. \n\u00a7 Local antimycotic treatment: Amphotericin B, nystatin, fluconazole \n\u00a7 Local antiviral treatment\nAminoquinuride / tetracaine -HCl , Aciclovir\u00ae \n\u00a7 Local anaesthesia: Benzocaine, Doxepin 0,5% p.o.\n\u00a7 Pain Therapy: Opioids if indicatedMucositis\nhttp://www.mascc.org/assets/documents/MukositisGuidelinesMASCC2006(dtV).pdf\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7Adsorbent agents \n\u00a7Carbo medicinalis; caoline / pectine, Al -Mg-silicate hydrate\n\u00a7Analgetics, opioids \n\u00a7Loperamide; codeine, morphine IV, tintura opii (tinture of opium), butylscopolamine\n\u00a7Pseudomembranous colitis\n\u00a7Metronidazole or (if not effective) vancomycin Diarrhea\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7Bulging agents \n\u00a7Psylium, flaxseed (shredded) \n\u00a7Osmotic laxatives\n\u00a7Macrogol > Lactulose (Cochrane review LoE 1a, AGO + )\n\u00a7Oral radio -opaque material: ultima ratio e.g. sodium amidotrizoate\n\u00a7Sorbitol   \n\u00a7Motility stimulating laxatives\n\u00a7Senna, Ricinus (Castrol Oil), Bisacodyl, sodium -picosulfate \n\u00a7Emollients (Internal lubricants e.g. paraffin)\n\u00a7Opioid -receptor -antagonists (in opioid -related constipation) \n\u00a7MethylnaltrexoneConstipation\nImportant Side Effect of Opioid Treatment\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n9. Skin & Subcutaneous Tissue Disorders \n(Alopecia)\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSkin toxicities\nOxford\nLoE GR AGO\n\u00a7Avoidance ofchemotherapy- induced alopecia by \nscalp cooling*1b +/-\n\u00a7Prophylaxis ofhand- foot -syndrome using urea \ncontaining lotions (5 -10%)1b +\n\u00a7Prophylaxis of nail changes and hand- foot -\nsyndrome by cooling hands during docetaxel \napplication2b +\n*Substance -and regimen specific\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nAGO: +/ -LOE 2b B\n\u25aaNangia J, Wang T, Osborne C, et al. Effect of Scalp Cooling Device on Alopecia in \nWomen Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized \nClinical Trial JAMA. 2017 Feb 14;317(6):596 -605. \nPrimary Outcome: hair preservation\nCooling: 50.5 % success vs. 49.5 % failure\nNon -cooling: 0 % success vs. 100 % failure\nFisher\u2019s exact test p < 0.001\nTwo Meta -analyses: AGO: +/ -LOE 1b \n\u25aaScalp cooling reduced relative risk (RR) of alopecia by 43% (RR, 0.57; 95% CI, 0.45 -\n0.72; I2= 11%; P < .00001). ( Rugo & Voigt, Clinical Breast Cancer 2018; 18(1): 19 -28.)\n\u25aaIncidence rate of scalp metastasis (SC vs. no -SC)  0.61% vs. 0.41%; P =0.43. ( Rugo & \nVoigt; BCRT 2017)Scalp Cooling: Scalp Cooling Alopecia \nPrevention Trial (SCALP) and metaanalyses\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n10. MUSCULOSKELETAL & CONNECTIVE TISSUE \nDISORDERS\n(see Chapter Osteooncology )\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSide Effects According Organ Systems\nIncidence, Prevention, Therapy\n11. General Disorders & Administration Site \nConditions\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deExtravasation of Potentially Necrotizing Compounds\n(Anthracyclines, Taxanes, Vinorelbine)\nOxford\nLoE GR AGO\n\u00a7Dexrazoxane fortreatment ofanthracycline -\nextravasations\n(exception :  liposomal Anthracy clines )2b B ++\n\u00a7Hyaluronic acid for treatment of taxane/vinorelbine -extravasations3b D ++\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nExtravasation of Chemotherapy\nRole of Dexrazoxane/Hyaluronic Acid\nDexrazoxane for treatment of anthracyclines paravasates\nDay 1: 1000 mg/m\u00b2 (max. 2000 mg), IV 1 \u20132 hrs\nDay 2: 1000 mg/m\u00b2 (max. 2000 mg), IV 1 \u20132 hrs\nDay 3:   500 mg/m\u00b2 (max. 1000 mg), IV 1 \u20132 hrs\nOtherwise or if treatment with dexrazoxane is not indicated, following measures are recommended:\n1. Local cooling: ice packs for 15 min every 6 hrs, for at least 3 days, alternatively: 24 h continuous ice cooling\n2. Local application (with swab) of dimethylsulfoxid 99% (DMSO) every 3- 4 hours for at least 3 days (better 14 \ndays),  allow it to air dry. The interval may be extended  to 6 hours from day 4 onward.\nHyaluronic Acid in case of Taxan/Vinorelbin Paravasates:\n\u00a71\u201310 Amp a 150 IU\n\u00a71 ml dissolvent (z.B. NaCl 0.9%)\n\u00a7Local anaesthesia\n\u00a7No thermotherapy after taxanes\n\u00a7Dry warmth 4 x daily 20 min during vincaalkaloids\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\u00a7Further supportive and palliative issues\n\u00a7Nutrition \n\u00a7Pain management\n\u00a7Palliative Care\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7Nutrient deficiency isa common medical problem affecting 15-40% of\ncancer patients . Itimpairs their quality oflifeand canaffect thesuccess of\ntreatment . \n\u00a7Integration ofnutritional advice into clinical management recommended\n\u00a7Fornutrition seeS3 guideline Palliative care and supportive therapyNutrition deficiency\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7Non -opioids; WHO Step 1 \nDiclofenac resinate, ibuprofen and / or metamizole,\nparacetamol (acetaminophen) \n\u00a7Mild opioids; WHO Step 2Tramadol (preferentially \u201eretard\u201c -formulations) \nor tilidine / naloxone (also as \u201eretard\u201c -formulations) \n\u00a7Strong opioids; WHO Step 3 \nMorphine, buprenorphine (sublingual or transdermal), fentanyl \n(transdermal), hydromorphone, oxycodone, as a back -up levomethadone. \nThe dose of opioids should be titrated step by step according to the analgetic effect.\n\u00a7Additional drugs \u2013\u201eadjuvants\u201c \nCanabinoide, Gabapentin, pregabalin, carbamazepine, amitriptyline, \nbisphosphonatesAnalgesia\nSupportive Care and Management of Side Effects\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePalliative Care\n\u00a7All patients should be offered palliative care after the diagnosis of a non -\ncurable cancer, regardless of whether a tumour -specific therapy is carried \nout. \n\u00a7Specialized palliative care should be integrated into oncological decision -\nmaking processes, e.g. by participating in interdisciplinary tumor \nconferences.\n\u00a7Patients with incurable cancer who are cared for in structures of \nspecialized palliative care (palliative care ward, specialized outpatient care \nsuch as SAPV) should have access to oncological councelling. \nhttps://www.leitlinienprogramm -onkologie.de/leitlinien/palliativmedizin/ \nSupportive Care and Management of Side EffectsDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1EBreast Cancer:\nSpecific Situations\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deBreast Cancer:\nSpecific Situations\n\u00a7Versions 2005 \u20132020: \nDall / Ditsch / Fehm / Fersis / Friedrich / Gerber / G\u00f6hring / \nHarbeck / Huober / Janni / Kolberg -Liedtke /Loibl / L\u00fcck / Lux / Maass / \nMundhenke / M\u00fcller / Oberhoff / Rody / Scharl / Schneeweiss / Sch\u00fctz / \nSinn / Solomayer / Stickeler / Thomssen\n\u00a7Version 2021:\nGluz / Sinn\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deBreast Cancer:\nSpecific Situations\n\u00a7Young patients\n\u00a7Pregnancy -and breast -feeding -associated BC \n\u00a7Elderly patients\n\u00a7Male patients\n\u00a7Inflammatory BC\n\u00a7Occult Breast Cancer (Cancer ofunknown primary \u2013axillary CUP)\n\u00a7Paget\u2018s disease\n\u00a7Malignant and Borderline Phyllodes Tumor\n\u00a7Angiosarcoma\n\u00a7Breast Implant -Associated Anaplastic Large -Cell Lymphoma (BIA -ALCL)\n\u00a7Metaplastic breast cancer\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deBreast Cancer in\nYoung Women \u2264 40 Years\nOxford\nLoE GR AGO\n\u00a7Aggressive biological behavior with worse prognosis 2a B\n\u00a7Local therapy independent of young age 2b B +\n\u00a7Guidelines adapted (neo -)adjuvant systemic                           \ntreatment (see respective chapters)1b A ++\n\u00a7GnRHa as ovarian protection                                                              \n(see chapter gynecological problems)1a B +\n\u00a7Genetic and fertility counseling 2b B ++\n\u00a7Contraception counseling 2b B ++\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deBreast Cancer During Pregnancy*\nor Breast Feeding \u2013 Diagnostics and Surgery\nOxford\nLoE GR AGO\n\u00a7Breast imaging and biopsy like in non -pregnant 4 C ++\n\u00a7Staging if indicated ( bone scan after delivery) 5 D +\n\u00a7Full body MRI (without contrast agent ) 4 C +/-\n\u00a7Surgery like in non -pregnant patients 4 C ++\n\u00a7Sentinel node excision (technetium only) 2b B +\n\u00a7SLNE during 1sttrimester 5 D +/-\n\u00a7Sensitivity and specificity not established (during lactation); \nbreast feeding should be avoided for 24 hrs4 C ++\n\u00a7Blue dye ( not tested in pregnant animals or humans) 4 C --\n*Participation in register study recommended\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deBreast Cancer During Pregnancy\n-(Neo -)adjuvant Therapy -\nOxford\nLoE GR AGO\n\u00a7Radiation therapy during pregnancy 4 C -\n\u00a7(Neo -)adjuvant chemotherapy only after first \ntrimester (indication as in non- pregnant)++\n\u00a7Anthracyclines: AC, EC 2b B ++\n\u00a7Taxanes 2b B +\n\u00a7Platinum salts (carboplatin , cisplatin ) 4 C +/-\n\u00a7MTX (e.g. CMF) 4 D --\n\u00a7Endocrine treatment 4 D --\n\u00a7HER2 -targeted treatment 3a C --\n\u00a7Bisphosphonates , denosumab 4 D -\nTreatment ( Chemotherapy , surgical procedure and radiotherapy ) ofpatients with breast cancer during pregnancy should be\nassimilar aspossible tostandard treatment ofyoung , not pregnant patients with breast cancer .  \nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deBreast Cancer During Pregnancy*\n\u2013Delivery and Breast- Feeding \u2013\nOxford\nLoE GR AGO\n\u00a7Delivery should be postponed until sufficient\nfetal maturation (avoid iatrogenic prematurity)2b C ++\n\u00a7Termination of pregnancy does not improve maternal outcome 3b C\n\u00a7Delivery mode like in healthy women ; avoid delivery \nduring chemotherapy -induced leucocyte nadir4 C ++\n\u00a7If further systemic therapy is needed after delivery, breast feeding may be contra -indicated depending on \ndrug toxicities5 D ++\n*Participation in register study recommended\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deBreast Cancer and Pregnancy\n\u2013Family Planning \u2013\nOxford\nLoE GR AGO\n\u00a7After breast cancer diagnosis ,reproductive          \ntechniques can be used to induce pregnancy 5 D ++\n\u00a7Success rates for getting pregnant and for                 \ndeliver inga child lower in breast cancer patients                       \ncompared to non- cancer patients 5 D ++\n\u00a7Breast cancer patients of reproductive ageshould be offered fertility\ncounseling before                    \nstarting any kind of treatment 5 D ++\n\u00a7Breast cancer patients should not be advised                \nagainst getting pregnant independent of their tumor\u2018s                \nhormone receptor status5 D ++\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.dePregnancy Associated \nBreast Cancer*: Outcome\nOxford\nLoE\n\u00a7BC during pregnancy / lactation\n\u00a7Adequate treatment isessential 3a\n\u00a7Pregnancy and lactation after BC\n\u00a7Outcome not compromised 3a\n*Participation in register study recommended\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.de\u00a7No specific algorithm is available\n\u00a7Ability to tolerate treatment varies greatly (\u201efunctional reserve\u201c)\n\u00a7Comprehensive geriatric assessment (CGA) describes a multidisciplinary \nevaluation of independent predictors of morbidity and mortality for older individuals\n\u00a7 Physical, mental, and psycho -social health \n\u00a7 Basic activities of daily living (dressing, bathing, meal preparation, medication management, etc.) \n\u00a7 Living arrangements, social network, access to support services\n\u00a7Assessment tools :\n\u00a7 Charlson Comorbidity Index (widely used; good predictor over a 10 -year period)\n\u00a7 12 prognostic indicators to estimate 4 -year mortality risk\n\u00a7 Short screening tests (more qualitative evaluation)\n\u00a7 IADL (IADL = The Lawton Instrumental Activities of Daily Living Scale with 8 domains of function, that \nare measured), G8 \n\u00a7 Geriatric Prognostic Index (GPI), 3 parameters in oncological patients (psychological distress oracute\ndisease , >3 prescribed drugs , neuropsychological problems )Geriatric Assessment\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deTreatment for Fit Elderly Patients \n(Life Expectancy > 5 yrs. and Acceptable Comorbidities) \nOxford\nLoE GR AGO\n\u00a7Clinical geriatric assessment 2b B ++\n\u00a7Treatment according toguidelines 2a C ++\n\u00a7Surgery similar to \u201eyounger\u201c age 2b B ++\n\u00a7Endocrine treatment (endocrine responsive ) 1a A ++\n\u00a7Chemotherapy (standard regimens )\n\u00a7 < 70 years 1a A +\n\u00a7 > 70 years (especially N+, ER/PR -) 2a C +*\n\u00a7Radiotherapy 1a A +\n\u00a7Omit radiotherapy after BC Sif low -risk and endocrine \ntreatment 1b B +\n\u00a7Trastuzumab 2b C +\n*Study participation recommended \nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deTreatment for Frail Patients \n(Life Expectancy <5 yrs, Substantial Comorbidities)\nOxford\nLoE GR AGO\n\u00a7Reduced standard treatment 2b C ++\n\u00a7Options extrapolated from trials in elderly:\n\u00a7No breast surgery (consider endocrine options) 2b C +\n\u00a7Noaxillary clearing (\u2265 60 y, cN0, HR- pos) 2b B +\n\u00a7No radiotherapy (Tumor size <3 cm, pN0, HR- pos) 1b B ++\n\u00a7Hypofractionated radiotherapy 2b B +\n\u00a7No chemotherapy if >70y and negative risk -benefit analysis 2b C +\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deMale Breast Cancer: Diagnostic \nWork- Up and Loco -Regional Therapy\nOxford\nLoE GR AGO\n\u00a7Diagnostic work -up as in women 4 C +\n\u00a7Mammography 3b C +/-\n\u00a7Ultrasound 2b B ++\n\u00a7Standard -surgery : Mastectomy 4 C ++*\n\u00a7BCT is an option (tumor /breast relation) 4 C +*\n\u00a7Sentinel -node excision (SLNE) 2b B +\n\u00a7Radiotherapy as in women \n(consider tumor /breast relation!) 4 C +\n\u00a7Genetic counse ling if one additional relative affected \n(breast/ovarian cancer)2b B ++\n\u00a7Screening for 2ndmalignancies according to guidelines GCP ++\n*Participation in register study recommended\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deMale breast cancer- prognostic factors\nOxford\nLoE GR AGO\n\u00a7Nodal status 2b A ++\n\u00a7Age 2b B +\n\u00a7Tumor size 2b A ++\n\u00a7ER/PR Expression 2b A ++\n\u00a7Ki-67 Expression 2b C +/-\n\u00a7Grade 2b C +/-\n\u00a7Genomic signatures (e.g. OncotypeDx ) 2b B +\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deMale Breast Cancer: \nSystemic Therapy\nOxford\nLoE GR AGO\n\u00a7Adjuvant chemotherapy as in women 2a B ++\n\u00a7HER2 -targeted therapy (ifHER2 -positive) 5 D ++\n\u00a7Endocrine therapy 4 D ++\n\u00a7Tamoxifen 2b B ++\n\u00a7Aromatase inhibitors (adjuvant ) 2b B -*\n\u00a7Aromatase inhibitors (metastatic BC) 4 C +/-\n\u00a7GnRHa and AI ( metastatic BC) 4 C +*\n\u00a7Fulvestrant (metastatic BC) 4 C +/-\n\u00a7CDK4/6i (in combination )* 2b B +\n\u00a7Palliative chemotherapy as in women 4 C ++\n*Study participation recommended \nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deBenefit from Trimodal Treatment in \nInflammatory Breast Cancer\nMedian survival probability\nTrimodal therapy 72 months p<0.05\nSurgery alone 26 months\nOverall survival -probability (OS) 10 years -OS 5 years -OS\nTrimodal therapy 55.4% 37.3%\nSurgery & chemotherapy 42.9% 28.5%\nSurgery & radiotherapy 40.7% 23.5%\nSurgery alone 16.5%\nMultivariate analysis of OS Hazard Ratio 95% CI\nSurgery & chemotherapy & \nRT (trimodal therapy)1.00 -\nSurgery & chemotherapy 1.64 1.46 to 1.84\nSurgery & radiotherapy 1.47 0.96 to 2.24\nSurgery alone 2.28 1.80 to2.89\nRueth et al. J Clin Oncol 2014; 32:2018 \u20132024\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.de\u00a7N=8.550\n\u00a7On multivariable analysis , TNBC, positive margins , and not receiving either\nchemotherapy , hormonal therapy orradiotherapy were independently\nassociated with poor 5-year survival (p < 0.0001). Primary inflammatory breast cancer\n5yr-OS\npCR 77%p<0.0001\nNon -pCR 54%\nTN-IBC 37%p<0.0001\nother biologic subtypes (HR+/HER2\u2212, \nHR+/HER2+, HR\u2212/HER2+)60%\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deInflammatory Breast Cancer (IBC, cT4d)\nOxford\nLoE GR AGO\n\u00a7Invasive BC and clinical signs of  inflammation \n(e.g. \u2265 1/3 of the breast affected) determine \nstage cT4d ++\n\u00a7Staging 2c B ++\n\u00a7Skin punch biopsy (at least 2; detection rate < 75%) 2c B +\n\u00a7Treatment according to guidelines ( neoadjuvant or \nadjuvant \u2013as in non -IBC)2c B ++\n\u00a7Mastectomy after chemotherapy 2c B +\n\u00a7Breast conserving therapy in case of pCR (individual) 2b C +/-\n\u00a7Sentinel excision only 3b C -\n\u00a7Radiotherapy (PMRT) 2c B ++\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.de\u00a7Incidence: < 1% of metastatic axillary disease\n\u00a7In > 95% occult breast cancer, < 5% other primary\n\u00a7Immunhistology\nER-positive: 55%\nHER2 3+: 35%\nTriple -negative: 38%\n\u00a7Nodal status:\n\u00a71 -3 Ln-Met. in 48%\n> 3 Ln -Met in 52%\n\u00a7Outcome similar compared to breast cancer with similar tumor biology and tumor stageAxillary Metastasis in Occult Breast Cancer\n(Cancer of Unknown Primary \u2013Axillary CUP)\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deAxillary Metastasis in Occult Breast Cancer (Axillary \nCUP) Imaging Diagnostics\nOxford\nLoE GR AGO\n\u00a7Breast imaging incl. Breast -MRI 3 B ++\n\u00a7Exclude contralateral cancer 3 B ++\n\u00a7Exclude non -breast malignancy, especially\nin case of TNBC (e.g. skin, female genital tract,\nlung, thyroid gland, stomach)5 D ++\n\u00a7Staging (CT thorax / abdomen, pelvis, in certain \ncircumstances also thyroid sonography, HNT -exam)3 B ++\n\u00a7PET / PET -CT 3b B +\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deAxillary Metastasis in Occult Breast Cancer (ex. CUP)\nPathology, molecular pathology\nOxford\nLoE GR AGO\n\u00a7ER, PR, HER2, GATA3 (in some cases Ck5/6, Ck7, Ck20, \nSOX-10, PAX -8, TTF1, and others)5 D ++\n\u00a7Exclusion of other primary malignancies in case of \ntriple -negative phenotype or unusual histology, e.g. \nlung, female genital tract, HNT tumors,\nneuroendocrine ca.5 D ++\n\u00a7Gene expression profiling for determination \nor primary site \n(e.g. CUPprint , Pathwork , TOT, Theros CTID) 2c B +/-\n\u00a7NGS, epigenetics for determination of primary site \n(Panel -Sequencing, e.g. EPICup )2c B +/-\n\u00a7Prognostic gene expression tests 5 D --\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deAxillary Metastasis in Occult Breast Cancer \n(Axillary CUP): Therapy\nOxford\nLoE GR AGO\n\u00a7Axillary dissection 3a C ++\n\u00a7Mastectomy if breast MRI is negative 3a C --\n\u00a7(Neo -) adjuvant systemic therapy according \nto breast cancer guidelines (AGO)5 D ++\n\u00a7Breast irradiation if breast MRI is negative 2c B +\n\u00a7Irradiation of regional lymph nodes according to \nbreast cancer guidelines (AGO)3b B +\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.de\u00a7Definition: Paget\u2018s disease of the breast is characterized by an intraepidermal \ntumor manifestation originating in intraductal or invasive breast cancer. \n\u00a7Clinical presentation: skin eczema of the nipple, areola and surrounding skin; thickening, pigmentation and scaly skinPaget\u2018s Disease of the Breast\nFeature Frequency\nPresentation Paget\u2018s disease with invasive Ca. (37 -58%)\nPaget\u2018s disease mitDCIS (30 -63%)\nIsolated Paget\u2018s disease (4 -7%)\nIsolated Paget\u2018s disease with invasion (rare)\nIHC HER2- positive (83 -97%)\nER-positive (10 -14%)\nAR-positive (71 -88%)\nPrognosis and tumor \nbiologyBetter in isolated Paget\u2018s diseaseWorse if in combination with invasive breast cancer or DCIS \ncompared to isolated Paget\u2018s disease\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.dePaget\u2018s Disease of the Breast Diagnosis\nOxford\nLoE GR AGO\n\u00a7Histological verification by skin biopsy ++\n\u00a7Mammography , sonography 4 D ++\n\u00a7MRI of the breast if other imaging negative 4 C +\n\u00a7Immunohistochemistry (ER, PR, HER2, Ck7) \nto detect benign and HER2 -negative cases5 D ++\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.dePaget\u2018s Disease of the Breast -Therapy\nOxford\nLoE GR AGO\n\u00a7Paget\u2018 sdisease with underlying disease \n(invasive breast cancer, DCIS)\n\u00a7Therapy according to standard of underlying disease 5 D ++\n\u00a7Surgery must achieve R0 1c B ++\n\u00a7Isolated Paget\u2018s disease of the NAC: \n\u00a7Surgery must achieve R0 1c B ++\n\u00a7Surgical resection only, no adjuvant radiotherapy 4 D ++\n\u00a7Sentinel -node excision (SLNE) 2b B --\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.de\u00a7Name derived from greek term of \u201c Phyllon \u201d (leaf) due to its lobulated \nhistological aspect\n\u00a7Differential diagnosis may be problematic on core biopsy\n\u00a7Resection margin is independent prognostic parameter\n\u00a7Comparable rates of recurrence in association with BCT or mastectomy\n\u00a7In-Breast recurrence relatively frequently seen (10 -30%)\n\u00a7Distant metastasis relatively rare (< 10%) and almost exclusively seen in \nmalignant phyllodes tumor.\n\u00a7Adverse pathological criteria: marked stromal cellularity and overgrowth, \nincreased nuclear atypia, presence of large necrohemorrhagic areas, and \nhigh mitotic activity associated with increased risk of distant recurrenceBorderline and Malignant Phyllodes Tumor\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.de\u00a7Fibroepithelial tumors ofthebreast : frequency 0.3 \u2013 1% of all primary brteast tumorsPhyllodes tumor\nparameter frequencies\nGrading (3-STEP histological grading\nsystem )Benign (75%)\nBorderline (16%)\nMalignant (9%)\nMedian ageattime ofdiagnosis Benign PT: 39 y\nBorderline PT: 45 y\nMalignant PT: 47 y\nLocal recurrence Benign PT: 4 \u201317%\nBorderline PT: 14 \u201325%\nMalignant PT: 23 \u201330%\nMetastasis Benign PT: <1%\nBorderline : PT: 1.6%\nMalignant PT: 16 -22%\n10y OS: 86\u2013 90% ( range : 57\u2013100%)  depending on subtype and unfavorable histological criteria\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deBorderline and Malignant Phyllodes Tumor \nDiagnosis\nOxford\nLoE GR AGO\n\u00a7Mammography , sonography 3 C ++\n\u00a7Diagnosis on core biopsy, grade determination on \nresection specimen3 C ++\n\u00a7Breast MRI 3 C +/-\n\u00a7Staging only malignant PT (CT thorax, skeletal system) 5 D ++\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deBorderline and Malignant Phyllodes Tumor\nSurgery\nOxford\nLoE GR AGO\n\u00a7Borderline /malignant phyllodes tumor: Complete\nresection with adequate margins , min. > 1 mm 2b B ++\n\u00a7SLNE / Axillary dissection 4 C --\n\u00a7Treatment oflocal recurrence\n\u00a7R0 resection or simple mastectomy 4 C ++\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deSystematic Reviews (2016 \u2013 2021)\nRosenberger LH, et al.\nJ Clin Oncol 39: 178- 189, \n2021. PMID 33301374Contemporary Multi -Institutional \nCohort of 550 Cases of Phyllodes \nTumors (2007 -2017) Demonstrates a \nNeed for More Individualized Margin \nGuidelines.Local recurrence (all PT grades) was not reduced \nwith wider negative margin width ( \u22642 mm v. > \n2 mm); or final margin status (positive v \nnegative).\nThind A, et al. Ann R Coll Surg\nEngl. 102(3):165 -173, 2020. \nPMID 31918563Surgical margins for borderline and \nmalignant phyllodes tumours.\n(10 studies, 456 cases, 1990 \u20132019).No statistically significant difference between \n<1cm and \u22651cm margins in terms of local \nrecurrence rates or distant metastasis.\nLuY , et al. Ann Surg Oncol . \n90:342 \u201313, 2019. PMID \n30617873.Local Recurrence of Benign, Borderline, \nand Malignant Phyllodes Tumors of the \nBreast: A Systematic Review and Meta -\nanalysis. (54 studies, 9234 cases, 1995 \u2013\n2018).A positive margin and BCS both were \nsignificantly correlated with a higher LR risk for \nmalignant PTs but not for benign and borderline \nPTs.\nTan BY , et al. Histo -pathology. \n2016;68(1):5 -21. PMID: \n26768026Phyllodes tumours of the breast: a \nconsensus review.Tumour on ink, or <1 mm, should be considered \nas a positive margin. Excision with negative \nmargins should be achieved for recurrent and \nmalignant\nphyllodes tumours.\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deBorderline and Malignant Phyllodes Tumor\nAdjuvant Therapy\nOxford\nLoE GR AGO\n\u00a7Adjuvant radiotherapy (younger age, increased tumor\nvolume > 5 cm, close resection margin )\n\u00a7Local control 2b B +\n\u00a7Effect on disease -free survival 2b B -\n\u00a7Systemic adjuvant therapy (chemo, endocrine) 4 C --\n\u00a7Adjuvant Treatment oflocal recurrence\n\u00a7Radiotherapy, chemotherapy after R1 resection 4 C +/-\n\u00a7Distant metastasis (very rare)\n\u00a7Treatment like soft tissue sarcomas 4 C ++\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.de\u00a7Not infrequently associated with familial syndromes (Li -Fraumeni, \nfamilial adenomatous polyposis, neurofibromatosis type 1)\n\u00a7Primary sarcomas: angiosarcoma, undifferentiated sarcoma, \nleiomyosarcoma, liposarcoma, osteosarcoma\n\u00a7Secondary malignancies of the breast:\n\u00a7Radiotherapy -Associated Angiosarcoma\n\u00a7Breast Implant Associated Large -Cell Anaplastic Lymphoma (BI -ALCL)\n\u00a7Rare: intramammary sarcoma metastases\n\u00a7Staging: TNM (UICC) or AJCC scheme of the soft tissue sarcoma analogous \nto sarcoma of the breast\n\u00a7Grading: Analogous to the FNCLCC system for sarcoma or according to \nRosen (1988) for angiosarcomasSarcomas of the Breast\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.de\u00a7Most common primary sarcoma of the breast\n\u00a7Young age (median: 24 \u201346 years)\n\u00a7Indistinct tumor borders\n\u00a7Large tumor (median: 5 \u20137 cm)\n\u00a7Uncharacteristic findings on mammography and sonography\n\u00a7High local recurrence risk, even after mastectomy\n\u00a7More unfavorable prognosis than other primary sarcoma of the breastPrimary Angiosarcoma of the Breast\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.dePrimary Angiosarcoma of the Breast*\nDiagnosis\nOxford\nLoE GR AGO\n\u00a7Mammography, sonography to determine extent of \ndisease 3a C --\n\u00a7Preoperative MRI to determine the extent of disease 3a C ++\n\u00a7Diagnosis bycore biopsy 3a C ++\n\u00a7Diagnosis byFNB 3a C --\n\u00a7Staging (CT  thorax & abd.; angiosarcoma : MRI brain ) 4 D ++\n\u00a7Prognostic factors: size, grade, margins 3a C ++\n*Therapy in specialized centers recommended\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.dePrimary Angiosarcoma of the Breast*\nTherapy\nOxford\nLoE GR AGO\n\u00a7Surgery with wide clear margins, mostly as \nmastectomy2b C ++\n\u00a7Breast -conserving therapy 3a C -\n\u00a7SLNE or axillary dissection if cN0 3a C --\n\u00a7Adjuvant chemotherapy\n(anthracycline /taxane -based )4 C +/-\n\u00a7Adjuvant radiotherapy if high risk (size > 5 cm, R1) 4 C +/-\n*Therapy in specialized centres recommended\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.de\u00a7Cumulative incidence of radiotherapy -associated sarcoma: 3.2 per 1,000 \nafter 15 years\n\u00a7Clinical presentation\n\u00a7> 5 years after BCT or mastectomy with irradiation\n\u00a7usually intracutaneously or subcutaneously in the irradiation area with livid \ndiscoloration\n\u00a7multiple foci\n\u00a7most often in advanced stages (II \u2013III)\n\u00a7metastasis mostly pulmonary\n\u00a7lymph node metastasis possible\n\u00a7Prognosis is more unfavorable than in non -radiotherapy -associated \nsarcoma\n\u00a7Survival: after 5 yrsup to 50.5%, after 10 yrsup to 25.2%Secondary (Radiotherapy -associated) \nAngiosarcoma of the Breast\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deSecondary Angiosarcoma \nof the Breast Therapy\nOxford\nLoE GR AGO\n\u00a7Secondary mastectomy 3a C ++\n\u00a7Adjuvant chemotherapy\n(anthracycline /taxane -based ) 2b B +/-\n\u00a7Adjuvant radiotherapy if high -risk \n(size > 5 cm, R1)2b B +/-\n\u00a7Regional hyperthermia (to improve local control) \nplus chemotherapy and/or radiotherapy2b B +/-\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deAngiosarcoma of the Breast \nTreatment of Local Recurrence and Metastases\nOxford\nLoE GR AGO\nTreatment ofLocal Recurrence :\n\u00a7R0 resection 4 C ++\n\u00a7Adjuvant radiotherapy for high -risk patients \n(tumor size > 5 cm, R1)4 C +/-\nDistant Metastases / Unresectable Tumors:\n\u00a7Treatment like soft tissue sarcomas 4 C ++\n\u00a7Paclitaxel weekly / liposomal doxorubicin (asin angiosarcoma ) 2b B +\n\u00a7Antiangiogenic treatment (e.g. in angiosarcoma ) 4 C +/-\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deBreast Implant Associated Anaplastic Large Cell\nLymphoma (BIA -ALCL)\n\u00a7Aproximately 10.000.000 implant carriers\n\u00a7Rare disease , 3 % ofNon -Hodgkin Lymphomas, 0.04 -0.5 % ofall malignant\nbreast diseases\n\u00a71:3.000 \u201330.000 in women with textured implants (caveat : underreporting !)\n\u00a7Estimated incidence 0.6-1.2 / 100.000 women with implants (median age: 54 y)\n\u00a7Mainly associated with textured implants\n\u00a7Interval todiagnosis : 8 years (median)\n\u00a7Clinical symptoms\n\u00a7Swelling and seroma . (60 %)\n\u00a7Solid tumor (17 %)\n\u00a7Seroma and solid tumor (20 %)\n\u00a7Axillary lymphadenopathia (20%)\n\u00a7Histology : CD30+ / ALK -T-Cell Lymphoma\n\u00a7Mandatory registration asSAE ( \u00a73 MPSV to BfArM )\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.de\u00a7The cause ofBIA-ALCL isnot established ; however , ithasbeen proposed that lymphomagenesis may\nbedriven bya chronic in\ufb02ammatory reaction induced bycapsule contents orsurface . The risk for\nBIA-ALCL hasbeen shown tobesignificantly higher forimplants with grade 3 and 4 surfaces.BIA-ALCL -Surfaces ofBreast Implants\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deBIA-ALCL \u2013Diagnosis \nOxford\nLoE GR AGO\n\u00a7Breast US (assessment ofnew seromas > 1 year after implant\ninsert , solid lesion (sensitivity : 84%, specificity : 75%))3a D ++\n\u00a7Breast -MRI in confirmed cases 3a D ++\n\u00a7Staging (Imaging, e.g. CT, PET -CT) 3a D ++\n\u00a7Cytology oflate seromas\n\u00a7-> 50 ml \n\u00a7-Complete assessment\n\u00a7-flow -cytology (T-cellclone )\n\u00a7-BIA-ALCL specific cytologic diagnostic (CD 30+)3a D ++\n\u00a7Core needle biopsy in solid lesions\n\u00a7Lymphoma assessment ofresected tissue and histologic staging3a D ++\n\u00a7Documentation oftheimplant (manufacturer , size, volume , surface , \nBatch -number ) and entry in registry5 D ++\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deBIA-ALCL \u2013Therapy\nOxford\nLoE GR AGO\n\u00a7Implant resection and complete capsulectomy including\ntumorectomy3a C ++\n\u00a7Resection ofsuspicious lymph nodes , noroutine useof\nSentinel -Node -Biopsy , noaxillarx dissection4 D ++\n\u00a7Polychemotherapy ( e.g. CHOP) in cases of extra capsular \nextension4 D +\n\u00a7Radiotherapy in unresectable tumors 5 D +/-\n\u00a7Case discussion in an interdisciplinary tumor board in the\npresence ofa lymphoma specialist5 D ++\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deTNM Staging of BIA -ALCL (proposed)\nTNM -Category Definition\nTumor extent\n(cT/pT)T1 Confined to seroma or a layer on \nluminal side of capsule\nT2 Early capsule infiltration\nT3 Cell aggregates or sheets infiltrating \nthe capsule\nT4 Lymphoma infiltrates beyond the \ncapsule\nRegional lymph \nnodes (cN/pN)N0 No lymph node involvement\nN1 One regional lymph node positive\nN2 Multiple regional lymph nodes \npositive\nMetastasis\n(cM/pM)M0 No distant spread\nM1 Spread to other organs\nor distant sitesStage Definition\nIA T1 N0 M0\nIB T2 N0 M0\nIC T3 N0 M0\nIIA T4 N0 M0\nIIB T1-3 N1 M0\nIII T4 N1 -2 M0\nIV T any N any M1\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deBIA-ALCL: Diagnostic Pathways and \nAssessment\nLate Seroma\n>12 months since \n1stimplantUltrasound\nBreast + AxillaMassCore biopsy\n(any solid mass)Histology\nImmunohistology\nCapsule -related \nsolid tumor mass+/-\nMammogram\n(not useful if age < 40 yrs)EffusionFNA fluid\n(take > 50 ml)Cytology\nimmune -cytology \nfor CD30\nPathological\nskin lesion\nPathological\nlymph nodes\nLymphomata\nB-SymptomsSuspicion Imaging\nSkin biopsy\nPET CT\n(r/o systemic disease)MRI Breast\n(if diagnosis is \nindeterminate)Findings Samples Assessment\nFlow -Cytometry\nClonality studies\n(for T -cell rearragenemnts )Indeterminate?\nSuspicious?\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deBIA-ALCL Treatment Pathways\nBIA-ALCL\nconfirmedReferral to\nexperienced\nbreast cancer \ncenterEn-bloc \ncapsulectomy and  \ncomplete excision \n(mass)Stage I : No further \ntreatmentClinical follow -up \n(ultrasound /CT \nscan) 3\u2013 6 m for 2y, \nafterwards for 5y\nIndeterminatePET-CT & \nbreast MRI+/-other breast\n+/-axilla biopsy \n(SNB not recommended)Stage II -IV:\nConsider adjuvant \ntreatmentPET-CT if\nsymptomatic\nNegative for \nBIA-ALCLOutcome Workup\nClinical suspicion \nremainsChemo -\nimmunotherapySurgery Adjuvant Therapy Follow -up\nTreatment of infection/ \nbenign seroma (serial \naspiration, implant \nexchange with \ncapsulectomy)Options: Further \nimaging US/MRI/Repeat \nFNAC , Tertiary referralRoutine bloods\n(+/-bone marrow bx)\nMTD Discussion\nConsider diagnostic \ncapsulectomyRadiotherapy for \npositive margins / \nirresectable  thoracic \nwall infiltration but \nN0/M0Histological Staging \n(Clemens et al. 2016)\nMTD Discussion\nReports to  BfArM , \nmanufacturer, DGPR\u00c4C, \nPROFILE database (FDA)Treatment as per \nsystemic ALCL regimes\n24 -36 Gyin 15 \nfractions\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.de\u00a7Despite an increase of BIA -ALCL in association with texture implants the \nuse of textured implants is still permitted!\n\u201eFor the moment, textured implants can safely continue to be used with patient's fully informed \nconsent, and that women that have these type of implants already in place don't need to remove or \nsubstitute them, which would undoubtedly cause harm to many tens of thousands of women, to \nprevent an exceptionally rare, largely curable and currently poorly understood disease.\"BIA-ALCL \u2013EUSOMA- Recommendation\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deMetaplastic breast carcinoma\nDefinition: Metaplastic transformation of glandular tumor cells.\n\u2022Epithelial differentiation: squamous cell carcinoma, spindle cell carcinoma\n\u2022Heterologous (mesenchymal) differentiation: chondroid, osseous, or rhabdoid metaplastic \nbreast carcinoma\nClinicopathologic characteristics:\n\u2022< 1% of malignancies of the breast\n\u2022Same age group as NST carcinomas\n\u2022Circumscribed, palpable\n\u2022Rapidly growing, poor response to chemotherapy\n\u2022> 90% triple -negative\nAggressive:\n\u2022Highly malignant with heterologous (mesenchymal), squamous or high -grade spindle cell \ndifferentiation\n\u2022Uncertain malignant potential (low -grade) in adenosquamous or fibromatosis- like \ndifferentiation\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deMetaplastic breast carcinoma\n-high -grade -\nOxford\nLoE GR AGO\n\u00a7Surgical therapy and axillary staging according to\nstandard4 C ++\n\u00a7Adjuvant chemotherapy (rather chemoresistant ) 4 C ++\n\u00a7Neoadjuvant chemotherapy (rather chemoresistant ) 4 C +/-\n\u00a7Adjuvant endocrine therapy ifreceptor -positive 4 C +\n\u00a7Adjuvant radiotherapy according tostandard 4 C + +\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deMetaplastic breast carcinoma with uncertain malignant\npotential ( fibromatous and adenosquamous Ca.)*\nOxford\nLoE GR AGO\n\u00a7Surgical therapy and axillary staging according to\nstandard4 C ++\n\u00a7Adjuvant chemotherapy 4 C -\n\u00a7Neoadjuvant chemotherapy 4 C --\n\u00a7Adjuvant endocrine therapy (not applicable , since\ntriple -negative tumors )4 C -\n\u00a7Adjuvant radiotherapy according tostandard 4 C +\n* Reference pathology recommended\nBreast Cancer: Specific Situations\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1EBreast Cancer \nFollow -Up\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBreast Cancer \nFollow -Up\n\u00a7Versions 2002 \u20132020: \nBauerfeind / Bischoff / Blohmer / B\u00f6hme / Costa / Diel / Friedrich / \nGerber / Hanf / Heinrich / Huober / Janni / Kaufmann / Kolberg -\nLiedtke /K\u00fcmmel / Lux / Maass / M\u00f6bus / M\u00fcller -Schimpfle / \nMundhenke / Oberhoff / Rody / Scharl / Solbach / Solomayer / \nThomssen / W\u00f6ckel\n\u00a7Version 2021:\nGluz / L\u00fcftner\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBreast Cancer Follow -Up\nObjectives\nOxford\nLoE GR AGO\nEarly detection of curable events\n\u00a7In-breast recurrence 1a B ++\n\u00a7Loco -regional recurrence* 1a B ++\nEarly detection of contralateral cancers 1a B ++\nEarly detection of metastasis\n\u00a7Early detection of symptomatic metastases 3b C +\n\u00a7Early detection of asymptomatic metastases 1a A -\n*loco -regional recurrence is associated with a higher risk of mortality in node -positive, PR -negative, \nyounger patients and in patients with a short time between primary diagnosis and recurrence\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBreast Cancer Follow -Up\nObjectives \nOxford\nLoE GR AGO\n\u00a7Improve quality oflife 2b B +\n\u00a7Improve physical performance 2a B +\n\u00a7Reduction and/or early detection of therapy -related side \neffects (such as osteoporosis, cardiac failure, fatigue, neurotoxicity, \nlymphedema, sexual disorders, cognitive impairment, sterility, and \nsecondary tumors ) and start of necessary therapies2b B +\n\u00a7Participation in interventional programs during follow -\nup for breast cancer survivors in order to maximize \ntherapy adherence, assess life -style interventions, and \nimprove quality of life3b B +\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMonitoring after cardiotoxic therapy\n(anthracyclines, anti- HER2)\n\u00a7Echocardiography 6-12 months and 5 years after \ntreatment (in particular in case ofhighly dosed\nanthracycline -containing therapy orrisk factors like left\nsided radiotherapy , smoking , AHT, DM, dyslipidemia , \nadipositas , age>60 years , status after MI orother\ncardiac diseases , moderate- graded vitium )\n\u00a7BNP measurement in selected cases\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBreast Cancer Follow -Up\nObjectives\nOxford\nLoE GR AGO\n\u00a7Evaluation of current adjuvant therapy 2b B ++\n\u00a7 incl. monitoring of adherence to endocrine therapies\n\u00a7 Control of menopausal status, e.g. in case of CT -induced amenorrhea \n(FSH/2 or bleeding history) and addition of GnRH analoga (up to 2 \nyears after CT) if premenopausal status in women <45 years old,  or \nswitch to aromatase inhibitors (if postmenopausal) \n\u00a7Pro-active improvement of therapy adherence 5 D ++\n\u00a7 Patient information about efficacy data for 5 -10 years \nendocrine therapy\n\u00a7 Early therapy of side effects (sports, NSAIDs, vitamin D / calcium)\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBreast Cancer Follow -Up\nObjectives\nOxford\nLoE GR AGO\n\u00a7Psycho -social aspects of support and counseling 4 C +\n\u00a7Pregnancy, contraception, sexuality, quality of life, \nmenopausal symptoms, fear of recurrence\n\u00a7Inclusion of related persons (partner, family, friends, caregivers)\n\u00a7Second opinion regarding primary therapy 2c B ++\n\u00a7General counseling (e.g. changes in family history of \nbreast, ovarian, prostate, pancreas carcinoma with \nnew indication for genetic counseling, HRT, \nprophylactic surgery, breast reconstruction)2c C +\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBreast Cancer Follow -Up\nRecommended Interventions\nOxford\nLoE GR AGO\n\u00a7 Treatment of type II -diabetes  \n(> 25% undetected DM in postmenopausal BC patients)2a B ++\n\u00a7 Weight/lifestyle intervention (if BMI < 18.5 and > 30) 2a B +\n\u00a7 Over night fasting > 13h 2b B +\n\u00a7 Reduction of dietary intake (at least 15 % calories from fat) \nin HR -negative BC is associated with improved overall survival2b B +\n\u00a7 Stop smoking (smoking causes 2 -fold increase in BC -specific and 4 -fold increase \nin not directly BC -associated mortality)2b B ++\n\u00a7 Alcohol consumption reduction (below 6g/d)2b B +\n\u00a7 Moderate sport (in patients with reduced physical activity prior to diagnosis) (at least 150 minutes/w, 2x/w)1b A ++\n\u00a7 Distress reduction3b B +Interventions regarding lifestyle risks and comorbidity in order to reduce an unfavorable \nimpact on disease outcome\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nProlonged nightly fasting improves prognosis in breast cancer patients\nretrospective cohort study: \n2413 BC -pat. (no diabetes), nightly fasting more or less than 13 hrs\nFasting < 13 hrs: HR 1.36, 36% increase of risk for recurrence\nHR 1.21, n.s. increase of risk for mortality\nevery  2 -hrs-prolonged fasting was correlated with a 20% increase\nof sleeping durationNightly fasting\nMarinac CR, Nelson SH, Breen CI et al. JAMA Oncol 2016: 2:1049 -1055\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deRoutine Follow -Up Examinations in \nAsymptomatic Patients\nOxford\nTests: LoE GR AGO\n\u00a7History (specific symptoms) 1a A ++\n\u00a7Physical examination 1a B ++\n\u00a7Breast self -examination  5 D +\n\u00a7Mammography 1a A ++\n\u00a7Sonography of the breast 2a B ++\n\u00a7Routine MRI of the breast* 3a B +/-\n\u00a7Breast MRI if conventional imaging is inconclusive 3b B +\n\u00a7Pelvic examination 5 D ++\n\u00a7DXA -scan at baseline and repeat scan according to individual risk \nin women with premature menopause or women taking an AI5 D +\n*Consider in case of increased risk (age <50y, HR -neg., diagnostic assessability C/D in mammography + ultrasound)\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deRoutine Follow -Up Examinations in \nAsymptomatic Patients\nOxford\nLoE GR AGO\n\u00a7Routine biochemistry (incl. tumor markers) 1a A -\n\u00a7Blood tests for monitoring of acute and late toxicities 5 D +\n\u00a7Ultrasound of the liver 1a A -\n\u00a7Bone scan 1a A -\n\u00a7Chest X -ray  1a A -\n\u00a7CT of chest, abdomen, and pelvis 2a D -\n\u00a7Detection of isolated / circulating tumor cells 2a D -\n\u00a7PET 2b B -\n\u00a7Whole body MRI  2b B -\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nBackground fortoxicity management\nTamoxifen: Cholesterin, Triglyceride , Bilirubin, ALAT, ASAT, \ngamma -GT\nAromatase -Inhibitors: Cholesterin, Triglyceride , Bilirubin, ALAT, ASAT, \ngamma -GT\nAnthracyclines : pro-BNP, possibly Troponin\nTrastuzumab : pro-BNP, possibly Troponin\nCheckpoint -Inhibitors: Bilirubin, ALAT, ASAT, gamma -GT, Kreatinin, TSH, \nfT3/T4, Myoglobin\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEarly Detection of Potentially Curable Events\nOxford\nLoE GR AGO\nLocoregional recurrence (chest wall, in -breast):\n\u00a7Incidence 7 \u201320% (depending on time of F/U)\n\u00a7Breast self -examination 5 D +\n\u00a7Physical examination, mammography & US 1a A ++\n\u00a7Magnetic resonance imaging (MRI)* 3a B +/-\n*Consider in case of increased risk (age <50y, HR -neg., diagnostic assessability C/D in mammography + ultrasound)\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEarly Detection of Potentially Curable Events\nOxford\nLoE GR AGO\nContralateral breast cancer:\n\u00a7Relative risk: 2.5 \u20135 \n\u00a7Incidence: 0.5 \u20131.0 % / year \n\u00a7Breast self -examination 5 D +\n\u00a7Physical examination, mammography & US 1a A ++\n\u00a7Routine breast MRI* 3b B +/-\nMale breast cancer: analogous to BC in women** 5 D +\n*    Consider in case of increased risk: age <50y, HR -neg., diagnostic assessability C/D in mammography + ultrasound.\n**  See chapter \u201cBreast Cancer Specific Situations\u201d\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEarly Detection of Potentially Curable Events\nOxford\nLoE GR AGO\nCarcinomas in unrelated sites :\n\u00a7MDS (RR 10.9), AML (RR 2.6 \u20135.3), Colon RR 3.0; \nendometrium RR 1.6; ovary RR 1.5; lymphoma RR \n\u00a7Screening for secondary malignancies according to \ncurrent guidelines 5 D ++\n\u00a7Pelvic examination and PAP smear 5 D ++\n\u00a7Routine endometrial ultrasound / biopsy 1b B -\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deFollow -Up Care\nfor invasive/non -invasive Breast Cancer \nClinical follow -up Follow -up* Screening/\nFollow -up\nYears after primary therapy 1        2        3 4        5 > 5\nHistory, physical examination, \ncounselingevery 3 months\nDCIS every 6 monthsevery 6 months inv.: every 12 months\nSelf-examination monthly\nImaging modalities and \nbiochemistryindicated only if complaints, clinical findings, or suspicion of recurrence\nMonitoring of side effects of therapy\nMammo -\ngraphy and \nadditional \nsonographyBCT** both sides: every 12 months\nMastectomy contralateral every 12 months\nEchocardiography 6-12 months and 5 years after completion of cardiotoxic therapyRecommendations for asymptomatic pts. \n(mod. according to ASCO -ACS recommendations 2016, NCCN 2021, ESMO 2019 and S3 -guidelines 2017 )\n*Continued follow -up visits if still on adjuvant treatment\n**In pts after breast -conserving therapy (BCT):  First mammography 1 year after initial mammography or at least 6 months \nafter completion of radiotherapy\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBreast Cancer Follow -up\nDuration and Breast Nurses\nOxford\nLoE GR AGO\n\u00a7Duration of follow -up\n\u00a7up to 5 years 1c A ++\n\u00a7up to 10 years 1c A +\n\u00a7Surveillance by specialized breast nurses 2b B +/-*\n*Studies recommended\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7Intrinsic typing of breast cancer leads to subgroups \nwith different course of disease. Thus, postoperative\nsurveillance should be adapted to specific \ntime -dependent hazards of recurrence.\n\u00a7ER-positive patients have stable risk over many \nyears requiring long term surveillance.\n\u00a7However, patients with HER2 -positive disease and \nTNBC have more risk in the early phase of follow -up \nand should therefore receive more intense surveillance \nin the first years of follow -up.Luminal -like, HER2- positive and \nTriple -negative Breast Cancer Patients\nRibelles et al. BCR 2013\nBreast Cancer Follow-Up\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.01\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1ELoco -Regional Recurrence\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deLoco -regional Recurrence\n\u00a7Versions 2002 \u20132020: \nAudretsch / Bauerfeind / Brunnert / Budach / \nCosta / Dall / Fehm / Fersis / Friedrich / Harbeck / \nGerber / G\u00f6hring / Hanf / K\u00fchn/ Lisboa / Lux / Maass / \nMundhenke / Rezai / Simon / Solbach / Solomayer / \nSouchon / Thomssen / Wenz / W\u00f6ckel /\n\u00a7Version 2021:\nBlohmer / Ditsch\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nLoco -regional Recurrence\nIncidence and Prognosis\nLocalization 10-y. incidence (%) 5-y. Overall Survival (%)\nIpsilateral recurrence1\n(post BCS + irradition )10 (2 \u201320) 65  (45 \u201379)\nChest wall1\n(post mastectomy)4 (2\u201320) 50  (24 \u201378)\nAs above plus supraclavicular fossa2\nAxilla:34% 49% (3 -y. OS) \nAfter ALND1 1 (0.1 \u20138) 55  (31 \u201377)\nAfter SLNE4 1 93%\nMultiple localizations2 16 (8 \u201319) 21  (18 \u201323)\n1Haffty et al. Int J Radiat Oncol Biol Phys 21(2):293 -298, 1991;\n2Reddy JP. Int J Radiat Oncol Biol Phys 80(5):1453- 7, 2011;\n3Karabali -Dalamaga S et al. BrMed J 2(6139):730 -733,1978;\n4Andersson Y , et al. Br J Surg 99(2):226- 31,2012\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deLoco -regional \nRecurrence Staging\nOxford\nLoE GR AGO\nExaminations before treatment\n\u00a7Tissue biopsy 5 D ++\n\u00a7Re-assessment of ER, PR, HER2 3b B ++\n\u00a7Complete re -staging 5 D ++\n\u00a7\u201eLiquid biopsy\u201c 5 D -\n\u00a718F-FDG PET -CT 2b B -\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEarly Breast Cancer (M0) \u2013eBC\nPrognostic Factors I\nOxford\nFactor LoEOx2001 GR AGO\n\u00a7Tumor size \u2013pT 1a A ++\n\u00a7Axillary lymph node status \u2013pN 1a A ++\n\u00a7Histological tumor type (mucinous, tubular etc.) 2b B ++\n\u00a7Grade (Elston & Ellis) \u2013G 2a B ++\n\u00a7Age 2a B ++\n\u00a7Histologically proven peritumoral lymphatic vessel \nand vascular invasion (L1 V1) 1b B ++\n\u00a7pCR after NACT* in (luminal -B-like, HER2+, TN) 1a A ++\n\u00a7Increased risk of recurrence in           invasive -\nlobular BC, cT3/4, N+2a B +/-\n\u00a7Obesity (BMI > 30 kg/m\u00b2) 1b B +\n\u00a7Margins (resection status ) \u2013R0/R1 1a A +\n*NACT = Neoadjuvant Chemotherapy\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEarly Breast Cancer (M0) -eBC\nPrognostic Factors II\nOxford\nFactor LoE GR AGO\n\u00a7ER / PR 2a B ++\n\u00a7HER2 (IHC, ISH) 2b B ++\n\u00a7ER / PR / HER2/ Ki -67 to assess the \nmolecular type2b B ++\n\u00a7uPA / PAI -1 (Femtelle\u00ae ELISA) in N0 1a A +\n\u00a7Proliferation markers\n\u00a7Ki-67 before, during, or after treatment 1a B +\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7ER/PR: concordance central vslocal ishigh (97%; Plan B, SABCS 2014)\n\u00a7Grade: concordance central vslocal is68% ( PlanB , JCO 2016)\n\u00a7HER2: frequency offalse -positive test results 6% (ASCO /CAP JCO 2013)\n\u00a7Impact ofroutine pathologic review in N0 BC: 20% changes : grade 40%, LVI  26%, N \n15%, margin 12% (JCO 2012)\n\u00a7pN0 from MIRROR study : pN0 was upstaged in 22%, in central pathology review\n(Ann Oncol 2012)\n\u00a7Ki67: \n\u00a7Inter -and intraobserver variability in measurement ofKi-67 is high (J Nat. \nCancer Institute 2011)\n\u00a7High reproducibility forlow and high Ki67 levels (J Pathol 2002)\n\u00a7Standardized methodology improves analytical validity (JNCI 2020)Reproducibility \u2013Quality assurance iskeyfor\nclinical decision making\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nWang et al, Surg Oncol. 2013 Dec;22(4):247 -55.\nn = 15312 BC -patients, 22 studies, Hazard -ratios\nBCT vs. ME\nILRR 0.75 (0.65- 0.87)\nDM 0.68 (0.60- 0.76)\nTNBC -subtype vs. other subtype\nILRR 1.88 (1.58- 2.22)\nDM 2.12 (1.72- 2.62)\nTNBC -subtype vs. HER2 -subtype\nILRR 0.69 (0.53- 0.91)\nDM n.s.Metaanalysis: \nTNBC and Local Recurrence\nILRR: ipsilateral locoregional recurrence\nDM: distant metastasis\nTNBC: triple negative breast cancer\nBCT: breast conserving therapy\nME: mastectomy\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nRisk factors for loco -regional recurrence after \nmastectomy\nKarlsson et al. Ann Oncol 23:2852-8, 2012\nIBCSG -study, 13 randomised studies;  n = 8106 pts\nRisk factors for 10 years cumulative incidence\n\u00e015% chest wall age < 40; \u2265 4 pos. lymph nodes, 0 -7 pos. lymph nodes\n\u00e010% supraclavicular \u2265 4 pos. Lymph nodes\n\u00e05% local rrecurrence axilla age< 40; tumor size unknown , \n0-7 neg. lymph nodes\nPeng  G et al. Biosci Reports 39 (9), 2019\nmetaanalysis, 20 publications, n = 11.244 pts, pT1 -2 pN0 post mastectomy\nLocal recurrence risk\u00e0age HR 1,77 (p=0,001)\n\u00e0L1/V1 HR 2,23 (p<0,001)\n\u00e0Grading HR 1,66 (p<0,001)\n\u00e0Her2 -status HR 1,65 (p<0,027)\n\u00e0menopausal status HR 1,36 (p=0,015)\n\u00e0Resection margins HR 2,56 (p=0,014)\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEarly Breast Cancer (M0) -eBC\nPrognostic Factors III\nFactor LoE GR AGO\n\u00a7 Gene expression profiles (GEP, multigene assays , gene signatures)\n\u00a7 MammaPrint \u00ae (N0- 1) 1b A +*\n\u00a7 Oncotype DX\u00ae  (N0 -1, HR+ HER2 -) 1b A +*\n\u00a7 EndoPredict\u00ae (N0-1, HR+, HER2 -) 2b B +*\n\u00a7 Prosigna \u00ae (N0 -1, HR+, HER2 -) 2b B +*\n\u00a7 Breast Cancer IndexSM(N0-1, HR+ HER2 -)** 2b B +/-*\n\u00a7 PREDICT\u00ae algorithm (https://breast.predict.nhs.uk/) 1b A +\n\u00a7 Clinical -pathological score for lobular breast cancer (nodal status, tumor size, \nlymphovascular invasion LVI)2b B +/-\n\u00a7 CTS5 Clinical Treatment Score** 2b B +\n\u00a7 CPS-EG Score 2b B +\n*Should only be used in the context of clinical -pathological criteria (tumor size, nodal involvement, grade, Ki -67, ER, \nPR, HER2)\n** estimation oflate recurrenceOxford\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEarly Breast Cancer (M0) -eBC\nPrognostic Factors IV\nFactor LoE GR AGO\n\u00a7Disseminated tumor cells (DTC, in bone marrow) 1a A +/-\n\u00a7Circulating tumor cells (CTC, in blood, Cell Search \u00ae) $ 1b A +/-\n\u00a7CTC before NACT (regarding OS, DDFS, LRFI) 1b B +/-\n\u00a7Therapy decisions based on CTC phenotypes 3a C -\n\u00a7Cell-free DNA ( cfDNA, in blood, for DFS, PFS, OS) 2ba B +/-\n$Validated clinical data only available for this assayOxford\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deRisk factors for another relapse\nOxford\nLoE GR AGO\n\u00a7 Tumor size 2a B\n\u00a7 Multifocality 2a B\n\u00a7 Localisation 2b B\n\u00a7 Negative progesterone receptor 3b B\n\u00a7 High grade 3b C\n\u00a7 Omitted radiotherapy at first recurrence 3b C\n\u00a7 Omitted chemotherapy at first recurrence 3b C\nParameters of the locally recurrent tumor to define the risk for distant metastasis/survival\n\u00a7 Early (< 2- 3 yrs.) vs. late recurrence 2b B\n\u00a7 LVSI / Grade / ER -neg / positive margins (if \u2265 2 factors positive) 3b B\nPredictive factors for treatment considerations \n\u00a7 HER2 2b B ++\n\u00a7 ER and PR 2b B ++\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nPanet -Raymond V et al. Cancer 117:2035, 2011\nn= 6020 pts., retrospective cohort -study\npT1/2, N0 tumors , breast conserving treatment\n269  ipsilateral breast tumor recurrences (IBTR)\nMultivariate analysis :\nTTR < 48 months\nLVSI ( oftheLRR)\nER negative LR -tumor\nhigh grade\nclose margins ofrecurrent tumor\n\u2192 if \u2265 2 factors positive \u21d2worse OSClinicopathological Factors of the Recurrent Tumor to Predict \nOutcome in Patients with Ipsilateral Breast Tumor Recurrence \nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deIpsilateral Recurrence \nafter BCT Surgery\nOxford\nLoE GR AGO\n\u00a7Mastectomy (aim: R0) 3b B ++\n\u00a7Re-BCS with tumor- free margins (R0) +partial breast\nirradiation*2b B +\n\u00a7Re-BCS with tumor -free margins (R0) 2b B +/-\n\u00a7Axillary intervention after prior AxDiss if cN0 4 C -\n\u00a7SLNE after prior SLNE if cN0** 2a B -\n\u00a7Palliative surgery in M1 -situation \n(e.g. pain, ulceration , psychosocial indication)5 D +\n* After tumorboard presentation\n**If no sentinel lymph node can be identified, axillary dissection is not recommended; \nno operation outside the ipsilateral axilla is recommended\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2020.01\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMastektomy vs. BCS + partial breast irradiation\nHannoun -Levi et al. IntJ Radiat Oncol BiolPhys. 2020-1327 pts. from 7 European countries with first local recurrence 01/1995 -06/2017\n-ME vs. BCS + Brachytherapy\n-Propensity Score matched control (1:1): clinical and histopathological  factors\n-Primary endpoint:  5- y OS; secondary endpoints: e.g. 5 -J.-DFS, complications\n-Median follow -up 75.4 months\n-No differences in 5 -J. OS and sec. Endpoints: 5 -y -OS: 88 vs. 87%\ncumulative incidence 2. recurrence: 2.3 vs. 2.8%\n-5-y incidence of mastectomy after 1. recurrence 3.1%\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deChest -Wall Recurrence after Mastectomy / \nAxillary Recurrence - Surgery\nOxford\nLoE GR AGO\n\u00a7Curative situation : R0-resection (including deeper\nparts ofthechest wall in selected cases : HR -\npositive, primary N0)2b A ++\n\u00a7Palliative situation: Resection of deep parts of the \nchest wall5 D +/-\n\u00a7Palliative surgery in M1 -situation  \n(e.g. pain, ulceration, psychosocial)5 D +\n\u00a7SLNE after prior SLNE if cN0* 3b B -\n*If no sentinel lymph node can be identified, axillary dissection is not recommended; \nno operation outside the ipsilateral axilla is recommended\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deLoco -regional Recurrence after\nR0-Resection Systemic Treatment\nOxford\nLoE GR AGO\nAccording topathohistological re-evaluation of the \nrecurrent tumor (ER, PR, HER2)\n\u00a7Endocrine therapy in endocrine responsive  tumors 2b B ++\n\u00a7Chemotherapy (consider preoperative \nadministration )2b B +\n\u00a7In case of HER2 -positive disease, chemotherapy \n+ HER2 -targeted therapy5 D +\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7CALOR Trial update\nn = 163 (2003 -2010), me dian follow -up of 4.9 years, all R0 resection\n5-year disease -free survival: 69% (95% CI 56 -79) with chemotherapy \nvs. 57% (44 -67) without chemotherapy (hazard ratio 0.59 \n[95% CI 0.35 -0.99]; p=0.046): 24 (28%) patients vs. 34 (44%). \nAdjuvant chemotherapy was significantly more effective in \nER negative disease (p interaction =0.046).\nMultivariate analysis: predictors of survival\nchemotherapy for primary cancer (HR 3.55, p=0.03)\ninterval from primary surgery (HR 0.87, p=0.05)Loco -regional Recurrence\nChemotherapy\nWapnir IL et al.  Annals of Surgical Oncology, February 2017, Volume 24, Issue 2,  pp 398 \u2013406| Cite as\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7CALOR Trial updateLoco -regional Recurrence\nChemotherapy\nWapnir IL et al.  Annals of Surgical Oncology, February 2017, Volume 24, Issue 2,  pp 398 \u2013406ER-positive ER-negative\nEndpoint CT No-CT HR (95%CI) CT No-CT HR (95%CI)\n10-yr DFS 50% 59% 1.07 (0.57 \u2013 2.00) 70% 34% 0.29 (0.13 \u2013 0.67)\nInteraction P -Value =0.013\n10-yr OS 76% 66% 0.70 (0.32 \u2013 1.55) 73% 53% 0.48 (0.19 \u2013 1.20)\nInteraction P -value =0.53\n10-yr BCFI 58% 62% 0.94 (0.47 \u2013 0.85) 70% 34% 0.29 (0.13 \u2013 0.67)\nInteraction P -value = 0.034\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deLocoregional Recurrence in Case of \nR1-Resection/Inoperability \u2013Systemic Treatment\nOxford\nLoE GR AGO\nAccording tohistopathological pathohistological re-\nevaluation o f the recurrent tumor (ER, PR, HER2)\n\u00a7Endocrine -based therapy in endocrine responsive\ntumors corresponding tometastatic disease 2b B ++\n\u00a7Chemotherapy and targeted therapy (pre -or \npostoperative) corresponding to metastatic disease 2b B ++\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deIpsilateral Recurrence \nafter BCT Radiotherapy\nOxford\nLoE GR AGO\nAfter Re -BCS\n\u00a7Whole breast irradiation \n(in case of no prior adjuvant radiotherapy)3b C ++\n\u00a7Re-breast irradiation (Partial breast irradiation, brachytherapy / \nexternal beam RT, in case of prior adjuvant radiotherapy) 2b B +\nAfter mastectomy\n\u00a7Radiation of chest wall +/ -regional lymph nodes\n(14% involved supraclavicular metastasis) 2b B +/-\n\u00a7Radiation dose escalation (+10%) 3b C -\n\u00a7Repeated irradiation (e.g. as brachytherapy)  with hyperthermia 3a C +\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deChest -Wall Recurrence after Mastectomy / \nAxillary Recurrence Radiotherapy\nOxford\nLoE GR AGO\nChest -Wall Recurrence (R0 -Resection) after \nMastectomy\n\u00a7If no prior postmastectomy radiotherapy\n\u00a7 Curative situation: \nirradiation of the chest wall +/ -regional lymph nodes2b B +\n\u00a7Re-irradiation (chest wall + hyperthermia) 1b B +/-\nAxillary Recurrence\n\u00a7Irradiation of axilla after R0 -surgery\n\u00a7 No prior adjuvant irradiation of the axilla 3b C +\n\u00a7 Adjuvant irradiation of the axilla 5 D +/-\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deLoco -Regional Recurrence\nTreatment Options in Non Curative Cases\nOxford\nLoE GR AGO\n\u00a7Concomitant radio -chemotherapy 3b C +\n\u00a7Hyperthermia (in centers listed on DKG website)\n\u00a7In combination with radiotherapy 1b B +\n\u00a7In combination with chemotherapy 4 C +/-\n\u00a7Intra -arterial chemotherapy 4 C +/-\n\u00a7Photodynamic therapy 4 C +/-\n\u00a7Electrochemotherapy 3b C +/-\nLoco-Regional Recurrence\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\nEndocrine -based and targeted \nTherapy of Metastatic Breast \nCancer\nEndocrine-based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEndocrine Therapy of \nMetastatic Breast Cancer\n\u25aaVersions 2002 \u20132020: \nAlbert / Bischoff / Dall / Fasching / Fersis / Friedrich / Gerber / \nHuober / Janni / Jonat / Kaufmann / Kolberg -Liedtke / Loibl / \nL\u00fcftner / L\u00fcck / von Minckwitz / M\u00f6bus / M\u00fcller / Mundhenke / \nNitz / Schmidt / Schneewei\u00df / Sch\u00fctz / Stickeler / Thill / Untch\n\u25aaVersion 2021:\nGerber / W\u00f6ckel\nEndocrine-based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEndocrine Therapy in \nMetastatic Breast Cancer\nEndocrine -based therapy is first line treatment in patients with metastatic \nbreast cancer and positive (or unknown) hormone receptor (HR) status.\nException: imminent organ failure\nCaveat: HR may change during the course of disease. \nHistology of recurrent site should be obtained whenever possibleOxford LoE: 1a GR: A AGO: ++Indication\nEndocrine-based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nMeta -analysis based on 39 (mostly retrospective ) analyses , exclusively comparing\nprimary tumor and metastasis (nolymph nodes ):\nPooled discordance proportions were:\n\u00a7 19,3% (95% CI 1\u20444 15.8% to23.4%) forER\n\u00a7 30,9% (95% CI1\u20444 26.6% to35.6%) forPR\n\u00a7 10,3% (95% CI 1\u20444 7.8% to13.6%) forHER2\nPooled proportions of tumors shifting from positive to negative \n\u00a7 22.5% (95% CI = 16.4% to30.0%) forER\n\u00a7 49.4% (95% CI\u2009=\u200940.5% to58.2%) forPR\n\u00a7 21.3% (95% CI\u2009=\u200914.3% to30.5%)) forHER2\nPooled proportions of tumors shifting from negative to positive \n\u00a7 21.5% (95% CI\u2009=\u200918.1% to25.5%) forER\n\u00a7 15.9% (95% CI\u2009=\u200911.3% to22.0%) forPR\n\u00a7 9.5% (95% CI\u2009=\u20097.4% to12.1%) forHER2Comparison ER/PR and HER2\nMetastasis vs. Primary Tumor (N=5.521)\nEndocrine-based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEndocrine Therapy \nGeneral Considerations\n\u00a7In all lines of treatment, treatment options should consider prior \nendocrine therapies, age, and comorbidities as well as the respective \napproval status.\n\u00a7Premenopausal patients receiving GnRH analogues or after ovariectomy \ncan be treated like postmenopausal patients.\nEndocrine-based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMetastatic Breast Cancer\nEndocrine Resistance\nPrimary endocrine resistance :\n\u00a7Relapse within 2 years of adjuvant endocrine treatment (ET)\n\u00a7Progressive disease within first 6 months of first -line ET for MBC\nSecondary (required ) endocrine resistance :\n\u00a7Relapse while on adjuvant ET but after the first 2 years or a relapse within  \n12 months after completing adjuvant ET\n\u00a7PD \u2265 6 months after initiation ofETforMBC\nEndocrine-based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEndocrine Therapy in Premenopausal Patients \nwith HER2 -Negative Metastatic Breast Cancer\nOxford\nLoE GR AGO\n\u00a7GnRHa + Fulvestrant + CDK4/6i 2b B ++\n\u00a7GnRHa + AI + Ribociclib1b B ++\n\u00a7GnRHa + AI + Palbociclib / Abemaciclib3ba/5 C +\n\u00a7GnRHa + Tamoxifen + Palbociclib / Abemaciclib2b B +/-\n\u00a7GnRHa + Tamoxifen1a A +\n\u00a7Ovarian Function Suppression(OFS)2b B +\n\u00a7Tamoxifen 2b B +/-\n\u00a7GnRHa + AI ( first + second line)2b B +\n\u00a7GnRHa + Fulvestrant1b B +\n\u00a7Aromataseinhibitors without OFS3 D --\nEndocrine-based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEndocrine Mono- Therapy in Postmenopausal Patients \nwith HER2 -Negative Metastatic Breast Cancer\nOxford\nLoE GR AGO\n\u00a7Fulvestrant 500 mg 1b B +\n\u00a7Aromatase inhibitor * 1a A +\n\u00a7Tamoxifen 1a A +\n\u00a7Fulvestrant 250 mg + Anastrozole 1b B +/-\n\u00a7Repeat prior treatments 5 D +/-\n*There is no evidence for superiority of any specific aromatase inhibitor. As everolimus plus \nexemestane is indicated after AI treatment, a non -steroidal AI should be used in first line. \nEndocrine-based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEndocrine -Based Treatment Options for Postmenopausal \nPatients with HER2 -Negative Metastatic Breast Cancer\nOxford\nLoE GR AGO\n\u00a7CDK4/6 -Inhibitor ( Abemaciclib , Palbociclib , Ribociclib )\n\u00a7 + non -steroidal AI 1b B ++\n\u00a7 + Fulvestrant 1b B ++\n\u00a7Abemaciclib monotherapy 3 C +/-\n\u00a7Alpelisib + Fulvestrant (PIK3CA mutated ) 1b B +\n\u00a7Everolimus\n\u00a7 + Exemestane 1b A +\n\u00a7 + Tamoxifen 2b B +\n\u00a7 + Letrozole 2b B +/-\n\u00a7 + Fulvestrant 2baB +\n\u00a7CDK4/6 -Inhibitor beyond progression 5 D -\n\u00a7CDK4/6 -Inhibitor switch based on toxicity 5 D +/-\nEndocrine-based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEndocrine Therapy in Postmenopausal HER2 -Negative \nMetastatic Breast Cancer in Combination with Bevacizumab\nOxford\nLoE GR AGO\n\u00a7Maintenance bevacizumab  plus endocrine \ntherapy after remission with chemotherapy and \nbevacizumab1b B +/-\n\u00a7Bevacizumab plus endocrine treatment as first \nline therapy for advanced disease1b B +/-\nEndocrine-based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePARP Inhibitors in Patients with HER2 -negative, \ngBRCA -Mutant, Metastatic Breast Cancer\nOxford\nLoE GR AGO\n\u00a7Olaparib 1b A ++\nOxford\nLoE GR AGO\n\u00a7Talazoparib 1b B ++\nEndocrine-based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\nHER2- Positive and HR -Positive \nMetastatic Breast Cancer\nEndocrine-based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deEndocrine Therapy in Postmenopausal HER2 -\nPositive Metastatic Breast Cancer Patients\nOxford\nLoE GR AGO\n\u00a7Anastrozole + trastuzumab 1b B +/-\n\u00a7Letrozole + trastuzumab 2b B +/-\n\u00a7Letrozole + lapatinib 1b B +/-\n\u00a7Fulvestrant + lapatinib 1b B +/-\n\u00a7Abemaciclib + fulvestrant + trastuzumab (after T -DM1) 2baB +/-\n\u00a7Aromatase inhibitors + trastuzumab / pertuzumab * 2b B +/-\nPoor efficacy of endocrine therapy alone. \nConsider induction chemotherapy + anti -HER2 -therapy (followed by endocrine + anti -HER2 -\ntherapy as maintenance therapy)! \n*Study participation recommended\nEndocrine-based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deConcomitant or Sequential \nEndocrine -Cytostatic Treatment\nOxford\nLoE GR AGO\n\u00a7Concomitant endocrine -cytotoxic treatment 1b A -\n\u00a7May increase response rate and progression \nfree interval but not overall survival\n\u00a7May increase toxicity\n\u00a7Endocrine maintena nce therapy after \nchemotherapy +/-anti-HER2 therapy- induced \nresponse  +/-anti HER2 therapy2b B +\n\u00a7Increases progression -free interval\nEndocrine-based and targeted Therapy of Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast \nVersion 2021.1\nDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer\n\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E Chemotherapy With or Without\nTargeted Drugs* in Metastatic \nBreast Cancer\n*Substances without published evidence based on at least one phase III/II b trial were omitted\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deChemotherapy \u00b1Targeted Drugs in \nMetastatic Breast Cancer\n\u00a7Versions 2002 \u20132020: \nAlbert / Bischoff / Dall / Fehm / Fersis / Friedrichs / Harbeck / \nJackisch / Janni / Kolberg -Liedtke / L\u00fcftner / Lux / von Minckwitz / \nM\u00f6bus / M\u00fcller / Rody / Schaller / Scharl / Schmutzler / Schneeweiss / \nSch\u00fctz / Stickeler / Thill / Thomssen / Untch\n\u00a7Version 2021:\nJackisch / Schmidt\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMetastatic Breast Cancer ( mBC )\nDisease -Free and Overall Survival \nOxford\nLoE\n\u00a7In MBC, an increase in survival over time has been shown in \nclinical trials1b\n\u00a7Multiple lines of sequential  therapy are beneficial(at least similar efficacy, less toxicity)1b\n\u00a7Targeted drugs in combination with chemotherapy can induce \nsubstantial survival benefits1b\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMetastatic Breast Cancer\nEndocrine Resistance\nPrimary endocrine resistance :\n\u00a7Relapse within 2 years of adjuvant endocrine treatment (ET)\n\u00a7Progressive disease within first 6 months of first -line ET for MBC\nSecondary (required ) endocrine resistance :\n\u00a7Relapse while on adjuvant ET but after the first 2 years or a relapse within  \n12 months after completing adjuvant ET\n\u00a7PD \u2265 6 months after initiation ofET forMBC\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deTreatment of Metastatic Breast Cancer\nPredictive Factors for response\nTherapy Factor LoE GR AGO\n\u00a7 Endocrine therapy ER / PR (prim. tumor , better : metastasis ) 1a A ++\nResponse toprior therapy 2b B ++\nAutocrine receptor mutation (ESR1) 2b B +\n\u00a7 Alpelisib PIK3CA mutation (prim. tumor , metastases , \nplasma )1b A +\n\u00a7 Chemotherapy Response toprior therapy 1b A ++\n\u00a7 Anti -HER2 -therapy HER2 (prim. tumor, better: metastasis) 1a A ++\n\u00a7 Checkpoint -Inhibitors PD-L1 positivity#(PD-L1ic, CPS) in TNBC \n(primary tumor ormetastasis )1b B ++\n\u00a7 PARP- Inhibitors gBRCA1/2 -mutation 1a A ++\n\u00a7 Bone modifying drugs Bone metastasis 1a A ++\n\u00a7 Any therapy CTC  monitoring 1b A +*\n* In clinical trials ; # seechapter \u201epathology \u201cOxford\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\u00a7Mono -Chemotherapy: \n\u00a7Favorable therapeutic index *\n\u00a7Indicated in case of\n\u00a7Slow, not life-threatening progression\n\u00a7Insensitivity to or progression during endocrine therapy\n\u00a7Poly -Chemotherapy:\n\u00a7Unfavorable therapeutic index\n\u00a7Indicated to achieve rapid remission in the case of\n\u00a7Extensive symptoms\n\u00a7Visceral crisis (ABC -5 definition )\n\u00a7Survival benefit in comparison to sequential single -agent therapies with the same \ncompounds not proven Oxford LoE: 1b GR: A AGO: ++\n*Therapeutic index evaluates overall efficacy, toxicity, and impact on quality of lifeMetastatic Breast Cancer\nTreatment Rationale\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nDefinition ofvisceral crisis (ABC 5)\n\u00a7Visceral crisis is defined as severe organ dysfunction, as assessed by signs \nand symptoms, laboratory studies and rapid progression of disease. Visceral \ncrisis is not the mere presence of visceral metastases but implies important \norgan compromise leading to a clinical indication for the most rapidly \nefficacious therapy.\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\u00a7Evaluate compliance before and during therapy (especially in patients of \nolder age, with reduced performance status, or significant co -morbidities \nand secondary primaries)\n\u00a7Assess subjective and objective toxicities, symptoms, and performance as \nwell as quality of life (QoL) status repeatedly\n\u00a7Use dosages according to published protocols\n\u00a7Assess tumor burden at baseline and approx. every 2 months, i.e. every 2 -4 \ncycles. In slowly growing disease, longer intervals are acceptable. GR: A AGO: ++Metastatic Breast Cancer\nSystemic Therapy\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deOxford\nLoE GR AGO\n\u00a7As long as therapeutic index* remains positive 1a A ++\n\u00a7Treatment until progression 2b B +\n\u00a7Treatment until best response 2b B +/-\n\u00a7Change to alternative regimen before progression 2b B +/-\n\u00a7Stop therapy in case of 1c A ++\n\u00a7Progression\n\u00a7Non tolerable toxicityMetastatic Breast Cancer\nDuration of Cytotoxic Therapy\n*Therapeutic index evaluates overall efficacy, toxicity, and impact on quality of life\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deChemotherapy in  mBC\nGeneral Considerations -Drug Selection\n\u00a7Participation in clinical trials is recommended\n\u00a7The choice of systemic therapy depends on:\n\u00a7ER / PR, HER2, PD -L1 status, gBRCA status, PIK3CA, e.g. MSI, NTRK ( clinical actionability\nofmolecular targets )\n\u00a7Prior therapies (and their toxicities)\n\u00a7Disease -free interval after end of adjuvant treatment\n\u00a7Progression -free interval achieved by the previous line of therapy\n\u00a7Disease aggressiveness and localization of metastases\n\u00a7Estimated lifeexpectancy\n\u00a7Co-morbidities (including organ dysfunction )\n\u00a7Patient preferences and expectationsAGO: ++\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.demBC HER2- negative/HR- positive\n1st-Line Chemotherapy*\nLoE GR AGO\n\u00a7Monotherapy :\n\u00a7 Paclitaxel (q1w), Docetaxel (q3w) 1a A ++\n\u00a7 Doxorubicin , epirubicin , Peg -liposomal doxorubicin (Alip) 1b A ++\n\u00a7 Vinorelbine 3b B +\n\u00a7 Capecitabine 2b B +\n\u00a7 Nab-paclitaxel 2b B +\n\u00a7Polychemotherapy :\n\u00a7 A + T 1b A ++\n\u00a7 Paclitaxel + capecitabine 2b B +\n\u00a7 Docetaxel + capecitabine after adj. A 1b A +\n\u00a7 T + gemcitabine after adj. A 2b B ++\n\u00a7 A + C or Alip+ C 1b B ++Oxford\n*In patients with ER pos. tumors only if endocrine therapy is not indicated or should be discontinued\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.demBC HER2 -negative/HR- positive:\nChemotherapy after Anthracycline Treatment*\nOxford\nLoE GR AGO\n\u00a7Paclitaxel q1w 1a A ++\n\u00a7Docetaxel q3w 1a A ++\n\u00a7Capecitabine 2b B ++\n\u00a7Nab-paclitaxel 2b B ++\n\u00a7Peg-liposomal doxorubicin 2b B +\n\u00a7Eribulin 1b B +\n\u00a7Vinorelbine 2b B +\n\u00a7Docetaxel + Peg -liposomal doxorubicin 1b B +/-\n*Independent whether anthracyclines were used in adjuvant or 1stline metastatic situation\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.demBC HER2- negative/HR- positive: \nChemotherapy after Taxane and Anthracycline Treatment\nOxford\nLoE GR AGO\n\u00a7Capecitabine 2b B ++\n\u00a7Eribulin 1b B ++\n\u00a7Vinorelbine 2b B ++\n\u00a7(Peg)- liposomal Doxorubicin 2b B +\n\u00a7Taxane re-challenge * 2b B +\n\u00a7Anthracycline re-challenge * 3b C +\n\u00a7Metronomic therapy (e.g. cyclophos . + MTX) 2b B +\n\u00a7Gemcitabine + Cisplatin / Carboplatin 2b B +/-\n*At least one year disese -free after adjuvant treatment\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deTriple negative mBC PD-L1+ \nIndependent ofgermline mutation in BRCA 1/2 \nOxford\nLoE GR AGO\n\u00a7Atezolizumab + Nab-Paclitaxel first-line PD-L1 IC \u22651# \n(ifTFI \u2265 12 months )1b B +\n\u00a7Atezolizumab + Paclitaxel first line PD-L1 IC \u22651#1ba B -\n\u00a7Pembrolizumab + Chemo* first -line PD -L1 CPS \u226510# \n(after TFI \u22656 months)1b B +/-\n\u00a7 Pembrolizumab monotherapy (after chemotherapy w/o\nprevious immune oncology based therapy ) ifCPS \u226520#1ba B+/-\n# (seechapter \u201ePathology \u201c)\n* nab- Paclitaxel orPaclitaxel orCarboplatin / Gemcitabine\nTFI = therapy -free interval\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deTriple negative mBC independent ofPD-L1 \nStatus and Germline Mutations in BRCA 1/2\nOxford\nLoE GR AGO\n\u00a7Bevacizumab in addition tofirst-linechemotherapy1b B +\n\u00a7Sacituzumab Govitecan\n(after pretreatment with 2 standard therapies )1ba B +\n\u00a7Carboplatin (vs. Docetaxel ) 1b B +/-\n\u00a7Gemcitabin /Cisplatin (vs. Gem /Pac ) 1b A +\n\u00a7Nab-Paclitaxel /Carboplatin (vs. Carbo /Gem ) 2ba B +\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deTreatment options in mBC\nwith BRCA 1/2 orgPALB2 Mutation\nOxford\nLoE GR AGO\n\u00a7Standard ofcare, i.e. asin gBRCA 1/2 wildtype\ndisease++\n\u00a7Carboplatin (vs. Docetaxel ) (ifPlatinum -naive)1b B +\n\u00a7PARP- Inhibitors (HER2 -negative mBC)\n\u00a7HER2 -negative, gBRCA 1/2 mutation\n\u00a7 Olaparib 1b A ++\n\u00a7 Talazoparib 1b B ++\n\u00a7sBRCA 1/2 mutation\n\u00a7Olaparib2b B +/-\n\u00a7gPALB2 mutation\n\u00a7Olaparib2b B +/-\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMetastatic Breast Cancer\nBevacizumab Treatment in  HER2- neg. Disease \nLoE GR AGO\n\u00a71stline in combination with:\n\u00a7 Paclitaxel (q1w) 1b B +\n\u00a7 Capecitabine 1b B +\n\u00a7 Anthracyclines 2b B +/-\n\u00a7 Nab-Pac 2b B +/-\n\u00a7 Docetaxel (q3w) 1b B +/-\n\u00a7Cap+Bev as maintenance after Doc+Bev 1baB +/-\n\u00a72ndline in combination with:\n\u00a7 Taxanes 1b B +/-\n\u00a7 Capecitabine 1b B +/-\n\u00a7 Gemcitabine or vinorelbine 1b B -\n\u00a72ndline as treatment through multiple lines 1b B -Oxford\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deHER2- positive mBC\nAfter Trastuzumab orw/o Pretreatment (+ Chemotherapy ) \nOxford\nLoE GR AGO\n\u00a7Docetaxel + Trastuzumab + Pertuzumab 1b A ++\n\u00a7Paclitaxel (weekly ) + Trastuzumab + Pertuzumab 2b B ++\n\u00a7Nab-Paclitaxel + Trastuzumab + Pertuzumab 2b C +\n\u00a7Vinorelbine + Trastuzumab + Pertuzumab 3b B +\n\u00a71stline Chemotherapy * + Trastuzumab 1b B +\n\u00a7TBP: 2ndline Capecitabine + Trastuzumab 2b B +\n\u00a7Capecitabine + Lapatinib 1b B +\n\u00a7Taxane + Lapatinib 1b B +/-\n\u00a7Taxane + Trastuzumab + Everolimus 1b B -\n*Taxane ; Vinorelbine ; Paclitaxel /Carboplatin ; Capecitabine /Docetaxel ,\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deOxford\nLoE GR AGO\n\u00a7T-DM 1 \n(Recurrence after  6 months and after  taxanes and trastuzumab ) 2b B +\n\u00a7Trastuzumab + Lapatinib (HR-negative tumor) 2b B +\n\u00a7Trastuzumab mono 2b B +/-\n\u00a7Trastuzumab + Aromatase -Inhibitors (ER+) 2b B +/-*\n\u00a7Lapatinib + Aromatase -Inhibitors (ER+) 2b B +/-*\n\u00a7AI + Trastuzumab + Pertuzumab +\n\u00a7Abemaciclib + Trastuzumab + Fulvestrant 2b B +/-*\n\u00a7Trastuzumab + Pertuzumab +/-\n*See Chapter  \u201e endocrine +/-targeted Therapy \u201cHER2- positive mBC\nFurther Therap yOptions after Trastuzumab\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deOxford\nLoE GR AGO\n\u00a7T-DM 1 1b A ++\n\u00a7TBP: 2ndline Chemotherapy + Trastuzumab 2b B +\n\u00a72ndline Chemotherapy* + Trastuzumab \n+ Pertuzumab (if not used before)5 D +/-\n\u00a7Taxane + Trastuzumab + Pertuzumab 5 D +\n\u00a7Capecitabine + Trastuzumab + Pertuzumab 1ba B +/-\n\u00a7Capecitabine + Lapatinib 1b B +HER2- positive mBC\nTherapy after  Trastuzumab /Pertuzumab\n*e.g. Vinorelbine ; Taxane /Carboplatin ; Capecitabine /Docetaxel (Toxicity !)\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deOxford\nLoE GR AGO\n\u00a7Tucatinib + Trastuzumab + Capecitabine 1b B ++\n\u00a7Neratinib + Capecitabine 1b B +\n\u00a7Capecitabine + Lapatinib 1b B +\n\u00a7Capecitabine + Trastuzumab + Pertuzumab 1b B +/-\n\u00a7Trastuzumab Deruxtecan 2b B +\n\u00a7Experimental anti -HER2 regimes 5 D +HER2- positive mBC\nTherapy after T -DM 1\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMetastatic Breast Cancer\nLapatinib in HER2- positive Disease \nOxford\nLoE GR AGO\n\u00a7In combination with\n\u00a7Trastuzumab for heavily pre -treated pts (HR -negative) 2b B +\n\u00a7Paclitaxel in 1stline 1b B +/-\n\u00a7Capecitabine in > 2ndline 1b B +\n\u00a7Vinorelbine 2b B +/-\n\u00a7AI in ER -positive disease 2b B +/-\n\u00a7In patients with brain metastasis (radioresistance) \nin combination with capecitabine2b B +/-\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deImmunodiagnostic Tests\nand Immunotherapy\nOxford\nLoE GR AGO\n\u00a7Immundiagnostik\n\u00a7 Tumor tissue : PD-L1 IC status in TNBC 1b B +\n\u00a7 Blood: Immunological parameters5 D --\n\u00a7Systemic Immunotherapies\n\u00a7 Atezolizumab + Nab -Paclitaxel first -line TNBC, PD -L1 IC  \u22651#1b B +\n\u00a7 Atezolizumab + Paclitaxel first line TNBC, PD -L1 IC \u22651#1b B -\n\u00a7 Pembrolizumab + Chemo* in TNBC & PD -L1 CPS \u226510#1b B +/-\n\u00a7 Pembrolizumab -Monotherapy (after chemotherapy without Immun oncology\npretreatment ) ifCPS \u226520# 11baB +/-\n# (see chapter\u201ePathology \u201c)\n* nab- Paclitaxel orPaclitaxel orCarboplatin /Gemcitabine\n1CAVE: no label\nChemotherapy With or Without Targeted Drugs in Metastatic Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer \nOsteooncology and \nBone Health\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deOsteooncology and \nBone Health\n\u00a7Versions 2002 \u20132020: \nBischoff / B\u00f6hme / Brunnert / Dall / Diel / Fehm / \nFersis / Friedrich/ Friedrichs / Hanf / Huober / \nJackisch / Janni / Kolberg -Liedtke / Lux / Maas / Nitz / Oberhoff / \nSchaller / Scharl / Sch\u00fctz / Seegenschmi edt / Solbach / Solomayer / \nSouchon\n\u00a7Version 2021:\nBanys -Paluchowski / Kolberg -Liedtke\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBisphosphonates in Metastatic Breast Cancer\nOxford\nLoE GR AGO\n\u00a7Therapy of hypercalcemia 1a A ++\n\u00a7Reduction of skeletal events / complications 1a A ++\n\u00a7Reduction of bone pain 1a A ++\n\u00a7Increasing bone pain -free survival 1a A ++\n\u00a7Treatment beyond osseous progression 5 D ++\n\u00a7Use ofbone resorption markers fortherapy\nmonitoring5 D -\n\u00a7Bisphosphonates alone forpain control 5 D -\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deDenosumab in \nMetastatic Breast Cancer\nOxford\nLoE GR AGO\n\u00a7Therapy ofhypercalcemia 1a A ++\n\u00a7Reduction ofskeletal events / complications 1a A ++\n\u00a7Reduction ofbone pain 1a A ++\n\u00a7Increasing bone pain -free survival 1b A ++\n\u00a7Treatment beyond progression 5 D +\n\u00a7Progression while on bisphosphonates 4 C +/-\n\u00a7Use ofbone resorption markers fortherapy\nmonitoring5 D -\n\u00a7Denosumab alone forpain control 5 D -\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nLonger -Interval vsStandard Dosing of\nBone- Targeted Agents\n\u00a7 CALGB 70604 trial: n = 1822 patients with metastatic breast cancer , metastatic prostate cancer , ormultiple \nmyeloma , 795 completed thestudy\nSRE after 2 years : 29.5% zoledronic acid every 4 weeks\n28.6% zoledronic acid every 12 weeks\n\u00a7 OPTIMIZE -2 trial : n = 416 women with metastatic breast cancer , prior exposure to zoledronate or pamidronate\nfor approx. 1 year or more\nSRE after 1 year : 22.0% zoledronic acid every 4 weeks\n23.2% zoledronic acid every 12 weeks\n\u00a7 REaCT -BTA trial: n = 263 metastatic cancer (160 breast , 103 prostate )\nDenosumab (n = 148), zoledronate (n = 63) orpamidronate (n = 52) q4w vs. q12w\nPrimary endpoint (non -inferiority ofq12w vs. q4w in HRQoL) reached\nCumulative SSE after 1 year : 7.6% bone -targeted agent every 4 weeks\n16.6% bone -targeted agent every 12 weeks (p = 0.27)\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBone Modifying Agents for the \nTherapy of Bone Metastases\nOxford\nLoE GR AGO\n\u00a7Clodronate PO 1600 mg daily 1a A ++\n\u00a7Clodronate IV 1500 mg q3w / q4w 1a A ++\n\u00a7Pamidronate IV 90 mg\n\u00a7q3w/q4w 1a A ++\n\u00a7q12w 2b B +/-\n\u00a7Ibandronate IV 6 mg q3w / q4w 1a A ++\n\u00a7Ibandronate PO 50 mg daily 1a A ++\n\u00a7Zoledronate IV 4 mg \n\u00a7q4w 1a A +\n\u00a7q12w 1a A ++\n\u00a7Denosumab 120 mg SC\n\u00a7q4w 1a A ++\n\u00a7q12w 2b B +/-\n\u00a7Other dosing or schedules, e.g. from adjuvant studies or osteoporosis \ntherapy5 D --\n\u00a7Planned sequential therapy with multiple agents 2b B +/-\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSkeletal Metastases\nTreatment with Radionuclids\nOxford\nLoE GR AGO\n\u00a7Tumor progression after standard treatment of \nmultiple / disseminated metastases and intolerable \nbone pain1b B +\n\u00a7186Rhenium -hydroxyethyliden -diphosphonat 2b B +\n\u00a7153Samarium 1b B +\n\u00a789Strontium 1b B +\n\u00a7223Radium 2b C +\n\u00a7177Lu-EDTMP 2b C +\n\u00a7188Rhenium -HEDP 1b B +\nCave: potential benefits should be weighed against risk of myelosuppression \nwith pancytopenia\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMetastatic Bone Disease of the Spine\nIndications for surgery\n\u00a7Spinal cord compression\n\u00a7With progressive neurological symptoms\n\u00a7With pathological fractures\n\u00a7Instability of the spine\n\u00a7Lesions in pre -irradiated parts of the spineOxford LoE: 2b GR: C AGO: ++\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBone Metastases Acute Spinal\nCord Compression / Paraplegia\nOxford\nLoE GR AGO\n\u00a7Decompression surgery, reduction of tumor volume, \nstabilization surgery (< 24 h) and irradiation of the \nspine2b C ++\n\u00a7Irradiation of the spine (< 24 h)\n\u00a7Radiatiotherapy regimen (1 x 8 -10 Gy vs. multiple fractions ) \ndepending on prognosis , performance status and patient\u2018s\npreference3b C ++\n\u00a7Immediate start of treatment  1c D ++\n\u00a7Steroids (start at first symptoms) 2a C +\nClinical trials included patients with different tumor entities!\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSurgery for Bone Metastases\nTechnical Aspects\nSpine and limbs\n\u00a7Marrow splints\n\u00a7Plate osteosynthesis\n\u00a7Compound osteosynthesis (replacement by PMMA and osteosynthesis)\n\u00a7Vertebral replacement bytitanspacer\n\u00a7Tumor -Endoprothesis\n\u00a7Vertebroplasty / Kyphoplasty +/-thermoablation of the tumor\n\u00a7Kypho -IORT (in studies only )*\n\u00a7Resection of involved bone in oligometastatic disease  \n(sternum, ribs, vertebrae )Oxford LoE: 3b GR: C AGO: +\n*Study participation recommended\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMetastatic Bone Disease: \nRadiotherapy (RT)\nOxford\nLoE GR AGO\nBone metastases\n\u00a7With fracture risk 1a B ++\n\u00a7With functional impairment 1a B ++\n\u00a7With bone pain 1a B ++\nSingle dose RT = fractionated RT 2a B ++\n\u00a7With neuropathic bone pain 1b B ++\n\u00a7Asymptomatic isolated bone metastasis 5 D +/-\n\u00a7Reduction of radiation induced pain flare- up by    \ndexamethasone1b B +\n\u00a7Radiotherapy in combination with hyperthermia 2b B +/-\nLimited studies included breast cancer patients!\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMetastatic Bone Disease \nRecurrent Bone Pain after RT\nOxford\nLoE GR AGO\nRecurrent bone pain in pre -irradiated parts of skeleton\n\u00a7Single dose RT * 3b C ++\n\u00a7Fractionated RT * 3b C ++\n\u00a7Radionuclide therapy 3b C +\n\u00a7Magnetic resonance -guided focused ultrasound 1b B +\n\u00a7Radiofrequency ablation 4 C +\n\u00a7Cryoablation 4 C +\n*Dose and fractionation depending on location, interval from first RT, \nand dose and fractionation of first radiotherapy. \nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSide -Effects and Toxicity: Bisphosphonates \n(BP) and Denosumab ( Dmab )\nLoE\n\u00a7Renal function deterioration due to IV- aminobisphosphonates 1b\n\u00a7Osteonecrosis of the jaw (ONJ) mostly under IV -BP and \nDmab therapy (1.4 \u20132.8% /1.3 \u20133.2%)1b\n\u00a7Association with (simultaneous) anti -angiogenetic therapies 3b\n\u00a7Severe hypocalcemia (Dmab > BPs) 1b\n\u00a7Acute Phase Reaction (IV Amino -BPs, Dmab ) 10\u2013 30 % 1b\n\u00a7Gastrointestinal side effects (oral BPs) 2 \u201310 % 1b\n\u00a7Atypical femur fractures\n(absolute risk of 11 per 10,000 person years of BP use)2b\n\u00a7Extremely rare: Uveitis / Scleritis under BP treatment 4\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nFrequent side effects under treatment with \nBPs / Denosumab \nCave: Hypocalcemia under antiresorptive therapy in pts with bone metastases!Drug Acute\nphase -\nreactionKidney\nTox.Upper \nGIDiarrhea ONJ\nClodronate 1500 IV 0 + 0 0 0 Non-Amino.\nClodronate 1600 PO 0 0 + + 0 Non-Amino.\nIbandronate 50 mg PO 0 0 + 0 0 Aminobisph.\nIbandronate 6 mg IV + 0 0 0 + Aminobisph.\nZoledronate 4 mg IV (q4w oder q12w) + + 0 0 + Aminobisph.\nPamidronate 90 mg IV + + 0 0 + Aminobisph.\nZoledronate 4 mg IV q6m + 0 0 0 0 Aminobisph.\nDenosumab 120 mg SC q4w + 0 0 + +\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deRecommendations for Prevention of \nOsteonecrosis of the Jaw (ONJ)\n\u00a7During bisphosphonate ordenosumab treatment , avoid any elective dental \nprocedures involving jaw bone manipulations during treatment with\nbisphosphonates ordenosumab (LoE 2a, recommendation grade A )\n\u00a7Optimize dental status before start of bisphosphonate or denosumab treatment \n(LoE 2a, recommendation grade A )\n\u00a7Inform patients about ONJ risk and educate about early symptom reporting\n\u00a7In case of high risk for ONJ, use oral bisphosphonate\n\u00a7Good oral hygiene, limiting of alcohol intake and stopping smoking should be \nrecommended\n\u00a7Inadjuvant bisphosphonate therapy, ONJ was rare (<1%)Oxford LoE: 2a GR: A AGO: ++\nASORS Evaluation\nhttps://www.onkosupport.de/asors/content/e4126/e1743/e1861/e1862/e4628/LaufzettelAGSMOFarbefinal.pdf\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAdjuvant Bone Targeted Therapy for \nImprovement of Prognosis\nOxford\nLoE GR AGO\n\u00a7Clodronate (oral)\n\u00a7Postmenopausal patients 1a A +\n\u00a7Premenopausal patients 1a B +/-\n\u00a7Aminobisphosphonate (IV or oral)\n\u00a7Postmenopausal patients  1a A +\n\u00a7Premenopausal patients 1a B +/-\n\u00a7Denosumab (6 x 120 mg/3 \u20134w + 14 x 120 mg/3m)\n\u00a7Postmenopausal patients  Stage II and III 1b B -\n\u00a7Denosumab (60 mg SC q6m)\n\u00a7Postmenopausal patients undergoing AI therapy 1b B +/-\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deDosage of Adjuvant Bisphosphonates \nfor Improvement of Survival\n\u00a7Non -Aminobisphosphonates :\n\u00a7Clodronate PO1600 mg/d ( Bonefos / Clodronic acid)\n\u00a7Clodronate PO1040 mg/d ( Ostac / Clodronic acid)\n\u00a7Aminobisphosphonates :\n\u00a7Zoledronate IV4 mg/6 m ( Zometa / Zoledronic acid)\n\u00a7Ibandronate PO 50 mg/d ( Bondronat / Ibandronic acid)\n\u00a7Pamidronate PO ( orally not available in most countries )\n\u00a7Risedronate PO 35 mg/ w*(Actonel / Risedronic acid)\n\u00a7Alendronate PO 70 mg/ w(Fosamax / Alendronic acid)\n\u00a7Optimal duration yet to be defined; in adjuvant studies duration of BP treatment varied \nfrom 2 \u20135 years \nAminobisphosphonates include:\nZoledronic acid (65%), oral ibandronate (24%), oral pamidronate (8%), \noral risedronate (2%), oral alendronate (1%) (data from EBCTCG meta -analysis)\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nReduction in bone density of individual agents\n0,51377,6\n0 1 2 3 4 5 6 7 8Normal Postmenopausal womenAI in postmenopausalAI + GnRHa in premenopausalOvarian ablation after Chemo\nBone mineral density (%) \nreduction within 1 year\n(1) Kanis JA Osteoporosis 22, 1997, (2) Gnant M SABCS 2004, (3) Shapiro CL, \nJCO 19:3305, 2001\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nKyvernitakis et al Osteoporosis Int 2018\npremenopausal postmenopausalRisk of osteoporosis and tamoxifen\n(fracture risk)\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deTherapy and Prevention of Tumor \nTherapy -Induced Bone Loss / Osteoporosis\nOxford\nLoE GR AGO\n\u00a7Bisphosphonates\n\u00a7Therapy 1b B ++\n\u00a7Prevention (2\u20135 yrs) 1b A +\n\u00a7after discontinuation ofDenosumab (time -limited) 3c C +\n\u00a7Denosumab\n\u00a7Therapy 1b B ++\n\u00a7Prevention (uptomax. 3 yrs) 1b A +/-\n\u00a7Hormone replacement therapy 5 D -\n\u00a7Clinical risk assessment for osteoporosis at baseline\naccording toDVO S3 -guidelines++\n\u00a7DXA -Scan at baseline in ptswith endocrine therapy and/ or\npremature menopause5 D +\n\u00a7Antiresorptive therapy according toaccording toDVO S3 -\nguidelines++\n\u00a7Repeat DXA -scan based on risk 5 D +\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deTherapy and Prevention of Tumor Therapy -\nInduced Bone Loss / Osteoporosis\nOxford\nLoE GR AGO\n\u00a7Physical activity 4 C ++\n\u00a7Avoid immobilisation 4 C ++\n\u00a7Calcium (1000 \u20131500 mg/d)** 4 C ++\n\u00a7Vitamine D3 suppl. (800\u2013 2000 U/d or 20,000 U/w) 4 C ++\n\u00a7Stop smoking, reduction of alcohol 2b B ++\n\u00a7Avoid BMI < 20 mg/m23b C ++\n\u00a7Bisphosphonates after discontinuation of Denosumab \n(time -limited) 3c C +\n\u00a7Drugs approved for osteoporosis treatment\nin adults (see next slide)Further recommendations (based on DVO -guidelines for \ntreatment, diagnosis and prevention of osteoporosis)*\n*http://www.dv -osteologie.or g/osteoporose -leitlinien\n**if nutritional supply is insufficient (in combination with Vit D3 only)\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nEffect of Denosumab Discontinuation\nFREEDOM / FREEDOM Extension Trial\nN=1001, \u2265 2 dose of Denosumab or placebo, follow up \u2264 7 months after \ndiscontinuation treatment\nVertebral fracture rate per 100 participant year:\n1.2 during denosumab therapy\n7.1 after denosumab therapy \n8.5 placebo\nNon vertebral fracture rate per 100 participant year:\n2.8 after denosumab vs. 3.8 placebo (n.s.)\nMultiple vertebral fracture (% of all vertebral fractures): \n60.7% after denosumab therapy vs. 38.7% placebo; p=0.049\nCummings SR  et al. J Bone Miner Res  2017\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMedical Treatment ofOsteoporosis\n*Drugs tested in clinical studies with breast cancer patients and tumor therapy -induced osteoporosis\n**Elevated risk of myocardial infarction. Substance restricted to postmenopausal pts. with severe osteoporosis and high \nfracture risk.LoE GR AGO\n\u00a7Alendronate 70 mg PO/w* 1b B ++\n\u00a7Denosumab 60 mg SC/6m* 1b B ++\n\u00a7Ibandronate 150 mg PO/m* 1b B ++\n\u00a7Ibandronate 3 mg IV/3 m 1b B ++\n\u00a7Parathyroid hormone (1-84) 100 \u00b5g SC/d 1b B +\n\u00a7Raloxifene 60 mg PO/d ( improves spine only ) 1b B +/-\n\u00a7Risedronate 35 mg PO/w* 1b B ++\n\u00a7Strontium ranelate 2 g PO/d** 1b B +\n\u00a7Teriparatide (1-34) 20 \u00b5g SC/d 1b B +\n\u00a7Zoledronate 5 mg IV/12m* 1b B ++Oxford\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dehttps://www.dv -\nosteologie.org/uploads/Leitlinie%202017/DVO%20Leitlinie_\nKitteltaschenversion_16012020.pdf\nDiagram courtesy of the DVO\nOsteooncology and Bone Health\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer \nSpecific Sites of Metastases\nSpecific Sites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSpecific Sites Of Metastases\nLocal Approaches to Metastatic Disease\n\u00a7Versions 2002 \u20132020: \nAlbert / Bauerfeind / Bischoff / B\u00f6hme / Brunnert / Dall / Diel / Fehm / \nFersis / Friedrich / Friedrichs / Gerber / Hanf / Janni / Kolberg -Liedtke / \nKreipe / Loibl /  L\u00fcck / Lux / Maass / Oberhoff / Rezai /Rody / Schaller / \nSch\u00fctz / Seegenschmiedt / Solomayer / Souchon / Thomssen\n\u00a7Version 2021:\nMundhenke / Park -Simon / Thomssen\nSpecific Sites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSpecific Sites of Metastases\n\u00a7Liver and lung metastases\n\u00a7Malignant pleural and pericardial effusions \n\u00a7Ascites\n\u00a7Bone marrow involvement\n\u00a7Soft tissue metastases\n\u00a7Any other organs\nSee also chapters \u201eCNS Metastases \u201c and \u201eLocoregional Recurrence \n(Loco -Regional Recurrence Treatment Options in Non Curative Cases)\u201c\nSpecific Sites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deGeneral Treatment Aspects of Metastases\nOxford\nLoE GR AGO\n\u00a7Histological / cytological verification 3 B +\n\u00a7Systemic therapy preferred 2a B ++*\n\u00a7Consider surgery only in case of good response to \npalliative treatment, oligometastases2b C +\n\u00a7Radiation for patients in good physical condition with late onset of oligometastases3a B +\n\u00a7Local treatment in the case of pain, exulceration , persistence after systemic \ntreatment, bowel obstruction, hydrocephalus occlusus , \nspinal cord compression 5 D +/-\n\u00a7Systemic treatment after surgery 5 D ++\n*See chapters with systemic treatment recommendations\nSpecific Sites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deLocal Therapy \nin Primary Metastatic Disease\nOxford\nLoE GR AGO\n\u00a7Surgery (R0) of the primary tumor (no OS Benefit)* 1b B -\n\u00a7In case of symptoms by primary tumor 5 D +/-\n\u00a7In case of bone metastases only 2b B +/-\n\u00a7In case of visceral metastases 2b B -\n\u00a7Axillary surgery forcN1 5 D +/-\n\u00a7Sentinel if cN0 5 D -\n\u00a7Radiotherapy of the primary tumor\n\u00a7Alone (without surgery ) 3a C +/-\n\u00a7After local surgical treatment with BCS or mastectomy \n(according to adjuvant indication)3a C +\n*Individualized procedure in case ofoligometastatic disease\nSpecific Sites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nRandomized Phase III Trials\nTrial n Prior to  \nRandomizationLocal \nControlImproved OS \nPrimary EndpointQoL\nECOG -Acrin\n2108256 4-8 months\nsystemic therapyyes no ns\nTata \nMemorial \nHospital350 chemotherapy yes no -\nMF07- 01 278 no systemic therapy yes no\nin post analysis evaluation\nimproved OS (notably in \nsolitary bone mets .)-\nABCSG -28* 90 no systemic therapy yes no ns\nJCOG 1017 410 completed , results not reported so far\nnsnot significant *trial terminated due topoor recruitment\nSpecific Sites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deLiver Metastases \nLocal Therapy\nOxford\nLoE GR AGO\n\u00a7Resection of liver metastases (R0) 3a B +/-\nHR-positive: chemotherapy -sensitive, long disease -free \ninterval, absence of extrahepatic disease, \u2264 3 metastases \nHER2 -positive: age< 50y, metastasis < 5 cm, nofurther\nmetastasis\n\u00a7Regional chemotherapy 3b C +/-\n\u00a7Regional radiotherapy\n[SIRT, stereotactic body radiosurgery with volumetric\nintensity modulated arctherapy (SRS -VMAT), radiochemo -\nembolization , other modalities ]3b C +/-\n\u00a7Thermoablation\n(RFA, LITT, cryotherapy )3b C +/-\nSpecific Sites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.dePulmonary Metastases\nLocal Therapy\nOxford\nLoE GR AGO\n\u00a7Before any surgery: staging and biopsy \n(CT-guided FNA / CNB or transbronchial FNA, EBUS)3a B +\n\u00a7Resection of pulmonary metastases by VATS or conventional resection \n\u00a7In case of multi -locular metastatic disease 3a B -\n\u00a7In case of single / few unilateral metastasis\nwith curative intent 3a B +/-\n\u00a7Thermoablation (CT- guided RFA, LITT) 3b C +/-\n\u00a7Regional radiotherapy 3a B +/-\n(e.g. stereotactic body radiosurgery with volumetric intensity modulated arc therapy (SRS -VMAT))\n*VATS = video -assisted thoracic surgery\nSpecific Sites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nMalignant Pleural Effusions (MPE)\nIncidence:\n\u00a7\u223c10 % of patients with metastatic breast cancer\n\u00a7~17-30 % of all MPE are caused by breast cancer\nClinical presentation:   \n\u00a7Extensive MPE are mostly due to malignancy\n\u00a7The majority of MPE are symptomatic [dyspnea (80%), dull chest pain (30%), \nnonproductive cough (10%)] \n\u00a7Survival is related to the presence of additional metastases,age, ECOG PS and extent of involving the pleural surface\nDiagnostic procedures :\n\u00a7Clinical examination\n\u00a7Imaging techniques (chest X-Ray, US, CT -Scan)\n\u00a7Proven malignant effusion [cytology (\u2192 50% false negative), histology by thoracoscopy)\nSpecific Sites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMalignant Pleural Effusion (MPE)\nLocal Therapy\nOxford\nLoE GR AGO\n\u00a7If short life expectancy, less invasive procedures should be \nconsidered4 C ++\n\u00a7VATS and Talcum -pleurodesis * 1b B ++\n\u00a7Chemical pleurodesis *\n\u00a7 Talcum powder 1a B +\n\u00a7 Bleomycin , Doxycycline , Mitoxantrone 2b C +/-\n\u00a7 Povidone -iodine (20 ml of 10% solution) 1b B +\n\u00a7Continous pleural drainage 2a B ++\n\u00a7Systemic treatment after pleurodesis 3b C +/-\n\u00a7Serial thoracocentesis 4 C +/-\n*Adequate pain -relief\nVATS: video -assisted thoracoscopic surgery\nSpecific Sites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMalignant Ascites\nLocal Therapy\nOxford\nLoE GR AGO\nAscites :\n\u00a7Puncture, drainage in symptomatic patiens 4 D ++\n\u00a7Continous drainage of ascites 3b D +\n\u00a7Systemic therapy 3b D ++\n\u00a7Local chemotherapy 3b D +/-\nSpecific Sites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMalignant Pericardial Effusion \nLocal Therapy\nOxford\nSymptomatic pericardial effusion: LoE GR AGO\n\u00a7Drainage, fenestration 3b B ++\n\u00a7Combination with optimized systemic therapy 4 C ++\n\u00a7VATS (video -assisted thoracic surgery) 4 C +\n\u00a7Ultrasound -guided puncture and instillation of \ncytotoxic compounds\n\u00a7Bleomycin , cisplatinum, mitomycin C, mitoxantrone etc. 4 C +/-\n\u00a7Bevacizumab 4 C +/-\nSpecific Sites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deBone Marrow Infiltration\nAssociated with Pancytopenia\nOxford\nLoE GR AGO\n\u00a7Weekly chemotherapy with*:\n\u00a7Epirubicin , Doxorubicin, Paclitaxel 4 D ++\n\u00a7Capecitabine 4 D ++\n\u00a7HER2 -positive:\n\u00a7Add anti -HER2 -treatment 5 D ++\n\u00a7Hormone receptor- positive:\n\u00a7Endocrine -based therapy 4 C +\n*Consider pre -treatment\nSpecific Sites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSoft Tissue Metastasis\nLocal Therapy\nOxford\nLoE GR AGO\n\u00a7Surgery of limited locoregional metastasis \n(skin, muscular, nodal) with complete resection \n(R0) after exclusion of further metastasis 4 C +\n\u00a7Radiotherapy (after surgery or, if immediate surgery is not indicated):\n\u00a7Soft tissue metastasis 3b C +\n\u00a7Paresis, spinal cord compression 2b C ++\n\u00a7Plexus infiltration 3b C ++\nSpecific Sites of Metastases\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer \nCNS Metastases \nin Breast Cancer\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deCNS  Metastases in Breast Cancer\n\u00a7Versions 2003 \u20132020: \nBauerfeind / Bischoff / Diel / Ditsch / Fehm / Friedrich / Gerber / Huober / \nLoibl / L\u00fcck / Maass / M\u00fcller / Nitz / Jackisch / Jonat / Junkermann /    \nRody / Sch\u00fctz / Solbach / Stickeler / Witzel \n\u00a7Version 2021:\nRody / Huober\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deCNS  Metastases \nin Breast Cancer\n\u00a7Breast cancer is the 2ndmost common cause of CNS metastases\n\u00a7At autopsy:\n\u00a7Parenchymal CNS metastases: ~ 30\u2013 40% \n\u00a7Leptomeningeal CNS metastases: ~   5\u2013 16%\n\u00a7Increasing incidence (10 % \u21e840 % )\n\u00a7Increasing incidence due to \n\u00a7More effective treatment of extra -cerebral sites with improved prognosis \n\u00a7Increasing use of MRI for diagnostic evaluation\n\u00a7Lack of  specific knowledge about treatment of brain metastases in breast \ncancer since most studies are not breast cancer specific. Therefore, \nparticipation in the German registry study is recommended \n(www.gbg.de)\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deCNS Metastases in Breast Cancer\nTumour biology\n\u00a7Primary Tumor:\n\u00a7Negative hormone receptor status (basal -like cell type / triple -negative)\n\u00a7High grade, high Ki -67 index \n\u00a7HER2 and/or EGFR (HER1) overexpression\n\u00a7Molecular subtype (Luminal B, HER2 positive, triple -negative)\n\u00a7Brain metastases are more likely estrogen receptor negative \nand overexpress HER2 and/or EGFR\n\u00a7Discordance of molecular subtype between primary tumor and \nbrain metastases: for ER= 16.7%, for PR = 25.2 % and Her2 neu = \n10.4%\n\u00a7There is no evidence for BM -screening in asymptomatic BC -patients\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nDiagnosis -specific Graded Prognostic Assessment (DS -GPA) \nWorksheet to Estimate Survival from Brain Metastases (BM) \nby Diagnosis\n0 0.5 1 1.5 2 Score\nPrognostic Factor\nKPS  \u226450  60 70-80  90-100  n/a  ____  \nSubtype Basal  n/a  LumA  HER2  LumB  ____  \nAge, years  > 60  < 60  n/a  n/a  n/a  ____  \nSum total  ____  \nMedian survival byGPA: \nDS-GPA    0 -1.0  =   3.4 months\nDS-GPA 1.5 -2.0 =   7.7 months\nDS-GPA 2.5 -3.0 = 15.1 months\nDS-GPA 3.5 -4.0 = 25.3 months ; \nDS-GPA confirmed asprognostic factor\nSubtype : Basal: triple negative; LumA : ER/PR positive, HER2 negative; LumB : triple positive; HER2: \nER/PR negative, HER2 positive\nSperduto PW et al, JCO 2012;  Nagtegaal SHJ et al, Radiother Oncol 2019\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nWBRT -30-BC \u2013zur Absch\u00e4tzung des Risikos \nvon Hirnmetastasen\nCharacteristic 6-month OS rate \n(%)Scoring points\nKarnofsky performance score\n<70% 8 1\n70% 32 3\n>70% 72 7\nTime between 1.diagnosis of \nbreast cancer and WBRT\n\u226433 months 29 3\n\u226534 months 38 4\nExtra -cerebral metastatic \ndisease\nNo 53 5\nYes 28 3-Based on 170 patients \n-WBRT: whole brain radiotherapy alone\n-(30 Gy in 30 sessions)\nPrognostic \ngroupOS at 6 \nmonths (%)\n6-9 points 8\n10-12 points 41\n13-15 points 68\n16 points 100\nRegarding the PPV to identify patients who will live 6 months or longer after WBRT,  \nthe WBRT -30-BC (100%) was superior to both DS -GPA (74%) and Rades -Score (68%). Janssen S  et al, Radiol Oncol, 2019\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSingle / Solitary Brain Metastasis\nOxford\nLoE GR AGO\nLocal therapy alone: SRS (\u2264 4 cm) o. FSRT or resection 2b B ++\nResection + irradiation of the tumor bed (without WBRT) 1b B ++\nWBRT + Boost (SRS, FSRT) or resection + WBRT 2a B +\nWBRT alone\nPatients with reduced general condition and limited life expectancy2b B +\nHippocampal -sparing 2b B +/-\n\u00a7WBRT in addition to SRS/FSRT or tumor resection improves local \ncontrol and symptoms but has no survival benefit. WBRT impairs \nneurocognitive function.\nSRS = stereotactic radiosurgery (single session), FSRT = fractionated stereotactic RT; WBRT = whole brain radiotherapy, \nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deOligo -Brain Metastases\nOxford\nLoE GR AGO\nLocal therapy alone: SRS (\u2264 4 cm) or FSRT 2b B ++\nWBRT + Boost (SRS, FSRT) 2a B ++\nWBRT alone\nPatients with reduced general condition and limited life expectancy 2b B +\nHippocampal- sparing 2b C +/-\n\u00a7Maximal number of metastases treated by SRS depends on localization, size, and additional, \nfactors e.g. number of metastases, pre -treatment, Karnofsky.Index\n\u00a7WBRT in addition to SRS/FSRT improves local control and symptoms, but has no survival benefit. Additional WBRT seems to impair neurocognitive function\n\u00a7In case oflimited number ofbrain metastases , SRS/FSRT arepreferred\nSRS = stereotactic radiosurgery (single session), FSRT = fractionated stereotactic RT; WBRT = whole brain radiotherapy, \nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nStudy design:\nPatients with 1 -3 brain metastases, each < 3 cm by contrast MRI, were randomized to \nSRS alone or SRS + WBRT and underwent cognitive testing before and after treatment. \nThe primary endpoint was cognitive progression (CP) defined as decline > 1 SD from \nbaseline in any of the 6 cognitive tests at 3 months. Time to CP was estimated using cumulative incidence adjusting for survival as a competing risk.* \nConclusion:\nDecline in cognitive function, specifically immediate recall, memory and verbal fluency, \nwas more frequent with the addition of WBRT to SRS. Adjuvant WBRT did not improve \nOS despite better brain control. Initial treatment with SRS and close monitoring is recommended to better preserve cognitive function in patients with newly diagnosed \nbrain metastases that are amenable to SRS.NCCTG N0574 (Alliance): A Phase III Randomized Trial of \nWhole Brain Radiation Therapy (WBRT) in Addition to \nRadiosurgery (SRS) in Patients with 1 to 3 Brain Metastases\nBrown A, Asher AL, Ballman K, Farace E, Cerhan J, Anderson K, \net al. JAMA. 2016 Jul 26;316(4):401 -9. doi: 10.1001/jama.2016.9839*Remark: No hippocampus -sparing was applied\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\n\u00a7Only 12% of the patients had brain metastases from breast cancer.\n\u00a7Overall survival was similar in the WBRT and observation arms \n(median, 10.9 vs. 10.7 months, respectively; P = .89).\n\u00a7Intracranial progression caused death in 44% patients in the OBS \narm and in 28% patients in the WBRT arm.Adjuvant Whole -brain Radiotherapy Versus Observation After \nRadiosurgery or Surgical Resection of One to Three Cerebral \nMetastases: Results of the EORTC 22952 -26001 Study \n2-year relapse rate after whole- brain radiotherapy (WBRT) versus \nobservation after surgical resection or radiosurgery \nafter surgical resection \n(n=160)after radiosurgery \n(n=199)\nWBRT observation WBRT observation\nLocal recurrence 27% 59%\n(p<0.001)19% 31%\n(p=0.040)\nNew lesions 23% 42%\n(p=0.008)33% 48%\n(p=0.023)\nKocher M. J Clin Oncol 2011, 29:134 -141\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nFactors in favor of neurosurgery:\n\u00a7Histological verification e.g. after a long recurrence -free interval\n\u00a7Need for immediate decompression, life -threatening symptoms\n\u00a7Tumor size not allowing stereotactic radiotherapy\nFactors in favor of primary radiotherapy*:\n\u00a7Tumor location poorly amenable to surgery\n\u00a7More than four lesionsPossible Factors for Decision Making Neurosurgery \nversus Stereotactic Radiosurgery\n* stereotactic radiotherapy should bepreferred ifpossible\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deMultiple Brain Metastases \nifStereotactic Radiotherapy is not indicated\nOxford\nLoE GR AGO\n\u00a7WBRT (supportive steroids*) 1a A ++\n\u00a7Hippocampal -sparing radiotherapy 2b C +/-\n\u00a7Corticosteroids alone* 3a B +/-\n\u00a7Chemotherapy alone 3a D +/-\n\u00a7Radiochemotherapy for intracerebral control 3b C -\n\u00a7WBRT in case ofrecurrence ** 4 C +/-\n*adapted tosymptoms\n**can be discussed depending on time -interval from first radiation, prior dose, and localization if local therapy \n(surgery, SRS, FSRT) is not indicated and / or possible\nSRS = stereotactic radiosurgery\nFSRT = fractionated stereotactic radiotherapy\nWBRT = whole brain radiotherapy\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSymptomatic Therapy \nof Brain Metastases\nOxford\nLoE GR AGO\n\u00a7Anticonvulsants only if symptoms of seizures 3a C +\n\u00a7Glucocorticoids only if symptoms and / \nor mass effect (Dexamethasone with best evidence)3a C ++\n\u00a7For patients with bad prognosis and reduced physical common \nconditions best supportive care is an option5 D +\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deSystemic \nTherapy of Brain Metastases\nOxford\nLoE GR AGO\n\u00a7Chemotherapy alone as primary treatment 3a D -\n\u00a7HER2 pos.\n\u00a7Tucatinib + Trastuzumab + Capecitabine (after > 2 anti -\nHER2 -therapies)2b B +\n\u00a7T-DM1 2b B +/-\n\u00a7Lapatinib + Capecitabine 2b B +/-\n\u00a7Neratinib + Capecitabine 2b B +/-\n\u00a7Neratinib + Paclitaxel 2b B +/-\n\u00a7Continuation of the current systemic therapy if first \ndiagnosis of brain metastasis and stable extracranial \ndisease2c C +\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.de\nStudy Study type Therapy Efficacy endpoint\nHER2Climb1,\n2\nLin1\net al.\nMurthy2et \nalN=612With brain \nmet n=291\u00a7 Prospective, randomized (2:1)\n\u00a7 Basline brain MRI\n\u00a7 BM (n=291) classified as active \nor stableTuca + T + Cap (n=198)vs.\nPlac + T + Cap (n=93)\nInclusion: prior therapy with T -DM1, \nPer, TTucatinib vs Placeco:\u00a7 Median CNS -PFS: 9.9 vs 4.2 mo (HR=0.32, 95% CI 0.22 -0.48, p<0.001)\n\u00a7 Median OS: 18.1 vs 12.0 mo (HR=0.58, 95 % CI 0.40 -0.85, p=0.005)\n\u00a7 ORR -IC: 47.3 % (95 % CI 33.7 -61.2 %) vs 20.0 % (95% CI 5.7- 43.7 %), p=0.03\nEMILIA\n3\nKrop et alN=991with brain met n=95\u00a7 Retrospective, exploratory, not prespecified\n\u00a7 Pre study screening (MRI, CT)\n\u00a7 study enrollment possibel  if CNS-mets were asymptomaticT-DM1 versus L + Cap\nInclusion: PD after T , Pac\nNo prior T- DM1, L, CapT-DM1 vs L + Cap: \n\u00a7 Median PFS: 5.9 vs. 5.7 mo (HR=1.00; 95% CI 0.54 -1.84, p=1.000)\n\u00a7 Median time- to symptom -progression: 7.2 vs. 5.5 mo (HR=0.70, 95% CI 0.33 -\n1.48, p=0.338)\n\u00a7 Median OS: 26.8 vs. 12.9 mo (HR=0.38, 95% CI 0.18 -0.80, p=0.008)\nKAMILLA\n4\nMontemurro et al.N=2002\nN=398 with \nbaseline \nbrain met\u00a7 Phase IIIb, single arm\n\u00a7 Exploratory analysisT-DM1\nInclusion: \nLocally advanced/mbc\nIn pts with BM: Prior Anti -HER2 -\ntherapy (L,60% T 99%, Per 6%), and cht 99%; prior RT BM 57%)\n1line up to > 5line T-DM1\n\u2022 N=126 with measurable BM at baseline\n\u2022 CNS-ORR 21.4 % (95% CI 14.6 -29.6)\n\u2022 CBR 42.9 % (95% CI 34.1 -52.0)\n\u2022 Median PFS w or w/o BM: 5.5 (95% CI 5.3 -5.6)vs. 7.7 mo (95% CI 6.8 -8.1)\n\u2022 Median OS w or w/o BM: 18.9 (95% CI 17.1 -21.3 vs. 30.0 mo (95% CI 27.6 -31.2)\nNALA\n5\nSaura et alN=621,With brain met N=101\u00a7 Prospective, randomized (1:1)\n\u00a7 enrollment if CNS -mets were \nstable and asymptomatic\n\u00a7 Sec. Endpoint: incidence of \nCNS interventionN +Cap vs  L + Cap\nInclusion : \u2265 2 anti -HER2 therapies, 33% \nhad prior Tra,Per, T -DM1 N+Cap vs L+Cap:Cumulative incidence of CNS intervention : 22.8 % (95% CI 15.5- 30.9 %). 29.2 % (95% CI 22.5+36.1 %), p=0.043\nNEfERT -T\n6\nAwada et al.N= 479 \u2022 Exploratory not preplanned subgroup analysis  of randomized controlled trialN+Pac (n=242) vs T + Pac (n=237)\nInclusion: untreated metastatic or \nrecurrent HER2+ BC, L/T as \nadjuvant/neoadjuvant therapy allowedN+Pac vs T + Pac\n\u00a7 Incidence of CNS recurrences: RR 0.48, 95% CI 0.29 -0.79, p=0.002\n\u00a7 Time to CNS metastases: HR 0.45, 95% CI 0.26 -0.78, p=0.004\n\u00a7 2 years cumulative CNS incidence: N -Pac 10.1%; T -Pac 20.2% \nDESTINY -\nBreast01\n7\nModi et al.N= 184\nWith brain \nmet n=24\u00a7 Prospective, single arm, open \nlabel\n\u00a7 study enrollment possibel  if \nCNS-mets were stable and \nasymptomatic (n=24)Trastuzumab -Deruxtecan\nInclusion : prior therapy with T-DM1, \n66% had Per, 100% Tra, 54% other anti-\nHER2  \u2022 Trastuzumab -Deruxtecan :\n\u2022 Median CNS -PFS: 18.1 mo (95% CI 6.7 -18.1) (all patients 16.4 mo, 95% CI 12.7 -\nn.r.)\nLandscape\n8\nBachelot et al.N=45Untreated brain \nmetastasesSingle -arm, phase II L + Cap L+Cap\nObjective CNS response : 65.9 % (95% CI 50.1 -79.5)CNS-efficacy ofsystemic anti-HER2 therapy\n(T=Trastuzumab , Tuca =Tucatinib , Plac = Placebo, Cap = Capecitabine , L= Lapatinib , N=Neratinib , Pac=Paclitaxel , Per = Pertuzumab , BM = brain metastases , cht\n=chemotherapy )\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deLeptomeningeal Carcinomatosis: \nLocal Therapy\nOxford\nLoE GR AGO\nIntrathecal or  ventricular therapy\n\u00a7 MTX 10 \u201315 mg 2 \u20133x/ week (+/ -folinic acid rescue) 2b B +\n\u00a7 Liposomal  cytarabine 50 mg, q 2w * 3b C +\n\u00a7 Thiothepa 3b C +/-\n\u00a7 Steroids 4 D +/-\n\u00a7 Trastuzumab (HER2 pos. disease) 4 C +/-\nSystemic therapy 3b B +\nRadiotherapy\n\u00a7 Focal (bulky disease) 4 D +\n\u00a7 WBRT 4 D +\n\u00a7 Neuroaxis  (disseminated spinal lesions ) 4 D +/-\nDue to poor prognosis ,consider best supportive care, especially in  patients with poor performance status\n*Currently not available\nCNS Metastases in Breast Cancer\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer \nComplementary Therapy \nSurvivorship\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deComplementary Therapy \u2013Hormonal Treatment and \nAlternatives in Breast Cancer Survivors \u2013Survivorship\n\u00a7Versions 2002 \u20132020: \nAlbert / Bauerfeind / Blohmer / Fersis / Friedrich / Gerber / G\u00f6hring\n/ Hanf / Janni / K\u00fcmmel / L\u00fcck / von Minckwitz / Nitz / Oberhoff / \nRhiem / Scharl / Schmidt /  Sch\u00fctz / Thomssen /K\u00fcmmel / Sch\u00fctz\n\u00a7Version 2021:\nDall / Solomayer\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deUCT\nUnconventional Tx\nComplementary\nIn addition to \nscientifically \nbased medicineAlternative\nInstead of\nscientifically \nbased medicineCAM\nComplementary + alternative medicine\nUnconventional\nUnproven outsider\nmethods\u201eIntegrative Oncology\u201c \u201eUnconventional \nmethods\u201cCAM \nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deGood clinical practice\nS3 LL \u201c Komplement \u00e4rmedizin in der Behandlung von onkologischen PatientInnen\u201c\u00a7All patients should be asked as early as \npossible and repeatedly during the course of \nthe process regarding the interest in \ninformation complementary medical measures \nand, if interested, reliable sources of \ninformation should be referred.\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deGeneral Considerations\nOxford\nLoE GR AGO\n\u00a7CAM instead of loco- regional interventions 2b B --\n\u00a7CAM instead of systemic treatment 2b B --\n\u00a7Patients should be asked and advised about their \nuse of CAM modalities\n\u00a7Diagnostic procedures in connection with \ncomplementary and alternative therapy concepts \nwithout evidence (e.g. iris diagnostics, \nbioresonance) should not be recommended.\n\u00a7During an9 -cancer treatment: Beware of drug \ninteracZons\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deComplementary Therapy\nPre-and Postoperative\nOxford\nLoE GR AGO\nPreoperative:\n\u00a7 Hypnosis (reduces anxiety , pain, nausea ) 1b B +\nPostoperative:\n\u00a7 Acupuncture ( pain relief, anxiety) 1b B +/-\n\u00a7 Acupuncture ( nausea, vomiting ) 2b B +\n\u00a7 Massage therapy (pain relief) 2b C +/-\n\u00a7 Early postoperative exercise reduces upper -limb dysfunction \n(beware: increased wound drainage )     1a A +\n\u00a7 Physical exercise\n\u00a7 toreduce breast cancer related secondary lymphedema 1a A +\n\u00a7 asa prophylaxis oflymp edema 1b B +/-\n\u00a7 Prophylactic lymphatic drainage 1b B --\n\u00a7 Yoga (arm and shoulder pain) 2b C +\n\u00a7 Music therapy (reduces pain after mastectomy ) 2b C +/-\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deComplementary Treatment\nWhile on Cancer Treatment \u2013Impact on Toxicity I\nDuring anti -cancer treatment: Beware of drug interactions Oxford\nLoE GR AGO\n\u00a7 Mistletoe (Viscum album ) \nin order to reduce side effects 1a B +/-\n\u00a7 Thymic peptides\nlower risk of severe infections2a B +/-\n\u00a7 Ginseng\nin order to reduce cancer related fatigue; note: interacts with cytochrome P enzymes e.g. CYP 3A42b C -\n\u00a7 Ganoderma Lucidum\nmay improve fatigue, note: inhibits cytochrome P \nenzymes (e.g. CYP 3A4)2b C -\n\u00a7 L-Carnitine\n\u00a7 given for prevention of toxicity; however, increased chemotherapy -induced peripheral  \nneuropathy\n\u00a7 Improvement of cancer related fatigue1b\n1bBB--\n-\n\u00a7 Curcuminadjunct to reduce radiation -induced dermatitis1b B +/-\n\u00a7 Gingeradjunct to guideline -oriented medication to treat chemotherapy induced nausea & vomiting \u2013\nbeware of drug interactions1b C +/-\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deComplementary Treatment\nWhile on Cancer Treatment \u2013Impact on Toxicity II\nOxford\nLoE GR AGO\n\u00a7 Antioxidant supplements 1b B -\n\u00a7 various antioxidative extracts toreduce anthracyclin -\ninduced cardiotoxicity2b B +/-\n\u00a7 High dose vitamine C 1b C -\n\u00a7 Vitamine E 2b D -\n\u00a7 Selenium for alleviating therapy side effects 1b B -\n\u00a7 Co-Enzyme Q 10 ( fatique, QoL) 1b B -\n\u00a7 Proteolytic enzymes for reduction of chemotherapy- induced toxicity 3b B -\n\u00a7 Chinese herbal medicine improves wound healing 1b B -*inf\n\u00a7 Oxygen and ozone therapy 5 D --\n\u00a7 Short -term fasting (Qol , Fatigue ) 3b C +/-*\ninf: i.v. -infusion (in Germany not approved) \n*treatment in clinical trials recommended\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAdditional Complementary Therapy \nof Side Effects Related to Cancer Treatments\nOxford\nLoE GR AGO\n\u00a7Chinese medicinal herbs to treat the chemotherapy side effects \nin breast cancer patients1b B -\n\u00a7Homoeopathic medicine against therapy side effects 1b B +/-\n\u00a7Topical Silymarin for prophylaxis of acute dermatitis during radiotherapy3a B +/-\n\u00a7Massage toimprove on fatigue , pain , anxiety , nausea 1b C +/-\n\u00a7Transcutaneous Electrical Nerve stimulation (TENS) against cancer pain\n\u00a7Hydrotherapy 2b\n3bD\nC+/-\n+/-\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deAdditional Complementary Therapy \nof Side Effects Related to Cancer Treatments\nOxford\nLoE GR AGO\nAcupuncture in order to improve on\n\u00a7Chemotherapy -induced nausea andvomiting\n\u00a7(Electro) -Acupuncture asadjunct toentiemetic treatment 1b B +\n\u00a7Acupressure asadjunct toentiemetic treatment 1b B +\n\u00a7Pain\n\u00a7Cancer pain 1b B +\n\u00a7Aromatase -inhibitor \u2013induced athralgia 1a B +\n\u00a7TENS \u2013Transcutaneous Electrical Nerve Stimulations torelieve cancer\npain2b D +/-\n\u00a7Fatigue 1a B +\n\u00a7 Acupressure 1b B +\n\u00a7Anxiety anddepression 2b B +\n\u00a7Cognitive dysfunction 5 D +/-\n\u00a7Menopause syndrome in Breast Cancer Patients 1b B +\n\u00a7toimprove on frequency andseverity ofhotflashes 1b B +/-\n\u00a7Electro- Acupuncture toimprove on sleep andhotflashes 2a B +\n\u00a7Leucopenia (Moxibustion ) 2b B +/-\n\u00a7Treatment of chemotherapy induced polyneuropathy\n\u00a7prophylactic 1b B -\n\u00a7therapeutic 2b B +/-\n\u00a7Chronic lymph edema after Breast Cancer Treatment 2b B +/-\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deComplementary Treatment \nMind -Body Medicine I\nOxford\nLoE GR AGO\nMBSR (Mindfulness -Based Stress Reduction) 1a A +\nProgram improves quality of life, coping strategies, \nattentiveness, and lowers stress, anxiety, depression, \nfatigue, and sleep disturbances\nPhysical exercise / sport\nmin. 3x/week moderate endurance training in \ncombination with workout exercises (2x per week)\nimprove quality of life, cardio -respiratory fitness, \nphysical performance, sleep, pain, depression, \nlymphedema, and fatigue1a A ++\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deComplementary Treatment \nMind -Body Medicine II\nLoE GR AGO\nRelaxation technieques\nReduction of anxiety and nausea, improvement of quality of life, \nreduction of psychological stress2b C +/-\nYoga\nImproves sleep, quality of life, stress, anxiety, \ndepression, fatigue, and sleep1b A +\nQi Gong\nMay improve quality of life, fatigue, and mood2a B +/-\nTai Chi\nImproves quality of life, muscular strength, sleep2a B +/-\nHypnosis (in combination with cognitive training)\nImproves fatigue and muscle weakness under radiotherapy; also \nreduces distress 1b A +Oxford\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deCAM\nPrevention of Recurrence/Improvement of Overall Survival I\nModifiable Lifestyle Factors\nOxford\nLoE GR AGO\n\u00a7Physical exercise 2a A ++\n(equivalent to 3 \u20135 hrs moderate walking per week) \nimproves DFS and OS, cardio -respiratory fitness, \nphysical functioning\n\u00a7Reduce Smoking 2b A +\n\u00a7Reduce Alcohol consumption (< 6 g/day) 2b A +\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deModifiable Lifestyle Factors\nNutrition after Breast Cancer Diagnosis \nPrevention of Recurrence / Improvement of Overall Survival  II\nOxford\nLoE GR AGO\n\u00a7Adherence to normal BMI / weight loss\nif overweight, irrespective of HR -status1a A ++\n\u00a7Low fat dietdietary counseling recommended1a B +\n\u00a7Increased fiber intake (e.g. Flaxseed) 2a B +\n\u00a7Adherence to general nutrition guidelines (e.g. DGE, WCRF) similar to a Mediterranean Diet2a B ++\n\u00a7Dietary extremes 2a B --\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deComplementary Treatment\nPrevention of Recurrence / Improvement of Overall Survival III\nDietary Supplements \u2013Herbal Therapies\nLoE GR AGO\nPost treatment vitamin/antioxidant supplements does n ot appear to be associated with increased risk \nof recurrence (beware of drug/treatment interactions)2b B\nSmokers on antioxidant supplements are at higher risk for lung cancer 1b A\nFor Prevention of BC Recurrence:\n\u00a7 Antioxidants 2a B +/-\n\u00a7 Vitamine supplementation in patients on a balanced diet (esp. Vit C, E, D) 2a B +/-\n\u00a7 Soy-food (natural source of phytoestrogenes) 2a B +/-\n- food or concentrates containing \u2265 100 mg) isoflavones per day 2a B -\n\u00a7 Black Cohosh (Cimicifuga racemosa) 3b C +/-\n\u00a7 Antioxidant supplements (after completion of radiotherapy) 2b B +/-\n\u00a7 Green tea 3a C +/-\n\u00a7 Orthomolecular substances (Selenium, Zinc...) 5 D -\n\u00a7 Artificial carotenoids appear to be associated with worse outcome 2b B -\n\u00a7 Proteolytic enzymes (Papain, Trypsin, Chymotrypsin) 3b B -\n\u00a7 Mistletoe (Viscum album) 1b C -\n\u00a7 Thymic peptides (impact on OS) 2a B -\n\u00a7 Oxygen -and ozone therapy  5 D --\n\u00a7 Laetrile 1c D --\n\u00a7 Methadone 5 D --\n\u00a7 Cancer bush (Sutherlandia frutescens), \nDevil's claw (Harpagophytum procumbens),\nRooibos tea (Aspalathus linearis),\nBambara groundnut (Vignea subterranean)  5 D -\n\u00a7 Incense 5 D -Oxford\nComplementary Therapy Survivorship\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer \nGynecological Issues in \nBreast Cancer Patients\nGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deGynecologic Issues in \nBreast Cancer Patients\n\u00a7Versions 2015 \u20132020: \nAlbert / Bauerfeind / Blohmer / Fersis / Gerber / Hanf / Huober / \nLoibl  / Maas / Rody / Scharl / Thill / Witzel\n\u00a7Version 2021:\nReimer / Thomssen\nGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deHormone (Replacement) Therapy (HT) of Estrogen \nDeficiency after Diagnosis of Breast Cancer\nOxford\nLoE GR AGO\nSystemic hormone (replacement -) therapy\n\u00a7Endocrine responsive disease (ER pos.) 1b B -\n\u00a7Combin edtreatment TAM plus low dose HT 2b B +/-\n\u00a7Endocrine non- responsive disease (ERneg.) 2b D +/-\n\u00a7Tibolone 1b A --\nTopical vaginal application of\n\u00a7Estriol (E3 0.03 mg as treatment course*) 2b B +/-\n\u00a7DHEA locally 2b B -\n\u00a7Testosterone locally 2b B -\n\u00a7Estradiol (E2) during AI therapy 4 C -\n*4 weeks daily 1 x 1, followed by8 weeks 3 x 1 per week \u2013Note:. Elevated E3-blood levels only with start oftherapy ; \noncological endpoints were not studied . Non -hormonal alternatives should bepreferred, seeslide \u201eSexual Health \u201c\nGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deFurther Medical Approaches to Reduce \nMenopausal Symptoms I\nMedical approaches* (reduction of hot flushes)Oxford\nLoE GR AGO\n\u00a7Selective serotonin reuptake inhibitors and serotonin -(noradrenalin) \nreuptake inhibitors (SSRI- SNRI): reduce hot flashes in BC patients\n\u00a7 Venlafaxine 1a A +\n\u00a7 Desvenlafaxine 1b A +/-\n\u00a7 Sertraline, escitalopram 1b A +/-\n\u00a7Gabapentin (patients using TAM) 1a A +\n\u00a7Oxybutynine (2.5 mg/5 mg) 1b A +/-\n\u00a7Pregabalin 1b A +/-\n\u00a7Clonidine 0.05- 0.15 mg/die (patients using TAM) 2a B +/-\n\u00a7MPA (i.m. 500 mg single shot) (most potent, but endocrine agent!) 1b A +/-\n\u00a7Vitamin E 1b A -\n\u00a7Omega -3 fatty acids 1b A +/-\nMedical approaches (other treatment goals )\n\u00a7Melatonin (improvement in sleep quality) 2b C +\n\u00a7Duloxetine (treating arthralgias while on AI) 1b B +\n*Note: Substantial placebo -effect hasbeen proven (23-57%) LoE1b A +\nGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deCAM* -Approaches to \nReduce Menopausal Symptoms II\n* Complementary and Alternative Medicine\nDuring anti -cancer treatment: Beware of drug interactions!Oxford\nLoE GR AGO\n\u00a7 Soy-derived phytoestrogens \u2013isoflavonoids * \nHot flushes\nSleep disturbance\nTopical vaginal application1b\n1b\n1bB\nB\nB-\n+/-\n+/-\n\u00a7 Red Clover isoflavonoids *\nHot flushes, sleep disturbance 1b B +/-\n\u00a7 Flaxseed -supplementation (40 g/d)  (in HR+ \u2264 10 g/d)\n(reduces relapses, no effect on hot flashes)2b B +/-\n\u00a7 Black Cohosh for hot flushes\n\u00a7 Black cohosh + St. John's Wort (fixed combination )1b\n1bB\nB+/-\n+/-\n\u00a7 St. John\u2018s Wort\n(pharmacokinetic interference with endocrine therapy , cyctotoxic drugs , \nand tyrosin kinase inhibitors ) 1b B +/-\n\u00a7 Ginseng root (Panax ginseng orP.  quinquefolius ) 1b B -\n\u00a7 Bromelain + Papain + Selenium + Lectin (for AI induced joint symptoms) 3b B +\n\u00a7 Homeopathic medicine toreduce hotflushes (consider placebo -effect ) 1b B +/-\n* might stimulate BC, especially in endocrine responsive disease \nGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deGeneral Approaches  to Reduce Menopausal \nSymptoms III -Integrative Oncology Aspects\nGeneral approaches:Oxford\nLoE GR AGO\n\u00a7Physical exercise 1A A ++\n\u00a7Cognitive behavioral therapy (CBT), hypnosis 1a A ++\n\u00a7Mind body -medicine\n(yoga , education, counselling , mindfulness training )1b B +\n(Electro) Acupuncture\n\u00a7Aromatase -inhibitor treatment induced arthralgia 1b B +\n\u00a7Hot flushes 1a B +/-\n\u00a7Depression 2b B +/-\n\u00a7Anxiety , Sleep 3b C +/-\nGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deOvarian Protection and Fertility Preservation in Premenopausal Patients \nReceiving (Neo)-Adjuvant Chemotherapy (CT) \nOxford\nLoE GR AGO\n\u00a7Fertility preservation counselling including \nreferral of all potential patients to appropriate \nreproductive specialists (further information        \nhttps://fertiprotekt.com/english )++\n\u00a7CTx+ GnRHa\n(preservation of ovarian function)\n(GnRHa application > 2 weeks prior to chemo -\ntherapy, independent of hormone receptor status )1a A +\n\u00a7CTx+ GnRHa\n(preservation of fertility )1b A +/-\nGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deOvarian Protection \u2013\nSynopsis ofRandomized Trials\nZORO PROMISE Munster et al. -US POEMS Option\nPatient number 60 (60 HR -) 281 (50 HR -) 49 (13 HR -) of124 218 (218 HR -) 227 (126 HR -)\nAge median 38 years 39 years 39 years Premenop . < 50 years premenopausal\nTreatment goserelin triptorelin triptorelin goserelin goserelin\nStart of treatment >2 weeks prior to cht >1 week prior to cht > 1 week prior to cht > 1 week prior tocht > 1 week prior tocht\nPrimary Endpoint menstruation at \nmonth 6 \nafter chemotherapyrate of early menopause at \nmonth 12 after chtmenstruationrate within 2 years\nafter chtOvarian failure at \n2 yrs after chtAmenorrhea with elevated\nFSH levels between 12 and\n24 months\nPrimary objective to detect 30% absolute increase \nof menstruation \nrateto detect at least 20% \nabsolute reduction in \nearly menopausetodetect 20% difference in \namenorrhea rate \u2013from 10% \nto30%To detect 20% -25% absolute \nreduction in earlymenopause\nMultivar. analysis age as only independent \npredictive factortreatment as only \nindependent predictive \nfactorn.d. Treatment asonly\nIndependent predictive factorAge, total \ncyclophosphamide dose and\nbaseline AMH\nResumption of menses at month \n1283% with LHRH vs. \n80% w/o93% with LHRHa vs. \n74% w/o74% with LHRH vs. \n68% w/o78% with LHRH vs. \n75% w/o; at 2 years ; \n22% with LHRH vs. 8%78% with LHRHa vs. 62% \namnorrhea rate between\nmonth 12 and 24\nMedian time to \nrestoration of \nmenses (months)6.1 with LHRHa vs. \n6.8 w/o; p=0.30not reached with LHRH \nvs. 6.7 w/o; p=0.075.8 with LHRH vs. \n5.0 w/o; p=0.58n.d. n.d.\nCyclophosph . dose 4600 vs. 4700mg 4080 vs. 4008 mg n.r. n.a. 5940 vs. 5940mg\nGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deAssessment of Ovarian Reserve \nOxford\nLoE GR AGO\nTests forfertility assessment\n\u00a7Anti -Mullerian Hormone 1b B +\n\u00a7Antral follicle count 3b B +\n\u00a7FSH 2ba B +\n\u00a7Combined test procedures for assessment of ovarian \nreserve*5 C +\n*Tests are suggested for women > 35y and infertility for 6 -12 months; the tests do not predict failure to conceive. \nThey should be used in counselling patients and to provide a rough estimate of the fertility window. Results may \ndecrease patient referral time to infertility centers.\nGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deContraceptive Options for Women \nafter Diagnosis of  Breast Cancer\nOxford\nLoE GR AGO\n\u00a7Barrier methods 5 D +\n\u00a7Sterilization (tubal ligation/salpingectomy/vasectomy) 5 D +\n\u00a7Non -hormonal intrauterine devices (IUDs) 3b D +\n\u00a7Levonorgestrel -releasing IUDs 2b C -\n\u00a7Removal in newly diagnosed patients 4 D +/-\n\u00a7Timing methods 5 D -\n\u00a7Injectable progestin -only contraceptives 5 D -\n\u00a7Progestin -only oral contraceptives 5 D -\n\u00a7Combined oral contraceptives 5 D -\n\u00a7Options of emergency contraception\n\u00a7Copper intrauterine device (Copper -IUD) 5 D +\n\u00a7Levonorgestrel, Ulipristal orally 5 D +\nGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deSexual Health / Vaginal Dryness\nEvaluationOxford\nLoE GR AGO\n\u00a7Assessment of sexual dysfunction 5 D +\n\u00a7Use of patient -reported questionnaires 4 C +\nTherapy of dyspareunia and v aginal dryness\n\u00a7Psychoeducational support, group therapy, sexual counselling, \nmarital counselling, psychotherapy1b B +\n\u00a7Topical vaginal treatment\n\u00a7Non -hormonal lubricants /moisturizers (also with physiotherapy) 1b B +\n\u00a7Estriol (E3 0.03 mg as treatment course*) 2b B +/-\n\u00a7DHEA local application 2b B -\n\u00a7Testosterone local application 2b B -\n\u00a7Estradiol (E2) during AI therapy 4 C -\n\u00a7Fractionated microablative CO2 -Laser/Vaginal Erbium:YAG -Laser 2a B +/-\n*4 weeks daily 1 x 1, followed by8 weeks 3 x 1 per week \u2013Note:. Elevated E3-blood levels only with start oftherapy ; \noncological endpoints were not studied . Non -hormonal alternatives should bepreferred.\nGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deAssessment of Sexual Health\n\u00a7Brief Sexual Symptom Checklist (BSSC -W)ref2\n\u00a7Screening -Questionnaire : Overall Sexual Function\n1.Are you satisfied with your sexual life? Yes -No\nIfNO, please continue toquestion 2\n2. How long have you been dissatisfied with your sexual life? \u2026\u2026\u2026\u2026\n3. The problem(s) with your sexual life is: (mark one or more)\n1.Problem with little or no interest in sex 0\n2.Problem with decreased genital sensation of clitoris or vagina (feeling) 0\n3.Problem with decreased vaginal lubrication (dryness) 0\n4.Problem reaching orgasm 0\n5.Problem with pain and/or cramping during sex 0\n6.Other \u2026\u2026\u2026.\n4.Which problem is most bothersome? 1 \u20132 \u20133 \u20134 \u20135 \u20136  (circle) \n5.Would you like to talk about it with your doctor? Yes \u2013No\n\u00a7Sexual Complaints Screener For Women (SCS -W)ref3\n\u00a7FSFI-19, FSFI -6ref5\nGynecological Issues in Breast Cancer Patients\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deDiagnosis and Treatment of Patients \nwith early and advanced Breast Cancer \nHealth literacy and communication\nHealth literacy and communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deHealth literacy\n\u00a7First Version 2020:\nRhiem / Schmidt\n\u00a7Version 2021: \nBauerfeind / Sch\u00fctz\nHealth literacy and communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deHealth literacy\nDefinition\n\u201cHealth literacy is linked to literacy and entails \npeople\u2019s knowledge, motivation and competences \nto access, understand, appraise, and apply health \ninformation\nin order to make judgments and take decisions in \neveryday life concerning healthcare, disease \nprevention and health promotion to maintain or \nimprove quality of life during the life course.\u201d\nS\u00d8rensen etal.,(2012)\nHealth literacy and communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deHealth literacy model\n(according to S\u00f6rensen)\nS\u00f8rensen K, Van den Broucke S, Fullam J, Doyle G, Pelikan J, Slonska Z, Brand H. Health \nliteracy and public health: A systematic review and integration of definitions and models. \nBMC Public Health. 2012, 12:80\nCompetencies\nAccess: seek , find, obtain\nhealth information .\nUnderstand : \nUnderstanding the health\ninformation received\nAppraise : Interpret, select , \nassess , review health\ninformationApply : Use health\ninformation tomake\ndecisions that support and\nimprove health\nHealth literacy and communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deHealth literacy\n\u00a7The more developed health literacy is, thebetter a person caninform himself or\nherself about health (e.g. prevention , therapy ) in everyday life, form an opinion\nand make self-determined decisions that maintain orimprove thequality oflife\nand health throughout theself-determined course oflife.\n\u00a7However , theextent ofhealth literacy ofa person depends not only on hisorher \nindividual prerequisites and acquired competencies , but especially on the\nprofessional quality , appropriateness , comprehensibility , form of\ncommunication and availability oftheinformation provided . \nHealth literacy and communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deHealth literacy\nUser participation\nReasons cited foroveruse , underuse and misuse in thehealth care system\ninclude theweak position ofpatients (SVR 2001).\nIn thecontext ofhealth literacy , thepatient is\n\u00a7More autonomous actor and co-designer \n\u00a7The one who takes responsibility and an active role in medical decisions\n\u00a7theperson who extracts theindividually relevant meaning from\nprofessionally offered information and behaves in accordance with\nindividual ideas about certain health situations\nSVR -Council of Experts for the Assessment of Developments in the Health Care System\nHealth literacy and communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deHealth literacy\nCommunication\nOxford\nLoE AGO\n3a +Aim ofa physician -patient communication : enable a self-\ndetermined decision based on sufficient health competence\nDoctor -patient communication iskeyforacquiring health competence . Itis\nthebasis forsuccessful oncological treatment and support . Core elements\nare, forexample :\n\u00a7Non -directive communication -i.e. those seeking advice have the right to \nchoose their own goals in life, even if they contradict generally accepted, \neven evidence -based, recommendations after well- founded consideration.\n\u00a7Comprehensible communication -i.e. geared to the level of knowledge, \nreception habits, competence requirements and preferences of the \ndifferent patients. \nHealth literacy and communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deHealth literacy\nBasic principles of communication\n\u00a7Communicate information truthfully and empathetically\n\u00a7Impart medical evidence -based knowledge\n\u00a7Critical debate ofpseude -scientific recommendations\n\u00a7Active listening\n\u00a7Showing empathy\n\u00a7actively listening and expressing empathy\n\u00a7Find out ifand how thepatient wants tobeinformed about his/her situation\n\u00a7useunderstandable language avoiding orexplaining technical terms\n\u00a7Continuously improve understanding through e.g. repetitions , breaks , summary , \ncomprehensible information material\n\u00a7Encourage asking questions and expressing feelings\n\u00a7Identifying individual stresses , problems and needs\n\u00a7Motivating self-determination and personal activities (\"empowerment \")\n\u00a7Giving hope forhealing and relief\n\u00a7Offer further assistance (e.g. psycho -oncology , self-help)\nHealth literacy and communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deHealth literacy\nevidence -based information\nEvidence -based information in health care should beused toanswer patients ' questions in \nan understandable way. They arebased on the current state ofknowledge and arefree from\ninfluence :\nrequirement forevidence -based health information asa discremination against pseude -scientific\nrecommendations :\n\u00a7The information on services orproducts may not beused directly orindirectly formarketing purposes .\n\u00a7The systematic search corresponds tothequestions relevant tothetarget group .\n\u00a7The selection ofevidence suitable fortheresearch question isjustified .\n\u00a7An undistorted presentation oftheresults relevant tothepatients (e.g. mortality , complaints , complications , health -\nrelated QoL) isavailable .\n\u00a7The presentation ofuncertainties isappropriate in terms ofcontent and language .\n\u00a7The presentation ofresults isclearly separated from thederivation ofrecommendations .\n\u00a7Consideration ofcurrent evidence tocommunicate figures , risk information and probabilities . \n\u00a7there must besufficient time forthedecision .\n\u00a7The possibility that themeasure may berefused must not bea reason forwithholding information . \nHealth literacy and communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deOxford\nLoE\n\u00a7Reduction of fear 2b\n\u00a7Trust in treating oncologists is increased 2b\n\u00a7Treatment satisfaction is increased 2a\n\u00a7Therapy adherence is increased 2a\n\u00a7Decision making is improved 2a\n\u00a7Mental complaints are improved 2aHealth literacy\nCommunication\nNon -directive and evidence -based doctor -patient communication geared to \nthe current needs, values, problems, resources and preferences of patients \nhas beneficial effects.\nHealth literacy and communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deOxford\nLoE AGO\nQualified training measures can help to promote \ncommunicative skills.+\ncommunication training for doctors  can e.g.\n\u00a7Enhance empathy 2a\n\u00a7Extend and enrich communication skills 2a\n\u00a7Increase patient satisfaction (information, \nsupport, consideration of concerns)2b\n\u00a7Improve transmission ofinformation 2bHealth literacy\nCommunication\nHealth literacy and communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deHealth literacy\nshared decision making -participatory decision\nOxford\nLoE GR AGO\n\u00a7Patients want to be integrated actively into \ndecision making and open discussions about \nprognosis, treatment options, and quality of life1b A\n\u00a7Doctors should motivate patients to ask \nquestions, demand clarification, express \nemotions, opinions, and preferences3b C +\nHealth literacy and communication\u00a9 AGO e. V.\nin theDGGG e.V. \nand\nin theDKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago- online.deHealth competence\nDecision support forpatients\nOxford\nLoE AGO\nThe use of decision support in the physician -patient \ncommunication +\n\u00a7 improves knowledge about treatment options 1a\n\u00a7 reduces the decision conflict 1a\n\u00a7 improves the level of information 1a\n\u00a7 increases the feeling about the clarity of personal values 1a\n\u00a7 encourages a more active role in decision -making 2b\n\u00a7 improves risk perception 2b\n\u00a7 improves the match between the chosen option and the patient's \nvalues3a\nHealth literacy and communication\u00a9 AGO e. V.\nin der DGGG e.V. \nsowie \nin der DKG e.V.\nGuidelines Breast\nVersion 2021.1E\nwww.ago-online.deDiagnosis and Treatment of Patients \nwith Early and Advanced Breast Cancer\nTherapy algorithms\nPreamble:\nTherapy options shown in the algorithms are based on the current AGO \nrecommendations, but cannot represent all evidence -based treatment options, since \nprior therapies, performance status, comorbidities, patient preference, etc. must be \ntaken into account for the actual treatment choice. In individual cases, other \nevidence- based treatment options (not listed here) may also be appropriate and \njustified.\nRegardless of approval status, the algorithms only take into account drugs that were \navailable in Germany at the time the algorithm was last updated. \nTherapy algorit hms\u00a9 AGO e. V.in der DGGG e.V. sowie in der DKG e.V.Guidelines BreastVersion 2021.1E\nwww.ago-online.deTherapyAlgorithms\u00a7Version 2021: Schneeweiss / Bauerfeind / Fehm / M\u00fcller / Thomssen / Witzel / W\u00f6ckel / Janni\u00a7Format legend:\u00a7Definitions, features, parameters\u00a7Therapy with grade of recommendation AGO+ or AGO++\u00a7Therapy with grade of recommendation AGO+/-(case by case decision)\u00a7Recommended path with grade of recommendation AGO+ oder AGO++\u00a7Path of case by case decision (grade of recommendation AGO+/-)\u00a7Arrow points to the next therapy option at progression\u00a7AGO grade of recommendationof thispath\nAGO++TextTextText\n\u00a9 AGO e. V.in der DGGG e.V. sowie in der DKG e.V.Guidelines BreastVersion 2021.1E\nwww.ago-online.deContent\u25aaeBC\u25aa(Neo)adjuvant therapyof HER2-positive breastcancer\u25aaAxillary surgery and neoadjuvant chemotherapy (NACT)\u25aaAdjuvant endocrine therapy in premenopausal patients\u25aaAdjuvant endocrine therapy in postmenopausal patients\u25aamBC\u25aaHR-positive/HER2-negative metastatic breast cancer: strategies\u25aaHR-positive/HER2-negative metastatic breast cancer: endocrine-based first line treatment\u25aaHER2-positive metastatic  breast cancer: 1st-3rd-line\u25aaTriple-negative metastatic breast cancer\u00a9 AGO e. V.in der DGGG e.V. sowie in der DKG e.V.Guidelines BreastVersion 2021.1E\nwww.ago-online.de(Neo)adjuvant Therapy of HER2-positive Breast Cancer\nCNB, core needle biopsy; HR, hormone receptor; Nx, Neratinib; pCR, pathological complete response; Pz, Pertuzumab; q3w, every 3 weeks; T-DM1, Trastuzumab emtansine; Tz, Trastuzumab; y, yearcT1 andcN0SurgerypT1 andpN0pT\u2265 2 orpN+Tz  + paclitaxel(Tz for 1y)2Tz-basedregimen(Tz for 1y)3,4PzTz-basedregimen(PzTzfor 1y)6,7pN0pN+cT\u2265 2 orpNCNB+PzTz-basedregimen(6-8 cycles)1,10pCR(ypT0/isandypN0)Tz to complete1y814 x T-DM1 q3w9SurgerypCR andcN0pCR andpNCNB+PzTzto complete1ynon-pCR\nNx1y(onlyHR+)5Tz + paclitaxel\nAGO+AGO++AGO+\nAGO+AGO+/-AGO++AGO+/-AGO+\nAGO++AGO+AGO+\u00a9 AGO e. V.in der DGGG e.V. sowie in der DKG e.V.Guidelines BreastVersion 2021.1D\nwww.ago-online.de\nALND, axillarylymphnodedissection; CNB,  coreneedlebiopsy; NACT, neoadjuvantchemotherapy; SN, sentinalnode; SLNE, sentinellymphnodeexcision; TAD , targetedaxillarydissection(SLNE + TLNE); TLNE, targetedlymphnodeexcision; ; * participationin AXSANA study recommended; **for radiotherapy procedures see recommendations for radiotherapypNCNB++ taggingthebiospsiednode(s)*cN+ypN1micsnypN0(i+)snypN0snNofurtherinterventionALNDNofurtherintervention**ALNDALND\nycN0 ycN+ AGO++AGO+/-AGO+/-AGO++AGO++AGO+\nAGO+SLNEcN0\nNACT\nAGO+/-NACTypN1sn\nNofurtherintervention**\nAGO+/-Nofurtherintervention**ALNDALNDALNDALNDNofurtherintervention**ypN0(i+)snypN+snypN0snypN0 ypN+ ypN0(i+) ALNDNofurtherintervention**TAD*SLNE*\nAGO+/-AGO+/-AGO+/-AGO+AGO+AGO+\nAGO+/-\nAGO+\nAGO+\nAGO++\nAGO+AxillarySurgeryand Neoadjuvant Chemotherapy(NACT)  \u00a9 AGO e. V.in der DGGG e.V. sowie in der DKG e.V.Guidelines BreastVersion 2021.1E\nwww.ago-online.deAdjuvant Endocrine Therapy in Premenopausal Patients\nAI, aromatase inhibitor; OFS, ovarian function suppression; Tam, tamoxifen; y, years Pre-orperimenopausalHigher riskfor recurrence*NoTam for 5y1\nYes\nAGO++Tam plus OFS** for2-5y3AGO++AGO+AIplus OFSfor 5y3,4ContinueTam for 5y2AGO+AGO+\n* Administration of chemotherapy was a surrogate marker for higher risk of recurrence in clinical trials ** OFS also in case of remaining or recurring ovarian function within 24 months after chemotherapy induced amenorrhea\u00a9 AGO e. V.in der DGGG e.V. sowie in der DKG e.V.Guidelines BreastVersion 2021.1E\nwww.ago-online.de\nAdjuvant Endocrine Therapy in Postmenopausal PatientsPostmenopausal beforethestartof adjuvant therapyRecommendEAT withAI for2-(5)yb,4Tam for5y1(veryold, verylowriskofrecurrenceorifcontraindicationsforAI arepresent)DiscussEAT2Tam for2-3y followedbyAI (complete5y)3AGO+AGO++AGO+\nAI, aromatase inhibitor; EAT, extended adjuvant therapy; Tam, tamoxifen; y, years; adecision criteria may include: condition after neo(adjuvant) chemotherapy  (indicating high risk), positive lymphnodestatus, T2/T3 tumors, elevated risk of recurrence  based on immuno-histochemical criteria or based on multi-gene expression assays,high CTS5-Score; bup to date no impact on overall survivalAI for5y3AI for2-3y followedbyTam (complete5y)3AGO++High riskofrecurrenceaAGO++\nNon-steroidalAI for5y3(invasive-lobularhistology)AGO+\n\u00a9 AGO e. V.in der DGGG e.V. sowie in der DKG e.V.Guidelines BreastVersion 2021.1E\nwww.ago-online.deHR-positive/HER2-negative Metastatic Breast Cancer: Strategies\nImminent organfailureSingle agentCTx/ ETx/ CDK4/6i\n\u2022CTxcombination1-4\u2022Single agentCTx\nStandard therapyCDK4/6ia+ AI orCDK4/6ia+ fulvestrant5,6\nAGO++AGO++\nAI, aromatase inhibitor; CDK4/6i, CDK4/6 inhibitor; CTx, chemotherapy; ETx, endocrine therapy; gBRCA1/2, germ line BRCA1/2 mutation;HR, hormone receptor; mBC, metastatic breast cancer; sPIK3CA, somatic PIK3CA mutation;  apremenopausal add OFS; b bevacizumab + paclitaxel or + capecitabine; cafter approval\u2022CTx+ bevacizumabbAGO+HR+ / HER2-mBC\nETx\nAGO+gBRCA1/2 mutationEndocrineresistent (progression\u2264 6 months)PARP inhibitor7-13\u2022Single agentCTx14\u2022CTx+ bevacizumabbEndocrinesensitive(progression> 6 months)ETx+ everolimus15AGO++AGO+AGO+AGO+\nETx\nsPIK3CA mutationETx+ alpelisib16\u00a9 AGO e. V.in der DGGG e.V. sowie in der DKG e.V.Guidelines BreastVersion 2021.1E\nwww.ago-online.deHR-positive/HER2-negative Metastatic Breast Cancer: Endocrine-based First Line Treatment\nPostmenopausalstandardtherapy(adjuvant tamoxifen)Fulvestrant36-38AI24-29Tamoxifen14CDK4/6i + AI16-23Postmenopausalstandardtherapy(adjuvant AI)CDK4/6i + fulvestrant30-35\nAGO+HR+ / HER2-mBC\nAGO++\nAGO++AGO+AGO+Premenopausalstandardtherapy\nAI, aromatase inhibitor; CDK4/6i, CDK4/6 inhibitor; GnRHa, GnRH agonist; HR, hormone receptor; mBC, metastatic breast cancerGnRHa+ fulvestrant+ CDK4/6i1,2,6GnRHa+ AI + ribociclib4,5\nGnRHa+ tamoxifen7,8\nTamoxifen13,15GnRHa+ AI orGnRHa+fulvestrant9-12\nAGO++AGO++AGO+AGO+AGO+/-GnRHa+ AI + palbocicliborabemaciclib3\nAGO+\u00a9 AGO e. V.in der DGGG e.V. sowie in der DKG e.V.Guidelines BreastVersion 2021.1D\nwww.ago-online.deAI, aromatase inhibitor; Cap, capecitabine; CTx, chemotherapy; ETx, endocrine treatment; Lap,lapatinib; mths, months; Ner, neratinib; Pz, pertuzumab; TBP, treatment beyond progression; T-DM1, trastuzumab emtansine; TFI, treatment-free interval; Tuc, tucatinib; Tz, trastuzumab;ano OS benefit, consider induction chemotherapy + anti-HER2-therapy (followed by ETx+ anti-HER2-therapy as maintenance therapy); b docetaxel(++), paclitaxel (++) or nab-paclitaxel (+); conly HR positive; donly for HR negativeHER2-positive Metastatic  Breast Cancer: 1st-3rd-line\nDe novometastaticorTFI > 6 mthsafter (neo-)adjuvantanti-HER2 regimenVinorelbine+Tz + Pz2T-DM13,4Cap + Lap7,8Tz-Deruxtecan10\nTuc+ Tz + Cap5,6Cap + Ner9\nExperimental anti-HER2-regimenSecondarymetastaticandTFI \u2264 6 mthsafter (neo-)adjuvant anti-HER2 regimenAfter (neo)adjuvantTz  +/-Pz15After (neo)adjuvantTz  +/-PzfollowedbyadjuvantT-DM1AI + Tz + Pzc,12\nCTx+ Tz (TBP)11UnsuitableforCTx/ patient\u2018spreferenceETx+ anti-HER2-regimena,16-20\nAGO+/-AGO++AGO+AGO+AGO+AGO+AGO++AGO++\nAGO+AGO+\nAGO+\nAGO+AGO+\nTaxaneb+Tz + Pz1\nAGO+\nTz + Lapd,13,14AGO+\n\u00a9 AGO e. V.in der DGGG e.V. sowie in der DKG e.V.Guidelines BreastVersion 2021.1E\nwww.ago-online.de\nTriple-negative Metastatic Breast CancerPD-L1 negaandgBRCAwt\nPD-L1 negaand gBRCAmutPaclitaxel orcapecitabine+bevacizumab, cisplatinum+ gemcitabine,carboplatin\u00b1nab-paclitaxel1-3,5,9,11,13,14\nAGO++AGO+\nA, anthracycline; Atezo, atezolizumab; Cap, capecitabine; gBRCA, germ line BRCA mutation; IHC, immunohistochemistry; mths, months; mut, mutated; neg, negative; nPac, nab-paclitaxel; Pac, paclitaxel; PD-L1, programmed cell death ligand 1; Pembro, pembrolizumab; pos, positive; T, taxane; TFI, tretament-free interval; wt, wild type; aIC<1% (neg) or \u22651% (pos); buse of not previously used compounds or regimen; cnPac, Pac oderCarboplatin+GemcitabinPacorCap + bevacizumab, carboplatin\u00b1nab-paclitaxeletc.1-3,5,9,11,13,14PARP-inhibitor4,8,9\nPARP-inhibitor4,6AGO++\nAGO++\nChemotherapy\u00b1bevacizumab1-3,5,9,11,13,14Carboplatin11NoprevioustherapywithA/TPrevioustherapywithA/T\nAGO+\nDetermination of1-2,4,6-9\u2022PD-L1 IHC\u2022gBRCAAGO++\nAlternative CTxb, 1-3,12-14or(after \u22652 lines)SacituzumabGovitecan16,17\nPD-L1 posaandgBRCAwtPD-L1 posaandgBRCAmutCarboplatin, Capecitabine etc.1-3,12-14Atezo+ nPac10(TFI\u226512 mths)PARP inhibitor4,8,9\nCarboplatin12\nPARP inhibitor4,8,9\nPembro+ CTxc,11(TFI\u22656 mths)\nAGO+AGO+/-\nAtezo+ nPac(TFI\u226512 mths)Pembro+ CTxc,11(TFI\u22656 mths)\nAtezo+ nPac10(TFI\u226512 mths)Pembro+ CTxc,11(TFI\u22656 mths)\nAGO++AGO+/-AGO+AGO+/-", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}